var images_info;if (!images_info) images_info =[]; images_info["93"]={"93136":{"type":"graphic_table","displayName":"Clinical score for infants with scalp hematomas","title":"Clinical score for infants with scalp hematomas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical score for infants with scalp hematomas</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk points</td> <td class=\"subtitle1\">Patient age (mo)</td> <td class=\"subtitle1\">Hematoma size</td> <td class=\"subtitle1\">Hematoma location</td> </tr> <tr> <td>0</td> <td>&#8805;12</td> <td>None</td> <td>Frontal</td> </tr> <tr> <td>1</td> <td>6 to 11</td> <td>Small (barely palpable)</td> <td>Occipital</td> </tr> <tr> <td>2</td> <td>3 to 5</td> <td>Medium (easily palpable)</td> <td>Temporal/parietal</td> </tr> <tr> <td>3</td> <td>0 to 2</td> <td>Large (very easily palpable)</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A score of 3 or more is associated with a significant risk of clinically important traumatic brain injury in infants with scalp hematomas.</div><div class=\"graphic_reference\">Reproduced with permission from: Bin SS, Schutzman SA, Greenes DS. Validation of a clinical score to predict skull fracture in head-injured infants. Pediatr Emerg Care 2010; 26:633. DOI:&nbsp;<A href=\"http://journals.lww.com/pec-online/pages/articleviewer.aspx?year=2010&amp;issue=09000&amp;article=00004&amp;type=abstract\">10.1097/PEC.0b013e3181ef0440</A>. Copyright © 2010 Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 93136 Version 5.0</div></div></div>"},"93139":{"type":"graphic_algorithm","displayName":"NICE identifying and managing risk of type 2 diabetes ","title":"National Institute for Health and Care Excellence (NICE): Identifying and managing risk of type 2 diabetes ","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">National Institute for Health and Care Excellence (NICE): Identifying and managing risk of type 2 diabetes </div><div class=\"cntnt\"><img style=\"width:580px; height:772px;\" src=\"images/PC/93139_Id_manage_risk_2_diabetes.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">BMI: body mass index; FPG: fasting plasma glucose; HbA<SUB>1c</SUB>: glycated hemoglobin.</div><div class=\"graphic_reference\">From: National Institute for Health and Care Excellence (2012) PH 38 Preventing type 2 diabetes: risk identification and interventions for individuals at high risk. London: NICE. Available from: <A spellcheck=true href=\"https://www.nice.org.uk/guidance/ph38\" target=_blank>https://www.nice.org.uk/guidance/ph38</A>. Reproduced with permission. Please note that NICE public health guidance is prepared for the National Health Service and local authorities in England. NICE guidance does not apply to the United States and NICE has not been involved in the development or adaptation of any guidance for use in the United States.</div><div id=\"graphicVersion\">Graphic 93139 Version 4.0</div></div></div>"},"93141":{"type":"graphic_table","displayName":"Clinical and laboratory evaluation on PEG and ribavirin","title":"Clinical and laboratory evaluation during treatment with peginterferon and ribavirin-containing regimens","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical and laboratory evaluation during treatment with peginterferon and ribavirin-containing regimens</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"15\" width=\"6%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Baseline</td> <td class=\"subtitle1\">Week 2</td> <td class=\"subtitle1\">Week 4</td> <td class=\"subtitle1\">Week 8</td> <td class=\"subtitle1\">Week 12</td> <td class=\"subtitle1\">Week 16</td> <td class=\"subtitle1\">Week 20</td> <td class=\"subtitle1\">Week 24</td> <td class=\"subtitle1\">Week 28</td> <td class=\"subtitle1\">Week 32</td> <td class=\"subtitle1\">Week 36</td> <td class=\"subtitle1\">Week 40</td> <td class=\"subtitle1\">Week 44</td> <td class=\"subtitle1\">Week 48</td> <td class=\"subtitle1\">6 months post-treatment</td> </tr> <tr> <td><strong>CBC + differential</strong></td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td><strong>LFTs</strong></td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td><strong>Electrolytes</strong></td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td><strong>TSH</strong></td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td><strong>Glucose</strong></td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td><strong>Pregnancy test</strong></td> <td class=\"centered\">+</td> <td colspan=\"14\">Further testing as indicated by the individual case</td> </tr> <tr> <td><strong>Clinical evaluation</strong></td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td><strong>Psychiatric assessment</strong></td> <td class=\"centered\">+</td> <td colspan=\"14\">Further testing as indicated by the individual case</td> </tr> <tr> <td><strong>Fundoscopic exam</strong></td> <td class=\"centered\">+</td> <td colspan=\"14\">Further testing as indicated by the individual case</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table lists suggested intervals for clinical and laboratory assessment for comorbidities and adverse effects prior to and during therapy for chronic hepatitis C infection with a regimen that contains peginterferon and ribavirin, specifically.<br />These suggestions are based on the opinion and experience of UpToDate contributors.</div><div class=\"graphic_footnotes\">CBC: complete blood count; LFTs: liver biochemical and function tests, including alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and bilirubin.</div><div id=\"graphicVersion\">Graphic 93141 Version 2.0</div></div></div>"},"93144":{"type":"graphic_diagnosticimage","displayName":"CT ovarian cancer pleural effusions","title":"Ovarian cancer with pleural metastasis and effusions on CT","html":"<div class=\"graphic\"><div style=\"width: 611px\" class=\"figure\"><div class=\"ttl\">Ovarian cancer with pleural metastasis and effusions on CT</div><div class=\"cntnt\"><img style=\"width:591px; height:357px;\" src=\"images/RADIOL/93144_CT_ovar_can_pleur_effus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan through the chest shows bilateral pleural effusions (dashed arrows), pleural metastasis (arrowhead), and a diffuse reticulonodular pattern (double arrow) in the lungs.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93144 Version 1.0</div></div></div>"},"93145":{"type":"graphic_diagnosticimage","displayName":"CT ovarian cancer duodenal obstruction ","title":"Duodenal obstruction from ovarian carcinoma on CT","html":"<div class=\"graphic\"><div style=\"width: 621px\" class=\"figure\"><div class=\"ttl\">Duodenal obstruction from ovarian carcinoma on CT</div><div class=\"cntnt\"><img style=\"width:601px; height:348px;\" src=\"images/RADIOL/93145_CT_ovr_can_duo_obstrct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A scout film (A) shows a distended stomach (asterisk) and a right ureteric stent (arrow). Image B is a CT scan through the upper abdomen and shows an air fluid level in a distended stomach (asterisk), a focal narrowing in the duodenum (arrow), and an ill-defined ovarian metastasis in the retroperitoneum at the site of obstruction (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93145 Version 1.0</div></div></div>"},"93146":{"type":"graphic_diagnosticimage","displayName":"CT ovarian cancer hypercoagulable state","title":"Ovarian cancer with hypercoagulable state and complications on CT scan","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Ovarian cancer with hypercoagulable state and complications on CT scan</div><div class=\"cntnt\"><img style=\"width:599px; height:449px;\" src=\"images/RADIOL/93146_CT_ovar_can_hyprcg_stt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image A is a CT scan through the pelvis and shows a thrombus in the left femoral vein (arrow). A CT scan of the posterior fossa of the same patient shows a wedge shaped infarction in the right cerebellar hemisphere (arrow) likely as a result of the hypercoagulable state. Image C shows bilateral pulmonary emboli (arrows) in a second patient. Image D of the same patient shows a wedge shaped pulmonary infarction in the lateral basal segment of the right lower lobe (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93146 Version 1.0</div></div></div>"},"93147":{"type":"graphic_diagnosticimage","displayName":"CT ascites distension ovarian cancer ","title":"Ovarian cancer with ascites and abdominal distension on CT scan","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Ovarian cancer with ascites and abdominal distension on CT scan</div><div class=\"cntnt\"><img style=\"width:600px; height:303px;\" src=\"images/RADIOL/93147_CT_ascit_dist_ovar_canc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan through the abdomen shows a large amount of ascites resulting in a distended abdomen. A calcified ovarian mass (arrowhead) arises from the pelvis. Image B is a coronal reconstruction and shows a distended abdomen filled with ascitic fluid (arrow). Image C is a sagittal reconstruction and shows abdominal distension caused by ascites (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93147 Version 1.0</div></div></div>"},"93148":{"type":"graphic_diagnosticimage","displayName":"CT inguinal and umbilical adenopathy peritoneal carcinomatosis","title":"Peritoneal carcinomatosis inguinal and umbilical adenopathy on CT","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Peritoneal carcinomatosis inguinal and umbilical adenopathy on CT</div><div class=\"cntnt\"><img style=\"width:599px; height:403px;\" src=\"images/RADIOL/93148_CT_ingn_umbl_adno_carc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image A is a CT scan through the lower pelvis and shows a low density right-sided inguinal lymph node in a patient with ovarian cancer. Image B is a CT scan through the mid abdomen of a second patient with ovarian carcinoma and shows a tumor nodule in the umbilicus (arrowhead) known as a&nbsp;Sister Mary Joseph node. Image B also shows omental metastases (arrow). Image C is a CT scan through the lower pelvis of a patient with Fallopian tube carcinoma and shows inguinal adenopathy (double arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93148 Version 1.0</div></div></div>"},"93149":{"type":"graphic_diagnosticimage","displayName":"CT ovarian carcinoma primary lesion","title":"Primary ovarian carcinoma on CT scan","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Primary ovarian carcinoma on CT scan</div><div class=\"cntnt\"><img style=\"width:598px; height:419px;\" src=\"images/RADIOL/93149_CT_ov_carc_prim_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image A is a CT scan through the pelvis and shows a cystic mass (arrow) with fine septations (arrowhead). Image B is a CT scan of a second patient and shows a solid primary ovarian cancer (arrow). Image C is CT scan of a third patient and shows a primary ovarian cancer with both solid (arrowhead) and cystic (arrow) features. Image D shows a primary ovarian carcinoma with psammomatous calcifications (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93149 Version 1.0</div></div></div>"},"93150":{"type":"graphic_diagnosticimage","displayName":"CT ovarian carcinoma metastases","title":"Ovarian carcinoma metastases on CT","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Ovarian carcinoma metastases on CT</div><div class=\"cntnt\"><img style=\"width:598px; height:456px;\" src=\"images/RADIOL/93150_CT_ovar_carcin_metasts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image A is a CT scan through the mid abdomen and shows circumaortic metastatic ovarian lymphadenopathy. Image B shows a calcified metastatic paraaortic lymph node (arrow). Image C shows cystic metastases in the liver from ovarian carcinoma. Image D shows calcified metastases in the liver from ovarian carcinoma and metastatic calcification on the splenic capsule (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93150 Version 1.0</div></div></div>"},"93152":{"type":"graphic_diagnosticimage","displayName":"CT and MRI ovarian metastases","title":"Ovarian carcinoma metastases on CT and MRI","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Ovarian carcinoma metastases on CT and MRI</div><div class=\"cntnt\"><img style=\"width:599px; height:443px;\" src=\"images/RADIOL/93152_CT_MRI_ovarian_metast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan through the upper abdomen (A) shows an indeterminate lesion in the spleen (arrow) in a patient with ovarian carcinoma. A T2 weighted image shows a cystic centre (arrowhead) and a thick solid rim (arrow) consistent with an isolated metastasis. A CT scan performed four months later shows a growing splenic nodule (arrow) and new ascites (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography; MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 93152 Version 1.0</div></div></div>"},"93154":{"type":"graphic_diagnosticimage","displayName":"Chest x-ray ovarian carcinoma","title":"Ovarian carcinoma on chest x-ray","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Ovarian carcinoma on chest x-ray</div><div class=\"cntnt\"><img style=\"width:594px; height:347px;\" src=\"images/RADIOL/93154_Chst_x_ovarian_carcino.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image A is a chest x-ray in anteroposterior projection and shows diffuse bilateral reticulonodular disease in a patient with metastatic ovarian carcinoma. This pattern is consistent with lymphangitis carcinomatosa. A lateral examination (B) shows bilateral small pleural effusions (arrow).</div><div id=\"graphicVersion\">Graphic 93154 Version 1.0</div></div></div>"},"93156":{"type":"graphic_diagnosticimage","displayName":"CT pleural metastases ovarian carcinoma","title":"Ovarian carcinoma and pleural metastases on CT","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Ovarian carcinoma and pleural metastases on CT</div><div class=\"cntnt\"><img style=\"width:600px; height:231px;\" src=\"images/RADIOL/93156_CT_plr_met_ovar_carcin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan through the chest (A) shows bilateral pleural effusions (short arrows), pleural metastasis (thick arrow), and a diffuse reticulonodular pattern (arrowheads) in the lungs. Image B shows calcified pleural metastases (arrows) in a patient with ovarian carcinoma.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93156 Version 1.0</div></div></div>"},"93157":{"type":"graphic_diagnosticimage","displayName":"CT metastases to ovaries","title":"Gastric carcinoma with metastases to ovaries on CT","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Gastric carcinoma with metastases to ovaries on CT</div><div class=\"cntnt\"><img style=\"width:551px; height:454px;\" src=\"images/RADIOL/93157_CT_metastases_ovaries.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan through the lower pelvis shows bilateral ovarian masses (arrowheads) in a patient with gastric carcinoma. There is a small amount of pelvic ascites (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93157 Version 1.0</div></div></div>"},"93158":{"type":"graphic_table","displayName":"Spectrum of primary ovarian insufficiency","title":"Clinical states in the spectrum of primary ovarian insufficiency<sup>[1,2]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical states in the spectrum of primary ovarian insufficiency<sup>[1,2]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical state</td> <td class=\"subtitle1\">Serum FSH level</td> <td class=\"subtitle1\">Fertility</td> <td class=\"subtitle1\">Menses</td> <td class=\"subtitle1\">AMH</td> </tr> <tr> <td>Normal</td> <td>Normal</td> <td>Normal</td> <td>Regular</td> <td>Normal</td> </tr> <tr> <td>Occult*</td> <td>Normal</td> <td>Reduced</td> <td>Regular</td> <td>Low</td> </tr> <tr> <td>Biochemical</td> <td>Elevated</td> <td>Reduced</td> <td>Regular</td> <td>Low</td> </tr> <tr> <td>Overt</td> <td>Elevated</td> <td>Reduced</td> <td>Irregular or absent</td> <td>Low</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FSH: follicle-stimulating hormone; AMH: anti-M&uuml;llerian hormone; POI: primary ovarian insufficiency.<br />* Both AMH and antral follicle count may be low in occult POI. While these markers may predict response to gonadotropin stimulation, their accuracy is limited in predicting pregnancy during assisted reproduction. Levels of both are low in more advanced cases of POI<sup>[3,4]</sup>.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med 2009; 360:606.</li>&#xD;&#xA;    <li>Welt CK, Smith PC, Taylor AE. Evidence of early ovarian aging in fragile X premutation carriers. J Clin Endocrinol Metab 2004; 89:4569.</li>&#xD;&#xA;    <li>Broekmans FJ, Kwee J, Hendriks DJ, et al. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 2006; 12:685.</li>&#xD;&#xA;    <li>La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update 2014; 20:124.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 93158 Version 3.0</div></div></div>"},"93161":{"type":"graphic_picture","displayName":"Endoscopic spectrum of pouchitis and pouch disorders","title":"Endoscopic spectrum of pouchitis and pouch disorders","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic spectrum of pouchitis and pouch disorders</div><div class=\"cntnt\"><img style=\"width:432px; height:851px;\" src=\"images/GAST/93161_Endoscopic_pouchitis_pouch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Normal pouch with owls' anatomy of the pouch inlet and the tip of \"J\".<br />(B) Diversion pouchitis.<br />(C) Classic pouchitis with diffuse inflammation.<br />(D) <EM>Clostridium difficile</EM> pouchitis with pseudomembrane.<br />(E) Ischemic pouchitis with asymmetric distribution of inflammation in the pouch body.<br />(F) Cuffitis.<br />(G) Crohn disease with pouch vaginal fistula opening (arrow).<br />(H) Anastomotic sinus due to surgical leak (arrow).</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Gastroenterology and Hepatology. Shen B. Acute and chronic pouchitis: Pathogenesis, diagnosis and treatment. Nat Rev Gastroenterol Hepatol 2012; 9:323. Copyright &copy; 2012. <a href=\"http://www.nature.com/nrgastro\" target=\"_blank\">www.nature.com/nrgastro</a>.</div><div id=\"graphicVersion\">Graphic 93161 Version 1.0</div></div></div>"},"93162":{"type":"graphic_figure","displayName":"Variation in the disease courses of pouchitis","title":"Variation in the disease courses of pouchitis","html":"<div class=\"graphic\"><div style=\"width: 640px\" class=\"figure\"><div class=\"ttl\">Variation in the disease courses of pouchitis</div><div class=\"cntnt\"><img style=\"width:620px; height:434px;\" src=\"images/GAST/93162_Variation_disease_pouchitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">UC: ulcerative colitis; FAP: familial adenomatous polyposis.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Gastroenterology and Hepatology. Shen B. Acute and chronic pouchitis: Pathogenesis, diagnosis and treatment. Nat Rev Gastroenterol Hepatol 2012; 9:323. Copyright &copy; 2012. <a href=\"http://www.nature.com/nrgastro\" target=\"_blank\">www.nature.com/nrgastro</a>.</div><div id=\"graphicVersion\">Graphic 93162 Version 1.0</div></div></div>"},"93163":{"type":"graphic_picture","displayName":"Ileal pouch cancer","title":"Ileal pouch cancer","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Ileal pouch cancer</div><div class=\"cntnt\"><img style=\"width:598px; height:464px;\" src=\"images/GAST/93163_Cncr_ptnt_wo_macro_endo_lsn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic (A), narrow band imaging (B), and macroscopic (C) views of the rectal cuff show no obvious mass or lesion. Histology shows invasive cancer (D).</div><div class=\"graphic_reference\">Liu ZX, Kiran RP, Bennett EA, et al. Diagnosis and management of dysplasia and cancer of the ileal pouch in patients with underlying inflammatory bowel disease. Cancer 2011; 117:3081. Copyright &copy; 2011 American Cancer Society. Reproduced with permission from John Wiley &amp; Sons, Inc.</div><div id=\"graphicVersion\">Graphic 93163 Version 3.0</div></div></div>"},"93165":{"type":"graphic_picture","displayName":"Histology of pouch mucosal","title":"Histology of pouch mucosal","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Histology of pouch mucosal</div><div class=\"cntnt\"><img style=\"width:598px; height:434px;\" src=\"images/GAST/93165_Histology_pouch_mucosal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Normal pouch mucosa with tall villi and normal villus/crypt ratio. No inflammatory cell infiltration in the epithelium and lamina propria.<br />(B) Mild pouchitis with mainly chronic changes including crypt distortion, mononuclear cell infiltrations in the lamina propria and base of the crypts.<br />(C) Acute pouchitis with cryptitis and ulcers.<br />(D) Acute pouchitis with crypt abscess.</div><div id=\"graphicVersion\">Graphic 93165 Version 1.0</div></div></div>"},"93166":{"type":"graphic_picture","displayName":"Endoscopy of the J pouch","title":"Endoscopy of the \"J\" pouch","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Endoscopy of the \"J\" pouch</div><div class=\"cntnt\"><img style=\"width:597px; height:476px;\" src=\"images/GAST/93166_Endoscopy_J_pouch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Endoscopic view of a normal pouch inlet area (tip of \"J\" and inlet) with a central ridge has an owl's eye appearance.<br />(B) Distorted pouch inlet area in a patient with pouch prolapse.<br />(C) Distorted pouch inlet area in a patient with Crohn disease.</div><div id=\"graphicVersion\">Graphic 93166 Version 1.0</div></div></div>"},"93168":{"type":"graphic_algorithm","displayName":"Diagnosis and management algorithm for acute pouchitis","title":"Diagnosis and management algorithm for acute pouchitis","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Diagnosis and management algorithm for acute pouchitis</div><div class=\"cntnt\"><img style=\"width:554px; height:436px;\" src=\"images/GAST/93168_Diag_manag_algo_acute_pouch.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\"><em>C. difficile</em>: <em>Clostridium difficile</em>; prn: as needed; 5-ASA: 5-aminosalicylic acid.</div><div id=\"graphicVersion\">Graphic 93168 Version 1.0</div></div></div>"},"93169":{"type":"graphic_algorithm","displayName":"Diagnostic algorithm for chronic antibiotic-refractory pouchitis","title":"Diagnostic algorithm for chronic antibiotic-refractory pouchitis","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Diagnostic algorithm for chronic antibiotic-refractory pouchitis</div><div class=\"cntnt\"><img style=\"width:522px; height:293px;\" src=\"images/GAST/93169_Diag_alg_chr_antirefr_pouch.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\"><em>C. difficile</em>: <em>Clostridium difficile</em>; LFT: liver function tests; ANA: antinuclear antibodies; IgG4: immunoglobulin G4; CMV: cytomegalovirus; PSC: primary sclerosing cholangitis.</div><div id=\"graphicVersion\">Graphic 93169 Version 1.0</div></div></div>"},"93170":{"type":"graphic_picture","displayName":"Kidney biopsy findings in poststreptococcal glomerulonephritis","title":"Kidney biopsy findings in poststreptococcal glomerulonephritis","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Kidney biopsy findings in poststreptococcal glomerulonephritis</div><div class=\"cntnt\"><img style=\"width:598px; height:487px;\" src=\"images/PEDS/93170_Kidnbiopspoststrepglomer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Light microscopy showing a proliferative (exudative) glomerulonephritis. Note numerous neutrophils within glomerular capillaries (Periodic acid Schiff, 40x).<br />(B) Immunofluorescence microscopy showing bright granular capillary wall staining for C3 (40x).<br />(C) Immunofluorescence microscopy showing bright granular capillary wall staining for IgG (40x).<br />(D) Electron microscopy showing a subepithelial electron dense deposit (subepithelial hump, 79900x).</div><div class=\"graphic_reference\">Courtesy of Sanjeev Sethi, MD, Mayo Clinic.</div><div id=\"graphicVersion\">Graphic 93170 Version 2.0</div></div></div>"},"93171":{"type":"graphic_figure","displayName":"Physical exams to detect kyphosis","title":"Physical examination tests to detect kyphosis","html":"<div class=\"graphic\"><div style=\"width: 645px\" class=\"figure\"><div class=\"ttl\">Physical examination tests to detect kyphosis</div><div class=\"cntnt\"><img style=\"width:625px; height:426px;\" src=\"images/ENDO/93171_Phys_exams_detect_kyphosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Wall-occiput test is used to detect occult thoracic vertebral fractures. A positive test result in this review is defined as being unable to touch the wall with the occiput when standing with the back and heels against the wall and the head positioned such that an imaginary line from the lateral corner of the eye to the superior junction of the auricle is parallel to the floor.<br />(B) Rib-pelvis distance test is used to detect occult lumbar vertebral fractures. A positive test is defined as a distance of less than or equal to 2 fingerbreadths between the inferior margin of the ribs and the superior surface of the pelvis in the midaxillary line.</div><div class=\"graphic_reference\">Reproduced with permission from: Green AD, Colon-Emeric CS, Bastian L, et al. Does this woman have osteoporosis? JAMA 2004; 292:2890. Copyright &copy; 2004 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 93171 Version 4.0</div></div></div>"},"93172":{"type":"graphic_diagnosticimage","displayName":"Lung volume reduction using nitinol coils","title":"Use of nitinol coils for lung volume reduction in emphysema","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Use of nitinol coils for lung volume reduction in emphysema</div><div class=\"cntnt\"><img style=\"width:586px; height:587px;\" src=\"images/PULM/93172_Lung_vol_reduc_nitinol_coil.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fluoroscopic image of flexible bronchoscope deploying nitinol coils into right upper lobe. The coils are passed out into the subsegmental airways. After release from the bronchoscope, they resume their coiled shape, collecting and collapsing the emphysematous lung tissue.</div><div class=\"graphic_reference\">Used with permission, PneumRx, Inc. Copyright © 2014. All rights reserved.</div><div id=\"graphicVersion\">Graphic 93172 Version 1.0</div></div></div>"},"93175":{"type":"graphic_picture","displayName":"Drug-induced erythroderma","title":"Drug-induced erythroderma","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Drug-induced erythroderma</div><div class=\"cntnt\"><img style=\"width:523px; height:590px;\" src=\"images/DERM/93175_Drug_induced_erythroderma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Red and scaly skin involving more than 90 percent of the body surface area in a patient with erythrodermic skin reaction.</div><div id=\"graphicVersion\">Graphic 93175 Version 2.0</div></div></div>"},"93176":{"type":"graphic_picture","displayName":"Hypersensitivity vasculitis","title":"Hypersensitivity vasculitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Hypersensitivity vasculitis</div><div class=\"cntnt\"><img style=\"width:590px; height:559px;\" src=\"images/DERM/93176_Hypersensitivity_vasculitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Palpable purpura involving the lower legs of a patient with drug-induced hypersensitivity vasculitis.</div><div id=\"graphicVersion\">Graphic 93176 Version 1.0</div></div></div>"},"93177":{"type":"graphic_table","displayName":"Pediatric causes of ADH release","title":"Causes of antidiuretic hormone (ADH) release in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of antidiuretic hormone (ADH) release in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Specific causes</td> </tr> <tr> <td>Physiologic</td> <td>Hypovolemia, hyperosmolality</td> </tr> <tr> <td>Pulmonary</td> <td>Pneumonia, bronchiolitis, asthma, pneumothorax, cystic fibrosis, positive pressure mechanical ventilation</td> </tr> <tr> <td>Central nervous system (CNS)</td> <td>Meningitis, encephalitis, CNS tumor, brain trauma, pain, anxiety, hypoxia, nausea</td> </tr> <tr> <td>Metabolic</td> <td>Hypothyroidism, hypoadrenalism</td> </tr> <tr> <td>Medication effect</td> <td>Vincristine, carbamazepine, cyclophosphamide, narcotics</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Somers MJG. Fluid and electrolyte therapy in children. In: Pediatric Nephrology, 6th ed, Avner ED, Harmon WH, Niaudet P, Yoshikawa N (Eds), Springer-Verlag, Berlin 2009.</div><div id=\"graphicVersion\">Graphic 93177 Version 1.0</div></div></div>"},"93178":{"type":"graphic_table","displayName":"Causes of pediatric hyponatremia","title":"Causes of hyponatremia in children: Based on patient's volume status and renal sodium handling","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of hyponatremia in children: Based on patient's volume status and renal sodium handling</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Circulating arterial volume</td> <td class=\"subtitle1\" colspan=\"2\">Urinary sodium concentration</td> </tr> <tr> <td class=\"subtitle2\">&#60;25 mEq/L</td> <td class=\"subtitle2\">&#62;25 mEq/L</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\"><strong>Decreased</strong></td> <td>Gastroenteritis</td> <td>Adrenal insufficiency</td> </tr> <tr> <td>Cystic fibrosis</td> <td>Diuretics - Early effect</td> </tr> <tr> <td>Diuretics - Late effect</td> <td>Salt wasting</td> </tr> <tr> <td>Burns</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Bleeding</td> <td>&nbsp;</td> </tr> <tr> <td rowspan=\"3\"><strong>Normal or increased</strong></td> <td>Cardiac failure</td> <td>SIADH</td> </tr> <tr> <td>Nephrotic syndrome</td> <td>Renal failure</td> </tr> <tr> <td>Cirrhosis</td> <td>Water intoxication</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SIADH: syndrome of inappropriate antidiuretic hormone.</div><div class=\"graphic_reference\">Adapted from: Somers MJG. Fluid and electrolyte therapy in children. In: Pediatric Nephrology, 6th ed, Avner ED, Harmon WH, Niaudet P, Yoshikawa N (Eds), Springer-Verlag, Berlin 2009.</div><div id=\"graphicVersion\">Graphic 93178 Version 2.0</div></div></div>"},"93179":{"type":"graphic_algorithm","displayName":"Snakebite algorithm Sri Lanka","title":"Algorithm for diagnosis of the snakebite in Sri Lanka","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Algorithm for diagnosis of the snakebite in Sri Lanka</div><div class=\"cntnt\"><img style=\"width:594px; height:354px;\" src=\"images/EM/93179_Snakebite_algo_Sri_Lanka.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission of the American Society of Tropical Medicine and Hygiene, from: Ariaratnam CA, Rezvi Sheriff MH, Arambepola C, et al. Syndromic approach to treatment of snake bite in Sri Lanka based on results of prospective national hospital-based survey of patients envenomed by identified snakes. Am J Trop Med Hyg 2009; 81:725; permission conveyed through Copyright Clearance Center, Inc. Copyright © 2009.</div><div id=\"graphicVersion\">Graphic 93179 Version 3.0</div></div></div>"},"93180":{"type":"graphic_algorithm","displayName":"Australian snakebite algorithm local effects","title":"Diagnostic algorithm for Australian snakebites based upon local effects","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Diagnostic algorithm for Australian snakebites based upon local effects</div><div class=\"cntnt\"><img style=\"width:582px; height:337px;\" src=\"images/EM/93180_Austr_snkbt_local_effects.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Accuracy can be improved by matching&nbsp;the results of this algorithm&nbsp;with known snake fauna for the region where the bite occurred. Also, refer to the UpToDate algorithm \"Diagnostic algorithm for Australian snakebites based upon systemic effects\" to give a best guess regarding the type of snake most likely to have caused the bite</div><div class=\"graphic_reference\">Reproduced with permission from: White J. Snakebite &amp; spiderbite managment guidelines South Australia. Department of Health, Government of South Australia, 2006. Copyright © 1998, 2006 Julian White, MB, BS, MD, FACMT.</div><div id=\"graphicVersion\">Graphic 93180 Version 1.0</div></div></div>"},"93181":{"type":"graphic_algorithm","displayName":"Australian snakebite algorithm systemic effects","title":"Diagnostic algorithm for Australian snakebites based upon systemic bite effects","html":"<div class=\"graphic\"><div style=\"width: 641px\" class=\"figure\"><div class=\"ttl\">Diagnostic algorithm for Australian snakebites based upon systemic bite effects</div><div class=\"cntnt\"><img style=\"width:621px; height:473px;\" src=\"images/EM/93181_Austr_snkbt_systc_effects.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagnostic accuracy can be improved by utilizing this algorithm with known snake fauna for the region where the bite occurred and by referring to the UpToDate algorithm \"Diagnostic algorithm for Australian snakebites based upon local effects\".</div><div class=\"graphic_footnotes\">FDP: fibrin degradation products; XDP: cross-linked fibrin degradation products.<br />* A tiger snake bite evaluated soon after envenoming may initially show only coagulopathy with subsequent paralysis or myolysis as further toxicity develops.</div><div class=\"graphic_reference\">Reproduced with permission from: White J. Snakebite &amp; spiderbite managment guidelines South Australia. Department of Health, Government of South Australia, 2006. Copyright &copy; 1998, 2006 Julian White, MB, BS, MD, FACMT.</div><div id=\"graphicVersion\">Graphic 93181 Version 2.0</div></div></div>"},"93188":{"type":"graphic_figure","displayName":"Dissection showing foot plantar flexor tendons","title":"Dissection demonstrating continuation of foot plantar flexor tendons","html":"<div class=\"graphic\"><div style=\"width: 639px\" class=\"figure\"><div class=\"ttl\">Dissection demonstrating continuation of foot plantar flexor tendons</div><div class=\"cntnt\"><img style=\"width:619px; height:769px;\" src=\"images/EM/93188_Dssctdmnstcntnplntrflxr.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Lower limb. In: Clinically Oriented Anatomy, 7th ed, Moore KL, Dalley AF, Agur A (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 93188 Version 3.0</div></div></div>"},"93189":{"type":"graphic_figure","displayName":"Arteries and muscle layers of foot","title":"Arteries and muscle layers of foot","html":"<div class=\"graphic\"><div style=\"width: 803px\" class=\"figure\"><div class=\"ttl\">Arteries and muscle layers of foot</div><div class=\"cntnt\"><img style=\"width:783px; height:433px;\" src=\"images/EM/93189_Arteriesmusclelayerfoot.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Lower limb. In: Clinically Oriented Anatomy, 7th ed, Moore KL, Dalley AF, Agur A (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 93189 Version 3.0</div></div></div>"},"93190":{"type":"graphic_figure","displayName":"Nerves of foot - Dorsal and plantar views","title":"Nerves of foot - Dorsal and plantar views","html":"<div class=\"graphic\"><div style=\"width: 823px\" class=\"figure\"><div class=\"ttl\">Nerves of foot - Dorsal and plantar views</div><div class=\"cntnt\"><img style=\"width:803px; height:801px;\" src=\"images/EM/93190_Nrvfootdrslplntrview.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Lower limb. In: Clinically Oriented Anatomy, 7th ed, Moore KL, Dalley AF, Agur A (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 93190 Version 3.0</div></div></div>"},"93192":{"type":"graphic_figure","displayName":"Arteries of foot: Overview","title":"Arteries of foot: Overview","html":"<div class=\"graphic\"><div style=\"width: 818px\" class=\"figure\"><div class=\"ttl\">Arteries of foot: Overview</div><div class=\"cntnt\"><img style=\"width:798px; height:478px;\" src=\"images/EM/93192_Arteriesfootoverview.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The anterior tibial artery becomes the dorsalis pedis artery when it crosses the talocrural joint.<br />(B) The medial and lateral plantar arteries are terminal branches of the posterior tibial artery. The deep plantar artery and perforating branches of the deep plantar arch provide anastomoses between the dorsal and the plantar arteries.</div><div class=\"graphic_reference\">Reproduced with permission from: Lower limb. In: Clinically Oriented Anatomy, 7th ed, Moore KL, Dalley AF, Agur A (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 93192 Version 4.0</div></div></div>"},"93193":{"type":"graphic_figure","displayName":"Tendons and ligaments on medial aspect of ankle and foot","title":"Tendons and ligaments on medial aspect of ankle and foot","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Tendons and ligaments on medial aspect of ankle and foot</div><div class=\"cntnt\"><img style=\"width:551px; height:487px;\" src=\"images/EM/93193_Tndlgmntmdlaspctanklft.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The relationships of the flexor tendons to the medial malleolus and sustentaculum tali are shown as they descend the posterolateral aspect of the ankle region and enter the foot. Except for the part tethering the flexor hallucis longus tendon, the flexor retinaculum has been removed.<br />(B) The four parts of the medial (deltoid) ligament of the ankle are demonstrated in this dissection.</div><div class=\"graphic_footnotes\">* Talonavicular ligament.</div><div class=\"graphic_reference\">Reproduced with permission from: Lower limb. In: Clinically Oriented Anatomy, 7th ed, Moore KL, Dalley AF, Agur A (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 93193 Version 4.0</div></div></div>"},"93194":{"type":"graphic_figure","displayName":"Sectional anatomy of ankle region","title":"Sectional anatomy of ankle region","html":"<div class=\"graphic\"><div style=\"width: 845px\" class=\"figure\"><div class=\"ttl\">Sectional anatomy of ankle region</div><div class=\"cntnt\"><img style=\"width:825px; height:540px;\" src=\"images/EM/93194_Sectionalanatomyanklergn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The orientation drawing depicts the structures visible in the MRI of the ankle.</div><div class=\"graphic_reference\">Reproduced with permission from: Lower limb. In: Clinically Oriented Anatomy, 7th ed, Moore KL, Dalley AF, Agur A (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 93194 Version 4.0</div></div></div>"},"93197":{"type":"graphic_picture","displayName":"Calf compression sleeve","title":"Calf compression sleeve","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calf compression sleeve</div><div class=\"cntnt\"><img style=\"width:443px; height:590px;\" src=\"images/EM/93197_Calf_compression_sleeve.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 93197 Version 2.0</div></div></div>"},"93199":{"type":"graphic_table","displayName":"Types of abnormal uterine bleeding in adolescent PCOS","title":"Types of abnormal uterine bleeding (AUB) suggestive of abnormal degree of anovulation in adolescent PCOS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Types of abnormal uterine bleeding (AUB) suggestive of abnormal degree of anovulation&nbsp;in adolescent PCOS</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Symptom</td> <td class=\"subtitle1\">Definition</td> </tr> <tr class=\"divider_bottom\"> <td>Primary amenorrhea</td> <td>Lack of menarche by 15 years of age or by three years after the onset of breast development.*</td> </tr> <tr class=\"divider_bottom\"> <td>Secondary amenorrhea</td> <td>More than 90 days without a menstrual period, after previously menstruating.</td> </tr> <tr class=\"divider_bottom\"> <td>Oligomenorrhea<br /> (infrequent AUB)</td> <td>Postmenarcheal year one: <ul class=\"decimal_heading\"> <li>Average cycle length &#62;90 days (fewer than four periods&nbsp;per year). </li> </ul> Postmenarcheal year two: <ul class=\"decimal_heading\"> <li>Average cycle length &#62;60 days (fewer than six periods&nbsp;per year). </li> </ul> Postmenarcheal years three to five: <ul class=\"decimal_heading\"> <li>Average cycle length &#62;45 days (fewer than eight periods per year). </li> </ul> Postmenarcheal&nbsp;year six and after: <ul class=\"decimal_heading\"> <li>Average cycle length &#62;38 to 40 days (fewer than nine periods per year). </li> </ul> </td> </tr> <tr> <td>Excessive uterine bleeding<sup>&#182;</sup></td> <td>Bleeding more frequently than every 21 days or is heavy or prolonged&nbsp;(lasts more than seven days or soaks more than one pad or tampon every one to two hours).</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">AUB: abnormal uterine bleeding; PCOS: polycystic ovary syndrome; DUB: dysfunctional uterine bleeding.</div><div class=\"graphic_footnotes\">* Bone age of 15 years may be substituted for chronological age in girls with earlier than average age at puberty onset.<br />¶ Encompasses frequent intermenstrual,&nbsp;heavy, and/or prolonged&nbsp; AUB, \"polymenorrhea\" and \"menometrorrhagia.\" Formerly termed \"dysfunctional uterine bleeding\" (DUB).</div><div class=\"graphic_reference\">Modified from: Rosenfield RL. Adolescent anovulation: Maturational mechanisms and implications. J Clin Endocrinol Metab 2013; 98:3572.<br />​Updates reflected in the version published in: Rosenfield RL. The diagnosis of polycystic ovary syndrome in adolescents. Pediatrics 2015; 136:1154.</div><div id=\"graphicVersion\">Graphic 93199 Version 6.0</div></div></div>"},"93200":{"type":"graphic_picture","displayName":"Endotracheal tube kink","title":"Kinking of an endotracheal tube resulting in barotrauma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Kinking of an endotracheal tube resulting in barotrauma</div><div class=\"cntnt\"><img style=\"width:443px; height:590px;\" src=\"images/PULM/93200_Endotracheal_tube_kink.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 55-year-old female was endotracheally intubated and placed on mechanical ventilation for acute respiratory distress syndrome associated with severe pancreatitis. High airway pressures were noted and barotrauma with left-sided pneumothorax required placement of a thoracostomy tube. Difficulty passing the in-line suction catheter was noted. The patient was extubated and re-intubated. The original endotracheal tube was found to have a large kink that greatly narrowed its diameter.</div><div id=\"graphicVersion\">Graphic 93200 Version 1.0</div></div></div>"},"93203":{"type":"graphic_table","displayName":"Local anesthetics for peripheral nerve block","title":"Local anesthetics commonly used for peripheral nerve block","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Local anesthetics commonly used for peripheral nerve block</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Anesthetic</td> <td class=\"subtitle1\">Onset (minutes)</td> <td class=\"subtitle1\">Duration of anesthesia* (hours)</td> <td class=\"subtitle1\">Duration of analgesia* (hours)</td> <td class=\"subtitle1\">Maximum dose*&#182; (mg/kg)<br /> without/with epi</td> </tr> <tr> <td>2% lidocaine</td> <td>10 to 20</td> <td>2 to 5</td> <td>3 to 8</td> <td>4.5/7</td> </tr> <tr> <td>1.5% mepivacaine</td> <td>10 to 20</td> <td>2 to 5</td> <td>3 to 10</td> <td>5/7</td> </tr> <tr> <td>0.2% ropivacaine</td> <td>15 to 30</td> <td>n/a</td> <td>5 to 16</td> <td>3/3.5</td> </tr> <tr> <td>0.5% ropivacaine</td> <td>15 to 30</td> <td>4 to 12</td> <td>5 to 24</td> <td>3/3.5</td> </tr> <tr> <td>0.25% bupivacaine</td> <td>15 to 30</td> <td>n/a</td> <td>5 to 26</td> <td>2.5/3</td> </tr> <tr> <td>0.5% bupivacaine (+epi)</td> <td>15 to 30</td> <td>5 to 15</td> <td>6 to 30</td> <td>2.5/3</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">epi: epinephrine; n/a: not applicable.<br />* Duration varies widely by site of injection. These&nbsp;are generalized ranges of duration.<br />¶&nbsp;Maximal doses&nbsp;represent general guidelines for tissue infiltration, nerve block, or epidural injection. Systemic toxicity may occur with doses&nbsp;below the recommended range, particularly with intravascular injection. Doses in excess of the recommended maximums have been administered without toxicity. These recommendations do not account for the site of injection, rate of administration,&nbsp;or the presence of risk factors for systemic toxicity (eg, renal or hepatic dysfunction, cardiac failure, pregnancy,&nbsp;or extremes of age).</div><div class=\"graphic_reference\">Adapted from: Gadsen J. Local Anesthetics: Clinical Pharmacology and Rational Selection. The New York School of Regional Anesthesia website, October 2013. Available at: <a href=\"http://www.nysora.com/regional-anesthesia/foundations-of-ra/3492-local-anesthetics-clinical-pharmacology-and-rational-selection.html\" target=\"_blank\">http://www.nysora.com/regional-anesthesia/foundations-of-ra/3492-local-anesthetics-clinical-pharmacology-and-rational-selection.html</a> (Accessed January 9, 2014).</div><div id=\"graphicVersion\">Graphic 93203 Version 9.0</div></div></div>"},"93204":{"type":"graphic_picture","displayName":"Piezogenic pedal papules","title":"Piezogenic pedal papules","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Piezogenic pedal papules</div><div class=\"cntnt\"><img style=\"width:502px; height:436px;\" src=\"images/RHEUM/93204_Piezogenic_pedal_papules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photograph showing multiple soft, round, compressible, smooth, skin-colored papules (diameter 0.2 to 1.2 cm) on the medial aspect of the left heel of a 56-year-old woman.</div><div class=\"graphic_reference\">Reproduced with permission from: Ma DL, Vano-Galvan S. Piezogenic pedal papules. CMAJ 2013; 185:E847. Copyright © 2013 Canadian Medical Association. All rights reserved. This work is protected by copyright and the making of this copy was with the permission of Access Copyright. Any alteration of its content or further copying in any form whatsoever is strictly prohibited unless otherwise permitted by law.</div><div id=\"graphicVersion\">Graphic 93204 Version 1.0</div></div></div>"},"93206":{"type":"graphic_algorithm","displayName":"Cervical spine imaging of adults following trauma","title":"Cervical spine imaging of adults following trauma","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Cervical spine imaging of adults following trauma</div><div class=\"cntnt\"><img style=\"width:473px; height:464px;\" src=\"images/EM/93206_CSIadultsfollowingtrauma.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography; OR: operating room; C-spine: cervical spine; NEXUS: National Emergency X-Radiography Utilization Study; MRI: magnetic resonance imaging; SCIWORA: spinal cord injury without radiographic abnormality.<br />* Patients who are unresponsive or have an altered mental status and in whom there is concern for possible ligamentous injury of the C-spine, require immobilization of the C-spine until they can be evaluated clinically or an MRI is obtained. Clearance of the C-spine should be performed expeditiously. Refer to text for details.</div><div class=\"graphic_reference\">Courtesy of Maria E Moreira, MD.</div><div id=\"graphicVersion\">Graphic 93206 Version 2.0</div></div></div>"},"93207":{"type":"graphic_table","displayName":"General instructions for managing jet lag","title":"General instructions for managing jet lag","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">General instructions for managing jet lag</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Eastward travel</td> <td class=\"subtitle1\">Westward travel</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Before travel</strong></td> <td> <ul> <li>Move bedtime and wake time 30 minutes earlier per day starting 3 days prior to departure. </li> <li>To facilitate this shift, avoid light (including electronics) in the evening and seek bright light the first 2 to 3 hours after awakening. </li> </ul> </td> <td> <ul> <li>Move bedtime and wake time 30 minutes later per day starting 3 days prior to departure. </li> <li>To facilitate this shift, seek light in the evening and avoid bright light the first few hours after awakening. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td rowspan=\"4\"><strong>During travel</strong></td> <td> <ul> <li>Set watch to destination time. </li> </ul> </td> <td> <ul> <li>Set watch to destination time. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Avoid early morning (destination time) bright light. Use sunglasses on the plane if cabin lights are on and keep window shades down. </li> <li>Get lots of late morning and early afternoon (destination time) bright light. </li> </ul> </td> <td> <ul> <li>Get lots of late afternoon and evening (destination time) bright light. </li> <li>Avoid bright light (including electronics) during destination nighttime. Use sunglasses on the plane if cabin lights are on. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Attempt sleep during destination nighttime. </li> <li>If you cannot sleep during this period, avoid light (especially during the second half of the night) with dark sunglasses. </li> </ul> </td> <td> <ul> <li>Try to stay up to desired destination bedtime. </li> <li>Attempt sleep during destination nighttime. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Avoid sedative/hypnotic medications in flight. </li> </ul> </td> <td> <ul> <li>Avoid sedative/hypnotic medications in flight. </li> </ul> </td> </tr> <tr> <td rowspan=\"3\"><strong>On arrival</strong></td> <td class=\"divider_bottom\"> <ul> <li>Avoid early morning bright light.</li> <li>Get lots of late morning and early afternoon (destination time) bright light. </li> </ul> </td> <td class=\"divider_bottom\"> <ul> <li>Get lots of late afternoon and evening bright light. </li> <li>Avoid bright light during destination nighttime. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Take melatonin at desired destination bedtime. </li> <li>Falling asleep may be difficult the first few days. </li> </ul> </td> <td> <ul> <li>Melatonin is not helpful. </li> <li>Try to stay up to desired destination bedtime. Avoid evening nodding off. </li> <li>Staying asleep may be difficult the first few days; avoid electronics during awakenings. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Short naps (less than 45 minutes) and caffeine may help with alertness. </li> </ul> </td> <td> <ul> <li>Short naps (less than 45 minutes) and caffeine may help with alertness. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">General instructions are intended for eastward and westward travel&nbsp;across up to seven time zones. Specific timing may vary. See UpToDate&nbsp;topic on jet lag&nbsp;for suggestions for&nbsp;travel&nbsp;across eight or more time zones.</div><div id=\"graphicVersion\">Graphic 93207 Version 4.0</div></div></div>"},"93208":{"type":"graphic_table","displayName":"Electrolyte content-stool and therapeutic fluids for cholera","title":"Estimated electrolyte content of cholera stool and therapeutic fluids for cholera","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated electrolyte content of cholera stool and therapeutic fluids for cholera</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"5\" width=\"10%\"></colgroup><colgroup width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"5\">Millimoles/liter</td> <td class=\"subtitle1\" rowspan=\"2\">Comment</td> </tr> <tr> <td class=\"subtitle2\">Na+</td> <td class=\"subtitle2\">K+</td> <td class=\"subtitle2\">Cl&ndash;</td> <td class=\"subtitle2\">HCO3&ndash;</td> <td class=\"subtitle2\">Carbohydrate</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Electrolyte losses in stools</td> </tr> <tr> <td class=\"indent1\">Cholera stool, adult</td> <td class=\"centered\">130</td> <td class=\"centered\">20</td> <td class=\"centered\">100</td> <td class=\"centered\">45</td> <td class=\"centered\">--</td> <td rowspan=\"3\">Stool sodium losses in cholera are higher than in other diarrheal illnesses.</td> </tr> <tr> <td class=\"indent1\">Cholera stool, child</td> <td class=\"centered\">100</td> <td class=\"centered\">30</td> <td class=\"centered\">90</td> <td class=\"centered\">30</td> <td class=\"centered\">--</td> </tr> <tr> <td class=\"indent1\">Non-cholera stool, child (ETEC)</td> <td class=\"centered\">50</td> <td class=\"centered\">35</td> <td class=\"centered\">25</td> <td class=\"centered\">20</td> <td class=\"centered\">--</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Intravenous therapy</td> </tr> <tr> <td class=\"indent1\">Lactated Ringer's solution</td> <td class=\"centered\">130</td> <td class=\"centered\">4</td> <td class=\"centered\">109</td> <td class=\"centered\">28</td> <td class=\"centered\">--</td> <td rowspan=\"3\">Lactated Ringer's (LR) solution is preferred over normal saline because it contains potassium and bicarbonate. 'Dhaka solution' contains more potassium and bicarbonate than LR, and also contains dextrose.</td> </tr> <tr> <td class=\"indent1\">Normal saline</td> <td class=\"centered\">154</td> <td class=\"centered\">0</td> <td class=\"centered\">154</td> <td class=\"centered\">0</td> <td class=\"centered\">--</td> </tr> <tr> <td class=\"indent1\">Cholera saline (Dhaka solution)</td> <td class=\"centered\">133</td> <td class=\"centered\">13</td> <td class=\"centered\">154</td> <td class=\"centered\">48</td> <td class=\"centered\">140</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Oral rehydration therapy</td> </tr> <tr> <td class=\"indent1\">ORS (WHO 2002)</td> <td class=\"centered\">75</td> <td class=\"centered\">20</td> <td class=\"centered\">65</td> <td class=\"centered\">10 (citrate)</td> <td class=\"centered\">75 (glucose)</td> <td rowspan=\"3\">WHO ORS utilizes glucose as a carbohydrate source. Rice based ORS formulation have been found in randomized trials to reduce the duration of diarrhea and stool losses in severe cholera. A homemade preparation of ORS could be used in an emergency scenario.</td> </tr> <tr> <td class=\"indent1\">Rice based ORS (eg, CeraORS 75&#174;)</td> <td class=\"centered\">75</td> <td class=\"centered\">20</td> <td class=\"centered\">65</td> <td class=\"centered\">10 (citrate)</td> <td class=\"centered\">27 grams rice syrup solids</td> </tr> <tr> <td class=\"indent1\">Homemade ORS:<br /> <ul> <li>Half (1/2) teaspoon salt </li> <li>Six (6) teaspoons sugar </li> <li>1 liter of clean water </li> </ul> </td> <td class=\"centered\">~75</td> <td class=\"centered\">0</td> <td class=\"centered\">~75</td> <td class=\"centered\">0</td> <td class=\"centered\">~75</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 93208 Version 1.0</div></div></div>"},"93209":{"type":"graphic_picture","displayName":"Stevens-Johnson syndrome/toxic epidermal necrolysis histology","title":"Clinical and histologic features of toxic epidermal necrolysis","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Clinical and histologic features of toxic epidermal necrolysis</div><div class=\"cntnt\"><img style=\"width:598px; height:286px;\" src=\"images/DERM/93209_SJSTENhisto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Diffuse, coalescing, erythematous macules and patches with dusky centers and multiple bullae in a patient recently started on several new medications.<br />(B) There is a cell-poor subepidermal blister and epidermal necrosis. The dermal inflammatory infiltrate is sparse.</div><div class=\"graphic_reference\">Reproduced with permission from: Wu H, Branding-Bennett HA, Harrist TJ. Noninfectious vesiculobullous and vesiculopustular diseases. In: Lever's Histopathology of the Skin, 10th ed, Elder DE, Elenitsas R, Johnson B Jr, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 93209 Version 5.0</div></div></div>"},"93210":{"type":"graphic_picture","displayName":"Rice-water stools of cholera","title":"Rice-water stools of cholera","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rice-water stools of cholera</div><div class=\"cntnt\"><img style=\"width:318px; height:252px;\" src=\"images/ID/93210_Rice_water_stools_cholera.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The passage of profuse \"rice-water\" stool is characteristic of severe cholera. The stool is&nbsp;watery with flecks of mucous and has the appearance of water in which rice has been washed.</div><div id=\"graphicVersion\">Graphic 93210 Version 1.0</div></div></div>"},"93211":{"type":"graphic_figure","displayName":"Orbital decompression surgery anatomy","title":"Orbital decompression surgery anatomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Orbital decompression surgery anatomy</div><div class=\"cntnt\"><img style=\"width:434px; height:448px;\" src=\"images/ENDO/93211_Orbital_decomp_surgery_anat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagram to show extent of medial wall orbital&nbsp;decompression. Note, to achieve an effective decompression, the posterior half of the bony bar (\"strut\") between the maxillary antrum and the ethmoid air cells should be removed.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Eye. Verity DH, Rose GE. Acute thyroid eye disease (TED): Principles of medical and surgical management. Eye 2013; 27:308. Copyright &copy; 2013. <a href=\"http://www.nature.com/eye\" target=\"_blank\">www.nature.com/eye</a>.</div><div id=\"graphicVersion\">Graphic 93211 Version 2.0</div></div></div>"},"93213":{"type":"graphic_picture","displayName":"Normal portal tract","title":"Normal portal tract","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Normal portal tract</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93213_Normal_portal_tract_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The triad of portal vein, bile duct, and hepatic arteriole are portrayed. The interlobular bile duct (shown) is lined by cuboidal epithelium with the nuclei placed equidistant from each other. Note that size of the accompanying hepatic arteriole is similar to the bile duct. The hepatic arteriole supplies the bile duct via the biliary plexus.</div><div id=\"graphicVersion\">Graphic 93213 Version 2.0</div></div></div>"},"93214":{"type":"graphic_picture","displayName":"Acute lobular hepatitis lobular disarray","title":"Acute lobular hepatitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Acute lobular hepatitis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93214_Acute_lobu_hepatit_disarray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This medium-power magnification photo demonstrates lobular disarray and many foci of spotty necrosis. Some hepatocytes are undergoing ballooning degeneration.</div><div id=\"graphicVersion\">Graphic 93214 Version 1.0</div></div></div>"},"93215":{"type":"graphic_picture","displayName":"Acute lobular hepatitis acidophilic body","title":"Acute lobular hepatitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Acute lobular hepatitis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93215_ALH_acidophilic_body.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An arrow is pointing to an acidophilic (apoptotic) body. This structure, previously known as a Councilman body, represents a single dead (apoptotic) hepatocyte. Within the acidophilic body is an intensely dark, irregular structure that represents a degenerated nucleus. The nuclear chromatin is no longer visible, unlike the chromatin seen in the nuclei in surrounding hepatocytes.</div><div id=\"graphicVersion\">Graphic 93215 Version 1.0</div></div></div>"},"93216":{"type":"graphic_picture","displayName":"Acute lobular hepatitis spotty necrosis","title":"Acute lobular hepatitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Acute lobular hepatitis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93216_ALH_spotty_necrosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Foci of spotty necrosis (arrows) are composed of cellular debris engulfed by macrophages along with inflammatory cells. Their presence indicates hepatocyte damage.</div><div id=\"graphicVersion\">Graphic 93216 Version 2.0</div></div></div>"},"93217":{"type":"graphic_picture","displayName":"Acute lobular hepatitis ballooning degeneration","title":"Acute lobular hepatitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Acute lobular hepatitis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93217_ALH_ballooning_degeneration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ballooning degeneration is a form of hepatocyte injury and is seen as marked swelling of the cell (arrows) resulting in lighter staining of the cytoplasm. The cellular organelles are damaged.</div><div id=\"graphicVersion\">Graphic 93217 Version 1.0</div></div></div>"},"93218":{"type":"graphic_picture","displayName":"Severe acute lobular hepatitis","title":"Severe acute hepatitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Severe acute hepatitis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93218_Severe_acute_lobular_hepat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the marked inflammatory infiltrate present. These inflammatory cells are mostly lymphocytes; neutrophils are not necessary to make a diagnosis of acute hepatitis. There is also bridging necrosis, which is exemplified by the linear pink material in the photo representing loss and/or necrosis of a single row or several rows of hepatocytes. Bridging necrosis as shown here typically links one vascular structure to another. The patient had a marked elevation in alanine aminotransferase level that may have been due to numerous liver cells undergoing necrosis.</div><div id=\"graphicVersion\">Graphic 93218 Version 1.0</div></div></div>"},"93219":{"type":"graphic_picture","displayName":"Severe acute hepatitis high power","title":"Severe acute hepatitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Severe acute hepatitis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93219_Severe_acute_hepatitis_high.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power magnification of an inflammatory infiltrate. Arrows point to lymphocytes surrounding a single hepatocyte.</div><div id=\"graphicVersion\">Graphic 93219 Version 1.0</div></div></div>"},"93220":{"type":"graphic_picture","displayName":"Acute cholestatic hepatitis bilirubinostasis","title":"Acute cholestatic hepatitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Acute cholestatic hepatitis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93220_ACH_bilirubinostasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The liver parenchyma shows bilirubinostasis. Arrows point to dilated canalicular structures that contain a yellow-green substance characteristic of bile. Some of the hepatocytes are swollen, indicative of feathery degeneration that results from cholestasis.</div><div id=\"graphicVersion\">Graphic 93220 Version 1.0</div></div></div>"},"93222":{"type":"graphic_algorithm","displayName":"Algorithmic approach to cough in palliative care patients","title":"Algorithmic approach to cough in palliative care patients","html":"<div class=\"graphic\"><div style=\"width: 886px\" class=\"figure\"><div class=\"ttl\">Algorithmic approach to cough in palliative care patients</div><div class=\"cntnt\"><img style=\"width:866px; height:900px;\" src=\"images/PALC/93222_Algo_apprch_cough_pall_care.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmonary disease; ACE: angiotensin converting enzyme.<br />* More extensive imaging to assess for etiology, if consistent with goals of care.<br />¶ Brachytherapy is a consideration for major airway or endobronchial tumors.<br />​Δ Other peripherally acting antitussives that may be available in specific countries include levodropropazine, moguisteine, levocloperastine, or sodium cromoglycate.</div><div class=\"graphic_reference\">Adapted from: Estfan B, LeGrand S. Management of cough in advanced cancer. J Support Oncol 2004; 2:523.</div><div id=\"graphicVersion\">Graphic 93222 Version 3.0</div></div></div>"},"93226":{"type":"graphic_picture","displayName":"Chronic hepatitis C virus infection","title":"Hepatitis C virus infection with lymphoid aggregates","html":"<div class=\"graphic\"><div style=\"width: 682px\" class=\"figure\"><div class=\"ttl\">Hepatitis C virus infection with lymphoid aggregates</div><div class=\"cntnt\"><img style=\"width:662px; height:496px;\" src=\"images/GAST/93226_Chronic_HCV_infection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photomicrograph shows a portal tract with a lymphoid aggregate (arrow). Lymphoid aggregates or lymphoid follicles are typically seen in chronic viral hepatitis (hepatitis C or hepatitis B) and rarely, autoimmune hepatitis. An arrow points to a focus of interface hepatitis.</div><div id=\"graphicVersion\">Graphic 93226 Version 2.0</div></div></div>"},"93227":{"type":"graphic_picture","displayName":"HCV mild chronic inflammation","title":"Chronic hepatitis C virus infection","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Chronic hepatitis C virus infection</div><div class=\"cntnt\"><img style=\"width:476px; height:353px;\" src=\"images/GAST/93227_HCV_mild_chron_inflammation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A portal tract with mild chronic inflammation. Focal spillage of inflammatory cells into the limiting plate (the first row of hepatocytes surrounding the portal tract) is termed interface hepatitis. The more severe the degree of interface hepatitis, the faster the progression of the liver disease and fibrous tissue deposition.</div><div id=\"graphicVersion\">Graphic 93227 Version 1.0</div></div></div>"},"93228":{"type":"graphic_picture","displayName":"AIH bridging necrosis","title":"Autoimmune hepatitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Autoimmune hepatitis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93228_AIH_bridging_necrosis_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe liver injury as exemplified by bridging necrosis (highlighted by arrows). Note that within this necrotic area, there is congestion and some pigment deposited within macrophages (termed ceroid macrophages). Only very few viable hepatocytes, if any, remain.</div><div id=\"graphicVersion\">Graphic 93228 Version 1.0</div></div></div>"},"93229":{"type":"graphic_picture","displayName":"AIH interface hepatitis","title":"Autoimmune hepatitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Autoimmune hepatitis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93229_AIH_interface_hepatitis_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A portal tract is shown and is expanded secondary to dense chronic mononuclear inflammation composed mostly of plasma cells and some lymphocytes. Note that the edge of this portal tract is irregular. This is due to interface hepatitis.</div><div id=\"graphicVersion\">Graphic 93229 Version 1.0</div></div></div>"},"93230":{"type":"graphic_picture","displayName":"AIH plasma cells","title":"Autoimmune hepatitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Autoimmune hepatitis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93230_AIH_plasma_cells_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power photomicrograph of a portal tract showing that the predominant cell population is made up of plasma cells (arrows). Plasma cells are characterized by eccentric nuclei, a clock-face chromatin pattern, and paranuclear clearing, known as a Hof.</div><div id=\"graphicVersion\">Graphic 93230 Version 1.0</div></div></div>"},"93231":{"type":"graphic_picture","displayName":"AIH severe interface hepatitis","title":"Autoimmune hepatitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Autoimmune hepatitis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93231_AIH_severe_interface_hepat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An example of interface hepatitis (arrows). Note that the inflammatory cells appear to surround individual or small groups of hepatocytes at the limiting plate. When interface hepatitis is severe, as in this case, the inflammatory cells go beyond the limiting plate and into the rest of the lobules.</div><div id=\"graphicVersion\">Graphic 93231 Version 1.0</div></div></div>"},"93233":{"type":"graphic_picture","displayName":"AIH with cirrhosis","title":"Autoimmune hepatitis with cirrhosis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Autoimmune hepatitis with cirrhosis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93233_AIH_with_cirrhosis_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Part of a cirrhotic nodule is portrayed (arrow). Note that the edge of the nodule is somewhat rounded and that the nodule is surrounded by fibrosis. As is typical for autoimmune hepatitis, the inflammatory cells consist of plasma cells.</div><div id=\"graphicVersion\">Graphic 93233 Version 1.0</div></div></div>"},"93235":{"type":"graphic_picture","displayName":"Acetaminophen toxicity coagulative necrosis","title":"Acetaminophen toxicity","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Acetaminophen toxicity</div><div class=\"cntnt\"><img style=\"width:590px; height:441px;\" src=\"images/GAST/93235_Acetaminophen_tox_coag_necr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrows point to hepatocytes that are undergoing coagulative necrosis in the centrilobular area, typical for acetaminophen toxicity. As shown in the photo, the affected hepatocytes have lost their nuclei and appear mummified.</div><div id=\"graphicVersion\">Graphic 93235 Version 1.0</div></div></div>"},"93236":{"type":"graphic_table","displayName":"Stress fractures associated sports","title":"Stress fractures associated with particular sports","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stress fractures associated with particular sports</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Sport</td> <td class=\"subtitle1\">High risk fracture</td> <td class=\"subtitle1\">Low risk fracture</td> </tr> <tr> <td>Baseball (pitchers)</td> <td>&nbsp;</td> <td>Humerus, scapula</td> </tr> <tr> <td>Basketball</td> <td>Fifth metatarsal</td> <td>Tibia</td> </tr> <tr> <td>Cheerleading</td> <td>Pars interarticularis</td> <td>Clavicle, radius, scaphoid</td> </tr> <tr> <td>Dance</td> <td>Pars interarticularis; sesamoids</td> <td>Tibia, fibula, navicular, metatarsals</td> </tr> <tr> <td>(American) football</td> <td>Pars interarticularis; fifth metatarsal</td> <td>Tibia</td> </tr> <tr> <td>Gymnastics</td> <td>Pars interarticularis; navicular</td> <td>Radius, scaphoid, midfoot</td> </tr> <tr> <td>Rowing</td> <td>&nbsp;</td> <td>Clavicle, rib</td> </tr> <tr> <td>Running &#38; track</td> <td>&nbsp;</td> <td>Metatarsals, fibula, tibia</td> </tr> <tr> <td>Skating</td> <td>Navicular</td> <td>Tibia, fibula, metatarsals</td> </tr> <tr> <td>Skiing (cross-country)</td> <td>Sesamoids</td> <td>Tibia </td> </tr> <tr> <td>Soccer (football)</td> <td>Femoral neck</td> <td>Tibia, tarsals, metatarsals</td> </tr> <tr> <td>Softball (fast-pitch)</td> <td>&nbsp;</td> <td>Rib, ulna, humerus, metacarpals</td> </tr> <tr> <td>Tennis</td> <td>Pars interarticularis</td> <td>Rib, tibia</td> </tr> <tr> <td>Volleyball</td> <td>Pars interarticularis</td> <td>Metatarsals, tibia</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Netter's Sports Medicine. Madden C, Putukian M, Young C, McCarty E (Eds), Philadelphia: Elsevier, 2010.</div><div id=\"graphicVersion\">Graphic 93236 Version 2.0</div></div></div>"},"93240":{"type":"graphic_diagnosticimage","displayName":"Imaging metastatic melanoma to liver","title":"Melanoma metastatic to liver by CT and angiography","html":"<div class=\"graphic\"><div style=\"width: 621px\" class=\"figure\"><div class=\"ttl\">Melanoma metastatic to liver by CT and angiography</div><div class=\"cntnt\"><img style=\"width:601px; height:308px;\" src=\"images/RADIOL/93240_Img_metastat_melan_liv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT scan through the liver (A) shows diffuse homogeneous enhancement (arrow) and ring enhancement patterns of metastatic melanoma. Image B shows arterial enhancement of liver metastases (arrows). The lesions are better appreciated on delayed imaging (C arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93240 Version 3.0</div></div></div>"},"93243":{"type":"graphic_diagnosticimage","displayName":"TIPS placement","title":"Transjugular intrahepatic portosystemic shunt (TIPS) placement","html":"<div class=\"graphic\"><div style=\"width: 607px\" class=\"figure\"><div class=\"ttl\">Transjugular intrahepatic portosystemic shunt (TIPS) placement</div><div class=\"cntnt\"><img style=\"width:587px; height:518px;\" src=\"images/RADIOL/93243_TIPS_procedure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A portal venogram performed via a transjugular approach during a TIPS procedure shows the catheter in the inferior vena cava (arrow) after placement of the stent (between arrowheads). The portal vein (asterisk), the umbilical vein (paragraph symbol), and a gastric varix (diamond symbol) are filled with contrast.<br />(B) Magnified view of the stent with the proximal portion in the hepatic vein (arrowhead) and the distal portion in the intrahepatic portion of the portal vein (arrow).</div><div id=\"graphicVersion\">Graphic 93243 Version 3.0</div></div></div>"},"93244":{"type":"graphic_table","displayName":"Causes of an elevated serum ACE level","title":"Causes of an elevated serum angiotensin converting enzyme (ACE) level","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of an elevated serum angiotensin converting enzyme (ACE) level</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Asbestosis</td> </tr> <tr> <td>Beryllium disease</td> </tr> <tr> <td>Coccidioidomycosis</td> </tr> <tr> <td>Diabetes mellitus</td> </tr> <tr> <td>Gaucher disease</td> </tr> <tr> <td>Hodgkin disease</td> </tr> <tr> <td>Hypersensitivity pneumonitis</td> </tr> <tr> <td>Hyperthyroidism</td> </tr> <tr> <td>Leprosy</td> </tr> <tr> <td>Lung cancer</td> </tr> <tr> <td>Primary biliary cirrhosis</td> </tr> <tr> <td>Sarcoidosis</td> </tr> <tr> <td>Silicosis</td> </tr> <tr> <td>Tuberculosis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Source: Studdy PR, Lapworth R, Bird R. Angiotensin-converting enzyme and its clinical significance: A review. J Clin Pathol 1983; 36:938.</div><div id=\"graphicVersion\">Graphic 93244 Version 1.0</div></div></div>"},"93247":{"type":"graphic_algorithm","displayName":"Ventilator-associated condition","title":"Ventilator-associated condition (VAC)","html":"<div class=\"graphic\"><div style=\"width: 509px\" class=\"figure\"><div class=\"ttl\">Ventilator-associated condition (VAC)</div><div class=\"cntnt\"><img style=\"width:489px; height:239px;\" src=\"images/PULM/93247_Ventilator_associ_condition.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">FiO<sub>2</sub>: fraction of inspired oxygen; PEEP: positive end expiratory pressure; VAE: ventilator-associated event.<br />* Daily minimum defined by lowest value of FiO<sub>2</sub> or PEEP during a calendar day that is maintained for at least one hour.<br />&para; Daily minimum PEEP values of 0 to 5 cm H<sub>2</sub>O are considered equivalent for the purposes of VAE surveillance.</div><div class=\"graphic_reference\">Reproduced from: National Healthcare Safety Network (NHSN). Surveillance for Ventilator-associated Events. Device-associated Module: Ventilator-Associated Event Protocol, January 2014. Centers for Disease Control and Prevention. Available at: <a href=\"http://www.cdc.gov/nhsn/acute-care-hospital/vae/\" spellcheck=\"true\" target=\"_blank\">http://www.cdc.gov/nhsn/acute-care-hospital/vae/</a> (Accessed August 22, 2014).</div><div id=\"graphicVersion\">Graphic 93247 Version 2.0</div></div></div>"},"93248":{"type":"graphic_algorithm","displayName":"Infection-related ventilator-associated complication","title":"Infection-related ventilator-associated complication (IVAC)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infection-related ventilator-associated complication (IVAC)</div><div class=\"cntnt\"><img style=\"width:355px; height:217px;\" src=\"images/PULM/93248_Infec_relat_vent_assoc_comp.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">VAC: ventilator-associated condition.</div><div class=\"graphic_reference\">Reproduced from: National Healthcare Safety Network (NHSN). Surveillance for Ventilator-associated Events. Device-associated Module: Ventilator-Associated Event Protocol, January 2014. Centers for Disease Control and Prevention. Available at: <a href=\"http://www.cdc.gov/nhsn/acute-care-hospital/vae/\" spellcheck=\"true\" target=\"_blank\">http://www.cdc.gov/nhsn/acute-care-hospital/vae/</a> (Accessed August 22, 2014).</div><div id=\"graphicVersion\">Graphic 93248 Version 1.0</div></div></div>"},"93249":{"type":"graphic_algorithm","displayName":"Possible ventilator-associated pneumonia","title":"Possible ventilator-associated pneumonia (VAP)","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Possible ventilator-associated pneumonia (VAP)</div><div class=\"cntnt\"><img style=\"width:505px; height:271px;\" src=\"images/PULM/93249_Possib_ventil_assoc_pneumon.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">VAC: ventilator-associated condition; IVAC: infection-related ventilator-associated complication; VAE: ventilator-associated event.<br />* Excludes the following:<br /><UL>&#xD;&#xA;<LI>​Normal respiratory/oral flora, mixed respiratory/oral flora, or equivalent</LI>&#xD;&#xA;<LI><EM>Candida</EM> species or yeast not otherwise specified</LI>&#xD;&#xA;<LI>Coagulase-negative <EM>Staphylococcus </EM>species</LI>&#xD;&#xA;<LI><EM>Enterococcus</EM> species</LI></UL></div><div class=\"graphic_reference\">Reproduced from: National Healthcare Safety Network (NHSN). Surveillance for Ventilator-associated Events. Device-associated Module: Ventilator-Associated Event Protocol, January 2014. Centers for Disease Control and Prevention. Available at: <a href=\"http://www.cdc.gov/nhsn/acute-care-hospital/vae/\" spellcheck=\"true\" target=\"_blank\">http://www.cdc.gov/nhsn/acute-care-hospital/vae/</a> (Accessed August 22, 2014).</div><div id=\"graphicVersion\">Graphic 93249 Version 1.0</div></div></div>"},"93253":{"type":"graphic_algorithm","displayName":"Probable ventilator-associated pneumonia","title":"Probable ventilator-associated pneumonia (VAP)","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Probable ventilator-associated pneumonia (VAP)</div><div class=\"cntnt\"><img style=\"width:475px; height:406px;\" src=\"images/PULM/93253_Prob_ventil_assoc_pneumonia.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">VAC: ventilator-associated condition; IVAC: infection-related ventilator-associated complication; CFU: colony forming units.<br />* Same organism exclusions as noted for possible VAP.</div><div class=\"graphic_reference\">Reproduced from: National Healthcare Safety Network (NHSN). Surveillance for Ventilator-associated Events. Device-associated Module: Ventilator-Associated Event Protocol, January 2014. Centers for Disease Control and Prevention. Available at: <A spellcheck=true href=\"http://www.cdc.gov/nhsn/acute-care-hospital/vae/\" target=_blank>http://www.cdc.gov/nhsn/acute-care-hospital/vae/</A> (Accessed August 22, 2014).</div><div id=\"graphicVersion\">Graphic 93253 Version 1.0</div></div></div>"},"93255":{"type":"graphic_figure","displayName":"Typical CPB setup","title":"Typical cardiopulmonary bypass setup","html":"<div class=\"graphic\"><div style=\"width: 707px\" class=\"figure\"><div class=\"ttl\">Typical cardiopulmonary bypass setup</div><div class=\"cntnt\"><img style=\"width:687px; height:610px;\" src=\"images/ANEST/93255_Typcl_CPB_set_up.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">ALF: arterial line filter; K+: cardioplegia solution; LV: left ventricular.</div><div class=\"graphic_reference\">Reproduced with permission from: Bruce Searles, MS, CCP, and Kit Hefner, MS, SUNY Upstate Medical University.</div><div id=\"graphicVersion\">Graphic 93255 Version 5.0</div></div></div>"},"93257":{"type":"graphic_diagnosticimage","displayName":"Angiography cavernous transformation of portal vein","title":"Cavernous transformation of portal vein on arteriography","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Cavernous transformation of portal vein on arteriography</div><div class=\"cntnt\"><img style=\"width:586px; height:455px;\" src=\"images/RADIOL/93257_Angigr_cav_trn_prt_vein.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The venous phase of a mesenteric angiogram shows an occluded portal vein (arrow) with venous collaterals in the porta hepatis (arrowhead).</div><div id=\"graphicVersion\">Graphic 93257 Version 1.0</div></div></div>"},"93258":{"type":"graphic_picture","displayName":"Upper airway stimulation device","title":"Upper airway stimulation device for obstructive sleep apnea","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Upper airway&nbsp;stimulation device for obstructive sleep apnea</div><div class=\"cntnt\"><img style=\"width:532px; height:305px;\" src=\"images/PULM/93258_Hypoglossal_nerve_stimulation_device.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 93258 Version 3.0</div></div></div>"},"93259":{"type":"graphic_waveform","displayName":"Electrocardiographic features of Wolff Parkinson White syndrome","title":"Electrocardiographic features of Wolff Parkinson White (WPW) syndrome","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Electrocardiographic features of Wolff Parkinson White (WPW) syndrome</div><div class=\"cntnt\"><img style=\"width:583px; height:598px;\" src=\"images/EM/93259_ECG_Wolff_Parkinson_White.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A)12 lead&nbsp;electrocardiogram demonstrating the classic findings of Wolff-Parkinson-White syndrome (WPW) with short PR interval, delta wave, and prolonged QRS. <br />(B) Single lead showing WPW with short PR interval (80 ms), delta wave, and prolonged QRS (120 ms).</div><div class=\"graphic_reference\">Courtesy of Jack C Salerno MD.</div><div id=\"graphicVersion\">Graphic 93259 Version 2.0</div></div></div>"},"93260":{"type":"graphic_table","displayName":"Oral direct thrombin and factor Xa inhibitors","title":"Perioperative management of oral direct thrombin inhibitors and factor Xa inhibitors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Perioperative management of oral direct thrombin inhibitors and factor Xa inhibitors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Anticoagulant</td> <td class=\"subtitle1\" rowspan=\"2\">Renal function and dose</td> <td class=\"subtitle1\" colspan=\"2\"> <p>Interval between last dose and procedure</p> NOTE: No anticoagulant is administered the day of the procedure</td> <td class=\"subtitle1\" colspan=\"2\">Resumption after procedure</td> </tr> <tr> <td class=\"subtitle2\">High bleeding risk</td> <td class=\"subtitle2\">Low bleeding risk</td> <td class=\"subtitle2\">High bleeding risk</td> <td class=\"subtitle2\">Low bleeding risk</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Dabigatran</td> <td> <p>CrCl &#62;50 mL/minute</p> Dose 150 mg twice daily</td> <td>Give last dose three days before procedure (ie, skip four doses on the two days before the procedure)</td> <td>Give last dose two days before procedure (ie, skip two doses on the day before the procedure)</td> <td style=\"vertical-align: middle;\" rowspan=\"8\">Resume 48 to 72 hours after surgery (ie, postoperative day 2 to 3)</td> <td style=\"vertical-align: middle;\" rowspan=\"8\">Resume 24 hours after surgery (ie, postoperative day 1)</td> </tr> <tr> <td class=\"divider_bottom\"> <p>CrCl 30 to 50 mL/minute</p> Dose 150 mg twice daily</td> <td class=\"divider_bottom\">Give last dose five days before procedure (ie, skip eight doses on the four days before the procedure)</td> <td class=\"divider_bottom\">Give last dose three days before procedure (ie, skip four doses on the two days before the procedure)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Rivaroxaban</td> <td> <p>CrCl &#62;50 mL/minute</p> Dose 20 mg once daily</td> <td class=\"divider_bottom\" rowspan=\"2\">Give last dose three days before procedure (ie, skip two doses on the two days before the procedure)</td> <td class=\"divider_bottom\" rowspan=\"2\">Give last dose two days before procedure (ie, skip one dose on the day before the procedure)</td> </tr> <tr> <td class=\"divider_bottom\"> <p>CrCl 30 to 50 mL/minute</p> Dose 15 mg once daily</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Apixaban</td> <td> <p>CrCl &#62;50 mL/minute</p> Dose 5 mg twice daily</td> <td class=\"divider_bottom\" rowspan=\"2\">Give last dose three days before procedure (ie, skip four doses on the two days before the procedure)</td> <td class=\"divider_bottom\" rowspan=\"2\">Give last dose two days before procedure (ie, skip two doses on the day before the procedure)</td> </tr> <tr class=\"divider_bottom\"> <td> <p>CrCl &#8804;50 mL/minute</p> Dose 2.5 mg twice daily</td> </tr> <tr> <td rowspan=\"2\">Edoxaban</td> <td> <p>CrCl 50 to 95 mL/minute</p> Dose 60 mg once daily</td> <td rowspan=\"2\">Give the last dose three days before the procedure (ie, skip two doses on the two days before the procedure)</td> <td rowspan=\"2\">Give the last dose two days before the procedure (ie, skip one dose on the day before the procedure)</td> </tr> <tr> <td> <p>CrCl &#8804;50 mL/minute*</p> Dose 30 mg once daily</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Bleeding risk is determined primarily by the type of surgery; patient comorbidities may also play a role. In patients undergoing neuraxial anesthesia or a very high bleeding risk procedure, a longer period of interruption may be warranted. In many low bleeding risk procedures, the anticoagulant does not need to be interrupted. Bridging anticoagulation may be appropriate preoperatively in patients with a very high thromboembolic risk who require more prolonged interruption of the anticoagulant (eg, for renal insufficiency) and/or postoperatively in patients who are unable to resume the anticoagulant (eg, unable to take oral medication due to intestinal ileus). Refer to the UpToDate topics on perioperative management of patients receiving anticoagulants for further details.</div><div class=\"graphic_footnotes\">CrCl: creatinine clearance. <br />* Product information varies in different countries regarding a lower limit of CrCl below which the drug should not be used.</div><div id=\"graphicVersion\">Graphic 93260 Version 9.0</div></div></div>"},"93261":{"type":"graphic_table","displayName":"Range of diagnostic criteria for gestational diabetes","title":"Range of diagnostic criteria for gestational diabetes mellitus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Range of diagnostic criteria for gestational diabetes mellitus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"5\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Approach</td> <td class=\"subtitle1\">Criteria</td> <td class=\"subtitle1\">Fasting mg/dL</td> <td class=\"subtitle1\">One-hour mg/dL</td> <td class=\"subtitle1\">Two-hour mg/dL</td> <td class=\"subtitle1\">Three-hour mg/dL</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Two step (100-gram load)</td> <td>Carpenter and Coustan</td> <td>95 (5.3 mmol/L)</td> <td>180 (10.0 mmol/L)</td> <td>155 (8.6 mmol/L)</td> <td>140 (7.8 mmol/L)</td> </tr> <tr class=\"divider_bottom\"> <td>NDDG</td> <td>105 (5.8 mmol/L)</td> <td>190 (10.6 mmol/L)</td> <td>165 (9.2 mmol/L)</td> <td>145 (8.0 mmol/L)</td> </tr> <tr class=\"divider_bottom\"> <td>Two step (75-gram load)</td> <td>CDA</td> <td>95 (5.3 mmol/L)</td> <td>191 (10.6 mmol/L)</td> <td>160 (8.9 mmol/L)</td> <td>&nbsp;</td> </tr> <tr> <td rowspan=\"2\">One step (75-gram load)</td> <td>WHO</td> <td>92 to 125 (5.1 to 6.9 mmol/L)</td> <td>180 (10.0 mmol/L)</td> <td>153 to 199 (8.5 to 11 mmol/L)</td> <td>&nbsp;</td> </tr> <tr> <td>IADPSG</td> <td>92 to 125 (5.1 mmol/L)</td> <td>180 (10.0 mmol/L)</td> <td>153 (8.5 mmol/L)</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These thresholds are for diagnosis of \"gestational diabetes.\" Diagnosis of \"overt diabetes\" and \"diabetes in pregnancy\" are based on different criteria (eg, IADPSG: fasting blood glucose ≥126 mg/dL [7.0 mmol/L] is consistent with \"overt diabetes\"; WHO: fasting blood glucose ≥126 mg/dL [7.0 mmol/L] or&nbsp;two-hour glucose ≥200 mg/dL [11.1 mmol/L] following a 75-gram oral glucose load is consistent with \"diabetes in pregnancy\").</div><div class=\"graphic_footnotes\">NDDG: National Diabetes Data Group; CDA: Canadian Diabetes Association; WHO: World Health Organization; IADPSG: International Association of Diabetes and Pregnancy Study Groups.</div><div class=\"graphic_reference\">Data from: VanDorsten JP, Dodson WC, Espeland MA, et al. National Institutes of Health consensus development conference statement: Diagnosing gestational diabetes mellitus. NIH Consens State Sci Statements 2013; 29:1.</div><div id=\"graphicVersion\">Graphic 93261 Version 6.0</div></div></div>"},"93263":{"type":"graphic_diagnosticimage","displayName":"Arteriogram SMA emboli","title":"Emboli to SMA on arteriography","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Emboli to SMA on arteriography</div><div class=\"cntnt\"><img style=\"width:597px; height:429px;\" src=\"images/RADIOL/93263_Arteriogram_SMA_emboli.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A selective arteriogram of the superior mesenteric artery (Image A) shows multiple emboli (arrows). Image B is a magnified view of the embolus of the ileocolic branch of the SMA (arrow).</div><div class=\"graphic_footnotes\">SMA: superior mesenteric artery.</div><div id=\"graphicVersion\">Graphic 93263 Version 2.0</div></div></div>"},"93265":{"type":"graphic_diagnosticimage","displayName":"Aortogram 3 vessel mesenteric disease","title":"3 vessel mesenteric disease on aortography","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">3 vessel mesenteric disease on aortography</div><div class=\"cntnt\"><img style=\"width:598px; height:459px;\" src=\"images/RADIOL/93265_Aorto_3_vess_mesen_dis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A lateral aortogram (A) shows severe stenosis of the celiac axis (arrowhead), occlusion of the SMA (arrow), and nonvisualization of the IMA. Image B is a magnified view and shows severe stenosis of the celiac axis (arrowhead) and occlusion of the SMA (arrow).</div><div class=\"graphic_footnotes\">SMA: superior mesenteric artery; IMA: inferior mesenteric artery.</div><div id=\"graphicVersion\">Graphic 93265 Version 2.0</div></div></div>"},"93266":{"type":"graphic_diagnosticimage","displayName":"Ultrasounds of perinatal testicular torsion","title":"Ultrasounds of perinatal testicular torsion in two neonates","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasounds of perinatal testicular torsion in two neonates</div><div class=\"cntnt\"><img style=\"width:434px; height:598px;\" src=\"images/PEDS/93266_US_perinatal_testic_torsion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Doppler flow ultrasound of a neonate with left perinatal testicular torsion. Note the lack of flow to the left testis (no color) and normal flow to the right testis. There is also a right hydrocele in the scrotal sac.<br />(B) Ultrasound of a neonate with right perinatal testicular torsion. The right testis&nbsp;has a&nbsp;heterogenous appearance&nbsp;on ultrasound and was found to be nonviable at the time of delayed right orchiectomy.</div><div class=\"graphic_footnotes\">RT: right; LT: left.</div><div id=\"graphicVersion\">Graphic 93266 Version 1.0</div></div></div>"},"93267":{"type":"graphic_diagnosticimage","displayName":"Nonocclusive mesenteric ischemia on angiography","title":"Nonocclusive mesenteric ischemia on angiography","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Nonocclusive mesenteric ischemia on angiography</div><div class=\"cntnt\"><img style=\"width:597px; height:372px;\" src=\"images/RADIOL/93267_Angi_non_occl_mes_isch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The A-P view aortogram (A)&nbsp;is of a patient with severe hypotension and&nbsp;shows diffuse spasm of the aorta and all the visceral vessels of the abdomen. Ischemic small bowel (arrowheads) was resected. Normal visceral perfusion is demonstrated in image B.</div><div class=\"graphic_footnotes\">A-P: anteroposterior.</div><div id=\"graphicVersion\">Graphic 93267 Version 2.0</div></div></div>"},"93268":{"type":"graphic_figure","displayName":"Central pancreatectomy for pancreatic injury","title":"Central pancreatectomy for pancreatic injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Central pancreatectomy for pancreatic injury</div><div class=\"cntnt\"><img style=\"width:422px; height:572px;\" src=\"images/SURG/93268_Central_pancreatectomy_for_pancreatic_injury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Central pancreatectomy has&nbsp;an&nbsp;advantage over distal or subtotal pancreatectomy in managing pancreatic&nbsp;injury. It&nbsp;preserves the tail of the pancreas and its endocrine and exocrine function, as well as the spleen, which is often sacrificed&nbsp;with distal pancreatectomy.</div><div id=\"graphicVersion\">Graphic 93268 Version 2.0</div></div></div>"},"93269":{"type":"graphic_diagnosticimage","displayName":"CT celiac artery compression collaterals","title":"Celiac artery compression syndrome on CT","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Celiac artery compression syndrome on CT</div><div class=\"cntnt\"><img style=\"width:518px; height:519px;\" src=\"images/RADIOL/93269_CT_cel_art_cmp_collats.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A coronal reconstruction of a CT shows a large pancreaticoduodenal artery (arrow) arising from the SMA and acting as collateral blood supply to the celiac artery, which has a stenosis at its origin.</div><div class=\"graphic_footnotes\">CT: computed tomography; SMA: superior mesenteric artery.</div><div id=\"graphicVersion\">Graphic 93269 Version 1.0</div></div></div>"},"93270":{"type":"graphic_diagnosticimage","displayName":"Imaging celiac artery compression syndrome","title":"Celiac artery compression syndrome on CT and aortography","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Celiac artery compression syndrome on CT and aortography</div><div class=\"cntnt\"><img style=\"width:507px; height:600px;\" src=\"images/RADIOL/93270_Img_cel_arte_comp_synd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A sagittal reconstruction of a CT scan (A) shows compression of the origin of the celiac axis (arrow). An axial image of the abdomen (B) shows the extremely narrowed celiac axis posterior to the median arcuate ligament. The median arcuate ligament is formed by the fusion of the two crura. Image C is a magnified view of B, and shows the right and left crura (arrowheads) behind which lies the compressed artery (arrow). Image D is a lateral projection of an aortogram and shows a stenosis of the celiac axis on its superior aspect caused by the median arcuate ligament.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93270 Version 1.0</div></div></div>"},"93272":{"type":"graphic_figure","displayName":"List of AKI biomarkers","title":"Use of biomarkers in diagnosis of AKI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Use of biomarkers in diagnosis of AKI</div><div class=\"cntnt\"><img style=\"width:365px; height:272px;\" src=\"images/NEPH/93272_List_AKI_biomarkers.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagnosis of AKI will be facilitated in the future using RIFLE/AKIN (or KDIGO) criterion combined with biomarker criterion. Increasing biomarker severity associated with increasing kidney damage is denoted by +/++/+++.</div><div class=\"graphic_footnotes\">AKI: acute kidney injury; AKIN: acute kidney injury network; RIFLE: acute dialysis quality initiative; KDIGO: Kidney Disease: Improving Global Outcomes.</div><div class=\"graphic_reference\">Reproduced with permission from the Acute Dialysis Quality Initiative Ten. <a href=\"http://www.adqi.org/\" target=_blank>www.adqi.org</a>. Copyright © 2013.</div><div id=\"graphicVersion\">Graphic 93272 Version 1.0</div></div></div>"},"93274":{"type":"graphic_picture","displayName":"Acetaminophen toxicity centrilobular necrosis","title":"Acetaminophen toxicity","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Acetaminophen toxicity</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93274_Acetamin_tox_centr_necrosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this photo, there is diffuse involvement of hepatocytes. Hepatocytes around the central venule (arrows) as well as those in zone 2 and zone 1 are affected. Note that the cytoplasm of the affected hepatocytes is eosinophilic (dark pink), a finding typical of this type of injury. The few remaining viable hepatocytes contain steatosis.</div><div id=\"graphicVersion\">Graphic 93274 Version 1.0</div></div></div>"},"93276":{"type":"graphic_picture","displayName":"Right heart failure liver low power","title":"Right-sided heart failure","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Right-sided heart failure</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93276_Right_HF_liver_low_power.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low-power magnification showing the portal tract in the center to be relatively normal, whereas the sinusoids appear widened and filled with blood (congestion).</div><div id=\"graphicVersion\">Graphic 93276 Version 1.0</div></div></div>"},"93277":{"type":"graphic_picture","displayName":"Right heart failure liver high power","title":"Right-sided heart failure","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Right-sided heart failure</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93277_Right_HF_liver_high_power.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power magnification showing sinusoidal dilatation (arrowheads). Within dilated sinusoids, red blood cells are clumped and appear to clog the sinusoidal spaces, findings indicative of severe congestion (arrows).</div><div id=\"graphicVersion\">Graphic 93277 Version 1.0</div></div></div>"},"93279":{"type":"graphic_picture","displayName":"Budd-Chiari H and E","title":"Chronic Budd-Chiari with cirrhosis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Chronic Budd-Chiari with cirrhosis</div><div class=\"cntnt\"><img style=\"width:756px; height:515px;\" src=\"images/GAST/93279_Budd_Chiari_H_and_E.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The biopsy shows distortion of the hepatic architecture by irregular bands of fibrosis (arrows). Patchy areas of the remaining hepatic parenchyma are seen.</div><div id=\"graphicVersion\">Graphic 93279 Version 2.0</div></div></div>"},"93280":{"type":"graphic_picture","displayName":"Budd-Chiari nodules trichrome","title":"Chronic Budd-Chiari syndrome with cirrhosis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Chronic Budd-Chiari syndrome with cirrhosis</div><div class=\"cntnt\"><img style=\"width:590px; height:590px;\" src=\"images/GAST/93280_Budd_Chiari_nodul_trichrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trichrome stain highlighting the dense fibrous tissue surrounding nodules, as well as intersecting through the parenchyma.</div><div id=\"graphicVersion\">Graphic 93280 Version 1.0</div></div></div>"},"93281":{"type":"graphic_picture","displayName":"Budd-Chiari fibrosis trichrome","title":"Chronic Budd-Chiari syndrome with cirrhosis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Chronic Budd-Chiari syndrome with cirrhosis</div><div class=\"cntnt\"><img style=\"width:590px; height:590px;\" src=\"images/GAST/93281_Budd_Chiari_fibro_trichrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trichrome stain demonstrating perisinusoidal fibrosis (arrows) and marked atrophy resulting in thinning of hepatocyte plates. Note that the sinusoidal spaces are markedly widened.</div><div id=\"graphicVersion\">Graphic 93281 Version 1.0</div></div></div>"},"93282":{"type":"graphic_picture","displayName":"ALD diffuse steatosis","title":"Alcoholic fatty liver","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Alcoholic fatty liver</div><div class=\"cntnt\"><img style=\"width:590px; height:472px;\" src=\"images/GAST/93282_ALD_diffuse_steatosis_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe steatosis, macrovesicular type. Hepatocytes containing fat vacuoles are present throughout the lobule, even those hepatocytes adjacent to the portal tract (right side of the photo). Macrovesicular steatosis is characterized by a single large vacuole occupying the entire hepatocyte and thereby pushing the nucleus to the edge of the cell. Macrovesicular steatosis can also be seen in nonalcoholic fatty liver disease.</div><div id=\"graphicVersion\">Graphic 93282 Version 1.0</div></div></div>"},"93284":{"type":"graphic_picture","displayName":"ALD cirrhosis","title":"Alcoholic steatohepatitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Alcoholic steatohepatitis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93284_ALD_cirrhosis_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this case, there are only a few hepatocytes that contain steatosis; however, there is also ballooning degeneration noted in some of these. The rest of the hepatocytes are devoid of steatosis. There is extensive fibrosis present, with fibrous septa surrounding micronodules.</div><div id=\"graphicVersion\">Graphic 93284 Version 1.0</div></div></div>"},"93285":{"type":"graphic_picture","displayName":"ALD Mallory hyaline","title":"Alcoholic steatohepatitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Alcoholic steatohepatitis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93285_ALD_Mallory_hyaline_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrows point to swollen (ballooned) hepatocytes that contain Mallory-Denk hyaline. Mallory-Denk hyaline is&nbsp;composed of damaged intermediate cytokeratin filaments, which make up the scaffolding of the hepatocytes.</div><div id=\"graphicVersion\">Graphic 93285 Version 1.0</div></div></div>"},"93290":{"type":"graphic_picture","displayName":"Stevens-Johnson syndrome/toxic epidermal necrolysis eyes","title":"Stevens-Johnson syndrome/toxic epidermal necrolysis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Stevens-Johnson syndrome/toxic epidermal necrolysis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/93290_SJSTENeyes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Marked conjunctival injection and discharge in a patient with Stevens-Johnson syndrome/toxic epidermal necrolysis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 93290 Version 2.0</div></div></div>"},"93294":{"type":"graphic_picture","displayName":"ALD bridging fibrosis trichrome","title":"Alcoholic cirrhosis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Alcoholic cirrhosis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93294_ALD_bridg_fibros_trichrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trichrome stain highlighting marked distortion of the hepatic architecture by bridging fibrous septa and nodule formation. Note the chicken-wire fibrosis.</div><div id=\"graphicVersion\">Graphic 93294 Version 1.0</div></div></div>"},"93295":{"type":"graphic_picture","displayName":"ALD ballooning degeneration","title":"Alcoholic steatohepatitis with ballooning degeneration","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Alcoholic steatohepatitis with ballooning degeneration</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93295_ALD_balloon_degeneration_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ballooning degeneration is a result of damage to the cytoskeleton of the hepatocyte resulting in swelling of the cell. The cell organelles, in particular the mitochondria, are susceptible to injury from toxins, in this case ethanol.</div><div id=\"graphicVersion\">Graphic 93295 Version 1.0</div></div></div>"},"93296":{"type":"graphic_picture","displayName":"ALD chicken-wire fibrosis","title":"Alcoholic steatohepatitis superimposed on chronic liver disease","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Alcoholic steatohepatitis superimposed on chronic liver disease</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93296_ALD_chicken_wire_fibros_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chicken-wire fibrosis is a descriptive term typically applied to a single hepatocyte or small groups of hepatocytes completely surrounded by delicate fibrous septa (arrows).</div><div id=\"graphicVersion\">Graphic 93296 Version 1.0</div></div></div>"},"93297":{"type":"graphic_picture","displayName":"ALD perisinusoidal fibrosis","title":"Alcoholic steatohepatitis with chicken-wire fibrosis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Alcoholic steatohepatitis with chicken-wire fibrosis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93297_ALD_perisinusoidal_fibr_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The central venule (arrow) is narrowed by fibrous tissue that surrounds it. This is known as central hyaline sclerosis. Arrowheads point to pericellular and perisinusoidal fibrosis that result in the appearance of the characteristic chicken-wire fibrosis.</div><div id=\"graphicVersion\">Graphic 93297 Version 1.0</div></div></div>"},"93298":{"type":"graphic_picture","displayName":"ALD Mallory-Denk hyaline in ballooned hepatocytes","title":"Alcoholic steatohepatitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Alcoholic steatohepatitis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93298_ALD_MD_hyaline_balloon_hepa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mallory-Denk hyaline appears like ropy or irregular intracytoplasmic material that stains intensely red or purple on hematoxylin and eosin stain. The Mallory-Denk hyaline is seen in the context of ballooned hepatocytes.</div><div id=\"graphicVersion\">Graphic 93298 Version 1.0</div></div></div>"},"93299":{"type":"graphic_picture","displayName":"NASH mild steatosis","title":"Nonalcoholic steatohepatitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Nonalcoholic steatohepatitis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93299_NASH_mild_steatosis_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photo shows mild steatosis and Mallory-Denk hyalines (arrows). Compared with alcoholic steatohepatitis, in patients with nonalcoholic steatohepatitis there are often fewer Mallory-Denk hyalines, and these are not as fully developed. In addition to steatosis and Mallory-Denk hyalines, some inflammatory cells may also be seen in the lobules (arrowheads).</div><div id=\"graphicVersion\">Graphic 93299 Version 1.0</div></div></div>"},"93300":{"type":"graphic_picture","displayName":"NASH trichrome stain","title":"Nonalcoholic steatohepatitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Nonalcoholic steatohepatitis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93300_NASH_trichrome_stain_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nonalcoholic steatohepatitis on trichrome stain. Note the Mallory-Denk hyalines, an aggregate of inflammatory cells (arrowhead), and delicate pericellular fibrosis (arrows) in a background of steatosis.</div><div id=\"graphicVersion\">Graphic 93300 Version 1.0</div></div></div>"},"93301":{"type":"graphic_picture","displayName":"Cholangitis fibrosis and inflammation","title":"Acute cholangitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Acute cholangitis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93301_Cholangitis_fibros_inflamm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A septal bile duct is shown surrounded by loose fibrous tissue (periductal fibrosis) and a mild infiltrate of inflammatory cells.</div><div id=\"graphicVersion\">Graphic 93301 Version 1.0</div></div></div>"},"93302":{"type":"graphic_picture","displayName":"Cholangitis trichrome","title":"Acute cholangitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Acute cholangitis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93302_Cholangitis_trichrome_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trichrome stain demonstrating that the fibrosis is loose and that the fibrous tissue fragments are being separated by edema. In this case, the fibrous tissue is deposited in irregular layers around the bile duct. The bile duct itself appears to be preserved.</div><div id=\"graphicVersion\">Graphic 93302 Version 1.0</div></div></div>"},"93303":{"type":"graphic_picture","displayName":"Cholangitis marginal-type ductular reaction","title":"Acute cholangitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Acute cholangitis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93303_Cholang_marg_ductular_react.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small portal tract with edema as exemplified by the separation of the portal structures. There are also scattered tissue fragments and a few inflammatory cells interspersed within. There is marginal-type ductular reaction (arrows), a finding that is typically seen in acute large-duct obstruction.</div><div id=\"graphicVersion\">Graphic 93303 Version 1.0</div></div></div>"},"93305":{"type":"graphic_figure","displayName":"Pre-exposure evaluation for health-care personnel ","title":"Pre-exposure evaluation for health-care personnel previously vaccinated with complete, ≥3-dose HepB vaccine series who have not had postvaccination serologic testing","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Pre-exposure evaluation for health-care personnel previously vaccinated with complete, ≥3-dose HepB vaccine series who have not had postvaccination serologic testing</div><div class=\"cntnt\"><img style=\"width:545px; height:396px;\" src=\"images/ID/93305_Pre_exp_eval_hlthcare_pers.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Should be performed 1-2 months after the last dose of vaccine using a quantitative method that allows detection of the protective concentration of anti-HBs. (&#8805;10 mIU/mL) (eg, enzyme-linked immunosorbent assay [ELISA]).<br /><span class=\"bullet\">&#8226;</span> A nonresponder is defined as a person with anti-HBs &#60;10 mIU/mL after &#8805;6 doses of HepB vaccine. Persons who do not have a protective concentration of anti-HBs after revaccination should be tested for HBsAg. If positive, the person should receive appropriate management or vaccination.</div><div class=\"graphic_reference\">Reproduced from: CDC Guidance for Evaluating Health-Care Personnel for Hepatitis B Virus Protection and for Administering Postexposure Management. MMWR Recomm Rep 2013; 62:1.</div><div id=\"graphicVersion\">Graphic 93305 Version 1.0</div></div></div>"},"93306":{"type":"graphic_table","displayName":"Postexposure management of health-care personnel after exposure","title":"Postexposure management of personnel after occupational percutaneous and mucosal exposure to blood and body fluids","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Postexposure management of personnel after occupational percutaneous and mucosal exposure to blood and body fluids</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Health-care personnel status</td> <td class=\"subtitle1\" colspan=\"2\">Postexposure testing</td> <td class=\"subtitle1\" colspan=\"2\">Postexposure prophylaxis</td> <td class=\"subtitle1\" rowspan=\"2\">Postvaccination serologic testing<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2\">Source patient (HBsAg)</td> <td class=\"subtitle2\">HCP testing (anti-HBs)</td> <td class=\"subtitle2\">HBIG*</td> <td class=\"subtitle2\">Vaccination</td> </tr> <tr class=\"divider_bottom\"> <td>Documented responder<sup>&#916;</sup> after complete series (&#8805;3 doses)</td> <td class=\"highlight_green_text centered\" style=\"vertical-align: middle;\" colspan=\"5\">No action needed</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Documented nonresponder<sup>&#9674;</sup> after 6 doses</td> <td>Positive/unknown</td> <td class=\"centered\">&ndash;<sup>&#167;</sup></td> <td>HBIG x2 separated by 1 month</td> <td class=\"centered\">&ndash;</td> <td>No</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td class=\"highlight_green_text centered\" colspan=\"4\">No action needed</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Response unknown after 3 doses</td> <td>Positive/unknown</td> <td>&#60;10 mIU/mL<sup>&#167;</sup></td> <td>HBIG x1</td> <td rowspan=\"2\">Initiate revaccination</td> <td rowspan=\"2\">Yes</td> </tr> <tr> <td>Negative</td> <td>&#60;10 mIU/mL</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>Any result</td> <td>&#8805;10 mIU/mL</td> <td class=\"highlight_green_text centered\" colspan=\"3\">No action needed</td> </tr> <tr> <td rowspan=\"2\">Unvaccinated/incompletely vaccinated or vaccine refusers</td> <td>Positive/unknown</td> <td class=\"centered\">&ndash;<sup>&#167;</sup></td> <td>HBIG x1</td> <td>Complete vaccination</td> <td>Yes</td> </tr> <tr> <td>Negative</td> <td class=\"centered\">&ndash;</td> <td>None</td> <td>Complete vaccination</td> <td>Yes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* HBIG should be administered intramuscularly as soon as possible after exposure when indicated. The effectiveness of HBIG when administered &gt;7 days after percutaneous, mucosal, or nonintact skin exposures is unknown. HBIG dosage is 0.06 mL/kg.<br />¶ Should be performed 1 to 2 months after the last dose of the HepB vaccine series (and 4 to 6 months after administration of HBIG to avoid detection of passively administered anti-HBs) using a quantitative method that allows detection of the protective concentration of anti-HBs (≥10 mIU/mL).<br />Δ A responder is defined as a person with anti-HBs ≥10 mIU/mL after ≥3 doses of HepB vaccine.<br /><FONT class=lozenge>◊</FONT> A nonresponder is defined as a person with anti-HBs &lt;10 mIU/mL after ≥6 doses of HepB vaccine.<br />§ HCP who have anti-HBs &lt;10 mIU/mL, or who are unvaccinated or incompletely vaccinated, and sustain an exposure to a source patient who is HBsAg-positive or has unknown HBsAg status, should undergo baseline testing for HBV infection as soon as possible after exposure, and follow-up testing approximately 6 months later. Initial baseline tests consist of total anti-HBc; testing at approximately 6 months consists of HBsAg and total anti-HBc.</div><div class=\"graphic_reference\">Reproduced from: CDC Guidance for Evaluating Health-Care Personnel for Hepatitis B Virus Protection and for Administering Postexposure Management. MMWR Recomm Rep 2013; 62:1.</div><div id=\"graphicVersion\">Graphic 93306 Version 2.0</div></div></div>"},"93307":{"type":"graphic_figure","displayName":"Global cholera cases reported to the World Health Organization","title":"Global cholera cases reported to the World Health Organization","html":"<div class=\"graphic\"><div style=\"width: 821px\" class=\"figure\"><div class=\"ttl\">Global cholera cases reported to the World Health Organization</div><div class=\"cntnt\"><img style=\"width:801px; height:489px;\" src=\"images/ID/93307_Global_cholera_cases_WHO.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There were no data listed for 1996.</div><div class=\"graphic_reference\">Reproduced with permission from: Global Health Observatory Data Repository. Cholera cases reported to WHO. World Health Organization, 2012. Copyright © 2012 World Health Organization. Available at: <A spellcheck=true href=\"http://www.who.int/gho/epidemic_diseases/cholera/cases/en/\" target=_blank>http://www.who.int/gho/epidemic_diseases/cholera/cases/en/</A>. (Accessed on October 7, 2014).</div><div id=\"graphicVersion\">Graphic 93307 Version 4.0</div></div></div>"},"93308":{"type":"graphic_table","displayName":"DDx splenic MZL","title":"Differential diagnosis of splenic marginal zone lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of splenic marginal zone lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Entity</td> <td class=\"subtitle1\" colspan=\"2\">Histology</td> <td class=\"subtitle1\" rowspan=\"2\">Immunophenotype</td> <td class=\"subtitle1\" rowspan=\"2\">Genetic features/other</td> </tr> <tr> <td class=\"subtitle2\">Peripheral blood</td> <td class=\"subtitle2\">Spleen and bone marrow</td> </tr> <tr class=\"divider_bottom\"> <td>Splenic marginal zone lymphoma</td> <td>Tumor cell resembles a lymphocyte with a round nucleus, condensed chromatin, and abundant basophilic cytoplasm with short surface \"villous\" projections that are often unevenly distributed around the circumference of the cell.</td> <td>In the white pulp, the neoplastic cells occupy both the mantle and marginal zones, usually with a central residual germinal center, which may be either atrophic or hyperplastic. The red pulp demonstrates both a diffuse and micronodular pattern of involvement with sinus infiltration. Nodular pattern of marrow involvement.</td> <td>Express surface immunoglobulin (eg, IgM+, IgD+), B cell antigens (CD19, CD20, CD22) and BCL-2. Expression of CD20 and surface immunoglobulin is bright. Frequently CD11c&nbsp;positive, subset is CD5 positive. Do not express CD25, CD103, or annexin A1.</td> <td>No specific translocations or genetic abnormalities; deletions of 7q relatively frequent compared with other lymphoproliferative disorders.</td> </tr> <tr class=\"divider_bottom\"> <td>Follicular lymphoma</td> <td>Overt involvement of the blood is unusual. When present, circulating cells have notches or clefts, and correspond to centrocytes.</td> <td>Follicular lymphoma cells are most often found in the white pulp and consist of a mixture of centrocytes and centroblasts.</td> <td>Unlike splenic marginal zone lymphoma, follicular lymphoma cells express CD10 and BCL-6.</td> <td>t(14;18)</td> </tr> <tr class=\"divider_bottom\"> <td>Mantle cell lymphoma</td> <td>Can have a leukemic phase with variable morphology.</td> <td>Monomorphous small to medium-sized B lymphocytes infiltrate both the red and white pulp.</td> <td>Typically positive for IgM, IgD, CD20 and CD5 and negative for CD23. Express cyclin D1.</td> <td>t(11;14)</td> </tr> <tr class=\"divider_bottom\"> <td>Hairy cell leukemia, classic</td> <td>Commonly demonstrates circulating mononuclear cells one to two times the size of a mature lymphocyte with abundant pale blue cytoplasm. The cytoplasmic outline is indistinct with varying numbers of projections. The nuclei are often eccentric, lack prominent nucleoli, and have a reticular chromatin pattern.</td> <td>Spleen is markedly enlarged with diffuse expansion of the red pulp and atrophy of the white pulp. The cords and sinuses of the red pulp are infiltrated by a monotonous population of tumor cells with a \"fried egg\" appearance. Dilated sinuses may form \"blood lakes.\"</td> <td>Most cases of hairy cell leukemia express CD20, CD22, CD11c, CD103, CD123, and CD25. Usually positive for annexin A1 and cyclin D1. Expression of CD20 and surface immunoglobulin is bright. Rare cases express CD5 or CD10.</td> <td>Nearly 100 percent have BRAF V600E mutation. Lacks the t(11;14) despite cyclin D1 positivity.</td> </tr> <tr class=\"divider_bottom\"> <td>Hairy cell leukemia, variant</td> <td>May show greater nuclear irregularity, more variation in cell size, larger cell size, prominent nucleoli.</td> <td>Similar to classic form of hairy cell leukemia.</td> <td>Typically lack one or more markers that characterize classic forms of hairy cell leukemia (eg, CD25, annexin A1).</td> <td>Lack the BRAF V600E mutation; approximately 50 percent have activating mutations in MEK1.</td> </tr> <tr class=\"divider_bottom\"> <td>Chronic lymphocytic leukemia (CLL)</td> <td>Circulating tumor cells are typically small, mature appearing lymphocytes with a dense nucleus, partially aggregated chromatin, and without discernible nucleoli. There is a narrow border of clear to slightly basophilic cytoplasm.</td> <td>Most cases demonstrate diffuse infiltration of both the red and white pulp with effacement of the follicles. Some cases appear micronodular and involve the marginal zones of the white pulp. In difficult cases identification of proliferation centers (pathognomonic for CLL, best seen in lymph nodes) may be helpful.</td> <td>Express CD23, CD43, CD5, IgD and/or IgM, BCL-2.</td> <td>Diverse genetic lesions, none specific for CLL; trisomy 12 and deletions of 11q, 13q, and 17p most common abnormalities.</td> </tr> <tr> <td>Lymphoplasmacytic lymphoma</td> <td>Circulating malignant cells often have a plasmacytoid appearance with an oval shape, abundant basophilic cytoplasm, a round eccentrically located nucleus with \"clock-face\" chromatin, absent nucleoli, and a perinuclear hof.</td> <td>Both the red and white pulp of the spleen may be infiltrated. The pattern is usually diffuse, without a distinct marginal zone or nodularity in the red pulp.</td> <td>Express high levels of surface immunoglobulin, usually of IgM type; surface IgD is usually lacking. Express pan B cell antigens (CD19, CD20, CD22, CD79a). Subset is CD5 positive. The plasma cells express CD138.</td> <td>Monoclonal immunoglobulin spike common, usually IgM.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 93308 Version 1.0</div></div></div>"},"93310":{"type":"graphic_picture","displayName":"High power light microscopy in poststreptococcal GN","title":"High power light microscopy in poststreptococcal glomerulonephritis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">High power light microscopy in poststreptococcal glomerulonephritis</div><div class=\"cntnt\"><img style=\"width:590px; height:482px;\" src=\"images/NEPH/93310_High_power_poststreptoco_GN.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light microscopy showing a proliferative (exudative) glomerulonephritis. Note numerous neutrophils within glomerular capillaries (Periodic acid Schiff, 40x).</div><div class=\"graphic_reference\">Courtesy of Sanjeev Sethi, MD, Mayo Clinic.</div><div id=\"graphicVersion\">Graphic 93310 Version 1.0</div></div></div>"},"93317":{"type":"graphic_picture","displayName":"PBC inflammatory cells","title":"Primary biliary cholangitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Primary biliary cholangitis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93317_PBC_inflammatory_cells_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An interlobular bile duct (arrow) is surrounded by a mixture of inflammatory cells, mainly lymphocytes, with some plasma cells, a few histiocytes, and occasional eosinophils.</div><div id=\"graphicVersion\">Graphic 93317 Version 2.0</div></div></div>"},"93318":{"type":"graphic_picture","displayName":"PBC florid duct lesion","title":"Primary biliary cholangitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Primary biliary cholangitis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93318_PBC_florid_duct_lesion_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A florid duct lesion, which is a pathognomonic finding in primary biliary cholangitis, is depicted. This is characterized by a damaged bile duct (short arrow) surrounded by a granuloma (long arrow). Note the chronic inflammatory infiltrate accompanying the lesion.</div><div id=\"graphicVersion\">Graphic 93318 Version 2.0</div></div></div>"},"93319":{"type":"graphic_picture","displayName":"PBC basement membrane disruption","title":"Primary biliary cholangitis stage 1","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Primary biliary cholangitis stage 1</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93319_PBC_base_membrane_disrupt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A florid duct lesion with minimal bile duct damage, but the basement membrane is disrupted by an infiltrate of inflammatory cells (long arrow). These inflammatory cells are composed of lymphocytes, some plasma cells, and occasional eosinophils (short arrows).</div><div id=\"graphicVersion\">Graphic 93319 Version 2.0</div></div></div>"},"93320":{"type":"graphic_picture","displayName":"PBC stage 1 inflammation","title":"Primary biliary cholangitis (primary biliary cirrhosis), stage 1","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Primary biliary cholangitis (primary biliary cirrhosis), stage 1</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93320_PBC_stage_1_inflammation_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A portal tract with mixed inflammation. The inflammatory cells are obscuring the bile duct. Arrows point to plasma cells, and arrowheads point to eosinophils. The other cell types making up the inflammation are mature lymphocytes and some histiocytes.</div><div id=\"graphicVersion\">Graphic 93320 Version 3.0</div></div></div>"},"93321":{"type":"graphic_picture","displayName":"PBC periportal granuloma","title":"Primary biliary cholangitis (primary biliary cirrhosis), stage III","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Primary biliary cholangitis (primary biliary cirrhosis), stage III</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93321_PBC_periportal_granuloma_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A periportal granuloma is shown (arrow). It is composed of histiocytes with lightly staining abundant cytoplasm. A multinucleated giant cell is also present, which is formed by the fusion of histiocyte cytoplasm, forming a syncytium. Note the presence of a hepatic arteriole to the right, indicating that the granuloma is in proximity to a portal tract.</div><div id=\"graphicVersion\">Graphic 93321 Version 3.0</div></div></div>"},"93322":{"type":"graphic_picture","displayName":"PSC bile duct scar","title":"Primary sclerosing cholangitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Primary sclerosing cholangitis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93322_PSC_bile_duct_scar_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bile duct scar (arrow). This represents a former bile duct that has been totally obliterated by dense fibrous tissue. Bile duct scars are recognized by the nodular round or oval structure located next to a hepatic artery.</div><div id=\"graphicVersion\">Graphic 93322 Version 1.0</div></div></div>"},"93323":{"type":"graphic_picture","displayName":"PSC histology","title":"Primary sclerosing cholangitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Primary sclerosing cholangitis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93323_PSC_histology_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A damaged bile duct is shown (arrow). Note the irregular outline of the bile duct. Alongside the bile duct is the accompanying hepatic arteriole. Normally, the bile duct and arteriole should be of similar size.</div><div id=\"graphicVersion\">Graphic 93323 Version 1.0</div></div></div>"},"93324":{"type":"graphic_picture","displayName":"Small duct PSC","title":"Primary sclerosing cholangitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Primary sclerosing cholangitis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93324_Small_duct_PSC_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bile duct scar (arrow) adjacent to a hepatic arteriole. There is advanced fibrosis as denoted by marked fibrous expansion of the portal tract with fibrous septa. Periportal hepatocytes contain bile.</div><div id=\"graphicVersion\">Graphic 93324 Version 1.0</div></div></div>"},"93326":{"type":"graphic_picture","displayName":"PSC onion skin fibrosis","title":"Primary sclerosing cholangitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Primary sclerosing cholangitis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93326_PSC_onion_skin_fibrosis_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Early changes of primary sclerosing cholangitis affecting a small interlobular bile duct. Layers of fibrous tissue are deposited around a small bile duct (arrows).</div><div id=\"graphicVersion\">Graphic 93326 Version 1.0</div></div></div>"},"93327":{"type":"graphic_picture","displayName":"Wilson disease rhodanine stain","title":"Wilson disease","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Wilson disease</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93327_Wilson_rhodanine_stain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rhodanine stain for copper. Red intracytoplasmic granules representing copper are found in periportal hepatocytes. Copper deposition in Wilson disease may be patchy and may not be seen in a needle liver biopsy specimen.</div><div id=\"graphicVersion\">Graphic 93327 Version 1.0</div></div></div>"},"93329":{"type":"graphic_picture","displayName":"Wand exercises for rotator cuff PI","title":"Wand exercises for rotator cuff","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Wand exercises for rotator cuff</div><div class=\"cntnt\"><img style=\"width:516px; height:300px;\" src=\"images/EM/93329_Wand_exer_rota_cuff_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Wand exercises such as these can be used to help maintain or improve shoulder motion.</div><div class=\"graphic_reference\">Courtesy of Mike Roberts, MPT, CSCS.</div><div id=\"graphicVersion\">Graphic 93329 Version 1.0</div></div></div>"},"93330":{"type":"graphic_diagnosticimage","displayName":"Ultrasound vitreous hemorrhage","title":"Ultrasound of vitreous hemorrhage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound of vitreous hemorrhage</div><div class=\"cntnt\"><img style=\"width:350px; height:503px;\" src=\"images/EM/93330_US_vitreous_hemorrhage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ocular ultrasound image shows vitreous hemorrhage (arrows).</div><div class=\"graphic_reference\">Courtesy of Hamid Shokoohi, MD of the George Washington University Department of Emergency Medicine.</div><div id=\"graphicVersion\">Graphic 93330 Version 1.0</div></div></div>"},"93332":{"type":"graphic_picture","displayName":"Sag sign of knee with PCL injury","title":"Sag sign of the knee with posterior cruciate ligament (PCL) injury","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Sag sign of the knee with posterior cruciate ligament (PCL)&nbsp;injury</div><div class=\"cntnt\"><img style=\"width:710px; height:804px;\" src=\"images/EM/93332_Sag_sign_knee.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The top&nbsp;photograph shows a positive sag sign in a young American football player soon after he sustained a tear of his posterior cruciate ligament (PCL). The bottom photograph shows a positive sag sign in another athlete with a torn PCL. Note the difference in contour just distal to the knee between the injured left and normal right lower extremities in the bottom photograph.</div><div class=\"graphic_reference\">Courtesy of Timothy Ryan Draper, DO and Francis G. O'Connor, MD, MPH, FACSM.</div><div id=\"graphicVersion\">Graphic 93332 Version 3.0</div></div></div>"},"93333":{"type":"graphic_algorithm","displayName":"Initial treatment of malignant glioma in older adults","title":"Initial treatment of malignant glioma in older adults","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Initial treatment of malignant glioma in older adults</div><div class=\"cntnt\"><img style=\"width:562px; height:394px;\" src=\"images/ONC/93333_Management_malignant_glioma.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">KPS: Karnofsky performance status; RT: radiation therapy; TMZ: temozolomide.<br />* Standard or short course RT.<br />&para; If known to be methylated.</div><div id=\"graphicVersion\">Graphic 93333 Version 4.0</div></div></div>"},"93340":{"type":"graphic_picture","displayName":"Reye syndrome microvesicular steatosis","title":"Reye syndrome","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Reye syndrome</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93340_Reye_microvesicular_steatos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microvesicular steatosis is characterized by numerous minute vacuoles within the hepatocyte (arrows). The nucleus remains in the center, which is in contrast to macrovesicular steatosis where the large single vacuole pushes the nucleus to the periphery.</div><div id=\"graphicVersion\">Graphic 93340 Version 1.0</div></div></div>"},"93341":{"type":"graphic_picture","displayName":"Reye syndrome Oil Red O stain","title":"Reye syndrome","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Reye syndrome</div><div class=\"cntnt\"><img style=\"width:590px; height:475px;\" src=\"images/GAST/93341_Reye_Oil_Red_O_stain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Frequently, microvesicular steatosis is difficult to ascertain, particularly after tissue processing. An Oil Red O stain performed on frozen sections that have not undergone processing with alcohol is preferred to highlight microvesicular steatosis.</div><div id=\"graphicVersion\">Graphic 93341 Version 1.0</div></div></div>"},"93342":{"type":"graphic_picture","displayName":"A1AT intracytoplasmic inclusions","title":"Alpha-1-antitrypsin deficiency","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Alpha-1-antitrypsin deficiency</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93342_A1AT_intracytoplasm_inclus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A special histochemical stain consisting of periodic acid-Schiff (PAS) with diastase digestion highlights the magenta-colored intracytoplasmic inclusions typical of alpha-1-anti-trypsin. This deposition is most pronounced in periportal/zone 1 hepatocytes.</div><div id=\"graphicVersion\">Graphic 93342 Version 1.0</div></div></div>"},"93343":{"type":"graphic_picture","displayName":"A1AT PAS with diastase","title":"Alpha-1-antitrypsin deficiency","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Alpha-1-antitrypsin deficiency</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93343_A1AT_PAS_with_diastase_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A periodic acid-Schiff with diastase (PAS-D) stain, showing that the inclusions may range in size from multiple tiny droplets to large single inclusions.</div><div id=\"graphicVersion\">Graphic 93343 Version 1.0</div></div></div>"},"93345":{"type":"graphic_picture","displayName":"Hepatic amyloidosis H and E","title":"Hepatic amyloidosis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Hepatic amyloidosis</div><div class=\"cntnt\"><img style=\"width:590px; height:436px;\" src=\"images/GAST/93345_Hepatic_amyloidosis_H_E_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On hematoxylin and eosin staining, a light-pink amorphous substance (arrow) is shown occupying the portal tract, highly suspicious for amyloidosis. This material was confirmed to have apple-green birefringence on Congo red stain when viewed under polarized light.</div><div id=\"graphicVersion\">Graphic 93345 Version 1.0</div></div></div>"},"93346":{"type":"graphic_picture","displayName":"Hepatic amyloidosis hepatocyte plate atrophy","title":"Hepatic amyloidosis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Hepatic amyloidosis</div><div class=\"cntnt\"><img style=\"width:590px; height:436px;\" src=\"images/GAST/93346_Hepa_amylo_hepatocyte_plate.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Amyloid can deposit in sinusoids (arrows), compressing hepatocytes with resultant atrophy of hepatocyte plates.</div><div id=\"graphicVersion\">Graphic 93346 Version 1.0</div></div></div>"},"93347":{"type":"graphic_picture","displayName":"Dubin-Johnson pigment 1","title":"Dubin-Johnson syndrome","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dubin-Johnson syndrome</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93347_Dubin_Johnson_pigment_1_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dubin-Johnson pigment (arrows) is seen as coarse granules in the hepatocyte and is more prominent in perivenular hepatocytes.</div><div id=\"graphicVersion\">Graphic 93347 Version 1.0</div></div></div>"},"93348":{"type":"graphic_picture","displayName":"Dubin-Johnson pigment 2","title":"Dubin-Johnson syndrome","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dubin-Johnson syndrome</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93348_Dubin_Johnson_pigment_2_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dubin-Johnson pigment (arrows) does not cause feathery degeneration/damage of hepatocytes, unlike bile, which does.</div><div id=\"graphicVersion\">Graphic 93348 Version 1.0</div></div></div>"},"93349":{"type":"graphic_picture","displayName":"Noncirrhotic portal HTN portal venopathy","title":"Idiopathic noncirrhotic portal hypertension (NCPH)","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Idiopathic noncirrhotic portal hypertension (NCPH)</div><div class=\"cntnt\"><img style=\"width:590px; height:354px;\" src=\"images/GAST/93349_NCPH_portal_venopathy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Obliterative portal venopathy, one form of idiopathic NCPH, is exemplified by markedly diminished portal vein lumina or total obliteration of the lumen (arrows). The portal tract is fibrotic, but there are no fibrous septa and definitely no cirrhosis, despite the patient having portal hypertension.</div><div id=\"graphicVersion\">Graphic 93349 Version 1.0</div></div></div>"},"93350":{"type":"graphic_picture","displayName":"Noncirrhotic portal HTN parenchyma atrophy","title":"Idiopathic noncirrhotic portal hypertension","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Idiopathic noncirrhotic portal hypertension</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93350_NCPH_parenchyma_atrophy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two portal tracts are adjacent to each other, indicative of parenchymal atrophy. Note the dense fibrosis and the absence of readily identifiable portal veins indicative of obliterative portal venopathy.</div><div id=\"graphicVersion\">Graphic 93350 Version 1.0</div></div></div>"},"93351":{"type":"graphic_picture","displayName":"NRH H and E stain","title":"Nodular regenerative hyperplasia","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Nodular regenerative hyperplasia</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93351_NRH_H_and_E_stain_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A more common form of idiopathic noncirrhotic portal hypertension than obliterative portal venopathy, nodular regenerative hyperplasia, as shown in this needle biopsy, is characterized by nodules composed of hyperplastic hepatocytes that are bordered by atrophic hepatocyte plates. The portal tract is located in the middle, termed reverse lobulation.</div><div id=\"graphicVersion\">Graphic 93351 Version 1.0</div></div></div>"},"93356":{"type":"graphic_table","displayName":"GO-FAR score to predict survival follow cardiac arrest","title":"GO-FAR score to predict neurologically intact survival following in-hospital cardiac arrest","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">GO-FAR score to predict neurologically intact survival following in-hospital cardiac arrest</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Variable</td> <td class=\"subtitle1\">&#946; coefficient (95% CI)</td> <td class=\"subtitle1\">OR</td> <td class=\"subtitle1\">GO-FAR score*</td> </tr> <tr> <td>Neurologically intact or with minimal deficits at admission<sup>&#916;</sup></td> <td class=\"centered\">&ndash;1.51 (&ndash;1.63 to 1.39)</td> <td class=\"centered\">0.22</td> <td class=\"centered\">&ndash;15</td> </tr> <tr> <td>Major trauma</td> <td class=\"centered\">1.03 (0.71 to 1.35)</td> <td class=\"centered\">2.80</td> <td class=\"centered\">10</td> </tr> <tr> <td>Acute stroke</td> <td class=\"centered\">0.78 (0.39 to 1.17)</td> <td class=\"centered\">2.18</td> <td class=\"centered\">8</td> </tr> <tr> <td>Metastatic or hematologic cancer</td> <td class=\"centered\">0.76 (0.57 to 0.96)</td> <td class=\"centered\">2.15</td> <td class=\"centered\">7</td> </tr> <tr> <td>Septicemia</td> <td class=\"centered\">0.73 (0.52 to 0.93)</td> <td class=\"centered\">2.07</td> <td class=\"centered\">7</td> </tr> <tr> <td>Medical noncardiac diagnosis</td> <td class=\"centered\">0.66 (0.54 to 0.78)</td> <td class=\"centered\">1.94</td> <td class=\"centered\">7</td> </tr> <tr> <td>Hepatic insufficiency</td> <td class=\"centered\">0.63 (0.37 to 0.90)</td> <td class=\"centered\">1.88</td> <td class=\"centered\">6</td> </tr> <tr> <td>Admit from skilled nursing facility</td> <td class=\"centered\">0.60 (0.33 to 0.87)</td> <td class=\"centered\">1.82</td> <td class=\"centered\">6</td> </tr> <tr> <td>Hypotension or hypoperfusion</td> <td class=\"centered\">0.52 (0.38 to 0.65)</td> <td class=\"centered\">1.67</td> <td class=\"centered\">5</td> </tr> <tr> <td>Renal insufficiency or dialysis</td> <td class=\"centered\">0.40 (0.28 to 0.52)</td> <td class=\"centered\">1.49</td> <td class=\"centered\">4</td> </tr> <tr> <td>Respiratory insufficiency</td> <td class=\"centered\">0.36 (0.24 to 0.47)</td> <td class=\"centered\">1.43</td> <td class=\"centered\">4</td> </tr> <tr> <td>Pneumonia</td> <td class=\"centered\">0.12 (&ndash;0.07 to 0.30)</td> <td class=\"centered\">1.12</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Age, y</td> </tr> <tr> <td class=\"indent1\">70-74</td> <td class=\"centered\">0.22 (0.06 to 0.38)</td> <td class=\"centered\">1.25</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">75-79</td> <td class=\"centered\">0.55 (0.38 to 0.72)</td> <td class=\"centered\">1.73</td> <td class=\"centered\">5</td> </tr> <tr> <td class=\"indent1\">80-84</td> <td class=\"centered\">0.64 (0.45 to 0.82)</td> <td class=\"centered\">1.89</td> <td class=\"centered\">6</td> </tr> <tr> <td class=\"indent1\">&#8805;85</td> <td class=\"centered\">1.08 (0.86 to 1.31)</td> <td class=\"centered\">2.96</td> <td class=\"centered\">11</td> </tr> <tr> <td>Constant</td> <td class=\"centered\">2.00 (1.87 to 2.13)</td> <td class=\"centered\">...</td> <td class=\"centered\">...</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Each variable in the left-hand column is associated with the score in the right-hand column. The score for all variables present in a patient should be summed and interpreted using the following categories:&#xD;&#xA;<ul class=\"decimal_heading\">&#xD;&#xA;    <li>Very low likelihood of survival (&lt;1 percent chance) &ndash; score of 24 or greater.</li>&#xD;&#xA;    <li>Low likelihood of survival (1 to 3 percent chance) &ndash; score 14 to 23.</li>&#xD;&#xA;    <li>Average likelihood of survival (&gt;3 to 15 percent chance) &ndash; score &ndash;5 to 13.</li>&#xD;&#xA;    <li>Higher than average likelihood of survival (&gt;15 percent chance) &ndash; score &ndash;15 to &ndash;6.</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">CPC: cerebral performance category; GO-FAR: Good Outcome Following Attempted Resuscitation; OR: odds ratio.<br />*&nbsp;Points for GO-FAR scores were assigned based on beta coefficients.<br />Δ CPC score of 1 at admission.</div><div class=\"graphic_reference\">Reproduced with permission from: Ebell MH, Jang W, Shen Y. Development and validation of the Good Outcome Following Attempted Resuscitation (GO-FAR) score to predict neurologically intact survival after in-hospital cardiopulmonary resuscitation. JAMA Intern Med 2013; 173:1872. Copyright &copy; 2013 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 93356 Version 5.0</div></div></div>"},"93358":{"type":"graphic_movie","displayName":"TEE 4C/5C view with LVOT obstruction and associated MR","title":"Transesophageal echocardiography 4-chamber/5-chamber view showing LVOT obstruction and associated MR","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Transesophageal echocardiography 4-chamber/5-chamber view showing LVOT obstruction and associated MR</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/93358_TEE4cham5chamviewvid.mp4\" style=\"width:512px;height:352px\"></div><img style=\"width:599px; height:419px;\" src=\"images/ANEST/93358_TEE4cham5chamviewimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Both LVOT obstruction and associated MR are shown.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; 4C: four-chamber; 5C: five-chamber; LVOT: left ventricular outflow tract; MR: mitral regurgitation.</div><div class=\"graphic_reference\">Reproduced with permission from&nbsp;Jonathan Mark, MD and the Durham VA Medical Center.</div><div id=\"graphicVersion\">Graphic 93358 Version 7.0</div></div></div>"},"93360":{"type":"graphic_diagnosticimage","displayName":"CT chronic active H pylori gastritis","title":"Chronic active H. pylori gastritis on CT","html":"<div class=\"graphic\"><div style=\"width: 607px\" class=\"figure\"><div class=\"ttl\">Chronic active H. pylori gastritis on CT</div><div class=\"cntnt\"><img style=\"width:587px; height:484px;\" src=\"images/RADIOL/93360_CT_chron_act_pyl_gastr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan through the upper abdomen shows thickened wall of the body of the stomach (dashed arrow) and antrum (arrow). The mucosa is hyperemic (arrowhead). H. pylori was recovered from the gastric biopsy, which also showed chronic active gastritis.</div><div class=\"graphic_footnotes\">CT: computed tomography; H. pylori: Helicobacter pylori.</div><div id=\"graphicVersion\">Graphic 93360 Version 2.0</div></div></div>"},"93361":{"type":"graphic_diagnosticimage","displayName":"X-ray CT pericardial tamponade","title":"Pericardial tamponade on x-ray and CT","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Pericardial tamponade on x-ray and CT</div><div class=\"cntnt\"><img style=\"width:600px; height:309px;\" src=\"images/RADIOL/93361_X_CT_pericard_tampona.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A patient presented to the emergency room with dyspnea. A chest x-ray (A) shows cardiomegaly and widened mediastinum (arrow). Image B shows an enlarged superior vena cava (arrowhead) and mediastinal adenopathy (arrow). Image C shows compression of the right ventricle (arrow) and a large malignant effusion (arrowhead). Cardiac catheterization confirmed tamponade physiology.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93361 Version 1.0</div></div></div>"},"93362":{"type":"graphic_diagnosticimage","displayName":"Angiography of angiodysplasia","title":"Angiodysplasia on arteriography","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Angiodysplasia on arteriography</div><div class=\"cntnt\"><img style=\"width:600px; height:381px;\" src=\"images/RADIOL/93362_Angiograp_angiodysplas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A superior mesenteric angiogram (A) shows the arterial phase of an extensive arteriovenous malformation of the ascending colon (arrowhead). Image B shows the venous phase and a large early draining vein (arrowhead).</div><div id=\"graphicVersion\">Graphic 93362 Version 1.0</div></div></div>"},"93363":{"type":"graphic_diagnosticimage","displayName":"CT and MRI aortic dissection Marfan syndrome","title":"Focal dissection of the descending aorta in Marfan syndrome on CT and MRI","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Focal dissection of the descending aorta in Marfan syndrome on CT and MRI</div><div class=\"cntnt\"><img style=\"width:599px; height:444px;\" src=\"images/RADIOL/93363_CT_MRI_aor_diss_marf.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT image through the heart (A) shows a communication (arrowhead) between the true lumen of the thoracic aorta and a large compressive false lumen (arrow). Image B is an MRI of the aorta&nbsp;in the lateral projection&nbsp;and shows a focal dissection with communication at mid aortic level (arrow) between the true lumen and the false lumen (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography; MRI: magnetic resonance.</div><div id=\"graphicVersion\">Graphic 93363 Version 2.0</div></div></div>"},"93364":{"type":"graphic_diagnosticimage","displayName":"X-ray ankylosing spondylitis of the cervical spine","title":"Ankylosing spondylitis of the cervical spine","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Ankylosing spondylitis of the cervical spine</div><div class=\"cntnt\"><img style=\"width:598px; height:472px;\" src=\"images/RADIOL/93364_X_anky_spon_cervicl_sp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral view of the cervical spine (A) in a patient with ankylosing spondylitis shows ossification of the anterior longitudinal ligament (arrowheads), which bridges adjacent vertebral bodies. This has resulted in bony fusion and ankylosis of the cervical vertebral bodies. Diffuse osteopenia is present. Image B is a magnified view and shows ossification of the anterior longitudinal ligaments (arrowheads).</div><div id=\"graphicVersion\">Graphic 93364 Version 2.0</div></div></div>"},"93365":{"type":"graphic_diagnosticimage","displayName":"Imaging incidentaloma papillary thyroid cancer on PET-CT","title":"Papillary thyroid cancer as incidentaloma on PET-CT","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Papillary thyroid cancer as incidentaloma on PET-CT</div><div class=\"cntnt\"><img style=\"width:600px; height:390px;\" src=\"images/RADIOL/93365_Img_inci_papi_carc_PET.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A PET-CT for staging cancer of the esophagus (arrowhead) reveals an active nodule in the neck (arrow). The axial image of the PET-CT (B) shows a hot nodule in the right lobe of the thyroid (arrow). An ultrasound guided biopsy of the nodule (C) shows the tip of the needle in the nodule (arrow). Papillary thyroid cancer was confirmed.</div><div class=\"graphic_footnotes\">PET-CT: positron emission tomography-computed tomography.</div><div id=\"graphicVersion\">Graphic 93365 Version 2.0</div></div></div>"},"93366":{"type":"graphic_diagnosticimage","displayName":"Lateral x-ray free air","title":"Free air lateral x-ray","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Free air lateral x-ray</div><div class=\"cntnt\"><img style=\"width:599px; height:359px;\" src=\"images/RADIOL/93366_Lateral_x_free_air.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A lateral examination (A) shows a small amount of air under the right hemidiaphragm (arrow) and a small amount of air under the left hemidiaphragm (arrowhead). Image B is a magnified view and highlights the small amount of air under the right hemidiaphragm (arrow) and a small amount of air under the left hemidiaphragm (arrowhead).</div><div id=\"graphicVersion\">Graphic 93366 Version 1.0</div></div></div>"},"93367":{"type":"graphic_table","displayName":"Recommended statin doses in adults with CKD","title":"Recommended doses (mg/day) of statins for treatment of adults with chronic kidney disease (CKD)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended doses (mg/day) of statins for treatment of adults with chronic kidney disease (CKD)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Statin</td> <td class=\"subtitle1\">eGFR stages G1 to G2</td> <td class=\"subtitle1\">eGFR stages G3a to G5, including patients on dialysis or with a kidney transplant</td> </tr> <tr> <td>Lovastatin</td> <td>General population</td> <td>ND</td> </tr> <tr> <td>Fluvastatin</td> <td>General population</td> <td>80*</td> </tr> <tr> <td>Atorvastatin</td> <td>General population</td> <td>20<sup>&#182;</sup></td> </tr> <tr> <td>Rosuvastatin</td> <td>General population</td> <td>10<sup>&#916;</sup></td> </tr> <tr> <td>Simvastatin-ezetimibe</td> <td>General population</td> <td>20 (simvastatin) and 10 (ezetimibe)<sup>&#9674;</sup></td> </tr> <tr> <td>Pravastatin</td> <td>General population</td> <td>40</td> </tr> <tr> <td>Simvastatin</td> <td>General population</td> <td>40</td> </tr> <tr> <td>Pitavastatin</td> <td>General population</td> <td>2</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Doses shown may differ from recommendations in approved product information for use in patients with renal impairment and are based on regimens shown to be beneficial in randomized trials conducted in patients with CKD; refer to topic. Lower doses than those used in major trials of statins in CKD populations may be appropriate for patients of Asian ancestry. Note that rosuvastatin 40 mg daily is not recommended for use in CKD G1 to G2 nontransplant patients, as it may increase the risk of adverse renal events. Cyclosporine inhibits the metabolism of certain statins, resulting in higher blood levels, and some combinations are contraindicated. To determine specific interactions, use the Lexi-Interact program included with UpToDate.</div><div class=\"graphic_footnotes\">CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; ND: no data available or not used.<br />For definitions of eGFR stages G1 through G5, refer to separate topic review of definition and staging of CKD, table on revised CKD classification based on GFR.<br />* Data based on ALERT.<br />¶&nbsp;Data based on 4D.<br />Δ Data based on AURORA.<br /><FONT class=lozenge>◊</FONT> Data based on SHARP.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Kidney International Supplements. KDIGO. Chapter 2: Pharmacological cholesterol-lowering treatment in adults. Kidney Int Suppl 2013; 3:271. Copyright &copy; 2013. <a href=\"http://www.nature.com/kisup\" target=\"_blank\">www.nature.com/kisup</a>.</div><div id=\"graphicVersion\">Graphic 93367 Version 5.0</div></div></div>"},"93368":{"type":"graphic_diagnosticimage","displayName":"X-ray free air and fluid level","title":"Free air and air-fluid level on x-ray","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Free air and air-fluid level on x-ray</div><div class=\"cntnt\"><img style=\"width:600px; height:283px;\" src=\"images/RADIOL/93368_X_free_air_fluid_level.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An A-P x-ray (A) shows free air under the diaphragm, a well-defined liver edge (dashed arrow), but no obvious free fluid. A lateral examination (B) shows an air fluid level (arrowhead) that was not obvious on the A-P examination. The free air above (arrow) outlines the liver edge with greater clarity (dashed arrow).</div><div class=\"graphic_footnotes\">A-P: anteroposterior.</div><div id=\"graphicVersion\">Graphic 93368 Version 1.0</div></div></div>"},"93369":{"type":"graphic_diagnosticimage","displayName":"CT esophageal stent migration","title":"Esophageal stent migration on computed tomography scan","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Esophageal stent migration on computed tomography scan</div><div class=\"cntnt\"><img style=\"width:599px; height:326px;\" src=\"images/RADIOL/93369_CT_esoph_stent_migrat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A scout image (A) shows an esophageal stent within the stomach (arrow). Image B is an axial image through the stomach and shows the stent in the stomach (arrow).</div><div id=\"graphicVersion\">Graphic 93369 Version 3.0</div></div></div>"},"93381":{"type":"graphic_table","displayName":"Differential diagnosis of South American bartonellosis","title":"Differential diagnosis of South American bartonellosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of South American bartonellosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Oroya fever (Carrion's disease)</td> </tr> <tr> <td class=\"indent1\">Malaria</td> </tr> <tr> <td class=\"indent1\">Dengue</td> </tr> <tr> <td class=\"indent1\">Typhoid fever</td> </tr> <tr> <td class=\"indent1\">Viral hepatitis</td> </tr> <tr> <td class=\"indent1\">Leptospirosis</td> </tr> <tr> <td class=\"indent1\">Brucellosis</td> </tr> <tr> <td class=\"indent1\">Systemic tuberculosis</td> </tr> <tr> <td class=\"indent1\">Hematological malignancy</td> </tr> <tr> <td class=\"indent1\">Parvovirus B19 infection</td> </tr> <tr> <td class=\"indent1\">Hemolytic anemia</td> </tr> <tr> <td class=\"indent1\">Aplastic anemia</td> </tr> <tr> <td class=\"subtitle1_single\">Verruga peruana (Peruvian wart)</td> </tr> <tr> <td class=\"indent1\">Bacillary angiomatosis</td> </tr> <tr> <td class=\"indent1\">Yaws</td> </tr> <tr> <td class=\"indent1\">Pyogenic granuloma</td> </tr> <tr> <td class=\"indent1\">Angioma</td> </tr> <tr> <td class=\"indent1\">Cutaneous lymphoma</td> </tr> <tr> <td class=\"indent1\">Capillary malformation</td> </tr> <tr> <td class=\"indent1\">Kaposi sarcoma</td> </tr> <tr> <td class=\"indent1\">Atypical mycobacterial infection</td> </tr> <tr> <td class=\"indent1\">Leprosy</td> </tr> <tr> <td class=\"indent1\">Lymphomatoid papillomatosis</td> </tr> <tr> <td class=\"indent1\">Fibrosarcoma</td> </tr> <tr> <td class=\"indent1\">Reticuloendotheliosis</td> </tr> <tr> <td class=\"indent1\"><em>Molluscum contagiosum</em></td> </tr> <tr> <td class=\"indent1\">Chickenpox</td> </tr> <tr> <td class=\"indent1\">Spitz nevus</td> </tr> <tr> <td class=\"indent1\">Cutaneous tuberculosis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 93381 Version 3.0</div></div></div>"},"93385":{"type":"graphic_picture","displayName":"Pigmented fungiform papillae","title":"Pigmented fungiform papillae of the tongue","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Pigmented fungiform papillae of the tongue</div><div class=\"cntnt\"><img style=\"width:590px; height:387px;\" src=\"images/DERM/93385_Pigment_fungiform_papillae.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pigmented spots on the tongue due to melanin deposition on the tips of the fungiform papillae may be seen in individuals with darker skin tones.</div><div class=\"graphic_reference\">Marcoval J, Notario J, Martin-Sala S, Figueras I. [Pigmentation of the fungiform papillae of the tongue: a report of 2 cases]. Actas Dermosifiliogr 2011; 102:739. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 93385 Version 1.0</div></div></div>"},"93387":{"type":"graphic_figure","displayName":"Extra-articular calcaneal fractures","title":"Extra-articular calcaneal fractures","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Extra-articular calcaneal fractures</div><div class=\"cntnt\"><img style=\"width:504px; height:331px;\" src=\"images/EM/93387_Extra-articular_calcaneal_fractures.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This diagram shows several common sites for extra-articular calcaneus fractures.</div><div id=\"graphicVersion\">Graphic 93387 Version 1.0</div></div></div>"},"93389":{"type":"graphic_table","displayName":"Steps in the management of esophageal foreign body obstruction","title":"Sequential steps in the management of esophageal foreign body obstruction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sequential steps in the management of esophageal foreign body obstruction</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Airway evaluation</td> </tr> <tr> <td>Assessment of the urgency of removal</td> </tr> <tr> <td>Radiological localization</td> </tr> <tr> <td>Medical management</td> </tr> <tr> <td>Endoscopic retrieval</td> </tr> <tr> <td>Monitoring for complications</td> </tr> <tr> <td>Endoscopic therapy and/or surgery for complications </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced by permission from Springer: Current Gastroenterology Reports. Triadafilopoulos G, Roorda A, Akiyama J. Update on foreign bodies in the esophagus: diagnosis and management. Curr Gastroenterol Rep 2013; 15:317. Copyright © 2013. <A spellcheck=true href=\"https://link.springer.com/journal/11894\" target=_blank>https://link.springer.com/journal/11894</A>.</div><div id=\"graphicVersion\">Graphic 93389 Version 4.0</div></div></div>"},"93392":{"type":"graphic_table","displayName":"Expert consensus recommendations regarding early repolarization","title":"Expert consensus recommendations regarding early repolarization from the HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Expert consensus recommendations regarding early repolarization from the HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Expert consensus statement on diagnosis</td> </tr> <tr> <td class=\"indent1\">1. ER syndrome is diagnosed in the presence of J-point elevation &#8805;1 mm in &#8805;2 contiguous inferior and/or lateral leads of a standard 12-lead ECG in a patient resuscitated from otherwise unexplained VF/polymorphic VT.</td> </tr> <tr> <td class=\"indent1\">2. ER syndrome can be diagnosed in an SCD victim with a negative autopsy and medical chart review with a previous ECG demonstrating J-point elevation &#8805;1 mm in &#8805;2 contiguous inferior and/or lateral leads of a standard 12-lead ECG.</td> </tr> <tr> <td class=\"indent1\">3. ER pattern can be diagnosed in the presence of J-point elevation &#8805;1 mm in &#8805;2 contiguous inferior and/or lateral leads of a standard 12-lead ECG.</td> </tr> <tr> <td class=\"subtitle1_single\">Expert consensus statement on therapeutic intervention</td> </tr> <tr> <td class=\"subtitle2_single\">CLASS I</td> </tr> <tr> <td class=\"indent1\">1. ICD implantation is recommended in patients with a diagnosis of ER syndrome who have survived a cardiac arrest.</td> </tr> <tr> <td class=\"subtitle2_single\">CLASS IIa</td> </tr> <tr> <td class=\"indent1\">2. Isoproterenol infusion can be useful in suppressing electrical storms in patients with a diagnosis of ER syndrome.</td> </tr> <tr> <td class=\"indent1\">3. Quinidine in addition to an ICD can be useful for secondary prevention of VF in patients with a diagnosis of ER syndrome.</td> </tr> <tr> <td class=\"subtitle2_single\">CLASS IIb</td> </tr> <tr> <td class=\"indent1\">4. ICD implantation may be considered in symptomatic family members of ER syndrome patients with a history of syncope in the presence of ST-segment elevation &#62;1 mm in &#8805;2 inferior or lateral leads.</td> </tr> <tr> <td class=\"indent1\">5. ICD implantation may be considered in asymptomatic individuals who demonstrate a high-risk ER ECG pattern (high J-wave amplitude, horizontal/descending ST segment) in the presence of a strong family history of juvenile unexplained sudden death with or without a pathogenic mutation.</td> </tr> <tr> <td class=\"subtitle2_single\">CLASS III</td> </tr> <tr> <td class=\"indent1\">6. ICD implantation is not recommended in asymptomatic patients with an isolated ER ECG pattern.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; VF: ventricular fibrillation; VT: ventricular tachycardia; ER: early repolarization; SCD: sudden cardiac death; ICD: implantable cardioverter defibrillator.</div><div class=\"graphic_reference\">Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. Heart Rhythm 2013; 10:1932. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 93392 Version 2.0</div></div></div>"},"93394":{"type":"graphic_picture","displayName":"Pelvic pressure pack","title":"Pelvic pressure pack","html":"<div class=\"graphic\"><div style=\"width: 644px\" class=\"figure\"><div class=\"ttl\">Pelvic pressure pack</div><div class=\"cntnt\"><img style=\"width:624px; height:581px;\" src=\"images/OBGYN/93394_Pelvicpressurepack.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photograph of a pelvic pressure pack, as constructed from an x-ray cassette drape, sterile gauze rolls, and an intravenous infusion setup.<br />(A) \"Dome\" of the pack.<br />(B, C, D) \"Neck\" of the pack.<br />(E) Gauze rolls.<br />(F) Intravenous tubing.<br />(G) Intravenous fluid bag (1 L).</div><div class=\"graphic_reference\">Reproduced with permission from: Dildy GA, Scott JR, Saffer CS, Belfort MA. An effective pressure pack for severe pelvic hemorrhage. Obstet Gynecol 2006; 108:1222. DOI: <a href=\"http://journals.lww.com/greenjournal/fulltext/2006/11000/an_effective_pressure_pack_for_severe_pelvic.25.aspx\" spellcheck=\"true\" target=\"_blank\">10.1097/01.AOG.0000241098.11583.a4</a>. Copyright &copy; 2006 American College of Obstetricians and Gynecologists. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 93394 Version 4.0</div></div></div>"},"93396":{"type":"graphic_table","displayName":"WHO one step diagnosis of GDM","title":"World Health Organization (WHO) thresholds for positive two-hour 75-gram oral GTT (2013). A diagnosis of \"gestational diabetes mellitus\" is made when one or more of the following glucose thresholds is met any time during pregnancy. ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">World Health Organization (WHO) thresholds for positive two-hour 75-gram oral GTT (2013). A diagnosis of \"gestational diabetes mellitus\" is made when one or more of the&nbsp;following glucose&nbsp;thresholds&nbsp;is&nbsp;met any time during pregnancy. </div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Fasting</td> <td>92 to 125 mg/dL (5.1 to 6.9 mmol/L)</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>OR</strong></td> </tr> <tr> <td>One hour</td> <td>&#8805;180 mg/dL (10.0 mmol/L)</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>OR</strong></td> </tr> <tr> <td>Two hour</td> <td>153 to 199 mg/dL (8.5 to 11.0 mmol/L) </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">By comparison, a diagnosis of \"diabetes mellitus&nbsp;in pregnancy\" is made if one or more of the following criteria are met: fasting plasma glucose ≥126 mg/dL (7.0 mmol/L), two-hour plasma glucose ≥200 mg/dL (11.1 mmol/L) following a 75-gram oral glucose load, random blood glucose ≥200 mg/dL (11.1 mmol/L) in the presence of diabetes symptoms. There are no established criteria for the diagnosis of \"diabetes mellitus in pregnancy\"&nbsp;based on the one-hour post-load value.</div><div id=\"graphicVersion\">Graphic 93396 Version 8.0</div></div></div>"},"93400":{"type":"graphic_diagnosticimage","displayName":"X-ray malposition IABP  ","title":"Malposition IABP on x-ray","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Malposition IABP on x-ray</div><div class=\"cntnt\"><img style=\"width:600px; height:269px;\" src=\"images/RADIOL/93400_X_ray_malposition_IABP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An x-ray in A-P projection shows the tip of the IABP (arrowhead) malpositioned in the aortic knob (arrow) near the origin of the left subclavian artery and well above the carina (asterisk). Image B shows the IABP (arrowhead) retracted to the level of the carina (asterisk), and at least 2 cm below the aortic knob (arrow).</div><div class=\"graphic_footnotes\">IABP: intra-aortic balloon pump; A-P: anteroposterior.</div><div id=\"graphicVersion\">Graphic 93400 Version 1.0</div></div></div>"},"93401":{"type":"graphic_table","displayName":"BWH staging system for cutaneous squamous cell carcinoma","title":"Brigham and Women's Hospital Tumor (T) Staging System for Cutaneous Squamous Cell Carcinoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Brigham and Women's Hospital Tumor (T) Staging System for Cutaneous Squamous Cell Carcinoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tumor staging system</td> <td class=\"subtitle1\">Definition</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">BWH</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>Zero&nbsp;high-risk factors*</td> </tr> <tr> <td class=\"indent1\">T2a</td> <td>One&nbsp;high-risk factor</td> </tr> <tr> <td class=\"indent1\">T2b</td> <td>Two&nbsp;to&nbsp;three high-risk factors</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>Greater than or&nbsp;equal to four&nbsp;high-risk factors or bone invasion</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BWH: Brigham and Women's Hospital; T: tumor stage from&nbsp;tumor, node, metastasis staging system.<br />* BWH high-risk factors include tumor diameter ≥2 cm, poorly differentiated histology, perineural invasion ≥0.1 mm, or tumor invasion beyond fat (excluding bone invasion, which automatically upgrades tumor to BWH stage T3).</div><div id=\"graphicVersion\">Graphic 93401 Version 3.0</div></div></div>"},"93404":{"type":"graphic_diagnosticimage","displayName":"Metastatic renal cell lesion of the humerus","title":"Metastatic renal cell lesion of the humerus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Metastatic renal cell lesion of the humerus</div><div class=\"cntnt\"><img style=\"width:236px; height:503px;\" src=\"images/ONC/93404_Metas_ren_cell_les_humerus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain radiograph&nbsp;of a patient with a metastatic lesion of the proximal diaphysis of the humerus from renal cell carcinoma, illustrating an extensive expansile&nbsp;lytic process that extends to the cortex on both sides.</div><div id=\"graphicVersion\">Graphic 93404 Version 1.0</div></div></div>"},"93407":{"type":"graphic_figure","displayName":"Prophylactic total gastrectomy","title":"Prophylactic total gastrectomy","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Prophylactic total gastrectomy</div><div class=\"cntnt\"><img style=\"width:538px; height:425px;\" src=\"images/SURG/93407_Prophylactic_gastrectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For prophylactic total gastrectomy, once the stomach is isolated by dividing the gastric, gastroepiploic, and short gastric vessels, the esophagus and pylorus are divided. The omentum is preserved.</div><div id=\"graphicVersion\">Graphic 93407 Version 1.0</div></div></div>"},"93413":{"type":"graphic_table","displayName":"Modified Ashworth scale","title":"Modified Ashworth scale for grading spasticity<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified Ashworth scale for grading spasticity<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Grade</td> <td class=\"subtitle1\">Description</td> </tr> <tr> <td class=\"centered\">0</td> <td>No increase in muscle tone</td> </tr> <tr> <td class=\"centered\">1</td> <td>Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension</td> </tr> <tr> <td class=\"centered\">1+</td> <td>Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM</td> </tr> <tr> <td class=\"centered\">2</td> <td>More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved</td> </tr> <tr> <td class=\"centered\">3</td> <td>Considerable increase in muscle tone, passive movement difficult</td> </tr> <tr> <td class=\"centered\">4</td> <td>Affected part(s) rigid in flexion or extension</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reference:<br /><ol>&#xD;&#xA;    <li>Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987; 67:206.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 93413 Version 1.0</div></div></div>"},"93414":{"type":"graphic_figure","displayName":"WHO HIV testing low prevalence setting","title":"WHO HIV testing low prevalence* setting","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">WHO HIV testing low prevalence* setting</div><div class=\"cntnt\"><img style=\"width:469px; height:364px;\" src=\"images/ID/93414_WHO_HIV_test_low_prev_set.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">\"Assay A1\", \"A2\", \"A3\" represent three different assays (of any test format). \"Report\" = result may be reported.</div><div class=\"graphic_footnotes\">* Where the prevalence of HIV is &lt;5 percent in the population being tested.<br /><span class=\"bullet\">&bull;</span> If A1 is an antigen/antibody detection assay and A2 or A3 is an antibody-detection-only assay, re-testing should be performed with a second specimen taken after 14 days.<br />&Delta; For newly diagnosed individuals, a positive result should be confirmed on a second specimen to rule out laboratory error.<br /><span class=\"lozenge\">&loz;</span> Re-testing should be performed with a second specimen taken after 14 days to rule out potential seroconversion.</div><div class=\"graphic_reference\">Reproduced, with permission of the publisher, from Service Delivery Approaches to HIV Testing and Counselling (HTC): A Strategic HTC Programme Framework. Geneva, World Health Organization, 2012. Available at: <A href=\"http://www.who.int/hiv/pub/vct/htc_framework/en/\" target=_blank>http://www.who.int/hiv/pub/vct/htc_framework/en/</A> (Accessed January 23, 2014).</div><div id=\"graphicVersion\">Graphic 93414 Version 1.0</div></div></div>"},"93415":{"type":"graphic_figure","displayName":"WHO HIV testing high prevalence setting","title":"WHO HIV testing high prevalence* setting","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">WHO HIV testing high prevalence* setting</div><div class=\"cntnt\"><img style=\"width:409px; height:369px;\" src=\"images/ID/93415_WHO_HIV_testing_high_preval.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">\"Assay A1\", \"A2\", \"A3\" represent three different assays (of any test format). \"Report\": result may be reported.</div><div class=\"graphic_footnotes\">* Where the prevalence of HIV is &gt;5 percent in the population to be tested.<br /><span class=\"bullet\">&bull;</span> For newly diagnosed individuals, a positive result should be confirmed on a second specimen to rule out laboratory error.<br />&Delta; Re-testing should be performed on a second specimen taken after 14 days to rule out seroconversion.<br /><span class=\"lozenge\">&loz;</span> If A1 is an antigen/antibody detection assay and A2 or A3 is an antibody-detection-only assay, re-testing should be performed with a second specimen taken after 14 days.</div><div class=\"graphic_reference\">Reproduced, with permission of the publisher, from Service Delivery Approaches to HIV Testing and Counselling (HTC): A Strategic HTC Programme Framework. Geneva, World Health Organization, 2012. Available at: <a href=\"http://www.who.int/hiv/pub/vct/htc_framework/en/\" target=\"_blank\">http://www.who.int/hiv/pub/vct/htc_framework/en/</a> (Accessed on January 23, 2014).</div><div id=\"graphicVersion\">Graphic 93415 Version 1.0</div></div></div>"},"93417":{"type":"graphic_table","displayName":"Pretreatment evaluation CD","title":"Pretreatment evaluation in patients with Castleman's disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pretreatment evaluation in patients with Castleman's disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Investigation</td> <td class=\"subtitle1\">Common findings</td> </tr> <tr> <td>Complete blood count</td> <td>Anemia, thrombocytosis</td> </tr> <tr> <td>Serum chemistry</td> <td>Hypoalbuminemia, elevated lactate dehydrogenase</td> </tr> <tr> <td>Acute phase reactants</td> <td>Elevated ESR, CRP, ferritin, and fibrinogen</td> </tr> <tr> <td>SPEP, quantitative immunoglobulin, immunofixation</td> <td>Elevation in one or more immunoglobulin class (IgG, IgA, IgM), no M spike, IFE negative</td> </tr> <tr> <td>Serum cytokine levels: IL-6 and VEGF (in select cases)</td> <td>Elevated IL-6 (not all cases in UCD), elevated VEGF in small number of cases</td> </tr> <tr> <td>Serological investigations for autoimmune disorders: only if clinically suspected</td> <td>Variable</td> </tr> <tr> <td>Viral serology for HHV-8, HIV; if positive, quantitative assay. Staining of lymph node biopsy for HHV-8.</td> <td>Positive in limited number of cases. Rarely in hyaline vascular variant, more common in plasmacytic variant.</td> </tr> <tr> <td>Imaging: PET/CT</td> <td>Initially to detect any other area of lymph node involvement (distinguish UCD from MCD) and to assess disease activity by SUV (2.5 to 5)</td> </tr> <tr> <td>IgH gene rearrangement study on lymph node specimen</td> <td>Rule out clonal disorder, mainly occult lymphoma</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ESR: erythrocyte sedimentation rate; CRP: c-reactive protein; SPEP: serum protein electrophoresis; IFE: immunofixation; IL-6: interleukin-6; VEGF: vascular endothelial growth factor; UCD: unicentric Castleman's disease; HHV-8: human herpes virus 8; PET/CT: positron emission tomography/computed tomography; MCD: multicentric Castleman's disease; SUV: standardized uptake value.</div><div id=\"graphicVersion\">Graphic 93417 Version 1.0</div></div></div>"},"93422":{"type":"graphic_picture","displayName":"Patient with PMR","title":"Patient with PMR","html":"<div class=\"graphic\"><div style=\"width: 747px\" class=\"figure\"><div class=\"ttl\">Patient with PMR</div><div class=\"cntnt\"><img style=\"width:727px; height:277px;\" src=\"images/RHEUM/93422_Patient_with_PMR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Inability to abduct actively the arms above 90 degrees in a patient presenting with two weeks of proximal achiness and protracted morning stiffness.<br />(B) Painless active abduction of the shoulders after one week on prednisone 10 mg/day.</div><div class=\"graphic_footnotes\">PMR: polymyalgia rheumatica.</div><div class=\"graphic_reference\">From: Docken WP. Two inflammatory conditions&mdash;polymyalgia rheumatica and giant cell arteritis&mdash;share clinical connection. The Rheumatologist 2013. <a href=\"http://www.the-rheumatologist.org/article/two-inflammatory-conditionspolymyalgia-rheumatica-and-giant-cell-arteritisshare-clinical-connection/\" target=\"_blank\">http://www.the-rheumatologist.org/article/two-inflammatory-conditionspolymyalgia-rheumatica-and-giant-cell-arteritisshare-clinical-connection/</a>. Copyright &copy; 2013 American College of Rheumatology. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\" spellcheck=\"true\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 93422 Version 2.0</div></div></div>"},"93423":{"type":"graphic_picture","displayName":"Remitting seronegative symmetrical synovitis with pitting edema","title":"Remitting seronegative symmetrical synovitis with pitting edema","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Remitting seronegative symmetrical synovitis with pitting edema</div><div class=\"cntnt\"><img style=\"width:540px; height:338px;\" src=\"images/RHEUM/93423_Remit_seroneg_sym_synovitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An 80-year-old man with the&nbsp;acute onset of&nbsp;pain and swelling at the hands. Symptoms and signs responded briskly to prednisone 10 mg in the morning and 5 mg at&nbsp;night.</div><div class=\"graphic_reference\">Reproduced from: Docken WP. Polymyalgia rheumatica and giant cell arteritis. In: Targeted Treatment of the Rheumatic Diseases, Weisman MH, Weinblatt ME, Louie JS, Van Vollenhoven RF (Eds), Elsevier, 2010. p. 186.</div><div id=\"graphicVersion\">Graphic 93423 Version 2.0</div></div></div>"},"93424":{"type":"graphic_algorithm","displayName":"Overweight and obesity eval and treatment","title":"Overweight and obesity: Evaluation and treatment algorithm","html":"<div class=\"graphic\"><div style=\"width: 747px\" class=\"figure\"><div class=\"ttl\">Overweight and obesity: Evaluation and treatment algorithm</div><div class=\"cntnt\"><img style=\"width:727px; height:1054px;\" src=\"images/ENDO/93424_Overweight_obesity_eval_tx.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">BMI: body mass index; CVD: cardiovascular disease; BP: blood pressure.<br />* BMI measured as kg/m<SUP>2</SUP>.​<br />¶ Assess and treat obesity-related comorbidities: &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>Assess risk for presence of obesity-related comorbidities. Risk assessment for CVD and diabetes in a person with overweight or class I to III obesity includes history, physical examination, and clinical and laboratory assessments, including BP, fasting blood glucose, and fasting lipid panel (expert opinion). A waist circumference measurement is recommended for individuals with BMI 25 to &lt;35 kg/m<SUP>2</SUP> to provide additional information on risk. It is not necessary to measure waist circumference in patients with BMI &gt;35 kg/m<SUP innerHtml>2</SUP>, because the waist circumference will likely be elevated and it will add no additional risk information. The Panel recommends, by expert opinion, using the current cutpoints (&gt;88 cm or &gt;35 in for women and &gt;102 cm or &gt;40 in for men) as indicative of increased cardiometabolic risk.</LI>&#xD;&#xA;<LI>Because obesity is associated with increased risk of hypertension, dyslipidemia, diabetes, and a host of other comorbidities, the clinician should assess for associated conditions. The Panel recommends by expert opinion that intensive management of CVD risk factors (hypertension, dyslipidemia, prediabetes, or diabetes) or other obesity-related medical conditions (eg, sleep apnea) be instituted if they are found, regardless of weight loss efforts.</LI></UL></div><div class=\"graphic_reference\">Original figure modified for this publication. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 2013 Nov 7. DOI: 10.1016/j.jacc.2013.11.004. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 93424 Version 2.0</div></div></div>"},"93427":{"type":"graphic_picture","displayName":"Storiform fibrosis in IgG4-related disease","title":"Storiform fibrosis in IgG4-related disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Storiform fibrosis in IgG4-related disease</div><div class=\"cntnt\"><img style=\"width:399px; height:598px;\" src=\"images/RHEUM/93427_Storiform_fibrs_medis_mass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Swirling fibrotic tissue encasing cellular infiltrate in collagen fibrils. This biopsy was from a mediastinal mass from a 34-year-old man.<br />(B) Higher power view of storiform fibrosis amid a lymphoplasmacytic infiltrate.</div><div class=\"graphic_reference\">Courtesy of John H Stone, MD.</div><div id=\"graphicVersion\">Graphic 93427 Version 2.0</div></div></div>"},"93429":{"type":"graphic_diagnosticimage","displayName":"IgG4-related TIN with eosinophilia","title":"IgG4-related tubulointerstitial nephritis with eosinophilia","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">IgG4-related tubulointerstitial nephritis with eosinophilia</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/RHEUM/93429_Tublntrsttl_nphrts_w_esnpla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Renal biopsy from a 45-year-old man with a history of type 1 (IgG4-related) autoimmune pancreatitis. The patient presented with a serum creatinine of 2.5 mg/dL. A glomerulus is evident in this biopsy, but the inflammatory infiltrate is concentrated in the region of the tubules and interstitium. There is a lymphoplasmacytic infiltrate accompanied by fibrosis and ample numbers of eosinophils.</div><div class=\"graphic_reference\">Courtesy of John H Stone, MD.</div><div id=\"graphicVersion\">Graphic 93429 Version 1.0</div></div></div>"},"93430":{"type":"graphic_diagnosticimage","displayName":"Obliterative phlebitis in mediastinal mass","title":"Obliterative phlebitis in IgG4-related disease","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Obliterative phlebitis in IgG4-related disease</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/RHEUM/93430_Oblit_phlebt_mediastin_mss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 34-year-old man presented with a mediastinal mass that&nbsp;raised concern for a malignancy, but upon biopsy was found to have IgG4-related disease (IgG4-RD). This picture shows obliterative phlebitis, a histopathologic finding that is nearly pathognomonic of IgG4-RD. The vein is clearly outlined, but its lumen is nearly completely replaced with the same inflammatory infiltrate present elsewhere in the lesion. Obliterative arteritis (as opposed to phlebitis) can also occur, particularly in the lung, but is much less common than is venous involvement in IgG4-RD.</div><div class=\"graphic_reference\">Courtesy of John H Stone, MD.</div><div id=\"graphicVersion\">Graphic 93430 Version 1.0</div></div></div>"},"93431":{"type":"graphic_diagnosticimage","displayName":"Obliterative phlebitis elastin stain","title":"Obliterative phlebitis in a retroperitoneal mass from a patient with IgG4-related disease","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Obliterative phlebitis in a retroperitoneal mass from a patient with IgG4-related disease</div><div class=\"cntnt\"><img style=\"width:504px; height:381px;\" src=\"images/RHEUM/93431_Obliterat_phlbts_elast_stn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Elastin stain of a retroperitoneal biopsy from a patient with classic retroperitoneal fibrosis. The arteries and veins course in proximity to each other at most anatomic sites, including in the retroperitoneum. This elastin stain shows normal, orderly staining of the internal elastic lamina of the thick-walled artery. By contrast, the elastin within the wall of the vein (situated just above the artery in this picture) is highly disorganized, and the lumen of the vessel can no longer be visualized. The vein has been destroyed (obliterated) by the inflammatory process.</div><div class=\"graphic_reference\">Courtesy of John H Stone, MD.</div><div id=\"graphicVersion\">Graphic 93431 Version 1.0</div></div></div>"},"93432":{"type":"graphic_diagnosticimage","displayName":"Storiform fibrosis from maxillary sinus","title":"Storiform fibrosis in IgG4-related disease","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Storiform fibrosis in IgG4-related disease</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/RHEUM/93432_Storifrm_fibros_maxill_sns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pink, acellular areas stream through the lymphoplasmacytic infiltrate. This biopsy is from the maxillary sinus in a patient whose disease was limited to the maxillary and ethmoid sinuses.</div><div class=\"graphic_reference\">Courtesy of John H Stone, MD.</div><div id=\"graphicVersion\">Graphic 93432 Version 1.0</div></div></div>"},"93433":{"type":"graphic_diagnosticimage","displayName":"Storiform fibrosis within lacrimal gland","title":"Storiform fibrosis from the lacrimal gland of a patient with IgG4-related disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Storiform fibrosis from the lacrimal gland of a patient with IgG4-related disease</div><div class=\"cntnt\"><img style=\"width:427px; height:504px;\" src=\"images/RHEUM/93433_Strfrm_fibrs_w_lacrim_glnd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bands of storiform fibrosis stream through areas of cellular inflammatory infiltrate.</div><div class=\"graphic_reference\">Courtesy of John H Stone, MD.</div><div id=\"graphicVersion\">Graphic 93433 Version 1.0</div></div></div>"},"93435":{"type":"graphic_diagnosticimage","displayName":"Storiform fibrosis in lung","title":"Lymphoplasmacytic infiltrate with storiform fibrosis in lung","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lymphoplasmacytic infiltrate with storiform fibrosis in lung</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/RHEUM/93435_Lymphplmcyt_inflt_fbrs_lng.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lymphoplasmacytic infiltrate with storiform fibrosis in lung.</div><div class=\"graphic_reference\">Courtesy of John H Stone, MD.</div><div id=\"graphicVersion\">Graphic 93435 Version 1.0</div></div></div>"},"93437":{"type":"graphic_diagnosticimage","displayName":"TIN with obsolescent glomeruli","title":"Tubulointerstitial nephritis with obsolescent glomeruli in IgG4-related disease","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Tubulointerstitial nephritis with obsolescent glomeruli in IgG4-related disease</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/RHEUM/93437_Obsolescent_glomeruli_TIN.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tubulointerstitial nephritis with obsolescent glomeruli in a patient with IgG4-related disease. Occasional eosinophils are also observed.</div><div class=\"graphic_reference\">Courtesy of John H Stone, MD.</div><div id=\"graphicVersion\">Graphic 93437 Version 1.0</div></div></div>"},"93438":{"type":"graphic_diagnosticimage","displayName":"IgG4-positive cells in IgG4-related TIN","title":"IgG4 staining of renal biopsy in IgG4-related tubulointerstitial nephritis","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">IgG4 staining of renal biopsy in IgG4-related tubulointerstitial nephritis</div><div class=\"cntnt\"><img style=\"width:517px; height:197px;\" src=\"images/RHEUM/93438_IgG4_stain_renal_biops.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunohistochemical stains of renal biopsies for IgG4 in two patients with IgG4-related tubulointerstitial nephritis. Two core renal biopsies are shown. All brown-staining cells represent IgG4-positive plasma cells.</div><div class=\"graphic_reference\">Courtesy of John H Stone, MD.</div><div id=\"graphicVersion\">Graphic 93438 Version 1.0</div></div></div>"},"93439":{"type":"graphic_diagnosticimage","displayName":"Lacrimal gland histopath in IgG4-RD","title":"Lacrimal gland histopathology in IgG4-related disease","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lacrimal gland histopathology in IgG4-related disease</div><div class=\"cntnt\"><img style=\"width:504px; height:453px;\" src=\"images/RHEUM/93439_Strfrm_fbrss_lymphpl_infil.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lacrimal gland biopsy showing a lymphoplasmacytic infiltrate enmeshed within a stream of storiform fibrosis.</div><div class=\"graphic_reference\">Courtesy of John H Stone, MD.</div><div id=\"graphicVersion\">Graphic 93439 Version 1.0</div></div></div>"},"93441":{"type":"graphic_table","displayName":"Barkley Deficits in Executive Functioning Scale","title":"Barkley Deficits in Executive Functioning Scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Barkley Deficits in Executive Functioning Scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"5%\"></colgroup><colgroup width=\"47%\"></colgroup><colgroup span=\"4\" width=\"12%\"></colgroup> <tbody> <tr> <td colspan=\"4\">Name:</td> <td colspan=\"2\">Date:</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\">Sex (circle one):&nbsp;&nbsp;Male&nbsp;&nbsp;Female</td> <td colspan=\"2\">Age:</td> </tr> <tr> <td colspan=\"6\"><strong>Instructions:</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"6\">How often do you experience each of these problems? Please circle the number next to each item that best describes your behavior <strong>DURING THE PAST 6 MONTHS</strong>. Please ignore the sections marked \"Office Use Only.\"</td> </tr> <tr> <td class=\"subtitle1\" style=\"vertical-align: bottom; text-align: left;\" colspan=\"2\">Section 1 items</td> <td class=\"subtitle1\">Never or rarely</td> <td class=\"subtitle1\">Sometimes</td> <td class=\"subtitle1\">Often</td> <td class=\"subtitle1\">Very often</td> </tr> <tr> <td class=\"centered highlight_blue_text\">1.</td> <td>Procrastinate or put off doing things until the last minute</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">2.</td> <td>Poor sense of time</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">3.</td> <td>Waste or mismanage my time</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">4.</td> <td>Not prepared on time for work or assigned tasks</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">5.</td> <td>Fail to meet deadlines for assignments</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered highlight_blue_text\">6.</td> <td>Have trouble planning ahead or preparing for upcoming events</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">7.</td> <td>Forget to do things I am supposed to do</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">8.</td> <td>Can't seem to accomplish the goals I set for myself</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">9.</td> <td>Late for work or scheduled appointments</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">10.</td> <td>Can't seem to hold in mind things I need to remember to do</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">11.</td> <td>Can't seem to get things done unless there is an immediate deadline</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">12.</td> <td>Have difficulty judging how much time it will take to do something or get somewhere</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">13.</td> <td>Have trouble motivating myself to start work</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered highlight_blue_text\">14.</td> <td>Have difficulty motivating myself to stick with my work and get it done</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">15.</td> <td>Not motivated to prepare in advance for things I know I am supposed to do</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered highlight_blue_text\">16.</td> <td>Have trouble completing one activity before starting into a new one</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">17.</td> <td>Have trouble doing what I tell myself to do</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">18.</td> <td>Difficulties following through on promises or commitments I may make to others</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">19.</td> <td>Lack self-discipline</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">20.</td> <td>Have difficulty arranging or doing my work by its priority or importance; can't \"prioritize\" well</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">21.</td> <td>Find it hard to get started or get going on things I need to get done</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr class=\"highlight_blue_text divider_bottom\"> <td colspan=\"2\">Office Use Only&#8212;<strong>Section 1 total score</strong> __________</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"subtitle1\" style=\"vertical-align: bottom; text-align: left;\" colspan=\"2\">Section 2 items</td> <td class=\"subtitle1\">Never or rarely</td> <td class=\"subtitle1\">Sometimes</td> <td class=\"subtitle1\">Often</td> <td class=\"subtitle1\">Very often</td> </tr> <tr> <td class=\"centered\">22.</td> <td>I do not seem to anticipate the future as much or as well as others</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">23.</td> <td>Can't seem to remember what I previously heard or read about</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered highlight_blue_text\">24.</td> <td>I have trouble organizing my thoughts</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">25.</td> <td>When I am shown something complicated to do, I cannot keep the information in mind so as to imitate or do it correctly</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">26.</td> <td>I have trouble considering various options for doing things and weighing their consequences</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">27.</td> <td>Have difficulties saying what I want to say</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">28.</td> <td>Unable to come up with or invent as many solutions to problems as others seem to do</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">29.</td> <td>Find myself at a loss for words when I want to explain something to others</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">30.</td> <td>Have trouble putting my thoughts down in writing as well or as quickly as others</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">31.</td> <td>Feel I am not as creative or inventive as others of my level of intelligence</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">32.</td> <td>In trying to accomplish goals or assignments, I find I am not able to think of as many ways of doing things as others</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">33.</td> <td>Have trouble learning new or complex activities as well as others</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">34.</td> <td>Have difficulty explaining things in their proper order or sequence</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">35.</td> <td>Can't seem to get to the point of my explanations as quickly as others</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">36.</td> <td>Have trouble doing things in their proper order or sequence</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">37.</td> <td>Unable to \"think on my feet\" or respond as effectively as others to unexpected events</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">38.</td> <td>I am slower than others at solving problems I encounter in my daily life</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">39.</td> <td>Easily distracted by irrelevant events or thoughts when I must concentrate on something</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">40.</td> <td>Not able to comprehend what I read as well as I should be able to do; have to reread material to get its meaning</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">41.</td> <td>Cannot focus my attention on tasks or work as well as others</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">42.</td> <td>Easily confused</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">43.</td> <td>Can't seem to sustain my concentration on reading, paperwork, lectures, or work</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">44.</td> <td>Find it hard to focus on what is important from what is not important when I do things</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">45.</td> <td>I don't seem to process information as quickly or as accurately as others</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr class=\"highlight_blue_text divider_bottom\"> <td colspan=\"2\">Office Use Only&#8212;<strong>Section 2 total score</strong> __________</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"subtitle1\" style=\"vertical-align: bottom; text-align: left;\" colspan=\"2\">Section 3 items</td> <td class=\"subtitle1\">Never or rarely</td> <td class=\"subtitle1\">Sometimes</td> <td class=\"subtitle1\">Often</td> <td class=\"subtitle1\">Very often</td> </tr> <tr> <td class=\"centered\">46.</td> <td>Find it difficult to tolerate waiting; impatient</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">47.</td> <td>Make decisions impulsively</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">48.</td> <td>Unable to inhibit my reactions or responses to events or others</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered highlight_blue_text\">49.</td> <td>Have difficulty stopping my activities or behavior when I should do so</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered highlight_blue_text\">50.</td> <td>Have difficulty changing my behavior when I am given feedback about my mistakes</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">51.</td> <td>Make impulsive comments to others</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">52.</td> <td>Likely to do things without considering the consequences for doing them</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">53.</td> <td>Change my plans at the last minute on a whim or last minute impulse</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">54.</td> <td>Fail to consider past relevant events or past personal experiences before responding to situations (I act without thinking)</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered highlight_blue_text\">55.</td> <td>Not aware of things I say or do</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">56.</td> <td>Have difficulty being objective about things that affect me</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">57.</td> <td>Find it hard to take other people's perspectives about a problem or situation</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">58.</td> <td>Don't think about or talk things over with myself before doing something</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">59.</td> <td>Trouble following the rules in a situation</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered highlight_blue_text\">60.</td> <td>More likely to drive a motor vehicle much faster than others (excessive speeding)</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">61.</td> <td>Have a low tolerance for frustrating situations</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">62.</td> <td>Cannot inhibit my emotions as well as others</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">63.</td> <td>I don't look ahead and think about what the future outcomes will be before I do something ( don't use my foresight)</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">64.</td> <td>I engage in risk taking activities more than others are likely to do</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr class=\"highlight_blue_text divider_bottom\"> <td colspan=\"2\">Office Use Only&#8212;<strong>Section 3 total score</strong> __________</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"subtitle1\" style=\"vertical-align: bottom; text-align: left;\" colspan=\"2\">Section 4 items</td> <td class=\"subtitle1\">Never or rarely</td> <td class=\"subtitle1\">Sometimes</td> <td class=\"subtitle1\">Often</td> <td class=\"subtitle1\">Very often</td> </tr> <tr> <td class=\"centered highlight_blue_text\">65.</td> <td>Likely to take short cuts in my work and not do all that I am supposed to do</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">66.</td> <td>Likely to skip out on work early if my work is boring to do</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">67.</td> <td>Do not put as much effort into my work as I should or than others are able to do</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">68.</td> <td>Others tell me I am lazy or unmotivated</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered highlight_blue_text\">69.</td> <td>Have to depend on others to help me get my work done</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">70.</td> <td>Things must have an immediate payoff for me or I do not seem to get them done</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">71.</td> <td>Have difficulty resisting the urge to do something fun or more interesting when I am supposed to be working</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">72.</td> <td>Inconsistent in the quality or quantity of my work performance</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">73.</td> <td>Unable to work as well as others without supervision or frequent instruction</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">74.</td> <td>I do not have the willpower or determination that others seem to have</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">75.</td> <td>I am not able to work toward longer term or delayed rewards as well as others</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">76.</td> <td>I cannot resist doing things that produce immediate rewards even if they are not good for me in the long run</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr class=\"highlight_blue_text divider_bottom\"> <td colspan=\"2\">Office Use Only&#8212;<strong>Section 4 total score</strong> __________</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"subtitle1\" style=\"vertical-align: bottom; text-align: left;\" colspan=\"2\">Section 5 items</td> <td class=\"subtitle1\">Never or rarely</td> <td class=\"subtitle1\">Sometimes</td> <td class=\"subtitle1\">Often</td> <td class=\"subtitle1\">Very often</td> </tr> <tr> <td class=\"centered\">77.</td> <td>Quick to get angry or become upset</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">78.</td> <td>Overreact emotionally</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">79.</td> <td>Easily excitable</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">80.</td> <td>Unable to inhibit showing strong negative or positive emotions</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">81.</td> <td>Have trouble calming myself down once I am emotionally upset</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">82.</td> <td>Cannot seem to regain emotional control and become more reasonable once I am emotional</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">83.</td> <td>Cannot seem to distract myself away from whatever is upsetting me emotionally to help calm me down. I can't refocus my mind to a more positive framework.</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">84.</td> <td>Unable to manage my emotions in order to accomplish my goals successfully or get along well with others</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">85.</td> <td>I remain emotional or upset longer than others</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">86.</td> <td>I find it difficult to walk away from emotionally upsetting encounters with others or leave situations in which I have become very emotional</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">87.</td> <td>I cannot rechannel or redirect my emotions into more positive ways or outlets when I get upset</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">88.</td> <td>I am not able to evaluate an emotionally upsetting event more objectively</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">89.</td> <td>I cannot redefine negative events into more positive viewpoints when I feel strong emotions</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr class=\"highlight_blue_text divider_bottom\"> <td colspan=\"2\">Office Use Only&#8212;<strong>Section 5 total score</strong> __________</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td colspan=\"2\">Office Use Only<br /> <strong>Total of sections 1 to 5: Total EF summary score</strong> __________</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td colspan=\"2\">Office Use Only<br /> <strong>Count number of items answered 3 or 4</strong><br /> <strong>EF symptom count</strong> __________</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"highlight_gray_text\"> <td colspan=\"2\">Office Use Only<br /> <strong>Add items 1, 6, 14, 16, 24, 49, 50, 55, 60, 65, and 69</strong><br /> <strong>ADHD-EF index score</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted with permission of Guilford Press. Barkley RA. Barkley Deficits in Executive Functioning Scale (BDEFS). New York: The Guilford Press, 2011. Copyright &copy; 2011 Guilford Press.</div><div id=\"graphicVersion\">Graphic 93441 Version 1.0</div></div></div>"},"93452":{"type":"graphic_diagnosticimage","displayName":"Sigmoid volvulus X-marks-the-spot sign","title":"Sigmoid volvulus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sigmoid volvulus</div><div class=\"cntnt\"><img style=\"width:345px; height:886px;\" src=\"images/GAST/93452_Sgmd_vlvls_X_mrks__spt_sgn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 90-year-old woman with sigmoid volvulus.<br />(A) Drawing shows X-marks-the-spot sign caused by crossing transition points. Horizontal lines and schematic axial insets indicate levels of B and C. Oblique lines in insets indicate two transition zones oriented in opposite directions, producing an X shape.<br />(B) Contrast-enhanced axial computed tomography (CT) image through proximal-superior transition (arrows).<br />(C) Axial CT image 15 mm caudal to B through distal-inferior sigmoid transition (arrows), which is oriented in the direction opposite to the proximal transition.</div><div class=\"graphic_reference\">Panel A reproduced with permission from Jordan Winick. Copyright &copy; 2015. <br />Panels B and C reprinted with permission from the American Journal of Roentgenology. Levsky JM, Den EI, DuBrow RA, et al. CT findings of sigmoid volvulus. AJR Am J Roentgenol 2010 194:136. Copyright &copy; 2010 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 93452 Version 1.0</div></div></div>"},"93453":{"type":"graphic_diagnosticimage","displayName":"Sigmoid volvulus split-wall sign","title":"Sigmoid volvulus","html":"<div class=\"graphic\"><div style=\"width: 703px\" class=\"figure\"><div class=\"ttl\">Sigmoid volvulus</div><div class=\"cntnt\"><img style=\"width:683px; height:592px;\" src=\"images/GAST/93453_Sgmd_vlvls_splt_wll_sgn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 75-year-old man with sigmoid volvulus.<br />(A) Drawing shows split-wall sign caused by apparent separation of sigmoid walls by adjacent mesenteric fat (arrow) secondary to incomplete twisting. Horizontal lines and schematic axial insets indicate levels of B-D.<br />(B) Contrast-enhanced axial computed tomography (CT) image through the single beak-shaped transition point (arrow).<br />(C) Axial CT image 25 mm caudal to B shows mesenteric fat (arrow) separating the two sigmoid walls (arrowheads).<br />(D) Axial CT image 25 mm caudal to C shows the decompressed rectosigmoid (arrow).</div><div class=\"graphic_reference\">Panel A reproduced with permission from Jordan Winick. Copyright &copy; 2015.<br />Panels B, C, and D reprinted with permission from the American Journal of Roentgenology. Levsky JM, Den EI, DuBrow RA, et al. CT findings of sigmoid volvulus. AJR Am J Roentgenol 2010 194:136. Copyright &copy; 2010 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 93453 Version 1.0</div></div></div>"},"93454":{"type":"graphic_table","displayName":"Venomous snakes Asia","title":"Some medically important venomous snakes found in Asia*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Some medically important venomous snakes found in Asia*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"5\"><span class=\"red\">Consult a regional poison control center (</span><a href=\"http://www.who.int/ipcs/poisons/centre/\" target=\"_blank\">www.who.int/ipcs/poisons/centre/</a><span class=\"red\">) or clinician with expertise in treating bites caused by Asian snakes for medical therapy including indications for giving antivenom, specific antivenom to use, and dosing.</span></td> </tr> <tr> <td class=\"subtitle1\">Common name</td> <td class=\"subtitle1\">Scientific name</td> <td class=\"subtitle1\">Regional distribution</td> <td class=\"subtitle1\">Additional effects</td> <td class=\"subtitle1\">Antivenom</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Snakes causing paralysis</td> </tr> <tr> <td class=\"indent1\">King cobra</td> <td><em>Ophiophagus hannah</em></td> <td>Southeast Asia</td> <td>Local<sup>&#916;</sup></td> <td>Monovalent and polyvalent</td> </tr> <tr> <td class=\"indent1\">Philippines cobra</td> <td><em>Naja philippinensis</em></td> <td>Southeast Asia</td> <td>Uncommonly causes local necrosis</td> <td>Monovalent</td> </tr> <tr> <td class=\"indent1\">Thai spitting cobra</td> <td><em>Naja siamensis</em></td> <td>Southeast Asia</td> <td>Local<sup>&#916;</sup> injury and tissue necrosis predominates</td> <td>Monovalent and polyvalent</td> </tr> <tr> <td class=\"indent1\">Monocled cobra</td> <td><em>Naja kaouthia</em></td> <td>Southeast Asia</td> <td>Local<sup>&#916;</sup> and tissue necrosis</td> <td>Monovalent and polyvalent</td> </tr> <tr> <td class=\"indent1\">Chinese cobra</td> <td><em>Naja atra</em></td> <td>Southeast Asia and China</td> <td>Local swelling, necrosis possible</td> <td>Monovalent</td> </tr> <tr> <td class=\"indent1\">Indian cobra</td> <td><em>Naja naja</em></td> <td>India</td> <td>Local<sup>&#916;</sup>, necrosis common</td> <td>Polyvalent</td> </tr> <tr> <td class=\"indent1\">Asian coral snakes</td> <td><em>Calliophus</em> and <em>Maticora</em> species</td> <td>Southeast Asia</td> <td>Paralysis only</td> <td>No specific antivenom</td> </tr> <tr> <td class=\"indent1\">Kraits</td> <td><em>Bungarus</em> species</td> <td>Southeast Asia, India, and China</td> <td>Paralysis only typical, rhabdomyolysis for some species</td> <td>Polyvalent (limited benefit)</td> </tr> <tr> <td class=\"indent1\">Death adder</td> <td><em>Acanthophis</em> species</td> <td>Southeast Asia</td> <td>Paralysis only typical , mild anticoagulant coagulopathy for Papua New Guinea species</td> <td>Monovalent and polyvalent</td> </tr> <tr> <td class=\"indent1\">Russell's viper</td> <td><em>Daboia russelli</em></td> <td>Southeast Asia and India</td> <td>Local<sup>&#916;</sup>, coagulopathy, tissue necrosis, rhabdomyolysis, acute kidney injury, and paralysis</td> <td>Polyvalent</td> </tr> <tr> <td class=\"indent1\">Viper, Adders</td> <td><em>Vipera</em> and <em>Macrovipera</em> species</td> <td>Asia</td> <td>Local<sup>&#916;</sup>, coagulopathy, hypotension, and acute kidney injury</td> <td>Monovalent for some but <strong>not</strong> all species</td> </tr> <tr> <td class=\"indent1\">Long nosed viper</td> <td><em>Vipera ammodytes</em></td> <td>Asia</td> <td>Local<sup>&#916;</sup></td> <td>Monovalent and polyvalent</td> </tr> <tr> <td class=\"indent1\">Sea snakes</td> <td>Numerous genera and species</td> <td>Indo-Pacific oceans</td> <td>Rhabdomyolysis, secondary kidney failure</td> <td>Monovalent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Snakes causing local tissue damage<sup>&#916;</sup> and systemic illness without paralysis</td> </tr> <tr> <td class=\"indent1\">Green tree pit viper</td> <td><em>Trimeresurus</em> (note also listed as following genera in some publications: <em>Popeia</em>, <em>Crypteletrops</em>, <em>Viridovipera</em>, <em>Himalayophis</em>, <em>Parias</em>, <em>Peltopelor</em>, <em>Garthius</em> and some spp. transferred to other genera, <em>Protobothrops</em>, <em>Ovophis</em>) species</td> <td>SE Asia, China, India, and Japan</td> <td>Hemorrhage and coagulopathy (wide variation in severity, mix of clinical effects, depending upon species)</td> <td>Specific antivenom available for several species (<em>T. albolabris</em>, <em>T. flavoviridis</em>, <em>T. mucrosquamatus</em>)</td> </tr> <tr> <td class=\"indent1\">Carpet or saw scaled vipers</td> <td><em>Echis</em> species</td> <td>Asia and India</td> <td>Hemorrhage, coagulopathy, tissue necrosis, and acute kidney injury</td> <td>Polyvalent</td> </tr> <tr> <td class=\"indent1\">Asian pit vipers</td> <td><em>Gloydius</em> species</td> <td>Asia, China, and Japan</td> <td>Hemorrhage, tissue necrosis, and coagulopathy</td> <td>Species dependent:<br /> <ul> <li>Monovalent: <em>Gloydius blomhoffi</em> (Japan) </li> <li>Polyvalent: <em>Gloydius brevicaudus</em>, <em>G. intermedius</em>, and <em>G. ussuriensis</em> (East Asia) </li> <li>None: <em>Gloydius himalayanus</em> and <em>G. tsushimaensis</em> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Malayan pit viper</td> <td><em>Calloselasma rhodostoma</em></td> <td>Southeast Asia</td> <td>Hemorrhage, coagulopathy, tissue necrosis, and acute kidney injury</td> <td>Monovalent and polyvalent</td> </tr> <tr> <td class=\"indent1\">Hundred pace viper, sharp-nosed viper</td> <td><em>Deinagkistrodon acutus</em></td> <td>China</td> <td>Hemorrhage, tissue necrosis, and coagulopathy</td> <td>Monovalent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Antivenom name and manufacturer, comprehensive listings of venomous Asian snakes by geographical region, and more precise geographic distribution of specific snake species may be found at <a href=\"http://apps.who.int/bloodproducts/snakeantivenoms/database/\" target=\"_blank\">WHO snake and antivenom database</a> or at <a href=\"http://www.toxinology.com/fusebox.cfm?fuseaction=main.snakes.search\" target=\"_blank\">Toxinology snake search</a>.<br />&Delta; Local effects include swelling, blistering, hemorrhagic skin changes, and bruising.</div><div class=\"graphic_reference\">Data from:<br /><ol>&#xD;&#xA;    <li>White J. Overview of venomous snakes of the world. In: Medical Toxicology, 3rd ed, Dart RC (Ed), Lippincott, Williams, &amp; Wilkins, Philadelphia, 2004, p.1543.</li>&#xD;&#xA;    <li>Clinical toxinology resources. <a href=\"http://www.toxinology.com/\" target=\"_blank\">www.toxinology.com</a> (Accessed March 26, 2013).</li>&#xD;&#xA;    <li>Venomous snakes and antivenoms search interface, World Health Organization. <a href=\"http://apps.who.int/bloodproducts/snakeantivenoms/database/\" target=\"_blank\">http://apps.who.int/bloodproducts/snakeantivenoms/database/</a> (Accessed March 25, 2013).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 93454 Version 3.0</div></div></div>"},"93455":{"type":"graphic_table","displayName":"Venomous snakes Africa","title":"Some medically important venomous snakes found in Africa*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Some medically important venomous snakes found in Africa*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><span class=\"red\">Consult a regional poison control center (</span><a href=\"http://www.who.int/ipcs/poisons/centre/\">www.who.int/ipcs/poisons/centre/</a><span class=\"red\">) or clinician with expertise in treating bites caused by African snakes for medical therapy including indications for giving antivenom, specific antivenom to use, and dosing.</span></td> </tr> <tr> <td class=\"subtitle1\">Common name</td> <td class=\"subtitle1\">Scientific name</td> <td class=\"subtitle1\">Additional effects</td> <td class=\"subtitle1\">Antivenom</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Snakes causing paralysis</td> </tr> <tr> <td class=\"indent1\">Green and black mambas</td> <td><em>Dendroaspis</em> species</td> <td>Paralysis only typical; green mambas occasionally cause local tissue injury</td> <td>Polyvalent</td> </tr> <tr> <td class=\"indent1\">Desert black snake</td> <td><em>Walterinnesia aegyptia</em></td> <td>Paralysis only typical, occasionally local swelling, pain</td> <td>Polyvalent</td> </tr> <tr> <td class=\"indent1\">Egyptian cobra</td> <td><em>Naja haje</em></td> <td>Local pain, swelling, blistering</td> <td>Polyvalent</td> </tr> <tr> <td class=\"indent1\">Forest cobra</td> <td><em>Naja melanoleuca</em></td> <td>Paralysis only typical, local swelling</td> <td>Polyvalent</td> </tr> <tr> <td class=\"indent1\">Rinkhals spitting cobra, ring-necked spitting cobra</td> <td><em>Hemachatus haemachatus</em></td> <td>Local<sup>&#916;</sup>, can spit venom</td> <td>Polyvalent</td> </tr> <tr> <td class=\"indent1\">Cape cobra</td> <td><em>Naja nivea</em></td> <td>Paralysis only</td> <td>Polyvalent</td> </tr> <tr> <td class=\"indent1\">Berg adder</td> <td><em>Bitis atropos</em></td> <td>Local swelling</td> <td>None available</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Snakes causing local tissue damage<sup>&#916;</sup> and systemic illness without paralysis</td> </tr> <tr> <td class=\"indent1\">Puff adder</td> <td><em>Bitis arietans</em></td> <td>Coagulopathy, hemorrhage, tissue necrosis, hypotension, and acute kidney injury</td> <td>Polyvalent</td> </tr> <tr> <td class=\"indent1\">East African gaboon pit viper</td> <td><em>Bitis gabonica</em></td> <td>Coagulopathy, hemorrhage, tissue necrosis, hypotension, and acute kidney injury</td> <td>Polyvalent</td> </tr> <tr> <td class=\"indent1\">Rhinoceros viper</td> <td><em>Bitis nasicornis</em></td> <td>Coagulopathy, hemorrhage, tissue necrosis, hypotension, and acute kidney injury</td> <td>Polyvalent</td> </tr> <tr> <td class=\"indent1\">Carpet or saw scaled vipers</td> <td><em>Echis</em> species</td> <td>Hemorrhage, coagulopathy, tissue necrosis, and acute kidney injury</td> <td>Polyvalent and monovalent (do not use antivenoms raised against non-African <em>Echis</em> spp.)</td> </tr> <tr> <td class=\"indent1\">Horned viper</td> <td><em>Cerastes</em> species</td> <td>Coagulopathy</td> <td>Polyvalent</td> </tr> <tr> <td class=\"indent1\">Bush vipers</td> <td><em>Atheris</em>, <em>Proatheris</em> spp.</td> <td>Coagulopathy</td> <td>None available, but consider SAVP anti-<em>Echis</em> AV</td> </tr> <tr> <td class=\"indent1\">Mozambique spitting cobra</td> <td><em>Naja mossambica</em></td> <td>Tissue necrosis, venom spitter</td> <td>Polyvalent</td> </tr> <tr> <td class=\"indent1\">Black necked spitting cobra</td> <td><em>Naja nigricollis</em></td> <td>Tissue necrosis, venom spitter</td> <td>Polyvalent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Antivenom name and manufacturer, comprehensive listings of venomous African snakes by geographical region, and more precise geographic distribution of specific snake species may be found at&nbsp;<A href=\"http://apps.who.int/bloodproducts/snakeantivenoms/database/\" target=_blank>WHO snake and antivenom database</A> or at <A href=\"http://www.toxinology.com/fusebox.cfm?fuseaction=main.snakes.search\" target=_blank>Toxinology snake search</A>.<br />Δ Local effects include swelling, blistering, hemorrhagic skin changes, and bruising.</div><div class=\"graphic_reference\">Data from:<br /><ol>&#xD;&#xA;    <li>White J. Overview of venomous snakes of the world. In: Medical Toxicology, 3rd ed, Dart RC (Ed), Lippincott, Williams, &amp; Wilkins, Philadelphia, 2004, p.1543.</li>&#xD;&#xA;    <li>Clinical toxinology resources. <a href=\"http://www.toxinology.com/\" target=\"_blank\">www.toxinology.com</a> (Accessed March 26, 2013).</li>&#xD;&#xA;    <li>Venomous snakes and antivenoms search interface, World Health Organization. <a href=\"http://apps.who.int/bloodproducts/snakeantivenoms/database/\" target=\"_blank\">http://apps.who.int/bloodproducts/snakeantivenoms/database/</a> (Accessed March 25, 2013).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 93455 Version 3.0</div></div></div>"},"93456":{"type":"graphic_table","displayName":"Venomous snakes in Australia and the Pacific islands","title":"Some medically important snakes found in Australia and the Pacific islands*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Some medically important snakes found in Australia and the Pacific islands*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><span class=\"red\"><strong>Consult a regional poison control center (</strong></span><a href=\"http://www.who.int/ipcs/poisons/centre/\" target=\"_blank\"><strong>www.who.int/ipcs/poisons/centre/</strong></a><span class=\"red\"><strong>) or clinician with expertise in treating bites caused by Australian or Pacific Island snakes for medical therapy including indications for giving antivenom, specific antivenom to use, and dosing.</strong></span></td> </tr> <tr> <td class=\"subtitle1\">Common name</td> <td class=\"subtitle1\">Scientific name</td> <td class=\"subtitle1\">Additional effects</td> <td class=\"subtitle1\">Antivenom</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Snakes causing paralysis</td> </tr> <tr> <td class=\"indent1\">Tiger snake</td> <td><em>Notechis scutatus</em> (includes <em>N. ater</em>)</td> <td>Coagulopathy, rhabdomyolysis, and acute kidney injury</td> <td>Monovalent and polyvalent</td> </tr> <tr> <td class=\"indent1\">Rough scaled snake</td> <td><em>Tropidechis carinatus</em></td> <td>Coagulopathy, rhabdomyolysis, and acute kidney injury</td> <td>Monovalent and polyvalent</td> </tr> <tr> <td class=\"indent1\">Copperheads</td> <td><em>Austrelaps</em> species</td> <td>Rhabdomyolysis</td> <td>Monovalent and polyvalent</td> </tr> <tr> <td class=\"indent1\">Brown snakes</td> <td><em>Pseudonaja</em> species</td> <td>Coagulopathy and acute kidney injury predominate</td> <td>Monovalent and polyvalent</td> </tr> <tr> <td class=\"indent1\">Taipans</td> <td><em>Oxyuranus</em> species</td> <td>Coagulopathy, rhabdomyolysis, and acute kidney injury</td> <td>Monovalent and polyvalent</td> </tr> <tr> <td class=\"indent1\">New Guinea small-eyed snake</td> <td><em>Micropechis ikaheka</em></td> <td>Coagulopathy and rhabdomyolysis</td> <td>Polyvalent</td> </tr> <tr> <td class=\"indent1\">Death adder</td> <td><em>Acanthophis</em> species</td> <td>Paralysis only</td> <td>Monovalent and polyvalent</td> </tr> <tr> <td class=\"indent1\">Sea snakes</td> <td>Numerous genera and species</td> <td>Rhabdomyolysis, secondary kidney failure</td> <td>Monovalent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Snakes causing local tissue damage<sup>&#916;</sup> and systemic illness without paralysis</td> </tr> <tr> <td class=\"indent1\">Broad-headed snake</td> <td><em>Hoplocephalus</em> species</td> <td>Coagulopathy</td> <td>Monovalent (Tiger snake antivenom), polyvalent</td> </tr> <tr> <td class=\"indent1\">Red-bellied black snake</td> <td><em>Pseudechis</em> species</td> <td>Coagulopathy, rhabdomyolysis</td> <td>Monovalent (Tiger snake or Black snake antivenom), polyvalent</td> </tr> <tr> <td class=\"indent1\">Mulga, Papuan black, and Collett snakes</td> <td><em>Pseudechis</em> species</td> <td>Coagulopathy, rhabdomyolysis, and acute kidney injury</td> <td>Monovalent (Black snake antivenom), polyvalent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Antivenom name and manufacturer, comprehensive listings of venomous Australian snakes by geographical region, and more precise geographic distribution of specific snake species may be found at&nbsp;<A href=\"http://apps.who.int/bloodproducts/snakeantivenoms/database/\" target=_blank>WHO snake and antivenom database</A> or at <A href=\"http://www.toxinology.com/fusebox.cfm?fuseaction=main.snakes.search\" target=_blank>Toxinology snake search</A>.<br />Δ Local effects include swelling, blistering, hemorrhagic skin changes, and bruising.</div><div class=\"graphic_reference\">Data from:<br /><ol>&#xD;&#xA;    <li>White J. Overview of venomous snakes of the world. In: Medical Toxicology, 3rd ed, Dart RC (Ed), Lippincott, Williams, &amp; Wilkins, Philadelphia, 2004, p.1543.</li>&#xD;&#xA;    <li>Clinical toxinology resources. <a href=\"http://www.toxinology.com/\" target=\"_blank\">www.toxinology.com</a> (Accessed March 26, 2013).</li>&#xD;&#xA;    <li>Venomous snakes and antivenoms search interface, World Health Organization. <a href=\"http://apps.who.int/bloodproducts/snakeantivenoms/database/\" target=\"_blank\">http://apps.who.int/bloodproducts/snakeantivenoms/database/</a> (Accessed March 25, 2013).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 93456 Version 3.0</div></div></div>"},"93457":{"type":"graphic_table","displayName":"Venomous snakes in Central and South America","title":"Some medically important venomous snakes found in Central and South America*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Some medically important venomous snakes found in Central and South America*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><span class=\"red\">Consult a regional poison control center (</span><a href=\"http://www.who.int/ipcs/poisons/centre/\" target=\"_blank\">www.who.int/ipcs/poisons/centre/</a><span class=\"red\">) or clinician with expertise in treating bites caused by Central or South American snakes for medical therapy including indications for giving antivenom, specific antivenom to use, and dosing.</span></td> </tr> <tr> <td class=\"subtitle1\">Common name</td> <td class=\"subtitle1\">Scientific name</td> <td class=\"subtitle1\">Additional effects</td> <td class=\"subtitle1\">Antivenom</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Snakes causing paralysis</td> </tr> <tr> <td class=\"indent1\">Coral snakes</td> <td><em>Micrurus</em> species</td> <td>Paralysis only typical; occasional cases with rhabdomyolysis</td> <td>Monovalent</td> </tr> <tr> <td class=\"indent1\">Central and South American rattlesnakes</td> <td><em>Crotalus</em> species</td> <td>Local<sup>&#916;</sup> and acute kidney injury, coagulopathy, rhabdomyolysis</td> <td>Monovalent and polyvalent</td> </tr> <tr> <td class=\"indent1\">Neotropical rattlesnake (cascabel)</td> <td><em>Crotalus durissus</em></td> <td>Local, coagulopathy, hemorrhage, rhabdomyolysis, and acute kidney injury</td> <td>Monovalent and polyvalent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Snakes causing local tissue damage<sup>&#916;</sup> and systemic illness without paralysis</td> </tr> <tr> <td class=\"indent1\">Terciopelo, lancehead, Fer de Lance</td> <td><em>Bothrops</em> species</td> <td>Tissue necrosis, coagulopathy, hemorrhage</td> <td>Monovalent and polyvalent</td> </tr> <tr> <td class=\"indent1\">Brazilian lancehead</td> <td><em>Bothrops jararaca</em>, <em>B. jararacusu</em>, <em>B. moojeni</em></td> <td>Tissue necrosis, coagulopathy, hemorrhage, rhabdomyolysis, and acute kidney injury</td> <td>Monovalent and polyvalent</td> </tr> <tr> <td class=\"indent1\">Palm pit vipers</td> <td><em>Bothriechis</em> species</td> <td>Tissue necrosis</td> <td>Polyvalent (specific antivenom <strong>not</strong> available for all species)</td> </tr> <tr> <td class=\"indent1\">Bushmaster</td> <td><em>Lachesis muta</em></td> <td>Tissue necrosis and coagulopathy</td> <td>Monovalent and polyvalent</td> </tr> <tr> <td class=\"indent1\">Hog-nosed pit viper</td> <td><em>Porthidium</em> species</td> <td>Tissue necrosis</td> <td>Polyvalent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Antivenom name and manufacturer, comprehensive listings of venomous Central or South American snakes by geographical region, and more precise geographic distribution of specific snake species may be found at&nbsp;<A href=\"http://apps.who.int/bloodproducts/snakeantivenoms/database/\" target=_blank>WHO snake and antivenom database</A> or at <A href=\"http://www.toxinology.com/fusebox.cfm?fuseaction=main.snakes.search\" target=_blank>Toxinology snake search</A>.<br />Δ Local effects include swelling, blistering, hemorrhagic skin changes, and bruising.</div><div class=\"graphic_reference\">Data from:<br /><ol>&#xD;&#xA;    <li>White J. Overview of venomous snakes of the world. In: Medical Toxicology, 3rd ed, Dart RC (Ed), Lippincott, Williams, &amp; Wilkins, Philadelphia, 2004, p.1543.</li>&#xD;&#xA;    <li>Clinical toxinology resources. <a href=\"http://www.toxinology.com/\" target=\"_blank\">www.toxinology.com</a> (Accessed March 26, 2013).</li>&#xD;&#xA;    <li>Venomous snakes and antivenoms search interface, World Health Organization. <a href=\"http://apps.who.int/bloodproducts/snakeantivenoms/database/\" target=\"_blank\">http://apps.who.int/bloodproducts/snakeantivenoms/database/</a> (Accessed March 25, 2013).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 93457 Version 2.0</div></div></div>"},"93458":{"type":"graphic_table","displayName":"Venomous snakes Middle East","title":"Some medically important snakes found in the Middle East*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Some medically important snakes found in the Middle East*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><span class=\"red\">Consult a regional poison control center (</span><a href=\"http://www.who.int/ipcs/poisons/centre/\" target=\"_blank\">www.who.int/ipcs/poisons/centre/</a><span class=\"red\">) or clinician with expertise in treating bites caused by Middle Eastern snakes for medical therapy including indications for giving antivenom, specific antivenom to use, and dosing.</span></td> </tr> <tr> <td class=\"subtitle1\">Common name</td> <td class=\"subtitle1\">Scientific name</td> <td class=\"subtitle1\">Additional effects</td> <td class=\"subtitle1\">Antivenom</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Snakes causing paralysis</td> </tr> <tr> <td class=\"indent1\">Arabian cobra</td> <td><em>Naja arabica</em></td> <td>Paralysis only</td> <td>Polyvalent</td> </tr> <tr> <td class=\"indent1\">Central Asian cobra</td> <td><em>Naja oxiana</em></td> <td>Local<sup>&#916;</sup> and tissue necrosis</td> <td>Polyvalent</td> </tr> <tr> <td class=\"indent1\">Long-nosed viper</td> <td><em>Vipera ammodytes</em></td> <td>Local<sup>&#916;</sup></td> <td>Monovalent and polyvalent</td> </tr> <tr> <td class=\"indent1\">Persian horned viper</td> <td><em>Pseudocerastes persicus</em></td> <td>Paralysis only</td> <td>Polyvalent</td> </tr> <tr> <td class=\"indent1\">Vipers (Levant viper)</td> <td><em>Vipera</em> species and <em>Macrovipera lebetina</em></td> <td>Local<sup>&#916;</sup>, coagulopathy, hemorrhage, hypotension, and acute kidney injury</td> <td>Monovalent and polyvalent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Snakes causing local tissue damage<sup>&#916;</sup> and systemic illness without paralysis</td> </tr> <tr> <td class=\"indent1\">Carpet and saw-scaled vipers</td> <td><em>Echis</em> species</td> <td>Hemorrhage, coagulopathy, tissue necrosis, and acute kidney injury</td> <td>Polyvalent</td> </tr> <tr> <td class=\"indent1\">Puff adder</td> <td><em>Bitis arietans</em></td> <td>Coagulopathy, hemorrhage, tissue necrosis, hypotension, and acute kidney injury</td> <td>Polyvalent</td> </tr> <tr> <td class=\"indent1\">Palestinian viper</td> <td><em>Daboia palaestinae</em></td> <td>Tissue necrosis, coagulopathy, rhabdomyolysis, and hypotension</td> <td>Monovalent and polyvalent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Antivenom name and manufacturer, comprehensive listings of venomous Middle Eastern snakes by geographical region, and more precise geographic distribution of specific snake species may be found at&nbsp;<A href=\"http://apps.who.int/bloodproducts/snakeantivenoms/database/\" target=_blank>WHO snake and antivenom database</A> or at <A href=\"http://www.toxinology.com/fusebox.cfm?fuseaction=main.snakes.search\" target=_blank>Toxinology snake search</A>.<br />Δ Local effects include swelling, blistering, hemorrhagic skin changes, and bruising.</div><div class=\"graphic_reference\">Data from:<br /><ol>&#xD;&#xA;    <li>White J. Overview of venomous snakes of the world. In: Medical Toxicology, 3rd ed, Dart RC (Ed), Lippincott, Williams, &amp; Wilkins, Philadelphia, 2004, p.1543.</li>&#xD;&#xA;    <li>Clinical toxinology resources. <a href=\"http://www.toxinology.com/\" target=\"_blank\">www.toxinology.com</a> (Accessed March 26, 2013).</li>&#xD;&#xA;    <li>Venomous snakes and antivenoms search interface, World Health Organization. <a href=\"http://apps.who.int/bloodproducts/snakeantivenoms/database/\" target=\"_blank\">http://apps.who.int/bloodproducts/snakeantivenoms/database/</a> (Accessed March 25, 2013).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 93458 Version 2.0</div></div></div>"},"93459":{"type":"graphic_table","displayName":"Venomous snakes in Europe","title":"Some medically important snakes found in Europe*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Some medically important snakes found in Europe*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><span class=\"red\">Consult a regional poison control center (</span><a href=\"http://www.who.int/ipcs/poisons/centre/\" target=\"_blank\">www.who.int/ipcs/poisons/centre/</a><span class=\"red\">) or clinician with expertise in treating bites caused by European snakes for medical therapy including indications for giving antivenom, specific antivenom to use, and dosing.</span></td> </tr> <tr> <td class=\"subtitle1\">Common name</td> <td class=\"subtitle1\">Scientific name</td> <td class=\"subtitle1\">Additional effects</td> <td class=\"subtitle1\">Antivenom</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Snakes causing paralysis</td> </tr> <tr> <td class=\"indent1\">Vipers (Levant viper)</td> <td><em>Vipera</em> species and <em>Macrovipera lebetina</em></td> <td>Local<sup>&#916;</sup>, coagulopathy, hemorrhage, hypotension, and acute kidney injury</td> <td>Monovalent and polyvalent</td> </tr> <tr> <td class=\"indent1\">Long-nosed viper</td> <td><em>Vipera ammodytes</em></td> <td>Local<sup>&#916;</sup></td> <td>Monovalent and polyvalent</td> </tr> <tr> <td class=\"indent1\">European viper, European adder</td> <td><em>Vipera berus</em></td> <td>Local<sup>&#916;</sup> (predominant), tissue necrosis, coagulopathy</td> <td>Monovalent and polyvalent</td> </tr> <tr> <td class=\"indent1\">European asp</td> <td><em>Vipera aspis</em></td> <td>Local<sup>&#916;</sup> (predominant), tissue necrosis, coagulopathy</td> <td>Monovalent and polyvalent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Snakes causing local tissue damage<sup>&#916;</sup> and systemic illness without paralysis</td> </tr> <tr> <td class=\"indent1\">Central Asian pit viper</td> <td><em>Gloydius intermedius</em></td> <td>Hemorrhage, tissue necrosis, and coagulopathy</td> <td>Polyvalent</td> </tr> <tr> <td class=\"indent1\">Halys pit viper</td> <td><em>Gloydius halys</em></td> <td>Hemorrhage, tissue necrosis, and coagulopathy</td> <td>Monovalent and polyvalent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Antivenom name and manufacturer, comprehensive listings of venomous European snakes by geographical region, and more precise geographic distribution of specific snake species may be found at&nbsp;<A href=\"http://apps.who.int/bloodproducts/snakeantivenoms/database/\" target=_blank>WHO snake and antivenom database</A> or at <A href=\"http://www.toxinology.com/fusebox.cfm?fuseaction=main.snakes.search\" target=_blank>Toxinology snake search</A>.<br />Δ Local effects include swelling, blistering, hemorrhagic skin changes, and bruising.</div><div class=\"graphic_reference\">Data from:<br /><ol>&#xD;&#xA;    <li>White J. Overview of venomous snakes of the world. In: Medical Toxicology, 3rd ed, Dart RC (Ed), Lippincott, Williams, &amp; Wilkins, Philadelphia, 2004, p.1543.</li>&#xD;&#xA;    <li>Clinical toxinology resources. <a href=\"http://www.toxinology.com/\" target=\"_blank\">www.toxinology.com</a> (Accessed March 26, 2013).</li>&#xD;&#xA;    <li>Venomous snakes and antivenoms search interface, World Health Organization. <a href=\"http://apps.who.int/bloodproducts/snakeantivenoms/database/\" target=\"_blank\">http://apps.who.int/bloodproducts/snakeantivenoms/database/</a> (Accessed March 25, 2013).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 93459 Version 2.0</div></div></div>"},"93461":{"type":"graphic_picture","displayName":"Ear barotrauma","title":"Tympanic membrane barotrauma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Tympanic membrane barotrauma</div><div class=\"cntnt\"><img style=\"width:504px; height:349px;\" src=\"images/PEDS/93461_Ear_barotrauma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Airplane travel-related tympanic membrane barotrauma demonstrated by bleeding into the tympanic membrane.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 93461 Version 2.0</div></div></div>"},"93462":{"type":"graphic_picture","displayName":"SV-cPACNS histology","title":"Brain histology in a patient with angiography-negative, brain biopsy-positive, small vessel cPACNS","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brain histology in a patient with angiography-negative, brain biopsy-positive, small vessel cPACNS</div><div class=\"cntnt\"><img style=\"width:278px; height:373px;\" src=\"images/ALLRG/93462_SV_cPACNS_histology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brain biopsy of a four-year-old girl with small vessel cPACNS shows a lymphocytic intramural infiltrate.</div><div class=\"graphic_footnotes\">cPACNS: childhood primary angiitis of the central nervous system.</div><div id=\"graphicVersion\">Graphic 93462 Version 1.0</div></div></div>"},"93463":{"type":"graphic_diagnosticimage","displayName":"Radiographic findings in SV-cPACNS","title":"Radiographic findings in a patient with angiography-negative, brain biopsy-positive, small vessel cPACNS","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiographic findings in a patient with angiography-negative, brain biopsy-positive, small vessel cPACNS</div><div class=\"cntnt\"><img style=\"width:242px; height:284px;\" src=\"images/ALLRG/93463_Radiograph_find_SV_cPACNS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A four-year-old girl with small vessel vasculitis with diffuse white matter abnormalities seen on MRI.</div><div class=\"graphic_footnotes\">cPACNS: childhood primary angiitis of the central nervous system; MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 93463 Version 1.0</div></div></div>"},"93464":{"type":"graphic_table","displayName":"DDx of large vessel cPACNS","title":"Differential diagnosis of large vessel cPACNS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of large vessel cPACNS</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Noninflammatory vasculopathies</td> </tr> <tr> <td class=\"indent1\">Dissection</td> </tr> <tr> <td class=\"indent1\">Thromboembolic disease</td> </tr> <tr> <td class=\"indent1\">Moyamoya disease (idiopathic)</td> </tr> <tr> <td class=\"indent1\">Hemoglobin disorders</td> </tr> <tr> <td class=\"indent1\">Antiphospholipid syndrome</td> </tr> <tr> <td class=\"indent1\">Fibromuscular dysplasia</td> </tr> <tr> <td class=\"indent1\">Collagen vascular disorders</td> </tr> <tr> <td class=\"indent1\">Focal cerebral angiopathy</td> </tr> <tr> <td class=\"indent1\">Genetic syndromes associated with cerebral vasculopathy (neurofibromatosis type 1, Down syndrome, PHACES, CADASIL, Fabry syndrome, homocystinuria)</td> </tr> <tr> <td class=\"subtitle1_single\">Cerebral vasospasm conditions</td> </tr> <tr> <td class=\"indent1\">Channelopathies (including familiar hemiplegic migraine, calcium channelopathy)</td> </tr> <tr> <td class=\"indent1\">Reversible vasoconstriction syndrome (RVCS)</td> </tr> <tr> <td class=\"subtitle1_single\">Syndromes associated with cerebral vasculopathies</td> </tr> <tr> <td class=\"indent1\">Cogan syndrome</td> </tr> <tr> <td class=\"indent1\">Susac syndrome</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">cPACNS: childhood primary angiitis of the central nervous system; PHACES: Posterior fossa malformations, Hemangiomas, Arterial malformations, Coarctation of the aorta/Cardiac defects, Eye abnormalities, and Sternal defects; CADASIL: Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy.</div><div id=\"graphicVersion\">Graphic 93464 Version 1.0</div></div></div>"},"93465":{"type":"graphic_table","displayName":"DDx of SV-cPACNS","title":"Differential diagnosis of small vessel cPACNS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of small vessel cPACNS</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Nonvasculitic inflammatory brain diseases</td> </tr> <tr> <td class=\"indent1\">Demyelinating inflammatory brain diseases (multiple sclerosis, ADEM)</td> </tr> <tr> <td class=\"indent1\">Antibody mediated inflammatory brain diseases (anti-NMDAR encephalitis, limbic encephalitis, neuromyelitis optica, Hashimoto encephalitis, pediatric autoinflammatory neuropsychiatric disorder associated with streptococcal infections)</td> </tr> <tr> <td class=\"indent1\">T cell parenchymal inflammatory brain diseases (Rasmussen encephalitis)</td> </tr> <tr> <td class=\"indent1\">Granulomatous inflammatory brain diseases (neurosarcoidosis)</td> </tr> <tr> <td class=\"subtitle1_single\">Infections</td> </tr> <tr> <td class=\"indent1\">Tuberculosis</td> </tr> <tr> <td class=\"indent1\">JC virus</td> </tr> <tr> <td class=\"subtitle1_single\">Metabolic diseases</td> </tr> <tr> <td class=\"indent1\">Mitochondrial encephalopathy lactic acidosis and stroke-like episodes (MELAS)</td> </tr> <tr> <td class=\"indent1\">Rolandic mitochondrial encephalopathy (ROME)</td> </tr> <tr> <td class=\"indent1\">Polymerase gamma deficiency</td> </tr> <tr> <td class=\"subtitle1_single\">Malignancies</td> </tr> <tr> <td class=\"indent1\">Angiocentric lymphoma</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">cPACNS: childhood primary angiitis of the central nervous system; ADEM: acute disseminated encephalomyelitis; NMDAR: N-methyl-D-aspartate receptor; JC: John Cunningham.</div><div id=\"graphicVersion\">Graphic 93465 Version 2.0</div></div></div>"},"93466":{"type":"graphic_table","displayName":"Secondary CNS vasculitis","title":"Causes of secondary central nervous system (CNS) vasculitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of secondary central nervous system (CNS) vasculitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Infections (active or postinfectious)</td> </tr> <tr> <td class=\"indent1\">Viral (VZV, HIV, EBV, CMV, JCV, HBV, HCV)</td> </tr> <tr> <td class=\"indent1\">Bacterial (<em>Mycobacterium tuberculosis</em>, <em>Mycoplasma pneumonia</em>, <em>Streptococcus pneumoniae</em>)</td> </tr> <tr> <td class=\"indent1\">Fungal (<em>Aspergillus</em> spp, <em>Candida albicans</em>, <em>Actinomyces</em> spp)</td> </tr> <tr> <td class=\"subtitle1_single\">Systemic rheumatic diseases</td> </tr> <tr> <td class=\"indent1\">Systemic lupus erythematosus (SLE)</td> </tr> <tr> <td class=\"indent1\">ANCA-associated vasculitis</td> </tr> <tr> <td class=\"indent1\">Scleroderma</td> </tr> <tr> <td class=\"indent1\">Dermatomyositis</td> </tr> <tr> <td class=\"indent1\">Beh&#231;et disease</td> </tr> <tr> <td class=\"subtitle1_single\">Systemic inflammatory diseases</td> </tr> <tr> <td class=\"indent1\">Inflammatory bowel diseases</td> </tr> <tr> <td class=\"indent1\">Hemophagocytic lymphohistiocytosis</td> </tr> <tr> <td class=\"indent1\">Kawasaki disease</td> </tr> <tr> <td class=\"subtitle1_single\">Other systemic conditions or exposures</td> </tr> <tr> <td class=\"indent1\">Graft-versus-host disease (GVHD)</td> </tr> <tr> <td class=\"indent1\">Radiation-induced</td> </tr> <tr> <td class=\"indent1\">Drugs (cocaine, amphetamines)</td> </tr> <tr> <td class=\"indent1\">Malignancies</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">VZV: varicella zoster virus; HIV: human immunodeficiency virus; EBV: Epstein-Barr virus; CMV: cytomegalovirus; JCV: John Cunningham virus; HBV: hepatitis B virus; HCV: hepatitis C virus; ANCA: antineutrophil cytoplasmic antibody.</div><div id=\"graphicVersion\">Graphic 93466 Version 1.0</div></div></div>"},"93468":{"type":"graphic_diagnosticimage","displayName":"Migrated foreign body","title":"Migration of bullet into the airway","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Migration of bullet into the airway</div><div class=\"cntnt\"><img style=\"width:487px; height:190px;\" src=\"images/PULM/93468_Migrated_foreign_body.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain radiograph (A) and computed tomographic scan (B) show an endobronchial bullet that migrated from the mediastinum into the left mainstem bronchus over a prolonged period of time.</div><div id=\"graphicVersion\">Graphic 93468 Version 1.0</div></div></div>"},"93482":{"type":"graphic_diagnosticimage","displayName":"Chest x-ray CT LV aneurysm CHF pacemaker","title":"LV aneurysm with CHF arrhythmia, pacemaker on chest x-ray and CT scan","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">LV aneurysm with CHF arrhythmia, pacemaker on chest x-ray and CT scan</div><div class=\"cntnt\"><img style=\"width:598px; height:344px;\" src=\"images/RADIOL/93482_Chest_xray_CT_LV_CHF_pace.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest x-ray in the P-A projection shows a calcified left ventricular aneurysm (between arrows). A biventricular pacemaker is present. Image B is an axial image through the calcified aneurysm of the LV apex (arrow). A coronal reconstruction of the CT scan (C) shows a calcified ovoid aneurysm (arrow).</div><div class=\"graphic_footnotes\">LV: left ventricular; P-A: posteroanterior; CT: computed tomography; CHF: congestive heart failure.</div><div id=\"graphicVersion\">Graphic 93482 Version 1.0</div></div></div>"},"93483":{"type":"graphic_diagnosticimage","displayName":"CT LV aneurysm thrombus systemic emboli","title":"LV aneurysm with thrombus and embolic renal infarction","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">LV aneurysm with thrombus and embolic renal infarction</div><div class=\"cntnt\"><img style=\"width:600px; height:233px;\" src=\"images/RADIOL/93483_CT_LV_aneur_thromb_emb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan through the lower chest (A) shows thrombus in the LV apex (arrow). Image B shows an acute wedge shaped infarct in the left kidney (arrowhead). There is also scarring from prior infarcts in the right kidney (arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93483 Version 1.0</div></div></div>"},"93484":{"type":"graphic_diagnosticimage","displayName":"LV angiogram pseudoaneurysm  ","title":"LV pseudoaneurysm on left ventriculography","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">LV pseudoaneurysm on left ventriculography</div><div class=\"cntnt\"><img style=\"width:472px; height:485px;\" src=\"images/RADIOL/93484_LV_angiogr_psdaneurysm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A left ventriculogram in the right anterior oblique projection shows a large aneurysm (arrows) in the inferobasal region of the left ventricle. Surgery confirmed the presence of a pseudoaneurysm.</div><div class=\"graphic_footnotes\">LV: left ventricular.</div><div id=\"graphicVersion\">Graphic 93484 Version 1.0</div></div></div>"},"93485":{"type":"graphic_diagnosticimage","displayName":"Gross pathology LV aneurysm","title":"LV aneurysm on gross pathology","html":"<div class=\"graphic\"><div style=\"width: 609px\" class=\"figure\"><div class=\"ttl\">LV aneurysm on gross pathology</div><div class=\"cntnt\"><img style=\"width:589px; height:384px;\" src=\"images/RADIOL/93485_Gross_path_LV_aneurysm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A gross pathology specimen of an apical LV aneurysm shows a thin muscle wall with smooth white and fibrotic endothelium (asterisk) in contrast to the normal appearing glistening and transparent endothelium (&para;).</div><div class=\"graphic_footnotes\">LV: left ventricular.</div><div id=\"graphicVersion\">Graphic 93485 Version 2.0</div></div></div>"},"93487":{"type":"graphic_diagnosticimage","displayName":"Imaging normal and aneurysmal LV  ","title":"Normal and aneurysmal apex of the LV on angiography and CT","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Normal and aneurysmal apex of the LV on angiography and CT</div><div class=\"cntnt\"><img style=\"width:584px; height:479px;\" src=\"images/RADIOL/93487_Img_norm_aneurysm_LV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A normal LV angiogram (A) in the RAO projection shows a conical shape of the LV apex in systole (arrowhead). Image B shows an angiogram in the RAO projection with a dyskinetic aneurysmal bulge of the apex in systole (arrowhead). Image C is an axial CT&nbsp;image through the chest and shows a normal cone shape of the left ventricular apex (arrowhead). Image D shows an aneurysmal bulge of the apex of the left ventricle (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography; LV: left ventricular; RAO: right anterior oblique; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93487 Version 1.0</div></div></div>"},"93489":{"type":"graphic_diagnosticimage","displayName":"Chest x-ray calcified LV aneurysm","title":"Calcified LV aneurysm on chest x-ray","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Calcified LV aneurysm on chest x-ray</div><div class=\"cntnt\"><img style=\"width:600px; height:349px;\" src=\"images/RADIOL/93489_Chst_x_clc_LV_aneurysm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest x-ray in the P-A projection (A) shows a calcified left ventricular aneurysm with a rounded deformity of the LV (arrowhead). A magnified insert (B) shows the calcification (arrowhead). The lateral examination shows an abnormal bulge of the left ventricle (arrows).</div><div class=\"graphic_footnotes\">LV: left ventricular; P-A: posteroanterior.</div><div id=\"graphicVersion\">Graphic 93489 Version 1.0</div></div></div>"},"93490":{"type":"graphic_diagnosticimage","displayName":"Chest x-ray inferobasal LV aneurysm","title":"Inferobasal LV aneurysm on chest x-ray","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Inferobasal LV aneurysm on chest x-ray</div><div class=\"cntnt\"><img style=\"width:598px; height:307px;\" src=\"images/RADIOL/93490_Chest_xray_inferoba_LV_aneu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest x-ray in P-A projection (A) shows a calcified aneurysm (between arrows) overlying the spine. The aneurysm is better seen on the lateral examination (B), which shows a&nbsp;calcified aneurysm (between arrows) in the posterior and inferior aspect of the left ventricle.</div><div class=\"graphic_footnotes\">LV: left ventricular; P-A: posteroanterior.</div><div id=\"graphicVersion\">Graphic 93490 Version 1.0</div></div></div>"},"93492":{"type":"graphic_diagnosticimage","displayName":"CT scan inferobasal calcified aneurysm with thrombus","title":"Inferobasal LV aneurysm with thrombus on CT scan","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Inferobasal LV aneurysm with thrombus on CT scan</div><div class=\"cntnt\"><img style=\"width:598px; height:264px;\" src=\"images/RADIOL/93492_CT_inferobasal_aneury_throm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan without contrast through the left ventricle (A) shows a calcified aneurysm (arrow) in the inferobasal and septal region of the left ventricle. A CT scan with contrast performed five years later (B) shows thrombus within the aneurysm (arrow). The size of the aneurysm is unchanged.</div><div class=\"graphic_footnotes\">CT: computed tomography; LV: left ventricular.</div><div id=\"graphicVersion\">Graphic 93492 Version 2.0</div></div></div>"},"93494":{"type":"graphic_diagnosticimage","displayName":"Gross pathology and CT scan chronic apical LV aneurysm","title":"Smooth walled chronic LV aneurysm on gross pathology and CT","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Smooth walled chronic LV aneurysm on gross pathology and CT</div><div class=\"cntnt\"><img style=\"width:597px; height:410px;\" src=\"images/RADIOL/93494_Gross_path_CT_LV_aneurysm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A gross pathology specimen (A) of a chronic apical LV aneurysm shows a smooth, white, and fibrosed endocardium (A, arrow). A CT scan through the heart without contrast (B) shows a chronic apical LV aneurysm with fat replacement (arrows) in the scar due to a prior apical infarction. Image C is a CT scan through the heart with intravenous contrast, and shows a smooth walled apical aneurysm (arrow).</div><div class=\"graphic_footnotes\">LV: left ventricular; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93494 Version 1.0</div></div></div>"},"93495":{"type":"graphic_diagnosticimage","displayName":"CT acute MI LV thrombus","title":"Acute MI with thrombus in LV aneurysm on CT scan","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Acute MI with thrombus in LV aneurysm on CT scan</div><div class=\"cntnt\"><img style=\"width:494px; height:387px;\" src=\"images/RADIOL/93495_CT_acute_MI_LV_thrombus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan through the LV shows acute thrombus in an aneurysm of the LV apex (arrow). The 46-year-old patient presented with an acute MI that was complicated by severe apical dyskinesis and apical thrombus formation (arrow).</div><div class=\"graphic_footnotes\">LV: left ventricular; CT: computed tomography; MI: myocardial infarction.</div><div id=\"graphicVersion\">Graphic 93495 Version 1.0</div></div></div>"},"93497":{"type":"graphic_diagnosticimage","displayName":"CT non calcified aneurysm with thrombus","title":"Non-calcified thrombus in LV aneurysm on CT scan","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Non-calcified thrombus in LV aneurysm on CT scan</div><div class=\"cntnt\"><img style=\"width:596px; height:213px;\" src=\"images/RADIOL/93497_CT_non_calcif_aneury_thromb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan through the LV (A) shows a rounded deformity of the apex of the LV (arrow). The LAD is calcified (arrowhead). Image B shows non-calcified subacute thrombus in the aneurysm of the LV apex (arrow).</div><div class=\"graphic_footnotes\">LV: left ventricular; CT: computed tomography; LAD: left anterior descending.</div><div id=\"graphicVersion\">Graphic 93497 Version 1.0</div></div></div>"},"93499":{"type":"graphic_diagnosticimage","displayName":"CT calcified LV aneurysm with thrombus","title":"Calcified LV aneurysm with thrombus on CT scan","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Calcified LV aneurysm with thrombus on CT scan</div><div class=\"cntnt\"><img style=\"width:598px; height:357px;\" src=\"images/RADIOL/93499_CT_calcified_LV_aneur_throm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan through the heart (A) shows an apical LV aneurysm with calcified wall (arrow). There is thrombus in the aneurysm (arrowhead). The calcification indicates a chronic process. Image B is an axial CT scan through the heart and shows an apical LV aneurysm with a calcified wall (arrow). The thrombus in this case is calcified as well (arrowhead).</div><div class=\"graphic_footnotes\">LV: left ventricular; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93499 Version 1.0</div></div></div>"},"93501":{"type":"graphic_diagnosticimage","displayName":"CT calcified LV aneurysm","title":"Calcified LV aneurysm on CT scan","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Calcified LV aneurysm on CT scan</div><div class=\"cntnt\"><img style=\"width:541px; height:446px;\" src=\"images/RADIOL/93501_CT_calcified_LV_aneurysm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan through the heart shows a calcified rounded deformity of the apex of the LV (arrow) due to a prior apicoseptal infarction. No thrombus is present.</div><div class=\"graphic_footnotes\">LV: left ventricular; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93501 Version 1.0</div></div></div>"},"93503":{"type":"graphic_picture","displayName":"Mutton fat precipitates in ocular sarcoid","title":"Mutton fat keratitic precipitates due to anterior uveitis in sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mutton fat keratitic precipitates due to anterior uveitis in sarcoidosis</div><div class=\"cntnt\"><img style=\"width:358px; height:283px;\" src=\"images/PULM/93503_Mutton_fat_ocular_sarcoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mutton fat keratitic precipitates are a manifestation of lymphocytes in the anterior chamber of the eye (anterior uveitis) in a patient with sarcoidosis. The floating lymphocytes form gray-white clumps that have the appearance of mutton fat under slit lamp examination.</div><div class=\"graphic_reference\">From: Trobe JD. The Eyes Have It: An interactive teaching and assessment program on vision care. University of Michigan Kellogg Eye Center. Available at: <a href=\"http://www.kellogg.umich.edu/theeyeshaveit/acquired/sarcoidosis.html\" target=\"_blank\">http://www.kellogg.umich.edu/theeyeshaveit/acquired/sarcoidosis.html</a> (Accessed on December 26, 2014). Reproduced under the <a href=\"http://creativecommons.org/licenses/by/3.0/\" target=\"_blank\">Creative Commons Attribution 3.0 License</a>.</div><div id=\"graphicVersion\">Graphic 93503 Version 1.0</div></div></div>"},"93504":{"type":"graphic_picture","displayName":"Ciliary flush and posterior synechiae","title":"Ciliary flush with posterior synechiae causing an asymmetric pupil","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ciliary flush with&nbsp;posterior synechiae causing an asymmetric pupil</div><div class=\"cntnt\"><img style=\"width:360px; height:238px;\" src=\"images/PULM/93504_Ciliary_flush_post_synechia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The conjunctival vessels are dilated, predominantly at the edge of the iris.&nbsp;Posterior synechiae are a manifestation of anterior uveitis in sarcoidosis. The edge of the iris around the pupil is asymmetric due to synechiae adhering the iris to the anterior lens capsule.</div><div class=\"graphic_reference\">From: Trobe JD. The Eyes Have It: An interactive teaching and assessment program on vision care. University of Michigan Kellogg Eye Center. Available at: <a href=\"http://www.kellogg.umich.edu/theeyeshaveit/red-eye/anterior-uveitis.html\" target=\"_blank\">http://www.kellogg.umich.edu/theeyeshaveit/red-eye/anterior-uveitis.html</a> (Accessed on December 26, 2014). Reproduced under the <a href=\"http://creativecommons.org/licenses/by/3.0/\" target=\"_blank\">Creative Commons Attribution 3.0 License</a>.</div><div id=\"graphicVersion\">Graphic 93504 Version 2.0</div></div></div>"},"93505":{"type":"graphic_diagnosticimage","displayName":"Chest x-ray LV aneurysm","title":"LV aneurysm on chest x-ray","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">LV aneurysm on chest x-ray</div><div class=\"cntnt\"><img style=\"width:501px; height:520px;\" src=\"images/RADIOL/93505_Chest_xray_LV_aneurysm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest x-ray in the P-A projection shows a left ventricular aneurysm. There is an abnormal bulge of the left ventricle (arrow).</div><div class=\"graphic_footnotes\">LV: left ventricular; P-A: posteroanterior.</div><div id=\"graphicVersion\">Graphic 93505 Version 1.0</div></div></div>"},"93508":{"type":"graphic_diagnosticimage","displayName":"CT and SPECT perfusion normal and apicoseptal infarction","title":"Normal and infarcted apicoseptal region on CT and Sestamibi perfusion scan","html":"<div class=\"graphic\"><div style=\"width: 657px\" class=\"figure\"><div class=\"ttl\">Normal and infarcted apicoseptal region on CT and Sestamibi perfusion scan</div><div class=\"cntnt\"><img style=\"width:637px; height:448px;\" src=\"images/RADIOL/93508_CT_SPECT_perf_norm_apicosep.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image A is a coronal reconstruction of a CT scan and shows a normal LV apex (arrowhead). An adenosine Sestamibi perfusion scan shows normal perfusion at rest (B) and after stress (C). Image D is a coronal reconstruction of a CT scan and shows thrombus in the apex of a dyskinetic LV. Image E shows a gated SPECT myocardial perfusion scan of the patient, with a basal to distal anteroseptal fixed defect at rest, with a large defect at the apex (arrowhead). The scan is not significantly changed with stress (F) (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography; SPECT: single-photon emission computed tomography.</div><div id=\"graphicVersion\">Graphic 93508 Version 1.0</div></div></div>"},"93509":{"type":"graphic_diagnosticimage","displayName":"Ventriculography of normal and aneurysmal left ventricle","title":"Left ventriculography with normal and aneurysmal disease","html":"<div class=\"graphic\"><div style=\"width: 658px\" class=\"figure\"><div class=\"ttl\">Left ventriculography with normal and aneurysmal disease</div><div class=\"cntnt\"><img style=\"width:638px; height:211px;\" src=\"images/RADIOL/93509_Ventriculogra_norm_aneur_LV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image A is a left ventriculogram in the right anterior oblique projection and shows a normal LV apex during systole (arrow). Image B shows an aneurysm of the apex without thrombus. Image C is in similar projection and phase of systole, and shows an aneurysm of the apex with thrombus (arrow). Mitral regurgitation is present (arrowhead).</div><div class=\"graphic_footnotes\">LV: left ventricular.</div><div id=\"graphicVersion\">Graphic 93509 Version 1.0</div></div></div>"},"93512":{"type":"graphic_diagnosticimage","displayName":"MRI pseudoaneurysm inferobasal and septal wall LV","title":"MRI of a pseudoaneurysm of the inferobasal and septal wall of the LV","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">MRI of a pseudoaneurysm of the inferobasal and septal wall of the LV</div><div class=\"cntnt\"><img style=\"width:598px; height:293px;\" src=\"images/RADIOL/93512_MRI_pseudoan_inferob_sep_LV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image A is an MRI through the base of the left ventricle and shows a relatively wide mouthed pseudoaneurysm (arrow). Image B is a two chamber oblique projection and shows the pseudoaneurysm projecting and impinging on the base of the right ventricle (arrow).</div><div class=\"graphic_footnotes\">LV: left ventricular; MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 93512 Version 1.0</div></div></div>"},"93517":{"type":"graphic_table","displayName":"ALDEN algorithm","title":"Algorithm of drug causality for epidermal necrolysis (ALDEN)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Algorithm of drug causality for epidermal necrolysis (ALDEN)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"25%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\">Criterion</td> <td class=\"subtitle1_left\">Values</td> <td class=\"subtitle1_left\" colspan=\"2\">Rules to apply</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Delay from initial drug component intake to onset of reaction (index day)</td> <td>Suggestive: +3</td> <td>From 5 to 28 days</td> <td class=\"divider_bottom\" rowspan=\"6\">&ndash;3 to 3</td> </tr> <tr> <td>Compatible: +2</td> <td>From 29 to 56 days</td> </tr> <tr> <td>Likely: +1</td> <td>From 1 to 4 days</td> </tr> <tr> <td>Unlikely: &ndash;1</td> <td>&#62;56 days</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Excluded: &ndash;3</td> <td>Drug started on or after the index day</td> </tr> <tr class=\"divider_bottom\"> <td> <p>In case of previous reaction to the same drug, only changes for:</p> <p class=\"indent1\">Suggestive: +3: from 1 to 4 days</p> <p class=\"indent1\">Likely: +1: from 5 to 56 days</p> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Drug present in the body on index day</td> <td>Definite: 0</td> <td>Drug continued up to index day or stopped at a time point less than five times the elimination half-life* before the index day</td> <td class=\"divider_bottom\" rowspan=\"3\">&ndash;3 to 0</td> </tr> <tr> <td>Doubtful: &ndash;1</td> <td>Drug stopped at a time point prior to the index day by more than five times the elimination half-life* but liver or kidney function alterations or suspected drug interactions<sup>&#182;</sup> are present</td> </tr> <tr class=\"divider_bottom\"> <td>Excluded: &ndash;3</td> <td>Drug stopped at a time point prior to the index day by more than five times the elimination half-life*, without liver or kidney function alterations or suspected drug interactions<sup>&#182;</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Prechallenge/rechallenge</td> <td>Positive specific for disease and drug: 4</td> <td>SJS/TEN after use of same drug</td> <td class=\"divider_bottom\" rowspan=\"5\">&ndash;2 to 4</td> </tr> <tr> <td>Positive specific for disease or drug: 2</td> <td>SJS/TEN after use of similar<sup>&#916;</sup> drug or other reaction with same drug</td> </tr> <tr> <td>Positive unspecific: 1</td> <td>Other reaction after use of similar<sup>&#916;</sup> drug</td> </tr> <tr> <td>Not done/unknown: 0</td> <td>No known previous exposure to this drug</td> </tr> <tr class=\"divider_bottom\"> <td>Negative: &ndash;2</td> <td>Exposure to this drug without any reaction (before or after reaction)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Dechallenge</td> <td>Neutral: 0</td> <td>Drug stopped (or unknown)</td> <td class=\"divider_bottom\" rowspan=\"2\">&ndash;2 or 0</td> </tr> <tr class=\"divider_bottom\"> <td>Negative: &ndash;2</td> <td>Drug continued without harm</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Type of drug (notoriety)</td> <td>Strongly associated: 3</td> <td>Drug of the \"high-risk\" list according to previous case-control studies</td> <td class=\"divider_bottom\" rowspan=\"6\">&ndash;1 to 3</td> </tr> <tr> <td>Associated: 2</td> <td>Drug with definite but lower risk according to previous case-control studies</td> </tr> <tr> <td>Suspected: 1</td> <td>Several previous reports, ambiguous epidemiology results (drug \"under surveillance\")</td> </tr> <tr> <td>Unknown: 0</td> <td>All other drugs including newly released ones</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Not suspected: &ndash;1</td> <td>No evidence of association from previous epidemiology study with sufficient number of exposed controls<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Intermediate score = total of all previous criteria</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Other cause</td> <td class=\"divider_bottom\" rowspan=\"2\">Possible: &ndash;1</td> <td>Rank all drugs from highest to lowest intermediate score</td> <td class=\"divider_bottom\" rowspan=\"2\">&ndash;1</td> </tr> <tr class=\"divider_bottom\"> <td>If at least one has an intermediate score &#62;3, subtract 1 point from the score of each of the other drugs taken by the patient (another cause is more likely)</td> </tr> <tr> <td colspan=\"4\"><strong>Final score: &ndash;12 to 10</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">&lt;0: very unlikely; 0 to 1: unlikely; 2 to 3: possible; 4 to 5: probable; ≥6: very probable.</div><div class=\"graphic_footnotes\">SJS: Stevens-Johnson syndrome; TEN: toxic epidermal necrolysis; ATC: anatomical therapeutic chemical.<br />* Drug (or active metabolite) elimination half-life from serum and/or tissues (according to pharmacology textbooks), taking into account kidney function for drugs predominantly cleared by kidney and liver function for those with high hepatic clearance.<br />¶ Suspected interaction was considered when more than five drugs were present in a patient's body at the same time.<br />Δ Similar drug = same ATC code up to the fourth level (chemical subgroups).</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Clinical Pharmacology and Therapeutics. Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 2010; 88:60. www.nature.com/cpt. Copyright &copy; 2010.</div><div id=\"graphicVersion\">Graphic 93517 Version 4.0</div></div></div>"},"93522":{"type":"graphic_picture","displayName":"Microscopy - Nematode eggs","title":"Nematode eggs","html":"<div class=\"graphic\"><div style=\"width: 588px\" class=\"figure\"><div class=\"ttl\">Nematode eggs</div><div class=\"cntnt\"><img style=\"width:568px; height:378px;\" src=\"images/ID/93522_Microscopy_Nematode_eggs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Common nematode eggs and larvae easily recognized on microscopy (wet mount) include:<br />(A) <EM>Ascaris</EM><br />(B) <EM>Trichuris</EM> (wet mount with iodine)<br />(C) hookworm (wet mount with iodine)<br />(D) <EM>Enterobius</EM> (pinworm)<br />(E) <EM>Capillaria</EM><br />(F) <EM>Strongyloides</EM> rhabditiform larvae<br /><EM>Ascaris</EM> eggs are large with rough surfaces and a dark dense center (A). <EM>Trichuris</EM> eggs have distinctive mucus plugs at either end as well as a \"tea tray\" appearance (B). Hookworm eggs are optically clear at the edges with a dense center composed of one or more cells (C). <EM>Enterobius</EM> eggs have a distinctive oval shape with slight concavity (D). <EM>Capillaria</EM> eggs are similar to <EM>Trichuris</EM> but are smaller with more flattened ends (E). <EM>Strongyloides</EM> larva may be distinguished from hookworm larva by the presence of a short buccal cavity and primordial genitalia midway down the body (F).<br />The measurements given represent the range seen for the black bar lengths for each organism.</div><div class=\"graphic_reference\">Panels A, B, and C from: Danny Milner, MD.<br />Panels D, E, and F from: Centers for Disease Control and Prevention. DPDx - Laboratory Identification of Parasitic Diseases of Public Health Concern. Available at: <A href=\"http://www.cdc.gov/dpdx/\" target=_blank>http://www.cdc.gov/dpdx/</A> (Accessed March 13, 2014).</div><div id=\"graphicVersion\">Graphic 93522 Version 2.0</div></div></div>"},"93533":{"type":"graphic_picture","displayName":"Microscopy - Trematode eggs","title":"Trematode eggs","html":"<div class=\"graphic\"><div style=\"width: 607px\" class=\"figure\"><div class=\"ttl\">Trematode eggs</div><div class=\"cntnt\"><img style=\"width:587px; height:599px;\" src=\"images/ID/93533_Microscopy_Trematode_eggs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Common trematode eggs seen on easily recognized on microscopy (wet mount with iodine) include:<br />(A) <em>Schistosoma mansoni</em><br />(B) <em>Schistosoma haematobium</em><br />(C) <em>Schistosoma japonicum</em><br />(D) <em>Clonorchis</em><br />(E) <em>Fasciola</em><br />(F) <em>Paragonimus</em><br /><em>Schistosoma</em> eggs are the largest of the helminths and can be distinguished by their spines which are lateral (<em>S. mansoni</em>, A), terminal (<em>S. haematobium</em> and <em>S. intercalatum</em>, B), or vestigial (<em>S. japonicum</em> or <em>S. mekongi</em>, C). <em>Clonorchis</em> and <em>Opisthorchis</em> eggs have an operculum and small remnant at the opposite end (D). <em>Fasciola</em> and <em>Fasciolopsis</em> are also operculated but smooth (E). <em>Paragonimus</em> eggs are also operculated but have a thick, almost pointed opposite end (F).<br />The measurements given represent the length of the eggs along the long axis for each organism.</div><div class=\"graphic_reference\">Panels A-C reproduced from: Centers for Disease Control and Prevention. Public Health Image Library (PHIL). Available at: <a href=\"http://phil.cdc.gov/phil/home.asp\" target=\"_blank\">http://phil.cdc.gov/phil/home.asp</a> (Accessed on March 18, 2014).<br />Panels D-F reproduced from:Centers for Disease Control and Prevention. DPDx - Laboratory Identification of Parasitic Diseases of Public Health Concern. Available at: <a href=\"http://www.cdc.gov/dpdx/\" target=\"_blank\">http://www.cdc.gov/dpdx/</a> (Accessed on March 18, 2014).</div><div id=\"graphicVersion\">Graphic 93533 Version 1.0</div></div></div>"},"93539":{"type":"graphic_picture","displayName":"Microscopy - Protozoa","title":"Protozoa","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Protozoa</div><div class=\"cntnt\"><img style=\"width:582px; height:385px;\" src=\"images/ID/93539_Microscopy_Protozoa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Common protozoa easily recognized on microscopy include:<br />(A) <em>Entamoeba histolytica</em> (trichrome stain)<br />(B) <em>Giardia lamblia</em> (wet mount)<br />(C) <em>Cryptosporidium</em> (acid-fast stain)<br />(D) <em>Cystoisospora</em> (wet mount with exposure to ultraviolet light)<br />(E) <em>Cyclospora</em> (wet mount)<br />(F) <em>Balantidium coli</em> (wet mount with iodine)<br /><em>E. histolytica</em> may appear as a cyst form with chromatid bar (A). <em>Giardia lamblia</em> has distinctive flagella (B). <em>Cryptosporidium</em> is small with acid-fast staining (C). <em>Cystoisospora</em> (formerly <em>Isospora</em>) has an oblong shape, one or two nuclei, natural fluorescence, and acid-fast positivity (D). <em>Cyclospora</em> is similar to but larger than <em>Cryptosporidium</em>, with natural fluorescence and acid-fast positivity (E). <em>Balantidium coli</em> is the largest protozoan infecting humans and the only ciliate (F).<br />The measurements given represent the range seen for the black bar lengths for each organism.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx - Laboratory Identification of Parasitic Diseases of Public Health Concern. Available at: <a href=\"http://www.cdc.gov/dpdx/\" target=\"_blank\">http://www.cdc.gov/dpdx/</a> (Accessed March 13, 2014).</div><div id=\"graphicVersion\">Graphic 93539 Version 2.0</div></div></div>"},"93544":{"type":"graphic_table","displayName":"Risk factors for PAH in SSc","title":"Risk factors for pulmonary arterial hypertension in patients with systemic sclerosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for pulmonary arterial hypertension in patients with systemic sclerosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Long standing disease (&#62;5 years)</td> </tr> <tr> <td>Limited cutaneous disease</td> </tr> <tr> <td>Telangiectasia</td> </tr> <tr> <td>DLCO &#60;60 percent predicted</td> </tr> <tr> <td>FVC percent/DLCO percent &#62;1.6</td> </tr> <tr> <td>Anti-centromere antibody</td> </tr> <tr> <td>Anti-nucleolar pattern ANA</td> </tr> <tr> <td>Anti-U1 RNP antibody</td> </tr> <tr> <td>Absence of anti-Scl 70 antibody</td> </tr> <tr> <td>Older age at onset of scleroderma</td> </tr> <tr> <td>N-terminal pro BNP</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DLCO: diffusion capacity for carbon monoxide; FVC: forced vital capacity; RNP: ribonuclear protein; BNP: brain natriuretic peptide.</div><div id=\"graphicVersion\">Graphic 93544 Version 1.0</div></div></div>"},"93545":{"type":"graphic_figure","displayName":"Trigger sensitivity and work of breathing","title":"Flow versus pressure triggering and work of breathing","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Flow versus pressure triggering and work of breathing</div><div class=\"cntnt\"><img style=\"width:596px; height:653px;\" src=\"images/PULM/93545_Trggrsnstvtywrkbrth.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flow, airway opening pressure (Pao), esophageal pressure (Pes), and trans-diaphragmatic pressures (Pdi) traced over time during flow triggered (on right) and pressure triggered (on left) spontaneous ventilation. The portion of the deflection in Pes and Pdi from on first solid vertical line on the left, to the dashed line, represents the deflection between the initiation of inspiratory effort to the beginning of flow (dynamic PEEPi). Note that this deflection is smaller for Pes and Pdi during flow triggered (right) than pressure triggered (left) spontaneous breathing, hence imposing less work of breathing for the patient.</div><div class=\"graphic_footnotes\">dyn: dynes; Δ: change in.</div><div class=\"graphic_reference\">Reproduced by permission from: Springer. Intensive Care Medicine. Ranieri VM, Mascia L, Petruzzelli V, et al. Inspiratory effort and measurement of dynamic intrinsic PEEP in COPD patients: effects of ventilator triggering systems. Intensive Care Med 1995; 21:896. Copyright © 1995. <A spellcheck=true href=\"https://link.springer.com/journal/134\" target=_blank>https://link.springer.com/journal/134</A>.</div><div id=\"graphicVersion\">Graphic 93545 Version 3.0</div></div></div>"},"93546":{"type":"graphic_figure","displayName":"Auto-PEEP","title":"Auto-PEEP: Time-flow graphic","html":"<div class=\"graphic\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Auto-PEEP: Time-flow graphic</div><div class=\"cntnt\"><img style=\"width:640px; height:287px;\" src=\"images/PULM/93546_Auto_PEEP.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown on the upper graphic is time versus flow for an individual mechanically ventilated patient. When auto-PEEP is present, expiratory flow should reach zero before the onset of inspiration. The arrow indicates that inspiration for each breath begins before expiratory flow has reached zero.</div><div class=\"graphic_footnotes\">lpm: liters per minute.</div><div class=\"graphic_reference\">Reproduced with permission: Negligan P. Auto-PEEP: Beware of auto-PEEP in pressure controlled ventilation. Critical Care Medicine Tutorials. Available at: <a href=\"http://www.ccmtutorials.com/rs/mv/strategy/page17.htm\" spellcheck=\"true\" target=\"_blank\">http://www.ccmtutorials.com/rs/mv/strategy/page17.htm</a> (Accessed on October 15, 2014). Copyright &copy; 2002 Patrick Neligan.</div><div id=\"graphicVersion\">Graphic 93546 Version 1.0</div></div></div>"},"93548":{"type":"graphic_table","displayName":"Factors influencing decision-making","title":"Factors that influence the management of nodules 8 to 30 mm in size","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors that influence the management of nodules 8 to 30 mm in size</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Factor</td> <td class=\"subtitle1\">Level</td> <td class=\"subtitle1\">CT scan surveillance</td> <td class=\"subtitle1\">PET imaging</td> <td class=\"subtitle1\">Nonsurgical biopsy</td> <td class=\"subtitle1\">VATS wedge resection</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>Clinical probability of lung cancer</strong></td> <td>Very low (&#60;5%)</td> <td class=\"centered\">++++</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Low-moderate</td> <td class=\"centered\">+</td> <td class=\"centered\">+++</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> </tr> <tr class=\"divider_bottom\"> <td>High (&#60;65%)</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">(&#177; staging)</td> <td class=\"centered\">++</td> <td class=\"centered\">++++</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Surgical risk</strong></td> <td>Low</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> <td class=\"centered\">+++</td> </tr> <tr class=\"divider_bottom\"> <td>High</td> <td class=\"centered\">++</td> <td class=\"centered\">+++</td> <td class=\"centered\">++</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Biopsy risk</strong></td> <td>Low</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">++</td> <td class=\"centered\">+++</td> <td class=\"centered\">+++</td> </tr> <tr> <td class=\"divider_bottom\">High</td> <td class=\"centered\">++</td> <td class=\"centered\">+++</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>High suspicion of active infection or inflammation</strong></td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">++++</td> <td class=\"centered\">++</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Values and preferences</strong></td> <td>Desires certainty</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">+++</td> <td class=\"centered\">++++</td> </tr> <tr class=\"divider_bottom\"> <td>Risk averse to procedure-related complications</td> <td class=\"centered\">++++</td> <td class=\"centered\">+++</td> <td class=\"centered\">++</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td colspan=\"2\"><strong>Poor adherence with follow-up</strong></td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+++</td> <td class=\"centered\">++++</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Selection of modality (surveillance or biopsy) will depend on patient values and preferences; please refer to the UpToDate topic on diagnostic evaluation and management of the solitary pulmonary nodule for more details. Nonsurgical biopsy usually refers to image-guided or endoscopic biopsy.</div><div class=\"graphic_footnotes\">CT: computed tomography; PET: positron emission tomography; VATS: video-assisted thorascopic surgery.</div><div class=\"graphic_reference\">Reproduced from: Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143:e93S. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 93548 Version 3.0</div></div></div>"},"93550":{"type":"graphic_algorithm","displayName":"Preoperative pulmonary assessment","title":"Algorithm for pulmonary preoperative assessment of patients requiring lung resection","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">Algorithm for pulmonary preoperative assessment of patients requiring lung resection</div><div class=\"cntnt\"><img style=\"width:570px; height:343px;\" src=\"images/PULM/93550_Preoperative_pulmona_assess.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Physiologic evaluation resection algorithm.<br />Actual risks affected by parameters defined here and:&#xD;&#xA;<ul>&#xD;&#xA;    <li>Patient factors: Comorbidities, age.</li>&#xD;&#xA;    <li>Structural aspects: Center (volume, specialization).</li>&#xD;&#xA;    <li>Process factors: Management of complications.</li>&#xD;&#xA;    <li>Surgical access: Thoracotomy versus minimally invasive.</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">ppoDLCO: predicted postoperative diffusing capacity for carbon monoxide; ppoDLCO%: percent predicted postoperative diffusing capacity for carbon monoxide; ppoFEV<SUB>1</SUB>: predicted postoperative FEV<SUB>1</SUB>; ppoFEV<SUB innerHtml>1</SUB>%: percent predicted postoperative FEV<SUB>1</SUB>; SCT: stair climb test; SWT: shuttle walk test; CPET: cardiopulmonary exercise test; VO<SUB>2</SUB>max: maximal oxygen consumption.<br />* For pneumonectomy candidates, we suggest to use Q scan to calculate predicted postoperative values of FEV<SUB>1</SUB> or DLCO (PPO values = preoperative values X [1 - fraction of total perfusion for the resected lung]), where the preoperative values are taken as the best measured postbronchodilator values. For lobectomy patients, segmental counting is indicated to calculate predicted postoperative values of FEV<SUB>1</SUB> or DLCO (PPO values = preoperative values X [1 - y/z]), where the preoperative values are taken as the best measured postbronchodilator value and the number of functional or unobstructed lung segments to be removed is y and the total number of functional segments is z.<br />¶ For patients with a positive high-risk cardiac evaluation deemed to be stable to proceed to surgery we suggest to perform both pulmonary function tests and cardiopulmonary exercise test for a more precise definition of risk.<br />Δ PpoFEV<SUB>1</SUB> or ppoDLCO cut off values of 60% predicted values has been chosen based on indirect evidences and expert consensus opinion.<br />◊ Definition of risk: Low risk: The expected risk of mortality is below 1%. Major anatomic resections can be safely performed in this group. Moderate risk: Morbidity and mortality rates may vary according to the values of split lung functions, exercise tolerance and extent of resection. Risks and benefits of the operation should be thoroughly discussed with the patient. High risk: The risk of mortality after standard major anatomic resections may be higher than 10%. Considerable risk of severe cardiopulmonary morbidity and residual functional loss is expected. Patients should be counseled about alternative surgical (minor resections or minimally invasive surgery) or nonsurgical options.</div><div class=\"graphic_reference\">Reproduced from: Brunelli A, Kim AW, Berger KI, Addrizzo-Harris DJ. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143:e166S. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 93550 Version 2.0</div></div></div>"},"93559":{"type":"graphic_picture","displayName":"Mild fluorosis","title":"Mild fluorosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Mild fluorosis</div><div class=\"cntnt\"><img style=\"width:504px; height:334px;\" src=\"images/PEDS/93559_Mild_fluorosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mild fluorosis is indicated by a white flecked or lacy appearance to the enamel (arrows). The dental effects are limited to surface appearance.</div><div id=\"graphicVersion\">Graphic 93559 Version 1.0</div></div></div>"},"93564":{"type":"graphic_movie","displayName":"Releasing ETT introducer caught on arytenoids","title":"How to release an ETT introducer (bougie) caught on arytenoids","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">How to release an ETT introducer (bougie) caught on arytenoids</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/93564_ETTintroducerarytenovid.mp4\" style=\"width:512px;height:304px\"></div><img style=\"width:504px; height:378px;\" src=\"images/EM/93564_ETTintroducerarytenoimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ETI: endotracheal tube introducer (\"bougie\"); ETT: endotracheal tube.</div><div class=\"graphic_reference\">Reproduced with permission from: Aaron E Bair, MD, MSc, FAAEM, FACEP and Erik G Laurin, MD, FAAEM, FACEP.</div><div id=\"graphicVersion\">Graphic 93564 Version 3.0</div></div></div>"},"93566":{"type":"graphic_picture","displayName":"Common Indian cobra","title":"Common Indian cobra (<em>Naja naja</em>)","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Common Indian cobra (<em>Naja naja</em>)</div><div class=\"cntnt\"><img style=\"width:536px; height:538px;\" src=\"images/EM/93566_Common_Indian_cobra.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Julian White, MB, BS, MD, FACMT. Reproduced with permission. Unauthorized use of this image is strictly prohibited.</div><div id=\"graphicVersion\">Graphic 93566 Version 1.0</div></div></div>"},"93567":{"type":"graphic_picture","displayName":"Australian death adder","title":"Australian death adder (<em>Acanthophis antarcticus</em>)                                           ","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Australian death adder (<em>Acanthophis antarcticus</em>)                                           </div><div class=\"cntnt\"><img style=\"width:537px; height:539px;\" src=\"images/EM/93567_Australian_death_adder.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Julian White, MB, BS, MD, FACMT. Reproduced with permission. Unauthorized use of this image is strictly prohibited.</div><div id=\"graphicVersion\">Graphic 93567 Version 2.0</div></div></div>"},"93573":{"type":"graphic_picture","displayName":"Brazilian jararaca bite","title":"Brazilian jararaca (<em>Bothrops jararaca</em>) bite to foot with blistering","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Brazilian jararaca (<em>Bothrops jararaca</em>) bite to foot with blistering</div><div class=\"cntnt\"><img style=\"width:537px; height:537px;\" src=\"images/EM/93573_Brazilian_jararaca_bite.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Julian White, MB, BS, MD, FACMT. Reproduced with permission. Unauthorized use of this image is strictly prohibited.</div><div id=\"graphicVersion\">Graphic 93573 Version 1.0</div></div></div>"},"93574":{"type":"graphic_picture","displayName":"Malayan pit viper","title":"Malayan pit viper (<em>Calloselasma rhodostoma</em>)","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Malayan pit viper (<em>Calloselasma rhodostoma</em>)</div><div class=\"cntnt\"><img style=\"width:537px; height:535px;\" src=\"images/EM/93574_Malayan_pit_viper.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Julian White, MB, BS, MD, FACMT. Reproduced with permission. Unauthorized use of this image is strictly prohibited.</div><div id=\"graphicVersion\">Graphic 93574 Version 1.0</div></div></div>"},"93575":{"type":"graphic_picture","displayName":"Jararaca or Brazilian lance-head pit-viper","title":"Jararaca or Brazilian lance-head pit-viper (<em>Bothrops jararaca</em>)","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Jararaca or Brazilian lance-head pit-viper (<em>Bothrops jararaca</em>)</div><div class=\"cntnt\"><img style=\"width:537px; height:538px;\" src=\"images/EM/93575_Jararaca_Braz_lnc_pit_vip.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Julian White, MB, BS, MD, FACMT. Reproduced with permission. Unauthorized use of this image is strictly prohibited.</div><div id=\"graphicVersion\">Graphic 93575 Version 2.0</div></div></div>"},"93576":{"type":"graphic_picture","displayName":"Green pit viper","title":"Green pit viper (<em>Trimeresurus [Cryptelytrops] albolabri</em>)","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Green pit viper (<em>Trimeresurus [Cryptelytrops] albolabri</em>)</div><div class=\"cntnt\"><img style=\"width:537px; height:538px;\" src=\"images/EM/93576_Green_pit_viper.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Julian White, MB, BS, MD, FACMT. Reproduced with permission. Unauthorized use of this image is strictly prohibited.</div><div id=\"graphicVersion\">Graphic 93576 Version 2.0</div></div></div>"},"93577":{"type":"graphic_picture","displayName":"Saw scaled viper - India","title":"Saw scaled viper (India, <em>Echis carinatus</em>)","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Saw scaled viper (India, <em>Echis carinatus</em>)</div><div class=\"cntnt\"><img style=\"width:537px; height:537px;\" src=\"images/EM/93577_Saw_scaled_viper.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Julian White, MB, BS, MD, FACMT. Reproduced with permission. Unauthorized use of this image is strictly prohibited.</div><div id=\"graphicVersion\">Graphic 93577 Version 2.0</div></div></div>"},"93578":{"type":"graphic_picture","displayName":"Spitting cobra bite","title":"Spitting cobra bite to hand with ulceration (<em>Naja siamensis</em>)","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Spitting cobra bite to hand with ulceration (<em>Naja siamensis</em>)</div><div class=\"cntnt\"><img style=\"width:515px; height:447px;\" src=\"images/EM/93578_Spitting_cobra_bite.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Julian White, MB, BS, MD, FACMT. Reproduced with permission. Unauthorized use of this image is strictly prohibited.</div><div id=\"graphicVersion\">Graphic 93578 Version 1.0</div></div></div>"},"93580":{"type":"graphic_picture","displayName":"Indian krait","title":"Indian krait (<em>Bungarus caeruleus</em>)","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Indian krait (<em>Bungarus caeruleus</em>)</div><div class=\"cntnt\"><img style=\"width:533px; height:535px;\" src=\"images/EM/93580_Indian_krait.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Julian White, MB, BS, MD, FACMT. Reproduced with permission. Unauthorized use of this image is strictly prohibited.</div><div id=\"graphicVersion\">Graphic 93580 Version 1.0</div></div></div>"},"93581":{"type":"graphic_picture","displayName":"African black mamba              ","title":"African black mamba (<em>Dendroaspis polylepis</em>)","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">African black mamba (<em>Dendroaspis polylepis</em>)</div><div class=\"cntnt\"><img style=\"width:536px; height:538px;\" src=\"images/EM/93581_African_black_mamba.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Julian White, MB, BS, MD, FACMT. Reproduced with permission. Unauthorized use of this image is strictly prohibited.</div><div id=\"graphicVersion\">Graphic 93581 Version 1.0</div></div></div>"},"93582":{"type":"graphic_picture","displayName":"Indian Russells viper","title":"Indian Russell's viper (<em>Daboia russelli</em>)","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Indian Russell's viper (<em>Daboia russelli</em>)</div><div class=\"cntnt\"><img style=\"width:536px; height:532px;\" src=\"images/EM/93582_Indian_Russells_viper.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Julian White, MB, BS, MD, FACTM. Reproduced with permission. Unauthorized use of this image is strictly prohibited.</div><div id=\"graphicVersion\">Graphic 93582 Version 2.0</div></div></div>"},"93583":{"type":"graphic_picture","displayName":"European viper","title":"European viper (<em>Switzerland, Vipera aspis</em>)","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">European viper (<em>Switzerland, Vipera aspis</em>)</div><div class=\"cntnt\"><img style=\"width:538px; height:536px;\" src=\"images/EM/93583_European_viper.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Julian White, MB, BS, MD, FACMT. Reproduced with permission. Unauthorized use of this image is strictly prohibited.</div><div id=\"graphicVersion\">Graphic 93583 Version 1.0</div></div></div>"},"93584":{"type":"graphic_picture","displayName":"Australian tiger snake bite","title":"Australian tiger snake (<em>Notechis scutatus</em>) double bite to leg","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Australian tiger snake (<em>Notechis scutatus</em>) double bite to leg</div><div class=\"cntnt\"><img style=\"width:534px; height:537px;\" src=\"images/EM/93584_Australian_tiger_snake_bit.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Julian White, MB, BS, MD, FACMT. Reproduced with permission. Unauthorized use of this image is strictly prohibited.</div><div id=\"graphicVersion\">Graphic 93584 Version 1.0</div></div></div>"},"93585":{"type":"graphic_picture","displayName":"Myoglobinuria after mulga snake bite","title":"Myoglobinuria after mulga snake (<em>Pseudechis australis</em>) bite","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Myoglobinuria after mulga snake (<em>Pseudechis australis</em>) bite</div><div class=\"cntnt\"><img style=\"width:537px; height:537px;\" src=\"images/EM/93585_Myoglobinur_mulga_snk_bit.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Julian White, MB, BS, MD, FACMT. Reproduced with permission. Unauthorized use of this image is strictly prohibited.</div><div id=\"graphicVersion\">Graphic 93585 Version 1.0</div></div></div>"},"93586":{"type":"graphic_picture","displayName":"Puff adder bite","title":"Puff adder (<em>Bitis arietans</em>) bite to finger tip with local bruising and developing necrosis","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Puff adder (<em>Bitis arietans</em>) bite to finger tip with local bruising and developing necrosis</div><div class=\"cntnt\"><img style=\"width:537px; height:538px;\" src=\"images/EM/93586_Puff_adder_bite.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Julian White, MB, BS, MD, FACMT. Reproduced with permission. Unauthorized use of this image is strictly prohibited.</div><div id=\"graphicVersion\">Graphic 93586 Version 2.0</div></div></div>"},"93587":{"type":"graphic_algorithm","displayName":"Antiviral selection for HCV genotype 1 in treatment-naïve","title":"Antiviral selection for HCV genotype 1 infection in treatment-naïve adults","html":"<div class=\"graphic\"><div style=\"width: 978px\" class=\"figure\"><div class=\"ttl\">Antiviral selection for HCV genotype 1 infection in treatment-na&iuml;ve adults</div><div class=\"cntnt\"><img style=\"width:958px; height:510px;\" src=\"images/ID/93587_Antvrl_trt_HCV_gntp_1_infct.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>The preferred and first-line regimen options listed for each patient population are likely of comparably high efficacy. The choice between them is based on potential drug interactions, local availability, and individual financial or insurance limitations. Overall, we favor glecaprevir-pibrentasvir, ledipasvir-sofosbuvir, or sofosbuvir-velpatasvir for their simplicity of administration (once-daily dosing without the need to evaluate for baseline polymorphisms), and extensive data to support their use. Drug interactions are generally manageable but should be evaluated prior to initiation, particularly with NS3/4A protease inhibitor-containing regimens (such as glecaprevir-pibrentasvir). Alternative regimens either require longer durations for equivalent efficacy or are of less certain efficacy.</LI>&#xD;&#xA;<LI>Doses of direct-acting antivirals are standard. Daclatasvir dose adjustment is warranted with concomitant use of P450 inducers and inhibitors. If ribavirin is used, dosing is weight based: 1000 mg daily if &lt;75 kg and 1200 mg daily if ≥75 kg.</LI>&#xD;&#xA;<LI>This algorithm does not apply to patients with estimated glomerular filtration rate &lt;30 mL/min per 1.73 m<SUP>2</SUP> (or on dialysis). Refer to UpToDate content on HCV treatment in patients with renal impairment for more details.</LI></UL></div><div class=\"graphic_footnotes\">HCV: hepatitis C virus; RASs: resistance-associated substitutions.<br />* Ascites, hepatic encephalopathy, prolonged prothrombin time, decreased serum albumin, and/or hyperbilirubinemia.<br />¶ Treatment with ledipasvir-sofosbuvir for 8 instead of 12 weeks is a highly effective option for treatment-naïve patients without cirrhosis who have a baseline viral level &lt;6 million international units/mL. However, if such patients have negative traditional predictors of treatment response (ie, male gender, obesity, black race) or HIV infection, we favor treating for 12 weeks if possible.<br />Δ For subtype 1a-infected patients in whom elbasvir is being considered, testing for NS5A RASs should be performed. RASs that confer reduced susceptibility to elbasvir-grazoprevir include polymorphisms at M28, Q30, L31, and Y93. If these are present, the recommended regimen is elbasvir-grazoprevir with ribavirin for 16 weeks.<br /><FONT class=lozenge>◊</FONT> In the United States, daclatasvir plus sofosbuvir is not approved by the Food and Drug Administration for genotype 1 infection, so may not be a feasible option for most patients. The optimal administration of this regimen (ie, duration and with or without ribavirin) is uncertain for patients with cirrhosis.<br />§ If ombitasvir-paritaprevir-ritonavir plus dasabuvir is used in patients with cirrhosis, close monitoring for hepatic decompensation is warranted. This regimen is contraindicated in patients with Child Pugh Classes B and C cirrhosis.<br />¥ For subtype 1a-infected patients with cirrhosis in whom simeprevir plus sofosbuvir is being considered, testing for NS3/4A RASs should be performed. The Q80K mutation is associated with reduced susceptibility to simeprevir plus sofosbuvir. If this is present, we do not use simeprevir plus sofosbuvir in these patients.</div><div class=\"graphic_reference\">Reference: AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed&nbsp;August 23, 2017.</div><div id=\"graphicVersion\">Graphic 93587 Version 11.0</div></div></div>"},"93588":{"type":"graphic_algorithm","displayName":"Antiviral treatment algorithm for genotype 2 HCV infection","title":"Antiviral selection for HCV genotype 2 infection in adults","html":"<div class=\"graphic\"><div style=\"width: 978px\" class=\"figure\"><div class=\"ttl\">Antiviral selection for HCV genotype 2 infection in adults</div><div class=\"cntnt\"><img style=\"width:958px; height:470px;\" src=\"images/ID/93588_Antivrl_tx_gntyp_2_HCV_edt1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>The choice between these regimens is based on potential drug interactions, patient preference regarding dosing, local availability, and individual financial or insurance limitations. Overall, we suggest glecaprevir-pibrentasvir or sofosbuvir-velpatasvir regimens for patients without prior NS5A inhibitor exposure. They are extremely effective against genotype 2 infection. Daclatasvir plus sofosbuvir also appears highly effective, but has been studied in only a small number of genotype 2-infected patients.</LI>&#xD;&#xA;<LI>Doses of direct acting antivirals are standard. Daclatasvir dose adjustment is warranted with concomitant use of P450 inducers and inhibitors. If ribavirin is used, dosing is weight based: 1000 mg daily if &lt;75 kg and 1200 mg daily if ≥75 kg.</LI>&#xD;&#xA;<LI>This algorithm does not apply to patients with estimated glomerular filtration rate &lt;30 mL/min per 1.73 m<SUP>2</SUP> (or on dialysis). Refer to UpToDate content on HCV treatment in patients with renal impairment for more details.</LI></UL></div><div class=\"graphic_footnotes\">HCV: hepatitis C virus.<br />* Ascites, hepatic encephalopathy, prolonged prothrombin time, decreased serum albumin, and/or hyperbilirubinemia.<br />¶ This includes patients who are treatment naïve or failed prior treatment with peginterferon plus ribavirin.<br />Δ Glecaprevir-pibrentasvir is given for 8 weeks for those without cirrhosis and 12 weeks for those with compensated cirrhosis.</div><div class=\"graphic_reference\">Reference: AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed August 23, 2017.</div><div id=\"graphicVersion\">Graphic 93588 Version 7.0</div></div></div>"},"93589":{"type":"graphic_algorithm","displayName":"Antiviral treatment algorithm for genotype 3 HCV infection","title":"Antiviral selection for HCV genotype 3 infection in adults","html":"<div class=\"graphic\"><div style=\"width: 1287px\" class=\"figure\"><div class=\"ttl\">Antiviral selection for HCV genotype 3 infection in adults</div><div class=\"cntnt\"><img style=\"width:1267px; height:574px;\" src=\"images/ID/93589_Antivrl_tx_gntyp_3_HCV_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>The options listed for each patient population are likely of comparable high efficacy. The choice between them is based on potential drug interactions, patient preference regarding dosing, local availability, and individual financial or insurance limitations. Overall, we favor glecaprevir-pibrentasvir or sofosbuvir-velpatasvir regimens for patients without prior direct acting antiviral exposure.</LI>&#xD;&#xA;<LI>Doses of direct acting antivirals are standard. Daclatasvir dose adjustment is warranted with concomitant use of P450 inducers and inhibitors. If ribavirin is used, dosing is weight based: 1000 mg daily if &lt;75 kg and 1200 mg daily if ≥75 kg.</LI>&#xD;&#xA;<LI>This algorithm does not apply to patients with estimated glomerular filtration rate &lt;30 mL/min per 1.73 m<SUP>2</SUP> (or on dialysis). Refer to UpToDate content on HCV treatment in patients with renal impairment for more details.</LI></UL></div><div class=\"graphic_footnotes\">HCV: hepatitis C virus; RASs: resistance-associated substitutions.<br />* Ascites, hepatic encephalopathy, prolonged prothrombin time, decreased serum albumin, and/or hyperbilirubinemia.<br />&para; If glecaprevir-pibrentasvir is definitely to be used, NS5A RAS testing is not necessary.</div><div class=\"graphic_reference\">Reference: AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed August 23, 2017.</div><div id=\"graphicVersion\">Graphic 93589 Version 7.0</div></div></div>"},"93595":{"type":"graphic_table","displayName":"Management of hypotension after CPB","title":"Hemodynamic management of hypotension during and after weaning from CPB","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hemodynamic management of hypotension during and after weaning from CPB</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">CVP</td> <td class=\"subtitle1\">PAP</td> <td class=\"subtitle1\">PADP or PAWP*</td> <td class=\"subtitle1\">Cardiac output</td> <td class=\"subtitle1\">Blood pressure</td> <td class=\"subtitle1\">LV function by TEE</td> <td class=\"subtitle1\">RV function by TEE&nbsp;</td> <td class=\"subtitle1\">Diagnosis</td> <td class=\"subtitle1\">Response</td> </tr> <tr> <td> <p>Low</p> </td> <td> <p>Low</p> </td> <td> <p>Low</p> </td> <td> <p>Low</p> <p>&nbsp;</p> </td> <td>Low</td> <td>Normal or hyperdynamic</td> <td>Normal or hyperdynamic&nbsp;</td> <td>Hypovolemia</td> <td>Administer volume</td> </tr> <tr> <td>Low or normal</td> <td>Low or normal</td> <td>Low or&nbsp;normal&nbsp;</td> <td>&nbsp;High</td> <td>Low</td> <td>Normal or hyperdynamic</td> <td>Normal or hyperdynamic</td> <td>Vasoplegia</td> <td>Administer vasopressor</td> </tr> <tr> <td>High or normal</td> <td>High</td> <td>Low or normal<sup>&#182;</sup></td> <td>High</td> <td>Low</td> <td>Normal</td> <td>Normal or hypocontractile</td> <td>Pulmonary hypertension</td> <td>Administer pulmonary vasodilator</td> </tr> <tr> <td>High</td> <td>Normal or low</td> <td>Normal or high<sup>&#182;</sup></td> <td>Low</td> <td>Low</td> <td>Normal</td> <td> <p>Hypocontractile,</p> <p>often dilated&nbsp;</p> </td> <td> <p>Right ventricular dysfunction</p> </td> <td> <p>Administer inotropic agent</p> Administer pulmonary vasodilator</td> </tr> <tr> <td>Normal or high</td> <td>Normal or high</td> <td>High</td> <td>Low</td> <td>Low</td> <td> <p>Hypocontractile,</p> <p>often dilated</p> </td> <td>&nbsp;Normal</td> <td>Left ventricular dysfunction</td> <td> <p>Administer inotropic agent</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CPB: cardiopulmonary bypass; CVP: central venous pressure; <SPAN style=\"COLOR: black\">PAP: positive airway pressure; </SPAN>PADP: pulmonary artery diastolic&nbsp;pressure; PAWP: pulmonary artery wedge pressure; LV: left ventricular; TEE: transesophageal echocardiography; RV: right ventricular.<br />* PAWP should not be measured prior to neutralizing heparin following CPB. Initially, PADP is measured, the PADP may overestimate PAWP when patients have elevated pulmonary vascular resistance (eg, pulmonary hypertension).<br />¶&nbsp;PADP or PAWP are indirect measures of LV filling pressure. With RV dysfunction and dilation, ventricular septal shift may increase LV filling pressure despite low or normal LV filling volume.</div><div id=\"graphicVersion\">Graphic 93595 Version 6.0</div></div></div>"},"93596":{"type":"graphic_table","displayName":"Parameters during CPB","title":"Parameters during cardiopulmonary bypass","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Parameters during cardiopulmonary bypass</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Adequate activated clotting time&nbsp;(ACT), typically 400 to 480&nbsp;seconds</td> </tr> <tr> <td>pH 7.35 to 7.45</td> </tr> <tr> <td>pCO<sub>2</sub> 35 to 45 mmHg</td> </tr> <tr> <td>pO<sub>2</sub> 150 to 250 mmHg</td> </tr> <tr> <td>Flow rate 2.2 to 2.4 L/min/m<sup>2</sup></td> </tr> <tr> <td>MAP &#8805;65 mmHg in absence of cerebrovascular disease or aortic atherosclerosis</td> </tr> <tr> <td>MAP &#8805;75 mmHg in the presence of cerebrovascular disease or aortic atherosclerosis</td> </tr> <tr> <td>Mixed venous oxygen saturation &#8805;75%</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MAP: mean arterial pressure.</div><div id=\"graphicVersion\">Graphic 93596 Version 4.0</div></div></div>"},"93600":{"type":"graphic_table","displayName":"Using soft mist inhalers","title":"Technique for use of soft mist inhalers (SMIs)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Technique for use of soft mist inhalers (SMIs)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">The first time you use a soft mist inhaler,* you will need to insert the cartridge.</td> </tr> <tr> <td class=\"indent1\">Press the safety catch on the side and pull off the clear plastic base.</td> </tr> <tr> <td class=\"indent1\">Push the narrow end of the cartridge into the inhaler until it clicks.</td> </tr> <tr> <td class=\"indent1\">Push the cartridge against a firm surface or table top to be sure it has gone all the way in.</td> </tr> <tr> <td class=\"indent1\">Do not remove the cartridge after it has been inserted.</td> </tr> <tr> <td class=\"indent1\">Put the clear base back on. Press until you hear a click.</td> </tr> <tr> <td class=\"indent1\">Do not remove the clear base again.</td> </tr> <tr> <td class=\"subtitle1_single\">Prime the inhaler before the first dose.</td> </tr> <tr> <td class=\"indent1\">Hold the inhaler upright. Turn the clear base clockwise (to the right) until it clicks.</td> </tr> <tr> <td class=\"indent1\">Open the cap and point the inhaler towards the floor.</td> </tr> <tr> <td class=\"indent1\">Press the button on the side until you see a mist or cloud.</td> </tr> <tr> <td class=\"indent1\">Repeat 3 more times.</td> </tr> <tr> <td class=\"indent1\">If you do not use the inhaler for more than 3 days, repeat 1 time.</td> </tr> <tr> <td class=\"indent1\">If you do not use the inhaler for more than 3 weeks, repeat 4 times.</td> </tr> <tr> <td class=\"subtitle1_single\">To take a dose of medicine, hold inhaler upright with the cap closed. There is no need to shake it.</td> </tr> <tr> <td class=\"indent1\">Hold the top of the inhaler with 1 hand. With the other hand, turn the clear base clockwise (to the right) until it clicks. This prepares the dose of medicine.</td> </tr> <tr> <td class=\"indent1\">Open the cap.</td> </tr> <tr> <td class=\"indent1\">Breathe out slowly and fully.</td> </tr> <tr> <td class=\"indent1\">Put the mouthpiece in your mouth, and hold the inhaler horizontally, pointing toward the back of your throat.</td> </tr> <tr> <td class=\"indent1\">Seal your lips around the inhaler, but do not cover the air vents on the side.</td> </tr> <tr> <td class=\"indent1\">As you take a slow deep breath in, press and hold the button on the side of the inhaler. This releases the medicine in a soft mist.</td> </tr> <tr> <td class=\"indent1\">Breathe in to a full deep breath to get all the medicine into your lungs.</td> </tr> <tr> <td class=\"indent1\">Hold your breath for a count of 10.</td> </tr> <tr> <td class=\"indent1\">Remove inhaler from your mouth and breathe out slowly.</td> </tr> <tr> <td class=\"subtitle1_single\">The inhaler has a dose indicator on the side. When the arrow is in the red zone, the inhaler is almost empty. When the inhaler is completely empty, the arrow will point to \"0,\" and you will not be able to turn the base of the inhaler.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Soft mist inhalers are also known as Respimat inhalers.</div><div id=\"graphicVersion\">Graphic 93600 Version 3.0</div></div></div>"},"93604":{"type":"graphic_table","displayName":"Assessing pain in the ICU","title":"Pain scales for self-reporting patients in the intensive care unit (ICU)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pain scales for self-reporting patients in the intensive care unit (ICU)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of instrument</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>Self-report - unidimensional pain, thirst, or dyspnea scale</td> <td>0 to 10 numeric rating scale (NRS)</td> <td> <p>Higher numbers indicate greater pain (or dyspnea, or thirst) intensity. Example: 0 = no pain and 10 = worst possible pain. NRS has both construct and concurrent validity.</p> A 0 to 10 horizontal, visually enlarged laminated NRS for pain is most feasible and valid for ICU patients.</td> </tr> <tr class=\"divider_bottom\"> <td>Self-report - unidimensional pain or dyspnea scale</td> <td>0 to 10 cm visual analog scale (VAS)</td> <td>A 10 cm line, with anchors at either end. Example: one end is marked \"no pain\" and the other end is marked \"pain as bad as it could be\" or \"the worst imaginable pain.\" The patient makes a vertical line through the horizontal 10 cm line to indicate his or her pain intensity. The clinician then measures from the left of the horizontal line to the patient's vertical line with a ruler and assigns a score. Difficult for many patients to understand and use.</td> </tr> <tr class=\"divider_bottom\"> <td>Self-report - body outline diagram pain scale</td> <td>Identifies pain location. Diagram of front and back of a \"neutral\" body divided into body sections</td> <td>Patient is able to point to, or mark, the place or places on the diagram where pain is felt. Has been used with ICU patients.</td> </tr> <tr class=\"divider_bottom\"> <td>Self-report - multidimensional pain scale</td> <td>McGill Pain Questionnaire-Short Form (MPQ-SF)</td> <td>Scale with 11 sensory (such as sharp or throbbing) and four affective (such as fearful or sickening) words. MPQ-SF also has a VAS and a verbal scale. The 15-word scale has been used in ICU patients.</td> </tr> <tr> <td rowspan=\"3\">Self-report - multiple symptoms scale</td> <td>Condensed Form of the Memorial Symptom Assessment Scale (MSAS)</td> <td>Measures a diverse group of symptoms. Has been used with critically ill patients.</td> </tr> <tr> <td>Edmonton Symptom Assessment Scale</td> <td>Measures a diverse group of symptoms. Has been used with critically ill patients.</td> </tr> <tr> <td>10-item symptom assessment scale</td> <td>Modification of MSAS and Edmonton. Validated in ICU patients.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Intensive Care Medicine, Palliative care in the ICU: relief of pain, dyspnea, and thirst--a report from the IPAL-ICU Advisory Board, Vol. 40, 2014, p. 235, Puntillo K, Nelson JE, Weissman D, et al, © Springer-Verlag Berlin Heidelberg and ESICM 2013. With permission of Springer.</div><div id=\"graphicVersion\">Graphic 93604 Version 5.0</div></div></div>"},"93605":{"type":"graphic_table","displayName":"Opiod use in the ICU","title":"Opioid use for palliating pain the intensive care unit (ICU)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Opioid use for palliating pain the intensive care unit (ICU)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"90%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Element</td> <td class=\"subtitle1\">Key point</td> </tr> <tr class=\"divider_bottom\"> <td>Opioid dosing</td> <td> <p>ICU clinicians responsible for pain management should have knowledge of equianalgesic opioid dosing</p> <p>Dosing regimens should be based on a risks/benefits ration for an individual patient</p> <p>There is no maximum dose or duration of effect; these must be individualized</p> The \"normal dose\" for an individual patient is that which adequately relieves pain without unacceptable adverse effects</td> </tr> <tr class=\"divider_bottom\"> <td>Opioid administration</td> <td> <p>The preferred mode of initial therapy is rapid titration of opioids with small incremental IV doses</p> <p>Both remifentanil and sufentanil can be considered for use since both are short-acting opioids and may decrease the duration of mechanical ventilation and ICU length of stay and improve procedural pain management</p> <p>Dose&nbsp;and rate-related histamine release does not occur with fentanyl analogues and can be limited by slowing the rate of IV administration of opioids</p> Methadone has unpredictable pharmacokinetics and pharmacodynamics in opiate-na&#239;ve patients. The Patient's Q-T interval (corrected) of the electrocardiographic tracing should be monitored carefully if methadone is used at all.</td> </tr> <tr> <td>Opioids - other considerations</td> <td> <p>It is necessary to institute a bowel regimen with stimulant or osmotic laxative in all patients receiving sustained opioid administration unless there are contraindications such as small bowel obstruction</p> <p>Use of opioids in liver failure can be complicated since most opioids are at least partially metabolized in the liver, reducing opioid clearance. Fentanyl may be preferred opioid in liver failure although its half-life is prolonged with repeated dosing or use of high doses. Use opioids cautiously in patient with end-stage liver disease. Longer dosing intervals may be needed.</p> <p>Use of opioids in renal failure is associated with complex drug absorption, metabolism, and renal clearance. Meperidine has been removed from many hospital formularies and, even if available, potential toxicity contraindicates its use in renal failure. Use of codine and morphine is not recommended. Hydromorphone should be used cautiously; an active metabolite can accumulate between dialysis treatments. Fentanyl and methadone are relatively safe in renal failure since they have no active metabolites. However, neither is removed by dialysis.</p> <p>Opioids, especially when used chronically or in patients with renal failure, electrolyte disturbances, and dehydration, may cause neuroexcitatory effects, such as myoclonus. Myoclonus may resolve over a few days with decrease in opioid dose. Myoclonus, especially if mild, should not interfere with good pain control. Rotating opioid to a lower dose of another opioid with a different structure may reduce myoclonus within 24 hours. Fentanyl might be a better choice in this case since it has no active metabolites.</p> Certain opioids such as fentanyl distribute in fat which can prolong the opioid effects</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Intensive Care Medicine, Palliative care in the ICU: relief of pain, dyspnea, and thirst--a report from the IPAL-ICU Advisory Board, Vol. 40, 2014, p. 235, Puntillo K, Nelson JE, Weissman D, et al, &copy; Springer-Verlag Berlin Heidelberg and ESICM 2013. With permission of Springer.</div><div id=\"graphicVersion\">Graphic 93605 Version 4.0</div></div></div>"},"93606":{"type":"graphic_table","displayName":"Palliating dyspnea in the ICU","title":"Interventions for palliating dyspnea in the intensive care unit (ICU) patient","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interventions for palliating dyspnea in the intensive care unit (ICU) patient</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Intervention</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Mode of action</td> <td class=\"subtitle1\">Rationale</td> </tr> <tr class=\"divider_bottom\"> <td>Optimal positioning, usually upright with arms elevated and supported</td> <td>Whenever patient reports dyspnea or displays respiratory distress</td> <td>Increases pulmonary volume capacity</td> <td>Increases air exchange which may improve oxygenation and carbon dioxide clearance and reduce inspiratory effort</td> </tr> <tr> <td>Balance rest with activity</td> <td class=\"divider_bottom\" rowspan=\"2\">Guided by dyspnea/respiratory distress</td> <td class=\"divider_bottom\" rowspan=\"2\">Decreases excessive oxygen consumption</td> <td class=\"divider_bottom\" rowspan=\"2\">Prevents hypoxemia</td> </tr> <tr class=\"divider_bottom\"> <td>Space nursing care</td> </tr> <tr class=\"divider_bottom\"> <td>Oxygen as indicated by goals of therapy; not useful in normoxemia or when the patient is near death and in no distress</td> <td>Variable, guided by goals of therapy and patient characteristics</td> <td>Improves the partial pressure of oxygen; reduces lactic acidemia</td> <td>Treats hypoxemia</td> </tr> <tr class=\"divider_bottom\"> <td>Cold cloth on face</td> <td>As needed</td> <td>Trigeminal nerve stimulation; action on dyspnea unknown</td> <td>Anecdotal reports of patient relief; inexpensive; easy to perform</td> </tr> <tr class=\"divider_bottom\"> <td>Opioids, such as morphine or fentanyl</td> <td>Low dose titrated to the patient's report of dyspnea or display of dyspnea behaviors is effective; oral or parenteral; no evidence to support inhaled administration; no evidence on dosing regimens</td> <td>Uncertain direct effect; reduced brainstem sensitivity to oxygen and carbon dioxide; altered central nervous perception</td> <td>Strong evidence-base supports effectiveness</td> </tr> <tr> <td>Benzodiazepines, such as lorazepam or midazolam</td> <td>Low doses titrated to the patient's report of dyspnea or display of dyspnea behaviors; no evidence for benzodiazepine regimens</td> <td>Anxiolysis</td> <td>Fear or anxiety often accompanies dyspnea</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Intensive Care Medicine, Palliative care in the ICU: relief of pain, dyspnea, and thirst--a report from the IPAL-ICU Advisory Board, Vol. 40, 2014, p. 235, Puntillo K, Nelson JE, Weissman D, et al, © Springer-Verlag Berlin Heidelberg and ESICM 2013. With permission of Springer.</div><div id=\"graphicVersion\">Graphic 93606 Version 4.0</div></div></div>"},"93607":{"type":"graphic_table","displayName":"Palliating thirst in the ICU","title":"Palliation of thirst in the intensive care unit (ICU) patient","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Palliation of thirst in the intensive care unit (ICU) patient</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Key steps to assess and manage thirst in ICU patients</td> </tr> <tr> <td class=\"indent1\">1. Conduct regular thirst assessments in patients able to self-report</td> </tr> <tr> <td class=\"indent1\">2. Examine the mouth and tongue for dryness and cracking or infection, as indicators of thirst/dryness</td> </tr> <tr> <td class=\"indent1\">3. Recognize the risk profile for patient thirst including NPO status, and administration of anticholinergic medications and opioids</td> </tr> <tr> <td class=\"indent1\">4. Assume that the patient is experiencing thirst</td> </tr> <tr> <td class=\"indent1\">5. Do frequent mouth care</td> </tr> <tr> <td class=\"indent1\">6. Use water-soaked gauzes, water sprays, and ice chips frequently when permissible</td> </tr> <tr> <td class=\"indent1\">7. Consider the use of artificial saliva</td> </tr> <tr> <td class=\"indent1\">8. Consider the use of heater humidifiers in patients with high-flow oxygen therapy</td> </tr> <tr> <td class=\"indent1\">9. Evaluate and document the effectiveness of the thirst interventions</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NPO: nil per os.</div><div class=\"graphic_reference\">Intensive Care Medicine, Palliative care in the ICU: relief of pain, dyspnea, and thirst--a report from the IPAL-ICU Advisory Board, Vol. 40, 2014, p. 235, Puntillo K, Nelson JE, Weissman D, et al, © Springer-Verlag Berlin Heidelberg and ESICM 2013. With permission of Springer.</div><div id=\"graphicVersion\">Graphic 93607 Version 3.0</div></div></div>"},"93613":{"type":"graphic_table","displayName":"Recommendations for infant monitoring","title":"Recommendations for infant monitoring","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for infant monitoring</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Index</td> </tr> <tr class=\"divider_bottom\"> <td>Lithium</td> <td> <p>Lithium level</p> <p>Complete blood count</p> <p>Blood urea nitrogen/creatinine (BUN/Cr) levels</p> Thyroid stimulating hormone (TSH)</td> </tr> <tr class=\"divider_bottom\"> <td>Valproate</td> <td> <p>Valproate level (free and total)</p> <p>Platelets</p> Liver enzymes</td> </tr> <tr class=\"divider_bottom\"> <td>Carbamazepine</td> <td> <p>Carbamazepine (free and total)</p> <p>Complete blood count</p> Liver enzymes</td> </tr> <tr class=\"divider_bottom\"> <td>Lamotrigine</td> <td> <p>Rash</p> Liver enzymes</td> </tr> <tr class=\"divider_bottom\"> <td>Atypical antipsychotics</td> <td> <p>Weight</p> Blood sugar</td> </tr> <tr> <td>Typical antipsychotics</td> <td> <p>Stiffness</p> Creatine phosphokinase, if indicated</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Stowe ZN, The use of mood stabilizers during breastfeeding, The Journal of Clinical Psychiatry. Volume 68, Suppl pages 22-8, 2007. Copyright 2007, Physicians Postgraduate Press. Reprinted by permission.<br />Sharma V, Doobay M, Baczynski C. Bipolar postpartum depression: An update and recommendations. J Affect Disord 2017; 219:105.</div><div id=\"graphicVersion\">Graphic 93613 Version 2.0</div></div></div>"},"93614":{"type":"graphic_table","displayName":"Clinical global impression scale for complicated grief","title":"Clinical global impression scale for complicated grief","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical global impression scale for complicated grief</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">CGI severity</td> <td class=\"subtitle1\">CGI improvements</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">1.</td> </tr> <tr> <td class=\"indent1\"><strong>Normal -</strong> Feelings of grief are sometimes present but not intrusive. There is&nbsp;evidence of restoration of the capacity for joy and satisfaction in&nbsp;life,&nbsp;a sense of purpose in life, and a feeling that happiness is possible.</td> <td><strong>Very much improved - </strong>Distress and impairment from complicated grief are markedly improved compared to baseline. Patients feel very differently about the role grief plays in their lives compared to baseline. CG-CGI severity is usually no more than mild (3); however, patients can (rarely) be very much improved&nbsp;and grief symptoms&nbsp;may still be moderate (4) if baseline severity was very high (7).</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">2.</td> </tr> <tr> <td class=\"indent1\"> <p><strong>Borderline ill -</strong> Grief symptoms are present but rarely intrusive or distressing; there is little or no interference in activities and relationships, and evidence of some capacity for pleasure and satisfaction.</p> </td> <td><strong>Much improved -</strong> Distress and impairment from complicated grief are definitely improved compared to baseline, and this improvement is&nbsp;clinically significant. Patients notice some difference in the role that grief plays in their&nbsp;lives. CG-CGI severity is usually no more than moderate (4). However, a patient can be much improved and grief symptoms may still be marked (5) if baseline severity was very high (7).</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">3.</td> </tr> <tr> <td class=\"indent1\"><strong>Mildly ill -</strong> Complicated grief symptoms are present and sometimes intrusive and/or distressing but manageable and there is minimal or no&nbsp;functional impairment. There is engagement in activities and relationships with the potential for satisfaction and pleasure. Clinical significance is borderline or subthreshold.</td> <td><strong>Minimally improved -</strong> There is some&nbsp;improvement in distress and/or impairment from complicated grief compared to baseline, but the clinical significance of the change is questionable or minimal.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">4.</td> </tr> <tr> <td class=\"indent1\"><strong>Moderately ill -&nbsp;</strong>&nbsp;Complicated grief symptoms are present and intrusive on most days, at a level that is painful but bearable. There is some interference with activities and relationships, but functioning is not substantially impaired. There may be some avoidance of reminders of the loss. A sense of purpose or meaning is usually present, but there may be confusion about this. Suicidal thoughts may be present but there is usually a desire to live. Distraction is temporarily possible, but symptoms are persistent and clinically significant.</td> <td><strong>No change -</strong> Distress and impairment from complicated grief have not changed in any meaningful way since the baseline assessment.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">5.</td> </tr> <tr> <td class=\"indent1\"><strong>Markedly ill -</strong> Complicated grief symptoms are frequent and intrusive, at a level that causes substantial pain and definite interference with functioning. There is usually some avoidance of reminders of the loss, loss of a sense of purpose or meaning in life, and/or a feeling that joy and satisfaction are no longer possible; suicidal thoughts are usually present and may be prominent. There may be a feeling of just waiting to die. There is little relief from complicated grief symptoms; distraction is difficult and when possible, short-lived.</td> <td><strong>Minimally worse -</strong> Distress or impairment from complicated grief is somewhat worse since the baseline assessment, but the clinical significance of this change is questionable or minimal.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">6.</td> </tr> <tr> <td class=\"indent1\"><strong>Severely ill -</strong> Complicated grief symptoms are nearly constant on most days at a level that is severe and impairing; extensive avoidance is often present. There is often a belief that joy and satisfaction are no longer possible; there may be active suicidal ideation or indirect suicidal behavior (eg, cutting). Distraction is rarely possible and only partially effective and there may be periods of inability to function.</td> <td> <p><strong>Much worse -</strong> Distress and impairment from complicated grief are definitely worse since the baseline assessment, and this change is clinically significant. Increased level of care should be considered.</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">7.</td> </tr> <tr> <td class=\"indent1\"><strong>Among the most extremely ill patients - </strong>Complicated grief symptoms are present continuously or nearly continuously at a very severe level. The person is virtually unable to function in activities or relationships. There may be strongly held self-blaming or accusatory beliefs about the death that border on delusional. There is a conviction that joy and satisfaction are no longer possible. Avoidance is usually present and extensive. Active suicidal thoughts or indirect suicidal behavior are usually present.</td> <td><strong>Very much worse -</strong> Distress and impairment from complicated grief are markedly worse since the baseline assessment. There may be emergent clinically significant suicidal thinking or behavior, or risk of other serious consequences of worsening grief. Increased level of care is definitely needed.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 93614 Version 2.0</div></div></div>"},"93617":{"type":"graphic_table","displayName":"Skeletal events during systemic treatment ","title":"Skeletal events during systemic treatment for metastatic prostate cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Skeletal events during systemic treatment for metastatic prostate cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Drugs</td> <td class=\"subtitle1\">Definition of skeletal events</td> <td class=\"subtitle1\">Method of assessing skeletal events</td> <td class=\"subtitle1\">Median time to first SRE (mo)</td> <td class=\"subtitle1\">Hazard ratio (95% CI)</td> <td class=\"subtitle1\">p value</td> </tr> <tr> <td><strong>Saad et al (2002, 2004)</strong></td> <td>Zoledronic acid (n = 214) vs placebo (n = 208)</td> <td>Pathologic fractures; EBRT to bone, surgery to bone; SCC; change in neoplastic therapy for bone pain</td> <td>Periodic radiologic review: skeletal surveys every 3 months</td> <td>16&middot;0 vs 10&middot;5</td> <td>0&middot;68</td> <td>&#60;0&middot;01</td> </tr> <tr> <td><strong>Fizazi et al (2011)</strong></td> <td>Denosumab (n = 950) vs zoledronic acid (n = 951)</td> <td>Pathologic fracture; EBRT to bone; SCC, or surgery to bone</td> <td>Periodic radiologic review: skeletal surveys every 12 weeks</td> <td>20&middot;7 vs 17&middot;1</td> <td>0&middot;82</td> <td>&#60;0&middot;001</td> </tr> <tr> <td><strong>Scher et al (2012)</strong></td> <td>Enzalutamide (n = 800) vs placebo (n = 399)</td> <td>Pathologic fracture, EBRT to bone; SCC, surgery to bone; or change in antineoplastic therapy for bone pain</td> <td>No periodic radiologic review</td> <td>16&middot;7 vs 13&middot;3</td> <td>0&middot;69</td> <td>&#60;0&middot;01</td> </tr> <tr> <td><strong>Logothetis et al (2012)</strong></td> <td>Abiraterone + prednisone (n = 797) vs placebo + prednisone (n = 398)</td> <td>Pathologic fracture; EBRT to bone, SCC, surgery to bone</td> <td>No periodic radiologic review</td> <td>25&middot;0 vs 20&middot;3</td> <td>0&middot;62</td> <td>&#60;0&middot;001</td> </tr> <tr> <td><strong>Parker et al (2013)</strong></td> <td>Radium-223 + BSC (n = 614) vs placebo + BSC (n = 307)</td> <td>Pathologic fracture, EBRT to bone, SCC, surgery to bone</td> <td>No periodic radiologic review</td> <td>15&middot;6 vs 9&middot;8</td> <td>0&middot;66</td> <td>&#60;0&middot;001</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">%: percent; SCC: spinal cord compression; SRE: skeletal related event; BSC: best supportive care; EBRT: external beam radiation therapy.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;<li>Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96:879.</li>&#xD;&#xA;<li>Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458.</li>&#xD;&#xA;<li>Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377:813.</li>&#xD;&#xA;<li>Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367:1187.</li>&#xD;&#xA;<li>Logothetis CJ, Basch E, Molina A, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 2012; 13:1210.</li>&#xD;&#xA;<li>Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369:213.</li></ol></div><div id=\"graphicVersion\">Graphic 93617 Version 1.0</div></div></div>"},"93619":{"type":"graphic_table","displayName":"Metered dose inhaler technique with spacer or chamber PI","title":"Technique for use of a metered dose inhaler (MDI) with a spacer or chamber*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Technique for use of a metered dose inhaler (MDI) with a spacer or chamber*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Uncap mouthpiece and check for loose objects in the device.</td> </tr> <tr> <td>Prime your inhaler if this is the first time you are using it, if you have not used it for several days, or if you have dropped it. Priming an MDI usually involves shaking it and spraying it into the air (away from your face) a total of up to four times. See the information that came with your inhaler for exact instructions.</td> </tr> <tr> <td>Insert MDI into spacer.</td> </tr> <tr> <td>Shake canister vigorously for about five seconds.</td> </tr> <tr> <td>Hold the MDI upright with your index finger on the top of the medication canister and your thumb supporting the bottom of the inhaler. You may need to use the other hand to hold the spacer.</td> </tr> <tr> <td>Breathe out normally through your mouth.</td> </tr> <tr> <td>Put the mouthpiece between your teeth and close your lips tightly around mouthpiece of spacer. (If using a mask attached to the chamber, place the mask completely over your nose and mouth.)</td> </tr> <tr> <td>Make sure&nbsp;your tongue does not block the&nbsp;opening of the mouthpiece of the spacer.</td> </tr> <tr> <td>Press down the top of the canister with your index finger to release the medicine.</td> </tr> <tr> <td>At the same time, breathe in deeply and slowly through your mouth until your lungs are completely filled; this should take three to five seconds.</td> </tr> <tr> <td>Hold the medicine in your lungs for about 5 to 10 seconds. If you didn't get a full breath or can't hold your breath long enough, you can inhale a second time to fully empty the chamber and hold your breath again for about five seconds.</td> </tr> <tr> <td>If you need more than one puff, wait about 15 to 30 seconds between puffs. Shake canister again before the next puff. Do <strong>not</strong> load both puffs into the chamber and then empty the chamber with a single inhalation.</td> </tr> <tr> <td>When finished, recap mouthpiece.</td> </tr> <tr> <td>If your inhaler contains a steroid medicine (sometimes called glucocorticoid or corticosteroid), rinse your mouth and gargle with water after you use it. Then spit out the water. Do not swallow it.</td> </tr> <tr> <td>You can use your spacer for more than one medication. Just remove the first MDI and insert the other one.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These instructions do NOT apply to dry powder or soft mist inhalers. Cleaning instructions are provided separately.</div><div class=\"graphic_footnotes\">MDI: metered dose inhaler.<br />* We prefer to use a \"valved holding chamber\" for the spacer. The valve holds the medicine in the chamber. When you breathe out into the mouthpiece, your breath goes into the room and not into the chamber. This helps get the medicine into your lungs.</div><div id=\"graphicVersion\">Graphic 93619 Version 6.0</div></div></div>"},"93620":{"type":"graphic_figure","displayName":"Recommendations for vaccination in HIV-infected adults","title":"Recommendations for vaccination in HIV-infected adults","html":"<div class=\"graphic\"><div style=\"width: 928px\" class=\"figure\"><div class=\"ttl\">Recommendations for vaccination in HIV-infected adults</div><div class=\"cntnt\"><img style=\"width:908px; height:530px;\" src=\"images/ID/93620_RecvaccinatnHIVadulted1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adapted from the Advisory Committee on Immunization Practices (ACIP) recommended immunization schedules for adults and adolescents. These immunization schedules are available at <A href=\"https://www.cdc.gov/vaccines/schedules/hcp/index.html\" target=_blank>https://www.cdc.gov/vaccines/schedules/hcp/index.html</A>. Detailed information on these and other vaccines can be found at <A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/index.html\" target=_blank>https://www.cdc.gov/vaccines/hcp/acip-recs/index.html</A>.</div><div class=\"graphic_footnotes\">* <STRONG>Influenza vaccines</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer age-appropriate inactivated influenza vaccine (IIV) or recombinant influenza vaccine (RIV) to adults and adolescents annually.</LI>&#xD;&#xA;<LI>Administer IIV or RIV to pregnant women.</LI>&#xD;&#xA;<LI>For adults and adolescents with a history of hives-only egg allergy, administer IIV or RIV. Those with a history of egg allergy other than hives (eg, angioedema or respiratory distress) may receive IIV or RIV in a medical setting under supervision of a healthcare provider who can recognize and manage severe allergic conditions.</LI>&#xD;&#xA;<LI>A list of currently available influenza vaccines is available at <A href=\"https://www.cdc.gov/flu/protect/vaccine/vaccines.htm\" target=_blank>https://www.cdc.gov/flu/protect/vaccine/vaccines.htm</A>.</LI></UL>¶ <STRONG>Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer one dose of Tdap vaccine to adults and adolescents who were not previously vaccinated with Tdap, followed by a tetanus and diphtheria toxoids (Td) booster every 10 years.</LI>&#xD;&#xA;<LI>Administer one dose of Tdap vaccine to women during each pregnancy, preferably in the early part of gestational weeks 27 to 36.</LI>&#xD;&#xA;<LI>Information on the use of Tdap or Td vaccines as tetanus prophylaxis in wound management is available at <A href=\"https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5517a1.htm\" target=_blank>https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5517a1.htm</A>.</LI></UL>Δ <STRONG>Measles, mumps, and rubella (MMR) vaccine</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer a two-dose series of MMR vaccine at least one month apart to adults and adolescents with a CD4 cell count ≥200 cells/microL who do not have evidence of immunity to MMR (born before 1957, documentation of receipt of MMR vaccine, or laboratory evidence of immunity or disease).</LI>&#xD;&#xA;<LI>Pregnant women with a CD4 cell count ≥200 cells/microL who do not have immunity to rubella should receive a two-dose series of MMR vaccine at least one month apart after pregnancy.</LI>&#xD;&#xA;<LI>Adults and adolescents with a CD4 cell count &lt;200 cells/microL should not receive MMR vaccine.</LI></UL><FONT class=lozenge>◊</FONT> <STRONG>Varicella (VAR) vaccine</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer a two-dose series of VAR vaccine three months apart to adults and adolescents with a CD4 cell count ≥200 cells/microL who do not have evidence of immunity to VAR (documented receipt of two doses of VAR vaccine, born in the United States before 1980, diagnosis of VAR or zoster by a health care provider, or laboratory evidence of immunity).</LI>&#xD;&#xA;<LI>Those with a CD4 cell count &lt;200 cells/microL should not receive VAR vaccine.</LI></UL>§ <STRONG>Herpes zoster vaccine (HZV)</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>There is no recommendation for HZV for adults and adolescents with a CD4 cell count ≥200 cells/microL.</LI>&#xD;&#xA;<LI>Those with a CD4 cell count &lt;200 cells/microL should not receive HZV.</LI></UL>¥ <STRONG>Human papillomavirus (HPV) vaccine</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer a three-dose series of HPV vaccine at zero, one to two, and six months to adults and adolescents through age 26 years.</LI>&#xD;&#xA;<LI>Pregnant women are not recommended to receive HPV vaccine.</LI></UL>‡ <STRONG>Pneumococcal vaccines</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer one dose of 13-valent pneumococcal conjugate vaccine (PCV13) followed by one dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) at least two months later. Administer a second dose of PPSV23 at least five years after the first dose of PPSV23. If the most recent dose of PPSV23 was administered before age 65 years, at age 65 years or older, administer another dose of PPSV23 at least five years after the last dose of PPSV23.</LI></UL>† <STRONG>Hepatitis A (HepA) vaccine</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer a two-dose series of single antigen HepA vaccine at 0 and 6 to 12 months, or 0 and 6 to 18 months, depending on the vaccine; or a three-dose series of combined HepA and hepatitis B (HepA-HepB) vaccine at zero, one, and six months to adults and adolescents who may not have a specific risk but wants protection against HepA infection.</LI>&#xD;&#xA;<LI>Administer a HepA-containing vaccine series to adults and adolescents at risk which includes chronic liver disease, receive clotting factor concentrates, men who have sex with men, inject illicit drugs, and travel in countries with endemic HepA.</LI></UL>** <STRONG>Hepatitis B (HepB) vaccine</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer a three-dose series of single-antigen HepB vaccine or combined HepA-HepB vaccine at zero, one, and six months.</LI></UL>¶¶ <STRONG>Meningococcal vaccines</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer a two-dose primary series of serogroup A, C, W, and Y meningococcal (MenACWY) vaccine at least two months apart, and revaccinate every five years.</LI>&#xD;&#xA;<LI>Serogroup B meningococcal (MenB) vaccine is not routinely recommended.</LI>&#xD;&#xA;<LI>Young adults and adolescents age 16 through 23 years (preferred age range is 16 through 18 years) may receive MenB (a two-dose series of MenB-4C at least one month apart; or a three-dose series of MenB-FHbp at zero, one to two, and six months) based on individual clinical decision.</LI></UL>ΔΔ <STRONG><EM>Haemophilus influenza</EM> type b (Hib) vaccine</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Adults and adolescents with HIV infection are not routinely recommended to receive Hib vaccine.</LI>&#xD;&#xA;<LI>Administer Hib vaccine to those with asplenia, hematopoeitic stem cell transplant, and other indications.</LI></UL></div><div class=\"graphic_reference\">Reproduced from: Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at: <A href=\"http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/glchunk/glchunk_365.pdf\" target=_blank>http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/glchunk/glchunk_365.pdf</A>. Accessed on October 5, 2017.</div><div id=\"graphicVersion\">Graphic 93620 Version 4.0</div></div></div>"},"93621":{"type":"graphic_figure","displayName":"Vaccine schedules for HIV-infected children aged 0-6 years","title":"Recommendations for vaccination in HIV-infected and exposed children, aged 0 through 6 years*","html":"<div class=\"graphic\"><div style=\"width: 1321px\" class=\"figure\"><div class=\"ttl\">Recommendations for vaccination in HIV-infected and exposed children, aged 0 through 6 years*</div><div class=\"cntnt\"><img style=\"width:1301px; height:558px;\" src=\"images/ID/93621_VaccschedHIVchild06yrs.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This schedule is adapted from the 2013 United States Department of Health and Human Services (DHHS) Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children and from the 2015 Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for persons aged 0 through 18 years. It summarizes recommendations for routine administration of vaccines for HIV-infected children 0 through 6 years and indicates the recommended ages for vaccine administration in this population for childhood vaccines licensed in the United States. Any dose not administered at the recommended age should be administered at a subsequent visit, when indicated and feasible. Licensed combination vaccines may be used whenever any component of the combination is indicated and other components of the vaccine are not contraindicated and if approved by the Food and Drug Administration for that dose of the series, unless otherwise specified. Providers should consult the relevant ACIP statement for detailed recommendations. Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS). Guidance about how to obtain and complete a VAERS form is available at <A href=\"https://www.vaers.hhs.gov/\" target=_blank>https://www.vaers.hhs.gov</A> or telephone 800-822-7967.</div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.<br />* These recommendations should also be used for perinatally HIV-exposed children who are awaiting laboratory confirmation that they are HIV-uninfected although HIV can be reasonably excluded in most infants in the United States by four weeks of age (DHHS Pediatric ARV Guidelines).<br />¶ <STRONG>Hepatitis B (HepB) vaccine</STRONG><br /><EM>(Minimum age: Birth)</EM> &#xD;&#xA;<UL>&#xD;&#xA;<LI><STRONG>At birth:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer monovalent HepB vaccine to all newborns before hospital discharge.</LI>&#xD;&#xA;<LI>If mother is hepatitis B surface antigen (HBsAg)-positive, administer HepB vaccine and 0.5 mL of hepatitis B immune globulin (HBIG) within 12 hours after birth.</LI>&#xD;&#xA;<LI>If mother's HBsAg status is unknown, administer HepB vaccine within 12 hours after birth. For infants weighing &lt;2000 g, administer HBIG in addition to HepB vaccine within 12 hours of birth. Determine mother's HBsAg status as soon as possible and, if mother is HBsAg-positive, also administer HBIG for infants weighing ≥2000 g as soon as possible, but no later than age seven days.</LI></UL></LI>&#xD;&#xA;<LI><STRONG>After the birth dose:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>The HepB series should be completed with either monovalent HepB vaccine or a combination vaccine containing HepB. The second dose should be administered at ages one through two months. Monovalent HepB vaccine should be used for doses administered before six weeks. The final dose should be administered no earlier than age 24 weeks.</LI>&#xD;&#xA;<LI>Infants who did not receive a birth dose should receive three doses of a HepB-containing vaccine on a schedule of zero, one to two months, and six months, starting as soon as feasible.</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Four-month dose:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>It is permissible to administer four doses of HepB vaccine when combination vaccines are administered after the birth dose. If monovalent HepB vaccine is used for doses after the birth dose, a dose at age four months is not needed.</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Post-vaccination:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Infants born to HBsAg-positive mothers should be tested for HBsAg and the antibody to HBsAg (anti-HBs) one to two months after completion of at least three doses of a licensed HepB series, at ages 9 through 18 months (generally at the next well-child visit).</LI>&#xD;&#xA;<LI>Testing is recommended for HIV-infected children and should be performed one to two months after administration of the last dose of the vaccine series using a method that allows determination of a protective level of anti-HBs (≥10 mIU/mL).</LI>&#xD;&#xA;<LI>Children with anti-HBs &lt;10 mIU/mL after the primary schedule should receive a second series, followed by anti-HBs testing one to two months after the third dose, which usually is more practical than serologic testing after one or more doses of vaccine.</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Booster dose:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>In HIV-infected children, the need for booster doses has not been determined. Annual anti-HBs testing and booster doses when anti-HBs levels decline to &lt;10 mIU/mL should be considered in individuals with ongoing risk for exposure. Refer to <A href=\"https://www.cdc.gov/mmwr/PDF/rr/rr5416.pdf\" target=_blank>MMWR 2005; 54(No. RR-16)</A>.</LI></UL></LI></UL>Δ <STRONG>Rotavirus (RV) vaccines</STRONG><br /><EM>(Minimum age: Six weeks for both RV1 [Rotarix] and RV5 [RotaTeq])</EM> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Practitioners should consider the potential risks and benefits of administering RV vaccine to infants with known or suspected altered immunocompetence. Consultation with an immunologist or infectious disease specialist is advised. Limited safety and efficacy data are available for the administration of RV vaccines to infants who are potentially immunocompromised, including those who are HIV-infected. However, the following considerations support vaccination of HIV-exposed or HIV-infected infants: &#xD;&#xA;<UL>&#xD;&#xA;<LI>In infants born to HIV-positive mothers, the HIV diagnosis may not be established before the age of the first RV vaccine dose (only 1.5 to 3% of HIV-exposed infants in the United States will eventually be determined to be HIV-infected), and</LI>&#xD;&#xA;<LI>Vaccine strains of RV are considerably attenuated.</LI></UL></LI>&#xD;&#xA;<LI>The maximum age for the first dose in the series is 14 weeks and 6 days; for the final dose in the series, it is eight months and zero days. Vaccination should not be initiated for infants aged 15 weeks and 0 days or older.</LI>&#xD;&#xA;<LI>If RV1 is used, administer a two-dose series at two and four months.</LI>&#xD;&#xA;<LI>If RV5 is used, administer a three-dose series at ages two, four, and six months.</LI>&#xD;&#xA;<LI>If any dose in the series was RV5 or vaccine product is unknown for any dose in the series, a total of three doses of RV vaccine should be administered.</LI></UL><FONT class=lozenge>◊</FONT> <STRONG>Diphtheria and tetanus toxoids, and acellular pertussis (DTaP) vaccine</STRONG><br /><EM>(Minimum age: Six weeks)</EM> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer a five-dose series of DTaP vaccine at ages two, four, six, 15 through 18 months, and four through six years.</LI>&#xD;&#xA;<LI>The fourth dose may be administered as early as age 12 months, provided that at least six months have elapsed since the third dose. However, the fourth dose of DTaP need not be repeated if it was administered at least four months after the third dose of DTaP.</LI></UL>§ <STRONG><EM>Haemophilus influenzae</EM> type B (Hib) conjugate vaccine</STRONG><br /><EM>(Minimum age: Six weeks for PRP-T [ACTHIB, DTaP-IPV/Hib (Pentacel), and Hib-MenCY (MenHibrix)] and PRP-OMP [PedvaxHIB or COMVAX]; 12 months for PRP-T [Hiberix])</EM> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer a two- or three-dose Hib vaccine primary series and a booster dose (dose three or four, depending on vaccine used in primary series) at age 12 through 15 months to complete a full Hib vaccine series. &#xD;&#xA;<UL>&#xD;&#xA;<LI>The primary series with ActHIB, Hib-MenCY, or DTaP-IPV/Hib consists of three doses and should be administered at two, four, and six months. The primary series with PRP-OMP consists of two doses and should be administered at two and four months; a dose at age six months is not indicated.</LI>&#xD;&#xA;<LI>One booster dose (dose three or four, depending on vaccine used in primary series) of any Hib vaccine should be administered at age 12 through 15 months. PRP-T should not be used for doses at ages two, four, or six months for the primary series, but may be used as the final dose in children aged 12 months through 4 years who have received at least one prior dose of Hib-containing vaccine.</LI></UL></LI>&#xD;&#xA;<LI>Children aged 12 through 59 months who are at increased risk for Hib disease, including those with HIV infection, who have received either no doses or only one dose of Hib vaccine before age 12 months should receive two additional doses of Hib vaccine eight weeks apart; children who received two or more doses of Hib vaccine before age 12 months should receive one additional dose.</LI>&#xD;&#xA;<LI>One dose of Hib vaccine should be administered to unvaccinated or partially vaccinated persons aged five years or older who have HIV infection.</LI></UL>¥ <STRONG>Pneumococcal vaccines</STRONG><br /><EM>(Minimum age: Six weeks for pneumococcal conjugate vaccine [PCV]; two years for pneumococcal polysaccharide vaccine [PPSV23])</EM> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer a four-dose series of 13-valent PCV (PCV13) vaccine at ages two, four, and six months and at age 12 through 15 months.</LI>&#xD;&#xA;<LI>A PCV series begun with 7-valent PCV (PCV7) should be completed with PCV13. A single supplemental dose of PCV13 is recommended for children aged 14 months through 71 months who have received an age-appropriate series of PCV7.</LI>&#xD;&#xA;<LI>For HIV-infected children two through five years of age: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer one dose of PCV13 if three doses of PCV (PCV7 and/or PCV13) were received previously.</LI>&#xD;&#xA;<LI>Administer two doses of PCV13 at least eight weeks apart if fewer than three doses of PCV (PCV7 and/or PCV13) were received previously.</LI>&#xD;&#xA;<LI>Administer one supplemental dose of PCV13 if four doses of PCV7 or other age-appropriate complete PCV7 series was received previously.</LI>&#xD;&#xA;<LI>The minimum interval between doses of PCV (PCV7 or PCV13) is eight weeks.</LI>&#xD;&#xA;<LI>For children with no history of PPSV23 vaccination, administer PPSV23 at least eight weeks after the most recent dose of PCV13.</LI></UL></LI></UL>‡ <STRONG>Inactivated poliovirus vaccine (IPV)</STRONG><br /><EM>(Minimum age: Six weeks)</EM> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer a four-dose series of IPV at ages two, four, 6 through 18 months, and four through six years. If four or more doses are administered prior to age four years, an additional dose should be administered at ages four through six years. The final dose in the series should be administered on or after the fourth birthday and at least six months after the previous dose.</LI></UL>† <STRONG>Trivalent inactivated influenza vaccine (TIV)</STRONG><br /><EM>(Minimum age: Six months)</EM> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer annually to HIV-infected children aged six months through six years and to all their eligible close contacts (including household members). TIV is recommended for HIV-infected children.</LI>&#xD;&#xA;<LI>For healthy, non-pregnant close contacts aged 2 years through 49 years, either live, attenuated influenza vaccine (LAIV) or TIV may be used.</LI>&#xD;&#xA;<LI>Children receiving TIV should receive 0.25 mL if aged 6 through 35 months, or 0.5 mL if aged three years or older.</LI>&#xD;&#xA;<LI>Administer two doses (separated by at least four weeks) to children aged younger than nine years per current influenza vaccine recommendations. Refer to <A href=\"https://www.cdc.gov/mmwr/pdf/rr/rr6207.pdf\" target=_blank>MMWR 2013; 62(No. RR-7):1-43</A>.</LI></UL>** <STRONG>Measles, mumps, and rubella (MMR) vaccine</STRONG><br /><EM>(Minimum age: 12 months for routine vaccination)</EM> &#xD;&#xA;<UL class=double_footnote_list>&#xD;&#xA;<LI>Administer a two-dose series of MMR vaccine for all HIV-infected individuals aged ≥12 months who do not have other current evidence of measles, rubella, and mumps immunity and who do not have evidence of current severe immunosuppression: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Individuals aged ≤5 years must have CD4 percentages ≥15% for ≥6 months.</LI>&#xD;&#xA;<LI>Individuals aged &gt;5 years must have CD4 percentages ≥15% and CD4 cell counts ≥200 cells/microL for ≥6 months.</LI>&#xD;&#xA;<LI>In cases when CD4 percentages are not available for those aged ≤5 years, the assessment of severe immunosuppression can be based on age-specific CD4 cell counts at the time CD4 counts were measured (ie, absence of severe immunosuppression is defined as ≥6 months above age-specific CD4 cell count criteria: CD4 cell count &gt;750 cells/microL while aged ≤12 months, and CD4 cell count ≥500 cells/microL while aged one through five years).</LI>&#xD;&#xA;<LI>In cases when only CD4 cell counts or only CD4 percentages are available for those aged &gt;5 years, the assessment of severe immunosuppression can be based on the CD4 values (count or percentage) that are available.</LI></UL></LI>&#xD;&#xA;<LI>The first dose should be administered at ages 12 months through 15 months, and the second dose at ages four years through six years. The second dose may be administered before age four years, provided at least four weeks have elapsed since the first dose.</LI>&#xD;&#xA;<LI>For HIV-infected children who can receive MMR vaccine based on the CD4 percentage or cell count criteria above and who are planning international travel: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer one dose of MMR vaccine to infants aged 6 through 11 months before departure from the United States for international travel. These children should be revaccinated with two doses of MMR vaccine, the first at age 12 through 15 months (12 months if the child remains in an area where disease risk is high), and the second dose at least four weeks later.</LI>&#xD;&#xA;<LI>Administer two doses of MMR vaccine to children aged 12 months and older before departure from the United States for international travel. The first dose should be administered on or after age 12 months and the second dose at least four weeks later.</LI></UL></LI>&#xD;&#xA;<LI>Individuals with perinatal HIV infection who were vaccinated prior to establishment of effective combination antiretroviral therapy (ART) should receive two appropriately spaced doses of MMR vaccine once effective ART has been established (for individuals aged ≤5 years: Must have CD4 percentages ≥15% for ≥6 months; and for individuals aged &gt;5 years: Must have CD4 percentages ≥15% and CD4 cell counts ≥200 cells/microL for ≥6 months) unless they have other acceptable current evidence of measles, rubella, and mumps immunity.</LI>&#xD;&#xA;<LI>Measles, mumps, rubella, and varicella (MMRV) vaccine has not been studied in HIV-infected children and should not be substituted for MMR vaccine.</LI></UL>¶¶ <STRONG>Varicella (VAR) vaccine</STRONG><br /><EM>(Minimum age: 12 months)</EM> &#xD;&#xA;<UL class=double_footnote_list>&#xD;&#xA;<LI>Limited data are available on safety and immunogenicity of VAR vaccine in HIV-infected children aged one year through eight years in CDC immunologic categories 1 and 2 (CD4 percentages ≥15%) and clinical categories N, A, and B.</LI>&#xD;&#xA;<LI>Single-antigen VAR vaccine should be considered for HIV-infected children who have CD4 percentages ≥15%. Eligible children should receive two doses three months apart, with the first dose administered as soon as possible after the first birthday.</LI>&#xD;&#xA;<LI>VAR vaccine is not recommended for HIV-infected children who have evidence of severe immunosuppression (CD4 percentage &lt;15% at any age; CD4 cell count &lt;200 cells/microL for those older than age five years).</LI>&#xD;&#xA;<LI>MMRV vaccine has not been studied in HIV-infected children and should not be substituted for single-antigen VAR vaccine.</LI></UL>ΔΔ <STRONG>Hepatitis A (HepA) vaccine</STRONG><br /><EM>(Minimum age: 12 months)</EM> &#xD;&#xA;<UL class=double_footnote_list>&#xD;&#xA;<LI>Administer to all children aged 12 months through 23 months. The two doses in the series should be administered at least six months apart.</LI>&#xD;&#xA;<LI>Children who have received one dose of HepA vaccine before age 24 months should receive a second dose 6 to 18 months after the first dose.</LI>&#xD;&#xA;<LI>Two doses of HepA vaccine separated by 6 to 18 months is also recommended for children 24 months and older who have not already received the HepA vaccine series and who live in areas where vaccination programs target older children, who are at increased risk of infection, or for whom immunity against HepA is desired. Refer to <A href=\"https://www.cdc.gov/mmwr/indrr_2006.html\" target=_blank>MMWR 2006; 55(No. RR-7)</A>.</LI></UL><FONT class=double_lozenge>◊◊</FONT> <STRONG>Meningococcal vaccines</STRONG><br /><EM>(Minimum age: Six weeks for combination Hib-meningococcal conjugate vaccine serogroup CY [Hib-MenCY (MenHibrix)]; nine months for meningococcal conjugate vaccine [MenACWY-D (Menactra)]; two months for meningococcal conjugate vaccine [MenACWY-CRM (Menveo)]; two years for meningococcal polysaccharide vaccine [MPSV4])</EM> &#xD;&#xA;<UL class=double_footnote_list>&#xD;&#xA;<LI>Indications for meningococcal vaccine in this age group include anatomic and functional asplenia, persistent complement component deficiency, and travel to a high-risk area. Refer to UpToDate table on meningococcal vaccination.</LI>&#xD;&#xA;<LI>HIV-infected children are <STRONG>not</STRONG> considered at increased risk of meningococcal disease because of HIV infection, <EM>per se</EM>. Although the efficacy of meningococcal conjugate vaccine among HIV-infected children is unknown, providers can vaccinate HIV-infected children if otherwise indicated.</LI>&#xD;&#xA;<LI>HIV infected children 2 to 23 months of age who have indications for meningococcal vaccination should receive the vaccine schedule as recommended for the specific indication. Refer to UpToDate table on meningococcal vaccination.</LI>&#xD;&#xA;<LI>HIV-infected children ≥2 years of age who have indications for meningococcal vaccination should receive a two-dose primary meningococcal conjugate vaccine series (with the second dose administered two months or more after the first dose).</LI>&#xD;&#xA;<LI>HIV-infected children who remain at increased risk of meningococcal disease should be vaccinated every five years thereafter.</LI></UL></div><div class=\"graphic_reference\">Adapted from: U.S. Department of Health and Human Services. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children. Available at: <A href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/glchunk/glchunk_431.pdf\" target=_blank>http://aidsinfo.nih.gov/contentfiles/lvguidelines/glchunk/glchunk_431.pdf</A> (Accessed on February 4, 2014) and Akinsanya-Beysolow I, Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC. Advisory Committee on Immunization Practices recommended immunization schedules for persons aged 0 through 18 years - United States, 2014. MMWR Morb Mortal Wkly Rep 2014; 63:108.</div><div id=\"graphicVersion\">Graphic 93621 Version 5.0</div></div></div>"},"93622":{"type":"graphic_figure","displayName":"Vaccine schedules for HIV-infected children aged 7-18 years","title":"Recommendations for vaccination in HIV-infected and exposed children, aged 7 through 18 years","html":"<div class=\"graphic\"><div style=\"width: 665px\" class=\"figure\"><div class=\"ttl\">Recommendations for vaccination in HIV-infected and exposed children, aged 7 through 18 years</div><div class=\"cntnt\"><img style=\"width:645px; height:518px;\" src=\"images/ID/93622_VaccschdHIVchild718yrs.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This schedule is adapted from the 2013 United States Department of Health and Human Services Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children and from the 2014 Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for persons aged 0 through 18 years. It summarizes recommendations for routine administration of vaccines for HIV-infected children and adolescents aged 7 through 18 years and indicates the recommended ages for vaccine administration for vaccines licensed in the United States. Licensed combination vaccines may be used whenever a component of the combination is indicated and other components of the vaccine are not contraindicated and if approved by the Food and Drug Administration for that dose of the series, unless otherwise specified. Providers should consult the relevant ACIP statement for detailed recommendations. Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS). Guidance about how to obtain and complete a VAERS form is available at <A href=\"https://www.vaers.hhs.gov/\" target=_blank>https://www.vaers.hhs.gov</A> or telephone 800-822-7967.</div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.<br />* <STRONG>Tetanus and diphtheria toxoids, and acellular pertussis (Tdap) vaccine</STRONG><br /><EM>(Minimum age: 10 years for Boostrix; 11 years for Adacel)</EM> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer one dose of Tdap vaccine to all adolescents aged 11 through 12 years.</LI>&#xD;&#xA;<LI>Tdap may be administered regardless of the interval since the last tetanus and diphtheria toxoid (Td) vaccine.</LI>&#xD;&#xA;<LI>Administer one dose of Tdap vaccine to pregnant adolescents during each pregnancy (preferred during 27 through 36 weeks gestation) regardless of time since prior Td or Tdap vaccination.</LI>&#xD;&#xA;<LI>Individuals aged seven years and older who are not fully immunized with diphtheria and tetanus toxoids, and acellular pertussis (DTaP) vaccine should receive Tdap vaccine as one (preferably the first) dose in the catch-up series; if additional doses are needed, use Td vaccine. For children 7 through 10 years who receive a dose of Tdap as part of the catch-up series, an adolescent Tdap vaccine dose at age 11 through 12 years should NOT be administered. Td should be administered instead 10 years after the Tdap dose.</LI>&#xD;&#xA;<LI>Individuals aged 11 through 18 years who have not received Tdap should receive a dose followed by Td booster doses every 10 years thereafter.</LI></UL>¶ <STRONG>Human papillomavirus (HPV) vaccine</STRONG><br /><EM>(Minimum age: Nine years)</EM> &#xD;&#xA;<UL>&#xD;&#xA;<LI><STRONG>NOTE:</STRONG> Two HPV vaccines are licensed. A quadrivalent vaccine (HPV4) is licensed for use in females and males; a bivalent vaccine (HPV2) is licensed for use in females. Because these are not live virus vaccines, they can be administered to individuals who are immunosuppressed because of disease or medication, including those who are HIV-infected. However, the immune response and vaccine efficacy may be less than in immunocompetent individuals. &#xD;&#xA;<UL>&#xD;&#xA;<LI>HPV vaccines are most effective for both males and females when given before exposure to HPV through sexual contact.</LI>&#xD;&#xA;<LI>Administer a three-dose series of HPV vaccine on a schedule of zero, one to two, and six months to all adolescents aged 11 through 12 years.</LI>&#xD;&#xA;<LI>Administer the second dose one to two months after the first dose (minimum interval of four weeks), administer the third dose 24 weeks after the first dose and 16 weeks after the second dose (minimum interval of 12 weeks).</LI>&#xD;&#xA;<LI>Administer the series at ages 13 through 18 years if not previously vaccinated.</LI>&#xD;&#xA;<LI>The vaccine series may be started at age nine years.</LI></UL></LI></UL>Δ <STRONG>Meningococcal conjugate vaccine (MCV4)</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Adolescents aged 11 through 18 years with HIV infection should receive a two-dose primary series of MCV4 with at least eight weeks between doses.</LI>&#xD;&#xA;<LI>Individuals who receive the second dose of the primary series at or before age 11 to 12 years should receive a booster dose at age 16 years.</LI>&#xD;&#xA;<LI>Individuals who have a specific indication for meningococcal vaccination (such as anatomic or functional asplenia) and have already received a primary series should receive a booster MCV4 every five years. Refer to the UpToDate table on meningococcal vaccination recommendations for specific schedules based on indication.</LI>&#xD;&#xA;<LI>Although the efficacy of MCV4 among HIV-infected patients is unknown, HIV-infected patients aged 7 through 10 years may elect vaccination.</LI></UL><FONT class=lozenge>◊</FONT> <STRONG>Influenza vaccine (trivalent inactivated influenza vaccine [TIV])</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer annually to HIV-infected children and adolescents. Only TIV should be used in HIV-infected individuals. For healthy nonpregnant close contacts aged 2 through 49 years, either live, attenuated influenza vaccine (LAIV) or TIV can be used.</LI>&#xD;&#xA;<LI>Administer two doses (separated by at least four weeks) to children aged younger than nine years who are receiving influenza vaccine for the first time or based on previous influenza vaccine history, per current influenza vaccine recommendations. Refer to <A href=\"https://www.cdc.gov/mmwr/pdf/rr/rr6207.pdf\" target=_blank>MMWR 2013; 62(No. RR-7):1-43</A>.</LI></UL>§ <STRONG>Pneumococcal vaccines (13-valent pneumococcal conjugate vaccine [PCV13]; 23-valent pneumococcal polysaccharide vaccine [PPSV23])</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>For HIV-infected children aged 6 through 18 years: &#xD;&#xA;<UL>&#xD;&#xA;<LI>If neither PCV13 nor PPSV23 was previously received, administer one dose of PCV13 now and one dose of PPSV23 at least eight weeks later.</LI>&#xD;&#xA;<LI>If PCV13 has been received previously but PPSV23 has not, administer one dose of PPSV23 at least eight weeks after the most recent dose of PCV13.</LI>&#xD;&#xA;<LI>If PPSV23 has been received but PCV13 has not, administer one dose of PCV13 at least eight weeks after the most recent dose of PPSV23.</LI>&#xD;&#xA;<LI>A second dose of PPSV23 is recommended five years after the first dose of PPSV23.</LI></UL></LI></UL>¥ <STRONG>Hepatitis A (HepA) vaccine</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Two doses of HepA vaccine separated by 6 to 18 months are recommended for children 24 months and older who have not already received the HepA vaccine series and who live in areas where vaccination programs target older children, who are at increased risk of infection, or for whom immunity against HepA is desired. Refer to <A href=\"https://www.cdc.gov/mmwr/pdf/rr/rr5507.pdf\" target=_blank>MMWR 2006; 55(No. RR-7)</A>.</LI></UL>‡ <STRONG>Hepatitis B (HepB) vaccine</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Administer the three-dose series (at zero, one, and six months) to those who were not previously vaccinated.</LI>&#xD;&#xA;<LI>Post-vaccination testing is recommended for HIV-infected individuals. Testing should be performed one to two months after administration of the final dose. Individuals found to have antibody to HBsAg (anti-HBs) levels of &lt;10 mIU/mL after the primary series should be revaccinated. Administration of three doses on an appropriate schedule, followed by anti-HBs testing one to two months after the third dose, is usually more practical than serologic testing after one or two doses of vaccine. Modified dosing regimens, including doubling of the standard antigen dose, may increase response rates. However, data are limited on response to these alternative vaccination schedules. Refer to the topic on immunizations in HIV-infected individuals for UpToDate recommendations.</LI>&#xD;&#xA;<LI>In HIV-infected individuals, the need for booster doses has not been determined. Annual anti-HBs testing and booster doses when anti-HBs levels decline to &lt;10 mIU/mL should be considered in individuals with ongoing risk of exposure. Refer to <A href=\"https://www.cdc.gov/mmwr/PDF/rr/rr5416.pdf\" target=_blank>MMWR 2005; 54(No. RR-16)</A>.</LI></UL>† <STRONG>Inactivated poliovirus vaccine (IPV)</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>The final dose in the series should be administered on or after the fourth birthday and at least six months after the previous dose.</LI>&#xD;&#xA;<LI>For children who received an all-IPV or all-oral poliovirus (OPV) series, a fourth dose is not necessary if the third dose was administered at age ≥4 years.</LI>&#xD;&#xA;<LI>If both OPV and IPV were administered as part of a series, a total of four doses of IPV should be administered, regardless of a child's current age.</LI></UL>** <STRONG>Measles, mumps, and rubella (MMR) vaccine</STRONG> &#xD;&#xA;<UL class=double_footnote_list>&#xD;&#xA;<LI>Two doses of MMR vaccine are recommended for all HIV-infected individuals aged ≥12 months who do not have other current evidence of measles, rubella, and mumps immunity and who do now have evidence of current severe immunosuppression: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Individuals aged &gt;5 years must have CD4 percentages ≥15% and CD4 cell counts ≥200 cells/microL for ≥6 months.</LI>&#xD;&#xA;<LI>In cases when only CD4 counts or only CD4 percentages are available for those aged &gt;5 years, assessment of severe immunosuppression can be based on the CD4 values (count or percentage) that are available.</LI></UL></LI>&#xD;&#xA;<LI>If eligible and not previously vaccinated, administer two doses with the second dose at least 28 days after the first dose, or administer a second dose for those who received only one dose, with at least 28 days between doses.</LI>&#xD;&#xA;<LI>Individuals with perinatal HIV infection who were vaccinated prior to establishment of effective combination antiretroviral therapy (ART) should receive two appropriately spaced doses of MMR vaccine once effective ART has been established (individuals aged &gt;5 years: Must have CD4 percentages ≥15% and CD4 cell counts ≥200 cells/microL for ≥6 months) unless they have other acceptable current evidence of measles, rubella, and mumps immunity.</LI></UL>¶¶ <STRONG>Varicella (VAR) vaccine</STRONG> &#xD;&#xA;<UL class=double_footnote_list>&#xD;&#xA;<LI>Limited data are available on safety and immunogenicity of VAR vaccine in HIV-infected children aged one through eight years in Centers for Disease Control and Prevention immunologic categories 1 and 2 (CD4 percentages ≥15%) and clinical categories N, A, and B.</LI>&#xD;&#xA;<LI>VAR vaccine should be considered for HIV-infected children aged one through eight years with CD4 percentages ≥15%. Eligible children should receive two doses at least three months apart.</LI>&#xD;&#xA;<LI>Data are lacking on use of VAR vaccine in HIV-infected children older than age eight years. However, on the basis of expert opinion, the safety of VAR vaccine in HIV-infected individuals older than age eight years with similar levels of immune function (CD4 age-specific percentages ≥15% or count ≥200 cells/microL) is likely to be similar to that for children aged ≤8 years. Immunogenicity may be lower in HIV-infected adolescents (and adults).</LI>&#xD;&#xA;<LI>Weighing the risk of severe disease from wild varicella zoster virus and the potential benefit of vaccination, vaccination (two doses administered three months apart) can be considered for children and adolescents aged 9 through 18 years who lack evidence of immunity.</LI>&#xD;&#xA;<LI>VAR vaccine is <STRONG>not</STRONG> recommended for HIV-infected children or adolescents who have evidence of severe immunosuppression (CD4 percentage &lt;15% at any age; for those aged ≥5 years, CD4 count &lt;200 cells/microL).</LI>&#xD;&#xA;<LI>Measles, mumps, rubella, and varicella (MMRV) vaccine has not been studied in HIV-infected children and should not be substituted for single-antigen VAR vaccine.</LI>&#xD;&#xA;<LI>For evidence of immunity guidance and other details, refer to <A href=\"https://www.cdc.gov/mmwr/pdf/rr/rr5604.pdf\" target=_blank>MMWR 2007; 56(No. RR-4)</A>.</LI></UL><STRONG>NOTE: <EM>Haemophilus influenzae</EM> type B (Hib) conjugate vaccine</STRONG> &#xD;&#xA;<UL class=double_footnote_list>&#xD;&#xA;<LI>Hib conjugate vaccines are available in single- or combined-antigen preparations. Hib vaccine is recommended routinely for all children through age 59 months. One dose of Hib vaccine should be administered to unvaccinated or partially vaccinated individuals aged five years or older who are HIV-infected.</LI></UL></div><div class=\"graphic_reference\">Adapted from: U.S. Department of Health and Human Services. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children. Available at: <A href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/glchunk/glchunk_432.pdf\" target=_blank>http://aidsinfo.nih.gov/contentfiles/lvguidelines/glchunk/glchunk_432.pdf</A> (Accessed on February 4, 2014) and Akinsanya-Beysolow I, Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC. Advisory Committee on Immunization Practices recommended immunization schedules for persons aged 0 through 18 years - United States, 2014. MMWR Morb Mortal Wkly Rep 2014; 63:108.</div><div id=\"graphicVersion\">Graphic 93622 Version 5.0</div></div></div>"},"93655":{"type":"graphic_figure","displayName":"Carotid artery anatomy","title":"Carotid artery anatomy","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Carotid artery anatomy</div><div class=\"cntnt\"><img style=\"width:509px; height:667px;\" src=\"images/CARD/93655_Carotid_artery_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The top illustration shows the common carotid artery branching into the internal and external carotid arteries. The illustration at the bottom right of the graphic shows cross sectional (left) and longitudinal (right) views inside the carotid artery, with examples of both diseased (top) and healthy (bottom) arterial segments.</div><div id=\"graphicVersion\">Graphic 93655 Version 2.0</div></div></div>"},"93656":{"type":"graphic_diagnosticimage","displayName":"Chest x-rays bronchopulmonary dysplasia","title":"Sequential chest radiographs of bronchopulmonary dysplasia (BPD) in a premature infant","html":"<div class=\"graphic\"><div style=\"width: 607px\" class=\"figure\"><div class=\"ttl\">Sequential chest radiographs of bronchopulmonary dysplasia (BPD) in a premature infant</div><div class=\"cntnt\"><img style=\"width:587px; height:741px;\" src=\"images/RADIOL/93656_Xrays_bronchopulm_dysplasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image A is a chest radiograph taken after birth of a premature infant born at 25 weeks. The lungs are clear. Image B is a chest radiograph taken two weeks later, which shows a coarsened interstitial pattern and diffuse haziness. Image C is a radiograph that shows further coarsening of the lung markings five weeks after birth. Image D shows pulmonary congestion after closure of a patent ductus arteriosus (arrow shows clip). Image E is a magnification of image D and shows cystic changes in the lungs (arrows).</div><div id=\"graphicVersion\">Graphic 93656 Version 1.0</div></div></div>"},"93658":{"type":"graphic_figure","displayName":"Tracking of obesity during childhood","title":"Tracking of obesity during childhood (ages 5 to 14 years)","html":"<div class=\"graphic\"><div style=\"width: 636px\" class=\"figure\"><div class=\"ttl\">Tracking of obesity during childhood (ages 5 to 14 years)</div><div class=\"cntnt\"><img style=\"width:616px; height:388px;\" src=\"images/PEDS/93658_Track_obesity_during_child.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure demonstrates strong tracking of obesity from early childhood into adolescence, based on a longitudinal study from the United States. Among children with mild obesity in kindergarten (BMI 95th percentile), nearly half will be obese in eighth grade. Among children with severe obesity in kindergarten (BMI 99th percentile), nearly three quarters will be obese in eighth grade. Thus, a substantial component of adolescent obesity is established before five years of age. These observations provide support for the concept of interventions early in life to prevent and treat obesity.</div><div class=\"graphic_footnotes\">BMI: body mass index.</div><div class=\"graphic_reference\">Data from: Cunningham SA, Kramer MR, Narayan KM. Incidence of childhood obesity in the United States. N Engl J Med 2014; 370:403.</div><div id=\"graphicVersion\">Graphic 93658 Version 1.0</div></div></div>"},"93688":{"type":"graphic_movie","displayName":"Whip maneuver for reducing cuboid subluxation","title":"Whip maneuver for reducing cuboid subluxation","html":"<div class=\"graphic normal\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Whip maneuver for reducing cuboid subluxation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/93688_Whipmaneureduccuboidvid.mp4\" style=\"width:560px;height:336px\"></div><img style=\"width:424px; height:318px;\" src=\"images/EM/93688_Whipmaneureduccuboidimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Timothy Ryan Draper, DO, AAFP, CAQ Sports Medicine.</div><div id=\"graphicVersion\">Graphic 93688 Version 1.0</div></div></div>"},"93689":{"type":"graphic_picture","displayName":"Ankle compression sleeve","title":"Ankle compression sleeve","html":"<div class=\"graphic\"><div style=\"width: 637px\" class=\"figure\"><div class=\"ttl\">Ankle compression sleeve</div><div class=\"cntnt\"><img style=\"width:617px; height:368px;\" src=\"images/EM/93689_Ankle_compression_sleeve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photographs above show two types of ankle compression sleeves.</div><div class=\"graphic_reference\">Courtesy of Timothy Ryan Draper, DO, AAFP, CAQ Sports Medicine.</div><div id=\"graphicVersion\">Graphic 93689 Version 1.0</div></div></div>"},"93690":{"type":"graphic_picture","displayName":"Superficial muscles of the leg ankle and foot - Anterior view","title":"Superficial muscles of the leg, ankle, and foot: Anterior view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superficial muscles of the leg, ankle, and foot: Anterior view</div><div class=\"cntnt\"><img style=\"width:357px; height:434px;\" src=\"images/EM/93690_Sprfcmscllganklftantrr.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 93690 Version 3.0</div></div></div>"},"93691":{"type":"graphic_movie","displayName":"Locked subtalar joint","title":"Locked subtalar joint","html":"<div class=\"graphic normal\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Locked subtalar joint</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/93691_Lockedsubtalarjointvid.mp4\" style=\"width:560px;height:336px\"></div><img style=\"width:548px; height:411px;\" src=\"images/EM/93691_Lockedsubtalarjointimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video clip shows an examination of the subtalar joint in a patient with a history of surgical repair of a club foot. There is minimal motion at the subtalar joint.</div><div class=\"graphic_reference\">Courtesy of Timothy Ryan Draper, DO, AAFP, CAQ Sports Medicine.</div><div id=\"graphicVersion\">Graphic 93691 Version 1.0</div></div></div>"},"93692":{"type":"graphic_picture","displayName":"Superficial muscles of the leg ankle and foot - Lateral view","title":"Superficial muscles of the leg, ankle, and foot: Lateral view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superficial muscles of the leg, ankle, and foot: Lateral view</div><div class=\"cntnt\"><img style=\"width:401px; height:341px;\" src=\"images/EM/93692_Suprfimscllganklftltrl.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 93692 Version 3.0</div></div></div>"},"93693":{"type":"graphic_figure","displayName":"Superficial muscles of the leg ankle and foot - Medial view","title":"Superficial muscles of the leg, ankle, and foot: Medial view","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Superficial muscles of the leg, ankle, and foot: Medial view</div><div class=\"cntnt\"><img style=\"width:529px; height:261px;\" src=\"images/EM/93693_SprficlmscllganklftMdl.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 93693 Version 4.0</div></div></div>"},"93694":{"type":"graphic_picture","displayName":"Superficial muscles of the leg ankle and foot - Posterior view","title":"Superficial muscles of the leg, ankle, and foot: Posterior view","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Superficial muscles of the leg, ankle, and foot: Posterior view</div><div class=\"cntnt\"><img style=\"width:455px; height:681px;\" src=\"images/EM/93694_SprfcmscllganklftPstrr.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 93694 Version 3.0</div></div></div>"},"93695":{"type":"graphic_movie","displayName":"Examination of subtalar motion","title":"Examination of subtalar motion","html":"<div class=\"graphic normal\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Examination of subtalar motion</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/93695_Examinsubtalarmotionvid.mp4\" style=\"width:560px;height:336px\"></div><img style=\"width:424px; height:318px;\" src=\"images/EM/93695_Examinsubtalarmotionimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video clip shows a maneuver for assessing subtalar motion. The maneuver is performed by holding the patient's ankle firmly in dorsiflexion with one hand, and then passively inverting and everting the foot with the other hand. The patient examined in the video clip demonstrates normal subtalar motion.</div><div class=\"graphic_reference\">Courtesy of Timothy Ryan Draper, DO, AAFP, CAQ Sports Medicine.</div><div id=\"graphicVersion\">Graphic 93695 Version 2.0</div></div></div>"},"93696":{"type":"graphic_picture","displayName":"Tibialis anterior","title":"Tibialis anterior","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tibialis anterior</div><div class=\"cntnt\"><img style=\"width:330px; height:498px;\" src=\"images/EM/93696_Tibialisanterior.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 93696 Version 3.0</div></div></div>"},"93697":{"type":"graphic_picture","displayName":"Extensor digitorum longus","title":"Extensor digitorum longus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extensor digitorum longus</div><div class=\"cntnt\"><img style=\"width:327px; height:493px;\" src=\"images/EM/93697_Extensordigitorumlongus.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 93697 Version 3.0</div></div></div>"},"93698":{"type":"graphic_picture","displayName":"Midtarsal adduction test","title":"Midtarsal adduction test","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Midtarsal adduction test</div><div class=\"cntnt\"><img style=\"width:532px; height:203px;\" src=\"images/EM/93698_Midtarsal_adduct_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The midtarsal adduction test is used to help diagnose cuboid subluxation. Pain with adduction of the midfoot, while the ankle and subtalar joints are kept stable, represents a positive test.</div><div class=\"graphic_reference\">Courtesy of Timothy Ryan Draper, DO, AAFP, CAQ Sports Medicine.</div><div id=\"graphicVersion\">Graphic 93698 Version 1.0</div></div></div>"},"93699":{"type":"graphic_picture","displayName":"Peroneus longus","title":"Peroneus longus","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Peroneus longus</div><div class=\"cntnt\"><img style=\"width:471px; height:712px;\" src=\"images/EM/93699_Peroneuslongus.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 93699 Version 3.0</div></div></div>"},"93700":{"type":"graphic_picture","displayName":"Extensor hallucis longus","title":"Extensor hallucis longus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extensor hallucis longus</div><div class=\"cntnt\"><img style=\"width:205px; height:527px;\" src=\"images/EM/93700_Extensorhallucislongus.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 93700 Version 3.0</div></div></div>"},"93701":{"type":"graphic_picture","displayName":"Peroneus tertius","title":"Peroneus tertius","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Peroneus tertius</div><div class=\"cntnt\"><img style=\"width:471px; height:712px;\" src=\"images/EM/93701_Peroneustertius.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 93701 Version 3.0</div></div></div>"},"93702":{"type":"graphic_picture","displayName":"Peroneus brevis","title":"Peroneus brevis","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Peroneus brevis</div><div class=\"cntnt\"><img style=\"width:471px; height:712px;\" src=\"images/EM/93702_Peroneusbrevis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 93702 Version 3.0</div></div></div>"},"93703":{"type":"graphic_picture","displayName":"Tibialis posterior","title":"Tibialis posterior","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Tibialis posterior</div><div class=\"cntnt\"><img style=\"width:471px; height:712px;\" src=\"images/EM/93703_Tibialisposterior.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 93703 Version 3.0</div></div></div>"},"93704":{"type":"graphic_picture","displayName":"Flexor digitorum longus","title":"Flexor digitorum longus","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Flexor digitorum longus</div><div class=\"cntnt\"><img style=\"width:468px; height:712px;\" src=\"images/EM/93704_Flexordigitorumlongus.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 93704 Version 3.0</div></div></div>"},"93705":{"type":"graphic_picture","displayName":"Flexor hallucis longus","title":"Flexor hallucis longus","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Flexor hallucis longus</div><div class=\"cntnt\"><img style=\"width:467px; height:711px;\" src=\"images/EM/93705_Flexorhallucislongus.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 93705 Version 3.0</div></div></div>"},"93706":{"type":"graphic_table","displayName":"Eccentric exercises for peroneal tendinopathy","title":"Eccentric exercises for peroneal tendinopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Eccentric exercises for peroneal tendinopathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Exercise 1</td> <td>Heel drop and raise on step. Note starting position of foot.*</td> </tr> <tr> <td>Exercise 2</td> <td>Isometric contraction against a wall with foot everted</td> </tr> <tr> <td>Exercise 3</td> <td>Resistance band eccentric exercise</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">* Refer to text and photographs for details.</div><div class=\"graphic_reference\">Courtesy of Timothy Ryan Draper, DO, AAFP, CAQ Sports Medicine.</div><div id=\"graphicVersion\">Graphic 93706 Version 1.0</div></div></div>"},"93707":{"type":"graphic_picture","displayName":"Eccentric exercise on step for peroneal tendinopathy","title":"Eccentric exercise on step for peroneal tendinopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eccentric exercise on step for peroneal tendinopathy</div><div class=\"cntnt\"><img style=\"width:314px; height:482px;\" src=\"images/EM/93707_Ecc_exer_step_peron_tendin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the starting position for performing an eccentric exercise to treat peroneal tendinopathy. Note the placement of the toes and the starting position of heel below the step.</div><div class=\"graphic_reference\">Courtesy of Timothy Ryan Draper, DO, AAFP, CAQ Sports Medicine.</div><div id=\"graphicVersion\">Graphic 93707 Version 1.0</div></div></div>"},"93708":{"type":"graphic_picture","displayName":"Exercises for rehabilitation of peroneal tendinopathy","title":"Exercises for rehabilitation of peroneal tendinopathy","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Exercises for rehabilitation of peroneal tendinopathy</div><div class=\"cntnt\"><img style=\"width:533px; height:296px;\" src=\"images/EM/93708_Exrcs_rehab_peroneal_tendi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These photographs depict three exercises commonly used for the rehabilitation of peroneal tendinopathy.</div><div class=\"graphic_reference\">Courtesy of Timothy Ryan Draper, DO, AAFP, CAQ Sports Medicine.</div><div id=\"graphicVersion\">Graphic 93708 Version 1.0</div></div></div>"},"93710":{"type":"graphic_table","displayName":"Eccentric exercises for posterior tibialis tendinopathy","title":"Eccentric exercises for posterior tibialis tendinopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Eccentric exercises for posterior tibialis tendinopathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Exercise 1</td> <td>Eccentric heel drop and raise on step. Note starting position of foot.*</td> </tr> <tr> <td>Exercise 2</td> <td>Resistance band eccentric exercise</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">* Refer to text and photographs for details.</div><div class=\"graphic_reference\">Courtesy of Timothy Ryan Draper, DO, AAFP, CAQ Sports Medicine.</div><div id=\"graphicVersion\">Graphic 93710 Version 1.0</div></div></div>"},"93711":{"type":"graphic_diagnosticimage","displayName":"Fracture of the trapezium radiograph","title":"Fracture of the trapezium radiograph","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Fracture of the trapezium radiograph</div><div class=\"cntnt\"><img style=\"width:598px; height:381px;\" src=\"images/RADIOL/93711_Xray_fracture_trapezium.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image A is an A-P radiograph of the right hand in a cast and shows a non-displaced fracture (arrow) of the trapezium. The fracture (arrow) is more apparent on the magnified view (B).</div><div class=\"graphic_footnotes\">AP: anteroposterior.</div><div class=\"graphic_reference\">Courtesy of Gregory Waryasz, MD.</div><div id=\"graphicVersion\">Graphic 93711 Version 3.0</div></div></div>"},"93712":{"type":"graphic_diagnosticimage","displayName":"CT of vocal cord paresis","title":"Vocal cord paresis on CT","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Vocal cord paresis on CT</div><div class=\"cntnt\"><img style=\"width:598px; height:258px;\" src=\"images/RADIOL/93712_CT_vocal_cord_paresis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan through the neck (A) shows a paretic left vocal cord (arrow) accounting for the presenting symptom of hoarseness. Image B shows an enlarged lymph node posterior to the trachea in the region of the undersurface of the aortic arch, likely impinging on the recurrent laryngeal nerve.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93712 Version 1.0</div></div></div>"},"93713":{"type":"graphic_diagnosticimage","displayName":"X-ray stellate fracture of the patella","title":"Stellate patella fracture on x-ray","html":"<div class=\"graphic\"><div style=\"width: 648px\" class=\"figure\"><div class=\"ttl\">Stellate patella fracture on x-ray</div><div class=\"cntnt\"><img style=\"width:628px; height:324px;\" src=\"images/RADIOL/93713_Xray_stellate_fract_patella.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An A-P view of the right knee (A) shows a stellate patella fracture (arrow). Image B is a magnified view and shows a \"Y\" shaped comminuted fracture (arrows). Image C is a lateral view and shows a subtle vertical component of the fracture (arrow) and a small effusion (arrowhead).</div><div id=\"graphicVersion\">Graphic 93713 Version 1.0</div></div></div>"},"93714":{"type":"graphic_diagnosticimage","displayName":"MRI iliotibial band syndrome","title":"Iliotibial band syndrome on MRI","html":"<div class=\"graphic\"><div style=\"width: 653px\" class=\"figure\"><div class=\"ttl\">Iliotibial band syndrome on MRI</div><div class=\"cntnt\"><img style=\"width:633px; height:345px;\" src=\"images/RADIOL/93714_MRI_iliotibial_band_syndr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A coronal MRI using a fat suppressed proton density sequence (A) shows the iliotibial band (arrow) and the hyperintense edema of the soft tissues (arrowhead) between the ITB and the lateral epicondyle of the femur. Image B is an axial view and shows the ITB (arrow) and the inflamed and edematous soft tissues between the femur and the ITB.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; ITB: iliotibial band.</div><div class=\"graphic_reference\">Courtesy of Richard Waite, MD.</div><div id=\"graphicVersion\">Graphic 93714 Version 1.0</div></div></div>"},"93722":{"type":"graphic_table","displayName":"KDIGO criteria acute kidney injury for children","title":"Criteria for the Kidney Disease Improving Global Outcomes (KDIGO) acute kidney injury for children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for the Kidney Disease Improving Global Outcomes (KDIGO) acute kidney injury for children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"45%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Serum creatinine (SCr)</td> <td class=\"subtitle1\">Urine output</td> </tr> <tr> <td class=\"centered\">1</td> <td>Increase to 1.5 to 1.9 times baseline, OR increase of &#8805;0.3 mg/dL (&#8805;26.5 mcmol/L)</td> <td>&#60;0.5 mL/kg per hour for 6 to 12 h</td> </tr> <tr> <td class=\"centered\">2</td> <td>Increase to 2 to 2.9 times baseline</td> <td>&#60;0.5 mL/kg per hour for &#8805;12 h</td> </tr> <tr> <td class=\"centered\">3</td> <td> <p>Increase greater than 3 times baseline, OR</p> <p>SCr &#8805;4 mg/dL (&#8805;353.6 mcmol/L), OR</p> <p>Initiation of renal replacement therapy, OR</p> eGFR &#60;35 mL/min per 1.73 m<sup>2</sup> (&#60;18 years)</td> <td> <p>&#60;0.3 mL/kg per hour for &#8805;24 h, OR</p> Anuria for &#8805;12 h</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The time frames for the increases in serum creatinine are:<br /><ul class=\"decimal_heading\">&#xD;&#xA;    <li>Increase of SCr &ge;0.3 mg/dL (&ge;26.5 mcmol/L) within 48 hours</li>&#xD;&#xA;    <li>Increase in SCr &gt;1.5 times the baseline within the prior seven days</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">eGFR: estimated glomerular filtration rate; h: hours.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Kidney International Supplements. Summary of Recommendation Statements. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2012; 2:8. Copyright &copy; 2012. <a href=\"http://www.nature.com/kisup\" target=\"_blank\">www.nature.com/kisup</a>.</div><div id=\"graphicVersion\">Graphic 93722 Version 2.0</div></div></div>"},"93723":{"type":"graphic_table","displayName":"Supplies for peripartum hysterectomy","title":"Supplies for peripartum hysterectomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Supplies for peripartum hysterectomy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Surgical equipment and supplies</td> </tr> <tr> <td class=\"indent1\">Heavy clamps for vascular pedicles (eg, Heaney or Zeppelin; at least four clamps should be available)</td> </tr> <tr> <td class=\"indent1\">Kelly clamps (long and short), Kocher clamps for holding tissue</td> </tr> <tr> <td class=\"indent1\">Tonsil and right angle clamps for dissection</td> </tr> <tr> <td class=\"indent1\">Hand-held retractors</td> </tr> <tr> <td class=\"indent1\">Self-retaining retractor (eg, Bookwalter)</td> </tr> <tr> <td class=\"indent1\">Electrocautery device with appropriate grounding</td> </tr> <tr> <td class=\"indent1\">Bipolar tissue sealing device, if available</td> </tr> <tr> <td class=\"indent1\">Suction cannula(s) with wall suction</td> </tr> <tr> <td class=\"indent1\">Laparotomy packs and surgical sponges</td> </tr> <tr> <td class=\"indent1\">Hemostatic agents (eg, thrombin, gelatin products, cellulose products)</td> </tr> <tr> <td class=\"indent1\">Fluids for irrigation</td> </tr> <tr> <td class=\"indent1\">Standard cesarean delivery equipment, if indicated</td> </tr> <tr> <td class=\"indent1\">Multiple sutures (eg, #0-polyglactin 910, #2-0 polyglactin 910, polydioxanone for fascial closure)</td> </tr> <tr> <td class=\"subtitle1_single\">Patient preparation</td> </tr> <tr> <td class=\"indent1\">Allen stirrups, if readily available (for access to vagina and bladder)</td> </tr> <tr> <td class=\"indent1\">Bladder catheter (3-way, if possible)</td> </tr> <tr> <td class=\"indent1\">Vaginal preparation with povidone-iodine</td> </tr> <tr> <td class=\"indent1\">Abdominal preparation (povidone-iodine or chlorhexidine)</td> </tr> <tr> <td class=\"indent1\">Pneumatic compression boots</td> </tr> <tr> <td class=\"indent1\">Laparotomy drapes, and leg drapes if stirrups are used</td> </tr> <tr> <td class=\"indent1\">Broad-spectrum antibiotics (eg, cefotetan, cefazolin, gentamicin plus clindamycin)</td> </tr> <tr> <td class=\"subtitle1_single\">Patient stabilization</td> </tr> <tr> <td class=\"indent1\">Blood products (activate massive transfusion protocol, if available)</td> </tr> <tr> <td class=\"indent1\">Uterotonic agents (use until uterine blood supply is disconnected)</td> </tr> <tr> <td class=\"indent1\">Multiple large-bore intravenous lines</td> </tr> <tr> <td class=\"indent1\">Arterial line</td> </tr> <tr> <td class=\"indent1\">Warming devices for patient and for blood products</td> </tr> <tr> <td class=\"indent1\">Rapid blood infuser, if available</td> </tr> <tr> <td class=\"indent1\">Intubation equipment</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 93723 Version 2.0</div></div></div>"},"93724":{"type":"graphic_picture","displayName":"Maturational dyschromia","title":"Maturational dyschromia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Maturational dyschromia</div><div class=\"cntnt\"><img style=\"width:322px; height:503px;\" src=\"images/DERM/93724_Maturational_dyschromia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Maturational dyschromia is an uneven, ill-defined hyperpigmentation of the face most commonly seen in mature dark skin.</div><div id=\"graphicVersion\">Graphic 93724 Version 1.0</div></div></div>"},"93727":{"type":"graphic_picture","displayName":"Tinea corporis with pustules","title":"Tinea corporis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Tinea corporis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/93727_Tinea_corporis_pustules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Annular, erythematous plaque with pustules.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 93727 Version 2.0</div></div></div>"},"93728":{"type":"graphic_picture","displayName":"AMPLATZER Duct Occluder II","title":"The AMPLATZER Duct Occluder II device","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The AMPLATZER Duct Occluder II device</div><div class=\"cntnt\"><img style=\"width:422px; height:252px;\" src=\"images/PEDS/93728_AMPLATZER_Duct_Occluder_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">AMPLATZER and St. Jude Medical are trademarks of St. Jude Medical, Inc. or its related companies. Reprinted with permission of St. Jude Medical, Copyright &copy; 2014. All rights reserved.</div><div id=\"graphicVersion\">Graphic 93728 Version 1.0</div></div></div>"},"93729":{"type":"graphic_movie","displayName":"Whip maneuver variation for reducing cuboid subluxation","title":"Whip maneuver variation for reducing cuboid subluxation","html":"<div class=\"graphic normal\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Whip maneuver variation for reducing cuboid subluxation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/93729_Whipmaneuvariacuboidvid.mp4\" style=\"width:560px;height:336px\"></div><img style=\"width:424px; height:318px;\" src=\"images/EM/93729_Whipmaneuvariacuboidimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Timothy Ryan Draper, DO, AAFP, CAQ Sports Medicine.</div><div id=\"graphicVersion\">Graphic 93729 Version 1.0</div></div></div>"},"93730":{"type":"graphic_table","displayName":"Mitochondrial hepatopathies presenting in neonates or infants","title":"Genetic etiologies of mitochondrial hepatopathies presenting in neonates or infants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic etiologies of mitochondrial hepatopathies presenting in neonates or infants</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Mutation/syndrome</td> <td class=\"subtitle1\">Defect</td> <td class=\"subtitle1\">Onset/age of presentation</td> <td class=\"subtitle1\">Hepatic presentation</td> <td class=\"subtitle1\">Neurological features</td> <td class=\"subtitle1\">Other features</td> <td class=\"subtitle1\">Diagnostic tests</td> </tr> <tr> <td><em>DGUOK</em><sup>[1-3]</sup></td> <td>mtDNA depletion; complex I, III, IV</td> <td>Acute/early neonatal</td> <td>Neonatal liver failure, progressive cholestasis, neonatal hemochromatosis, hepatocellular carcinoma risk. Can have isolated liver disease.</td> <td>Hypotonia, developmental regression, nystagmus</td> <td>Lactic acidosis, hypoglycemia</td> <td><em>DGUOK</em> sequence analysis</td> </tr> <tr> <td><em>POLG</em><sup>[4,5]</sup></td> <td>mtDNA depletion; complex I, III, IV</td> <td>Acute/neonatal</td> <td>Neonatal liver failure, micro- or macrovesicular steatosis, cirrhosis</td> <td>Encephalopathy, seizures, myopathy, neuropathy, blindness, developmental regression</td> <td>Vomiting, GERD</td> <td><em>POLG</em> sequence analysis or panel</td> </tr> <tr> <td><em>MPV17</em>/Navajo neurohepatopathy<sup>[6,7]</sup></td> <td>mtDNA depletion; complex I, III, IV</td> <td>Acute/neonatal</td> <td>Isolated neonatal/infant liver failure, or in multisystem syndrome</td> <td>Progressive sensorimotor neuropathy. CNS white matter lesions</td> <td>Acidosis, FTT, corneal anesthesia/abrasions, acral mutilation</td> <td><em>MPV17</em> sequence analysis or panel</td> </tr> <tr> <td><em>TWINKLE</em><em> (C10ORF2)</em><sup>[8,9]</sup></td> <td>mtDNA depletion DNA helicase</td> <td>Acute/neonatal</td> <td>Neonatal liver failure, cirrhosis, elevated liver enzymes</td> <td>Encephalopathy (athetosis, ataxia, seizures), sensory neuropathy, deafness</td> <td>&nbsp;</td> <td><em>C10ORF2</em> <em>TWINKLE</em> sequence analysis</td> </tr> <tr> <td><em>TRMU</em><sup>[10,11]</sup></td> <td>Decreased mito translation (tRNA-modifying enzyme); complex I, III, IV</td> <td>Acute/neonatal</td> <td>Neonatal liver failure. Some recover, possibly with cirrhosis</td> <td>&nbsp;</td> <td>&nbsp;</td> <td><em>TRMU</em> sequence analysis</td> </tr> <tr> <td><em>TSFM, EFG1, EF-Tu, MRPS16</em><sup>[12]</sup></td> <td>Decreased mito translation (elongation)</td> <td>Acute/neonatal</td> <td>Liver dysfunction in infancy, hepatomegaly</td> <td>Hypotonia, dystonia</td> <td>Hypertrophic cardiomyopathy, tubulopathy</td> <td>Sequencing individual genes, eg, <em>TSFM</em> or exome sequencing</td> </tr> <tr> <td><em>SUCLG1</em><sup>[13]</sup></td> <td>mtDNA depletion abnormal succinate synthesis; complex I, III, IV</td> <td>Acute/neonatal</td> <td>Neonatal liver failure, episodic liver failure</td> <td>Hypotonia/myopathy (progressive), hearing loss</td> <td>Acidosis, elevated methylmalonic acid</td> <td><em>SUCLG1</em> sequence analysis</td> </tr> <tr> <td><em>BCS1L</em><sup>[14]</sup></td> <td>Complex III assembly deficiency</td> <td>Acute/neonatal</td> <td>Neonatal liver failure, cholestasis, hepatic iron overload</td> <td>&nbsp;</td> <td>Growth failure, aminoaciduria, lactic acidosis, early death (GRACILE syndrome)</td> <td><em>BCS1L</em> sequence analysis</td> </tr> <tr> <td><em>SCO1</em><sup>[15]</sup></td> <td>Complex IV deficiency</td> <td>Acute/neonatal</td> <td>Neonatal liver failure, hepatomegaly</td> <td>Hypotonia</td> <td>Acidosis</td> <td><em>SCO1 </em>sequence analysis</td> </tr> <tr> <td><em>FARS2</em><sup>[16]</sup></td> <td>Phenylalanyl tRNA synthetase</td> <td>Acute/neonatal</td> <td>Neonatal liver failure (Alpers-like)</td> <td>Intractable seizures, encephalopathy</td> <td>&nbsp;</td> <td><em>FARS2</em> sequence analysis on Nexgen</td> </tr> <tr> <td><em>SLC25A20</em><sup>[17]</sup></td> <td>Carnitine acylcarnitine translocase deficiency (carnitine, FAO)</td> <td>Acute/neonatal</td> <td>Neonatal liver failure, steatohepatitis</td> <td>Myopathy</td> <td>Hypoglycemia, cardiomyopathy</td> <td><em>SLC25A20</em> sequence analysis</td> </tr> <tr> <td>HADHA/LCHAD or trifunctional protein deficiency<sup>[18]</sup></td> <td>FAO defect</td> <td>Acute</td> <td>Hepatomegaly, fatty liver, elevated LFTs, cholestasis, liver failure, ALF</td> <td>Encephalopathy, peripheral neuropathy</td> <td>Acidosis, hypoglycemia, pigmentary retinopathy</td> <td><em>HADHA</em> sequence analysis</td> </tr> <tr> <td>CPT I deficiency<sup>[19]</sup></td> <td>Carnitine cycle FAO defect</td> <td>Acute/infancy</td> <td>Hepatomegaly, liver failure episodes</td> <td>Reye-like episodes of encephalopathy</td> <td>Hypoketotic hypoglycemia</td> <td><em>CPTIA</em> sequence analysis</td> </tr> <tr> <td>CPT II deficiency<sup>[19,20]</sup></td> <td>Carnitine cycle FAO defect</td> <td>Acute/severe neonatal</td> <td>Liver failure in infancy</td> <td>Seizures</td> <td>Hypoketotic hypoglycemia, cardiomyopathy, myopathy</td> <td><em>CPT2</em> sequence analysis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">mtDNA: mitochondrial DNA; GERD: gastroesophageal reflux disease; CNS: central nervous system; FTT: failure to thrive; GRACILE: growth retardation, aminoaciduria, cholestasis, iron overload, lactic acidosis, and early death; tRNA: transfer ribonucleic acid; FAO: fatty acid oxidation; HADHA: hydroxyacyl-CoA deHase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase alpha subunit; LCHAD: long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency; LFTs: liver function tests; ALF: acute liver failure;&nbsp;CPT: carnitine palmitoyltransferase; CoA: coenzyme A.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Dimmock DP, Zhang Q, Dionisi-Vici C, et al. Clinical and molecular features of mitochondrial DNA depletion due to mutations in deoxyguanosine kinase. Hum Mutat 2008; 29:330.</li>&#xD;&#xA;    <li>Labarthe F, Dobbelaere D, Devisme L, et al. Clinical, biochemical and morphological features of hepatocerebral syndrome with mitochondrial DNA depletion due to deoxyguanosine kinase deficiency. J Hepatol 2005; 43:333.</li>&#xD;&#xA;    <li>Pronicka E, Weglewska-Jurkiewicz A, Taybert J, et al. Post mortem identification of deoxyguanosine kinase (DGUOK) gene mutations combined with impaired glucose homeostasis and iron overload features in four infants with severe progressive liver failure. J Appl Genet 2011; 52:61.</li>&#xD;&#xA;    <li>Saneto RP, Naviaux RK. Polymerase gamma disease through the ages. Dev Disabil Res Rev 2010;16:163&ndash;74.</li>&#xD;&#xA;    <li>Tang S, Wang J, Lee N-C, et al. Mitochondrial DNA polymerase g mutations: an ever expanding molecular and clinical spectrum. J Med Genet 2011; 48:669.</li>&#xD;&#xA;    <li>Spinazzola A, Viscomi C, Fernandez-Vizarra E, et al. MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion. Nat Genet 2006; 38:570.</li>&#xD;&#xA;    <li>Wong LJ, Brunetti-Pierri N, Zhang Q, et al. Mutations in the MPV17 gene are responsible for rapidly progressive liver failure in infancy. Hepatology 2007; 46:1218.</li>&#xD;&#xA;    <li>Spinazzola A, Invernizzi F, Carrara F, et al. Clinical and molecular features of mitochondrial DNA depletion syndromes. J Inherit Metab Dis 2009; 32:143.</li>&#xD;&#xA;    <li>Hakonen AH, Isohanni P, Paetau A, et al. Recessive Twinkle mutations in early onset encephalopathy with mtDNA depletion. Brain 2007; 130:3032.</li>&#xD;&#xA;    <li>Schara U, von Kleist-Retzow JC, Lainka E, et al. Acute liver failure with subsequent cirrhosis as the primary manifestation of TRMU mutations. J Inherit Metab Dis 2011; 34:197.</li>&#xD;&#xA;    <li>Zeharia A, Shaag A, Pappo O, et al. Acute infantile liver failure due to mutations in the TRMU gene. Am J Hum Genet 2009; 85:401. </li>&#xD;&#xA;    <li>Vedrenne V, Galmiche L, Chretien D, et al. Mutation in the mitochondrial translation elongation factor EFTs results in severe infantile liver failure. J Hepatol 2012; 56:294.</li>&#xD;&#xA;    <li>Van Hove JL, Saenz MS, Thomas JA, et al. Succinyl-CoA ligase deficiency: a mitochondrial hepatoencephalomyopathy. Pediatr Res 2010; 68:159.</li>&#xD;&#xA;    <li>Kotarsky H, Karikoski R, Morgelin M, et al. Characterization of complex III deficiency and liver dysfuntion in GRACILE syndryome caused by a BCS1L mutation. Mitochondrion 2010; 10:497.</li>&#xD;&#xA;    <li>Valnot I, Osmond S, Gigarel N, et al. Mutations of the SCO1 gene in mitochondrial cytochrome c oxidase deficiency with neonatal-onset hepatic failure and encephalopathy. Am J Hum Genet 2000; 67:1104.</li>&#xD;&#xA;    <li>Elo JM, Yadavalli SS, Euro L, et al. Mitochondrial phenylalanyl-tRNA synthetase mutations underlie fatal infantile Alpers encephalopathy. Hum Mol Genet 2012; 21:4521.</li>&#xD;&#xA;    <li>Lopriore E, Reinoud JBJG, Verhoeven NM, et al. Carnitine-acylcarnitine translocase deficiency: phenotype, residual enzyme activity and outcome. Eur J Pediatr 2001; 160:101.</li>&#xD;&#xA;    <li>den Boer MEJ, Wanders RJA, Morris AAM, et al. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: clinical presentation and follow-up of 50 patients. Pediatrics 2002; 109:99.</li>&#xD;&#xA;    <li>Longo N, Amat di San Filippo C, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet 2006; 142C:77.</li>&#xD;&#xA;    <li>Olpin SE, Afifi A, Clark S, et al. Mutation and biochemical analysis in carnitine palmitoyltransferase type II (CPT II) deficiency. J Inherit Metab Dis 2003; 26:543.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: Molleston JP, Sokol RJ, Karnsakul W, et al. Childhood Liver Disease Research Education Network (ChiLDREN). Evaluation of the child with suspected mitochondrial liver disease. J Pediatr Gastroenterol Nutr 2013; 57:269. DOI: <a href=\"http://journals.lww.com/jpgn/Citation/2013/09000/Evaluation_of_the_Child_With_Suspected.4.aspx\" spellcheck=\"true\" target=\"_blank\">10.1097/MPG.0b013e31829ef67a</a>. Copyright &copy; 2013 ESPGHAN and NASPGHAN. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 93730 Version 4.0</div></div></div>"},"93734":{"type":"graphic_diagnosticimage","displayName":"X-ray posterior dislocation THR ","title":"Posterior dislocation following THR on x-ray","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior dislocation following THR on x-ray</div><div class=\"cntnt\"><img style=\"width:435px; height:597px;\" src=\"images/RADIOL/93734_X_post_dislocation_THR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An AP x-ray of the right hip shows a dislocated right THR. The metallic head (white asterisk) is displaced cranially and laterally from the cup (red asterisk). The&nbsp;femur has been forced into a horizontal position. Image B is a cross table lateral examination, and the femur is held vertically.&nbsp;The head of the prosthesis (white asterisk) is dislocated posteriorly and cranially in relation to the acetabula cup (red asterisk). Image C is an AP view obtained following reduction and shows the metallic head (white asterisk) appropriately positioned in the acetabula cup (red asterisk).</div><div class=\"graphic_footnotes\">THR: total hip replacement; AP: anteroposterior.</div><div id=\"graphicVersion\">Graphic 93734 Version 2.0</div></div></div>"},"93736":{"type":"graphic_diagnosticimage","displayName":"Radiograph LV assist device","title":"LV assist device on radiograph","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">LV assist device on radiograph</div><div class=\"cntnt\"><img style=\"width:599px; height:248px;\" src=\"images/RADIOL/93736_X_ray_LV_assist_device.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An A-P x-ray (A) shows an LV assist device (Impella) with the inflow (short arrow) in the body of the LV and the pump and outflow (arrow) in the proximal ascending aorta. The dashed arrow indicates the approximate position of the aortic valve. Image B is a magnified view and shows the inflow component (short arrow) and the extension of the catheter in the LV (arrowheads). The dashed arrow shows the approximate position of the aortic valve. The pump and outflow are distal to the valve (arrow).</div><div class=\"graphic_footnotes\">LV: left ventricle; A-P: anteroposterior; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93736 Version 2.0</div></div></div>"},"93737":{"type":"graphic_diagnosticimage","displayName":"X-ray migration pulmonary artery catheter","title":"Migration of pulmonary artery catheter on x-ray","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Migration of pulmonary artery catheter on x-ray</div><div class=\"cntnt\"><img style=\"width:599px; height:268px;\" src=\"images/RADIOL/93737_X_migrat_pulm_art_cath.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Following placement of a pulmonary artery catheter, an x-ray shows the tip (arrowhead) positioned near the origin of the descending&nbsp;right pulmonary artery about 3.4 cm from the midline. Image B is a follow-up examination and shows migration of the tip of the catheter (arrowhead) into the medial basal segmental artery. It is just over 5 cm from the midline.</div><div id=\"graphicVersion\">Graphic 93737 Version 1.0</div></div></div>"},"93738":{"type":"graphic_diagnosticimage","displayName":"Barium enema intestinal malrotation","title":"Intestinal malrotation on barium enema","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Intestinal malrotation on barium enema</div><div class=\"cntnt\"><img style=\"width:598px; height:378px;\" src=\"images/RADIOL/93738_BE_intestin_malrotat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A barium enema in an adult patient (A) reveals intestinal malrotation with the cecum (asterisk) and appendix (arrowhead) on the left side in the midabdomen. The ileocecal valve is incompetent and there is a significant amount of reflux into the small bowel (squares). Diverticulosis of the sigmoid colon is present (double arrow). Image B is a normal barium enema and shows the cecum in the right lower quadrant (asterisk) and reflux of contrast into terminal ileum which lies in the right lower quadrant (squares).</div><div class=\"graphic_footnotes\">BE: barium enema.</div><div id=\"graphicVersion\">Graphic 93738 Version 3.0</div></div></div>"},"93739":{"type":"graphic_diagnosticimage","displayName":"Barium swallow DES corkscrew esophagus","title":"DES with corkscrew esophagus on barium swallow","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">DES with corkscrew esophagus on barium swallow</div><div class=\"cntnt\"><img style=\"width:597px; height:470px;\" src=\"images/RADIOL/93739_Br_swll_DES_crksc_esph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Barium swallow performed in a 74-year-old man with retrosternal pain. (A)&nbsp;Marked spasm throughout the length of the esophagus produces a corkscrew-like appearance. (B) Magnified view of the distal esophagus. (C)&nbsp;Normal single contrast examination of the esophagus.</div><div class=\"graphic_footnotes\">DES: diffuse esophageal spasm.</div><div id=\"graphicVersion\">Graphic 93739 Version 2.0</div></div></div>"},"93741":{"type":"graphic_diagnosticimage","displayName":"Aural atresia and canal cholesteatoma","title":"Axial CT of canal cholesteatoma in a child with aural atresia/stenosis","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Axial CT of canal cholesteatoma in a child with aural atresia/stenosis</div><div class=\"cntnt\"><img style=\"width:518px; height:444px;\" src=\"images/ALLRG/93741_Aural_atresia_cholesteatoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrows surround the cholesteatoma.</div><div class=\"graphic_footnotes\">A: atresia plate; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93741 Version 3.0</div></div></div>"},"93743":{"type":"graphic_picture","displayName":"Macrostoma","title":"Macrostoma from a lateral facial cleft","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Macrostoma from a lateral facial cleft</div><div class=\"cntnt\"><img style=\"width:590px; height:437px;\" src=\"images/ALLRG/93743_Macrostoma.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 93743 Version 1.0</div></div></div>"},"93744":{"type":"graphic_picture","displayName":"Macroglossia due to lymphangioma","title":"Macroglossia secondary to infiltration by a lymphangioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Macroglossia secondary to infiltration by a lymphangioma</div><div class=\"cntnt\"><img style=\"width:354px; height:503px;\" src=\"images/ALLRG/93744_Macroglossia_lymphangioma.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 93744 Version 1.0</div></div></div>"},"93745":{"type":"graphic_picture","displayName":"Preauricular pit and branchial fistula","title":"Preauricular pit and fistula of the second branchial cleft in a newborn","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Preauricular pit and fistula of the second branchial cleft in a newborn</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/ALLRG/93745_Preauricu_pit_branch_fistul.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 93745 Version 1.0</div></div></div>"},"93746":{"type":"graphic_picture","displayName":"Pyriform sinus fistula","title":"Endoscopic cauterization of a pyriform sinus fistula that was causing recurrent cervical abscesses","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Endoscopic cauterization of a pyriform sinus fistula that was causing recurrent cervical abscesses</div><div class=\"cntnt\"><img style=\"width:598px; height:213px;\" src=\"images/ALLRG/93746_Pyriform_sinus_fistula.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These recurrent cervical abscesses were initially diagnosed as thyroid abscesses.</div><div id=\"graphicVersion\">Graphic 93746 Version 1.0</div></div></div>"},"93748":{"type":"graphic_diagnosticimage","displayName":"Percutaneous device PDA closure","title":"Angiographic images of percutaneous closure of a patent ductus arteriosus","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Angiographic images of percutaneous closure of a patent ductus arteriosus</div><div class=\"cntnt\"><img style=\"width:598px; height:363px;\" src=\"images/PEDS/93748_Percutan_device_PDA_closure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Angiogram demonstrating a PDA (arrow) with left-to-right shunt from the aorta (Ao) into the main pulmonary artery (MPA).<br />(B) Repeat angiogram after placement of an Amplatzer ductal occluder device (outlined). There is residual flow into the device, but no residual shunt into the main pulmonary artery. Flow into the device will resolve with reversal of heparinization, and ultimately the device will be completely endothelialized.</div><div class=\"graphic_footnotes\">PDA: patent ductus arteriosus.</div><div id=\"graphicVersion\">Graphic 93748 Version 1.0</div></div></div>"},"93749":{"type":"graphic_diagnosticimage","displayName":"Angiogram thoracic aorta normal and aneurysm","title":"Normal thoracic aorta and aneurysm on angiography","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Normal thoracic aorta and aneurysm on angiography</div><div class=\"cntnt\"><img style=\"width:598px; height:375px;\" src=\"images/RADIOL/93749_Ang_thr_aort_nrm_aneur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An aortogram in the left anterior projection (A) shows a normal thoracic aorta. Image B is an angiogram in the same projection showing an aneurysm of the ascending aorta (asterisk).</div><div id=\"graphicVersion\">Graphic 93749 Version 2.0</div></div></div>"},"93750":{"type":"graphic_diagnosticimage","displayName":"CT of thoracic aorta normal and aneurysmal","title":"Normal thoracic aorta and aneurysm on CT scan","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Normal thoracic aorta and aneurysm on CT scan</div><div class=\"cntnt\"><img style=\"width:599px; height:298px;\" src=\"images/RADIOL/93750_CT_thr_art_nrm_aneurys.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan at the level of the main pulmonary artery (A) shows a normal ascending aorta (dashed arrow), which is about the same size as the pulmonary artery (arrow). Image B shows an aneurysm of the ascending aorta (dashed arrow), which is much larger than the main pulmonary artery (arrow). The descending aorta shows early enlargement and atherosclerosis in the wall (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93750 Version 3.0</div></div></div>"},"93751":{"type":"graphic_table","displayName":"M-CHAT-RF test characteristics","title":"Psychometric properties of the M-CHAT-R and M-CHAT-R/F","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Psychometric properties of the M-CHAT-R and M-CHAT-R/F</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Test characteristic</td> <td class=\"subtitle1\">M-CHAT-R*</td> <td class=\"subtitle1\">M-CHAT-R/F<sup>&#182;</sup></td> </tr> <tr> <td>Sensitivity (95% CI)</td> <td>91% (86-96)</td> <td>85% (79-92)</td> </tr> <tr> <td>Specificity (95% CI)</td> <td>96% (95-96)</td> <td>99.3% (99-99)</td> </tr> <tr> <td>Negative predictive value</td> <td>99.9%</td> <td>99.99%</td> </tr> <tr> <td>Positive predictive value for ASD</td> <td>14%</td> <td>48%</td> </tr> <tr> <td>Positive predictive value for any developmental concern, including ASD (95% CI)</td> <td>Not reported</td> <td>95% (92-98)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">M-CHAT-R: Modified Checklist for Autism in Toddlers, Revised; M-CHAT-R/F: MCHAT-R with follow-up interview; CI: confidence interval; ASD: autism spectrum disorder.<br />* Total score of ≥3 on MCHAT-R with no follow-up interview.<br />¶ Total score of ≥3 on MCHAT-R and ≥2 on the follow-up interview.</div><div class=\"graphic_reference\">Data from: Robins DL, Casagrande K, Barton M, et al. Validation of the Modified Checklist for Autism in Toddlers, Revised With Follow-up (M-CHAT-R/F). Pediatrics 2014; 133:37.</div><div id=\"graphicVersion\">Graphic 93751 Version 3.0</div></div></div>"},"93752":{"type":"graphic_diagnosticimage","displayName":"Imaging of fusiform thoracic aneurysm","title":"Fusiform thoracic aneurysm on x-ray and CT","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Fusiform thoracic aneurysm on x-ray and CT</div><div class=\"cntnt\"><img style=\"width:598px; height:426px;\" src=\"images/RADIOL/93752_Img_fusifrm_thora_aort.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest x-ray (A) shows diffuse enlargement of the ascending aorta (arrows). Image B is a CT image in the axial plane and shows diffuse enlargement of the ascending aorta (arrow). Image C is a sagittal reconstruction of a CT scan and shows a fusiform aneurysm of the ascending aorta (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93752 Version 3.0</div></div></div>"},"93754":{"type":"graphic_diagnosticimage","displayName":"Imaging of saccular aneurysm thoracic aorta","title":"Saccular thoracic aneurysm on x-ray and aortography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Saccular thoracic aneurysm on x-ray and aortography</div><div class=\"cntnt\"><img style=\"width:450px; height:506px;\" src=\"images/RADIOL/93754_Img_sacc_ar_thor_aorta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest x-ray (A) shows a saccular aneurysm of the ascending aorta (arrow). Image B is an angiogram in left anterior oblique projection and shows a focal saccular aneurysm of the ascending aorta (arrow). Image C is a chest x-ray in the anteroposterior projection and shows a focal soft tissue density above the aortic knob (arrow). Image D is a CT scan through the aortic arch and shows a focal saccular aneurysm arising from the arch (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93754 Version 2.0</div></div></div>"},"93755":{"type":"graphic_diagnosticimage","displayName":"Imaging aortic arch aneurysm","title":"Aneurysm of the aortic arch on x-ray and CT scan","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Aneurysm of the aortic arch on x-ray and CT scan</div><div class=\"cntnt\"><img style=\"width:597px; height:384px;\" src=\"images/RADIOL/93755_Img_aortic_arch_aneur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest x-ray (A) shows enlargement of the aortic knob (arrowhead) and widening of the mediastinum (between arrows). Image B is a CT scan through the aortic arch and shows thrombus-filled aneurysm of the arch (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93755 Version 2.0</div></div></div>"},"93757":{"type":"graphic_diagnosticimage","displayName":"CT descending thoracic aortic aneurysm","title":"Thoracic aneurysm of descending aorta on CT","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Thoracic aneurysm of descending aorta on CT</div><div class=\"cntnt\"><img style=\"width:597px; height:231px;\" src=\"images/RADIOL/93757_CT_desc_thor_aor_aneur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A scout film of the chest (A) shows enlargement of the descending aorta (arrow). Image B is an axial view through the midchest and shows a descending thoracic aortic aneurysm with mural thrombus (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93757 Version 2.0</div></div></div>"},"93758":{"type":"graphic_diagnosticimage","displayName":"Aortogram descending thoracic aneurysm","title":"Thoracic aneurysm of the descending aorta on aortogram","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Thoracic aneurysm of the descending aorta on aortogram</div><div class=\"cntnt\"><img style=\"width:598px; height:396px;\" src=\"images/RADIOL/93758_Aortogrm_dsc_thr_aneury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An aortogram in the left anterior oblique projection (A) shows a diffuse aneurysm of the descending thoracic aorta (arrow). Image B is an anteroposterior view and shows the aneurysmal dilatation of the entire descending aorta (between arrows).</div><div id=\"graphicVersion\">Graphic 93758 Version 2.0</div></div></div>"},"93759":{"type":"graphic_diagnosticimage","displayName":"CT showing type II thoracoabdominal aneurysm","title":"Type II thoracoabdominal aneurysm on CT scan","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Type II thoracoabdominal aneurysm on CT scan</div><div class=\"cntnt\"><img style=\"width:598px; height:421px;\" src=\"images/RADIOL/93759_CT_II_thracoabdm_aneur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan reconstructed in the sagittal projection (A) shows a type II thoracoabdominal aneurysm that extends from the proximal descending aorta (arrow) to the infrarenal abdominal aorta (arrowhead). Image B is a CT scan reconstructed in the coronal plane and shows a type II thoracoabdominal aneurysm that extends from the proximal descending aorta (arrow) to the infrarenal abdominal aorta (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93759 Version 2.0</div></div></div>"},"93760":{"type":"graphic_table","displayName":"TKIs used for CML PI","title":"Comparison of tyrosine kinase inhibitors used for chronic myeloid leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of tyrosine kinase inhibitors used for chronic myeloid leukemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"15%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Generic name</td> <td class=\"subtitle1\">United States brand name</td> <td class=\"subtitle1\">How taken</td> <td class=\"subtitle1\">Risks and side effects</td> <td class=\"subtitle1\">Other</td> </tr> <tr class=\"divider_bottom\"> <td>Imatinib</td> <td>Gleevec</td> <td>Daily (or twice daily) with food</td> <td> <ul> <li>Low blood counts (increased infection) </li> <li>Swelling and fluid retention </li> <li>Diarrhea </li> <li>Rash </li> <li>Fatigue </li> <li>Muscle cramps </li> <li>Heart damage (uncommon) </li> <li>Liver damage (uncommon) </li> </ul> </td> <td>Most long-term safety data</td> </tr> <tr class=\"divider_bottom\"> <td>Nilotinib</td> <td>Tasigna</td> <td>Twice daily without food</td> <td> <ul> <li>Low blood counts (increased infection) </li> <li>Rash, itching </li> <li>Abnormal heart rhythm (called QT prolongation) </li> <li>Heart attack, stroke, and related events </li> <li>Electrolyte imbalance </li> <li>Liver damage </li> <li>Pancreatitis (inflammation of the pancreas that can cause stomach pain) </li> </ul> </td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Dasatinib</td> <td>Sprycel</td> <td>Daily with or without food</td> <td> <ul> <li>Low blood counts (increased infection and fatigue) </li> <li>Pleural or pericardial effusions (fluid around the lung or heart) </li> <li>Pulmonary hypertension (high blood pressure in the blood vessels that carry blood to the lungs; uncommon) </li> <li>Abnormal heart rhythm (called QT prolongation) </li> <li>Easy bleeding and bruising </li> <li>Headache </li> </ul> </td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Bosutinib</td> <td>Bosulif</td> <td>Daily with food</td> <td> <ul> <li>Low blood counts (increased infection and fatigue) </li> <li>Fever, fatigue, headache </li> <li>Swelling and fluid retention </li> <li>Diarrhea, nausea, vomiting </li> <li>Liver damage </li> </ul> </td> <td>&nbsp;</td> </tr> <tr> <td>Ponatinib</td> <td>Iclusig</td> <td>Daily with or without food</td> <td> <ul> <li>Low blood counts (increased infection and fatigue) </li> <li>Swelling and fluid retention </li> <li>Nausea, vomiting, diarrhea </li> <li>Heart failure </li> <li>High blood pressure </li> <li>Pancreatitis (inflammation of the pancreas that can cause stomach pain) </li> <li>Easy bleeding and bruising </li> <li>Heart attack, stroke, and related events </li> <li>Liver toxicity </li> </ul> </td> <td>Least long-term safety data; active in patients with BCR-ABL T315I mutation</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 93760 Version 1.0</div></div></div>"},"93761":{"type":"graphic_diagnosticimage","displayName":"Osteoarthritis knee replacement PI","title":"Osteoarthritis of the knee before and after replacement","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Osteoarthritis of the knee before and after replacement</div><div class=\"cntnt\"><img style=\"width:511px; height:478px;\" src=\"images/PI/93761_Osteoarth_kn_replac_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A shows&nbsp;an X-ray&nbsp;of a knee affected by arthritis. Panel B shows the same knee after surgery to replace the knee. In panel A, the arrow shows that the space between the thighbone (called the femur) and the shinbone (called the tibia) has narrowed. This has caused the bones to grind against each other and form spurs. In panel B, the femur and tibia each have new metal end-pieces. The arrow shows that the space between the two bones has been widened with a plastic spacer.</div><div id=\"graphicVersion\">Graphic 93761 Version 3.0</div></div></div>"},"93762":{"type":"graphic_picture","displayName":"Miliary TB of spleen","title":"Miliary tuberculosis of the spleen","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Miliary tuberculosis of the spleen</div><div class=\"cntnt\"><img style=\"width:376px; height:266px;\" src=\"images/ID/93762_Miliary_TB_of_spleen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Miliary tuberculosis of the spleen. The cut surface shows numerous gray-white granulomas.</div><div class=\"graphic_reference\">Reproduced from: Kumar V, Abbas AK, Fausto N, Mitchell RN. Robbins Basic Pathology, 8th ed, Saunders Elsevier, Philadelphia 2007. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 93762 Version 1.0</div></div></div>"},"93763":{"type":"graphic_picture","displayName":"Dyschromatosis universalis hereditaria","title":"Dyschromatosis universalis hereditaria (DUH)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dyschromatosis universalis hereditaria (DUH)</div><div class=\"cntnt\"><img style=\"width:504px; height:622px;\" src=\"images/DERM/93763_Dyschr_universa_hereditaria.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Alternating hypo- and hyperpigmented macules of varying size on the back of a patient with dyschromatosis universalis hereditaria.</div><div class=\"graphic_reference\">From: Sardana K, Goel K, Chugh S. Reticulate pigmentary disorders. Indian J Dermatol Venereol Leprol 2013; 79:17. DOI: <a href=\"http://www.ijdvl.com/article.asp?issn=0378-6323;year=2013;volume=79;issue=1;spage=17;epage=29;aulast=Sardana\" target=\"_blank\">10.4103/0378-6323.104665</a>. Reproduced with permission from Wolters Kluwer - Medknow. Copyright &copy; 2013 Indian Association of Dermatologists, Venereologists and Leprologists. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 93763 Version 1.0</div></div></div>"},"93764":{"type":"graphic_diagnosticimage","displayName":"CT showing type IV thoracoabdominal aneurysm","title":"Type IV thoracoabdominal aneurysm on CT scan","html":"<div class=\"graphic\"><div style=\"width: 589px\" class=\"figure\"><div class=\"ttl\">Type IV thoracoabdominal aneurysm on CT scan</div><div class=\"cntnt\"><img style=\"width:569px; height:538px;\" src=\"images/RADIOL/93764_CT_IV_thoracoabd_aneur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan in the axial projection (A) and reconstructed in the sagittal projection (B) show ectasia of the distal thoracic aorta (arrows A and B). Image C is an axial projection and Image D a reconstructed sagittal projection of the abdominal aorta and show a 6.2 cm aneurysm (arrows C and D) with a large amount of luminal thrombus (arrowheads C and D).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93764 Version 2.0</div></div></div>"},"93765":{"type":"graphic_diagnosticimage","displayName":"CT idiopathic aneurysm of the ascending aorta","title":"Idiopathic aneurysmal dilatation of the ascending aorta on CT scan","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Idiopathic aneurysmal dilatation of the ascending aorta on CT scan</div><div class=\"cntnt\"><img style=\"width:529px; height:523px;\" src=\"images/RADIOL/93765_CT_idio_aneur_asc_aorta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An MIP CT scan (A) in a 42-year-old man shows idiopathic dilatation of the ascending aorta (arrowhead). Image B is a sagittal reconstruction of a CT in a 40-year-old man and shows calcification (arrowhead) in a fusiform ascending aortic aneurysm (asterisk). Cystic medial necrosis is a possible contributing etiology for the aneurysmal changes of the ascending aorta in both cases.</div><div class=\"graphic_footnotes\">CT: computed tomography; MIP: maximum intensity projection.</div><div id=\"graphicVersion\">Graphic 93765 Version 2.0</div></div></div>"},"93767":{"type":"graphic_diagnosticimage","displayName":"Aortography multiple aneurysms","title":"Multiple aortic aneurysms on aortography","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Multiple aortic aneurysms on aortography</div><div class=\"cntnt\"><img style=\"width:599px; height:310px;\" src=\"images/RADIOL/93767_Aortograph_multi_aneur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An angiogram of the thoracic aorta (A) shows opacification of an aneurysmal ascending aorta (asterisk), and early opacification of the proximal descending aorta (arrow). Image B is a lateral projection of the abdominal aneurysm with thrombus and shows the calcified anterior wall of the aneurysm (arrow). Image C is an anteroposterior projection of the aortogram and shows a suprarenal aneurysm (asterisk) and the characteristic shape of a thrombus-filled infrarenal aneurysm (arrow).</div><div id=\"graphicVersion\">Graphic 93767 Version 2.0</div></div></div>"},"93768":{"type":"graphic_diagnosticimage","displayName":"Imaging Marfan syndrome annuloaortic ectasia","title":"Annuloaortic ectasia in Marfan syndrome on aortography and CT","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Annuloaortic ectasia in Marfan syndrome on aortography and CT</div><div class=\"cntnt\"><img style=\"width:598px; height:386px;\" src=\"images/RADIOL/93768_Img_Mrf_annloart_ectas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An aortogram in the left anterior oblique projection (A) shows aneurysm formation and annuloaortic ectasia (asterisk). Image B shows a CT scan reformatted in the coronal plane and shows aneurysmal formation and annuloaortic ectasia (asterisk) in Marfan syndrome. A prosthetic aortic valve is present (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93768 Version 2.0</div></div></div>"},"93769":{"type":"graphic_diagnosticimage","displayName":"Angiography coarctation bicuspid valve aortic ectasia","title":"Coarctation of the aorta, bicuspid aortic valve, and aortic ectasia on aortography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Coarctation of the aorta, bicuspid aortic valve, and aortic ectasia on aortography</div><div class=\"cntnt\"><img style=\"width:334px; height:514px;\" src=\"images/RADIOL/93769_Angio_crct_bcusp_ectas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An aortogram in the left anterior oblique projection shows postductal coarctation of the aorta (arrow) and aortic ectasia of the ascending aorta (asterisk). A bicuspid valve was present.</div><div id=\"graphicVersion\">Graphic 93769 Version 2.0</div></div></div>"},"93770":{"type":"graphic_diagnosticimage","displayName":"CT aortic stenosis ascending aortic aneurysm","title":"Calcific aortic stenosis and ascending aortic aneurysm on CT scan","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Calcific aortic stenosis and ascending aortic aneurysm on CT scan</div><div class=\"cntnt\"><img style=\"width:598px; height:240px;\" src=\"images/SURG/93770_CT_aort_sten_aort_aneur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan through the heart shows a calcified aortic valve (arrow). The patient has aortic stenosis. Image B shows an aneurysm of the ascending aorta (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93770 Version 2.0</div></div></div>"},"93775":{"type":"graphic_diagnosticimage","displayName":"X-ray syphilitic aortitis aneurysm","title":"Syphilitic aortitis ascending aortic aneurysm and aortic regurgitation on chest x-ray","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">Syphilitic aortitis ascending aortic aneurysm and aortic regurgitation on chest x-ray</div><div class=\"cntnt\"><img style=\"width:595px; height:467px;\" src=\"images/RADIOL/93775_X_syphilit_aortit_anr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lateral chest x-ray shows fine mural calcification limited to an aneurysm of the ascending aorta (arrowheads). The arch and descending aorta have no calcifications. A focal calcification in the annulus near the left coronary ostium is present (arrow). The left ventricle is enlarged (dashed arrow). Image B is a magnified view of the aneurysm. The arrowheads highlight the aneurysm. The arrow highlights the calcification in the aortic annulus.</div><div id=\"graphicVersion\">Graphic 93775 Version 2.0</div></div></div>"},"93776":{"type":"graphic_diagnosticimage","displayName":"MRI Marfan syndrome sinus of Valsalva aneurysm","title":"Sinus of Valsalva aneurysm and Marfan syndrome on MRI","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Sinus of Valsalva aneurysm and Marfan syndrome on MRI</div><div class=\"cntnt\"><img style=\"width:598px; height:311px;\" src=\"images/RADIOL/93776_MRI_Marfan_sn_Vals_anr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A coronal projection through the heart in a patient with Marfan syndrome shows a sinus of Valsalva aneurysm (asterisk) compressing the right atrium (arrow). Image B shows the sinus of Valsalva aneurysm overlaid in red.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 93776 Version 2.0</div></div></div>"},"93777":{"type":"graphic_diagnosticimage","displayName":"Imaging ruptured thoracic aortic aneurysm pleural space","title":"Rupture of thoracic aneurysm into pleural space x-ray and CT","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Rupture of thoracic aneurysm into pleural space x-ray and CT</div><div class=\"cntnt\"><img style=\"width:599px; height:262px;\" src=\"images/RADIOL/93777_Img_rpt_thr_aort_anr_pl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest x-ray in AP projection (A) shows a white out of the left hemithorax&nbsp;(asterisk) in a hypotensive patient. Image B is a an axial CT through the lower chest showing a distal thoracic aneurysm (asterisk) with a small pseudoaneurysm (arrowhead) and a pleural space filled with high-density clot (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography; AP: anteroposterior.</div><div id=\"graphicVersion\">Graphic 93777 Version 2.0</div></div></div>"},"93778":{"type":"graphic_diagnosticimage","displayName":"CT ruptured thoracic aneurysm hemopericardium","title":"Rupture of thoracic aneurysm and pericardial tamponade on CT","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Rupture of thoracic aneurysm and pericardial tamponade on CT</div><div class=\"cntnt\"><img style=\"width:598px; height:350px;\" src=\"images/RADIOL/93778_CT_rptd_thor_aneur_peri.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient presents with pericardial tamponade. A sagittal reconstruction of a CT scan shows a large ascending aortic aneurysm (asterisk). Image B shows a hemopericardium (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93778 Version 2.0</div></div></div>"},"93779":{"type":"graphic_diagnosticimage","displayName":"X-ray thoracic aortic aneurysm","title":"Thoracic aneurysm on chest x-ray","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Thoracic aneurysm on chest x-ray</div><div class=\"cntnt\"><img style=\"width:488px; height:510px;\" src=\"images/RADIOL/93779_X_thorac_aortic_aneury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest x-ray shows widening of the mediastinum (between arrows), obliteration of the aortopulmonary window (dashed arrow), and displacement of the trachea to the right (arrowhead).</div><div id=\"graphicVersion\">Graphic 93779 Version 2.0</div></div></div>"},"93780":{"type":"graphic_diagnosticimage","displayName":"CTA ascending aneurysm and aortic branches","title":"Ascending aortic aneurysm and aortic branches on CTA","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Ascending aortic aneurysm and aortic branches on CTA</div><div class=\"cntnt\"><img style=\"width:477px; height:498px;\" src=\"images/SURG/93780_CTA_asc_anr_aortc_brnch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CTA shows an ascending aortic aneurysm (asterisk) and detail of brachiocephalic (dashed arrows) and visceral arteries (double arrow) branching off the aorta.</div><div class=\"graphic_footnotes\">CTA: computed tomography angiography.</div><div id=\"graphicVersion\">Graphic 93780 Version 2.0</div></div></div>"},"93781":{"type":"graphic_picture","displayName":"Extramedullary plasmacytoma histology","title":"Extramedullary plasmacytoma: Histology","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Extramedullary plasmacytoma: Histology</div><div class=\"cntnt\"><img style=\"width:590px; height:445px;\" src=\"images/HEME/93781_Extramedullary_plasmacytoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure illustrates a biopsy specimen of a soft tissue plasmacytoma (extramedullary plasmacytoma) arising from the oropharynx. There are sheets of plasma cells. 40x magnification.</div><div id=\"graphicVersion\">Graphic 93781 Version 1.0</div></div></div>"},"93782":{"type":"graphic_picture","displayName":"Solitary plasmacytoma of bone","title":"Solitary plasmacytoma of the bone: Histology","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Solitary plasmacytoma of the bone: Histology</div><div class=\"cntnt\"><img style=\"width:590px; height:445px;\" src=\"images/HEME/93782_Solitary_plasmacytoma_bone.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Solitary plasmacytoma of bone arising from the orbit demonstrates sheets of plasma cells. 100x magnification.</div><div id=\"graphicVersion\">Graphic 93782 Version 1.0</div></div></div>"},"93783":{"type":"graphic_table","displayName":"Volume of future liver remnant after hepatic resection","title":"Volume of future liver remnant after hepatic resection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Volume of future liver remnant after hepatic resection</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Resection type</td> <td class=\"subtitle1\">Couinaud's segments</td> <td class=\"subtitle1\">Percentage of remnant liver mass (%)</td> </tr> <tr> <td>Right hepatectomy</td> <td class=\"centered\">1, 5, 6, 7, 8</td> <td class=\"centered\">35</td> </tr> <tr> <td>Left hepatectomy</td> <td class=\"centered\">2, 3, 4</td> <td class=\"centered\">65</td> </tr> <tr> <td>Right trisectionectomy</td> <td class=\"centered\">1, 4, 5, 6, 7, 8</td> <td class=\"centered\">25</td> </tr> <tr> <td>Left trisectionectomy</td> <td class=\"centered\">2, 3, 4, 5, 8</td> <td class=\"centered\">30</td> </tr> <tr> <td>Left lateral sectionectomy</td> <td class=\"centered\">2, 3</td> <td class=\"centered\">75</td> </tr> <tr> <td>Posterior sectionectomy</td> <td class=\"centered\">6, 7</td> <td class=\"centered\">70</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Reproduced with permission from: Yoo PS, Enestvedt K, Kulkarni S. Anatomic considerations in the surgical resection of hepatocellular carcinoma. J Clin Gatroenterol 2013; 47:S11. DOI: <a href=\"http://journals.lww.com/jcge/pages/articleviewer.aspx?year=2013&amp;issue=07001&amp;article=00006&amp;type=abstract\" target=\"_blank\">10.1097/MCG.0b013e318280ce5f</a>. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 93783 Version 3.0</div></div></div>"},"93785":{"type":"graphic_figure","displayName":"Coffee consumption and CVD risk","title":"Coffee consumption and risk of cardiovascular disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Coffee consumption and risk of cardiovascular disease</div><div class=\"cntnt\"><img style=\"width:404px; height:850px;\" src=\"images/PC/93785_CoffeeconsumptionriskCVD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Coffee consumption and risk of cardiovascular disease (n = 47).<br />(B) Coffee consumption and risk of coronary heart disease (n = 31).<br />(C) Coffee consumption and risk of stroke (n = 22).</div><div class=\"graphic_footnotes\">n: number of comparisons.</div><div class=\"graphic_reference\">From: Ding M, Bhupathiraju SN, Satija A, et al. Long-Term Coffee Consumption and Risk of Cardiovascular Disease: A Systematic Review and a Dose-Response Meta-Analysis of Prospective Cohort Studies. Circulation 2014; 129:643. DOI: <a href=\"http://circ.ahajournals.org/content/129/6/643.abstract\" spellcheck=\"true\" target=\"_blank\">10.1161/CIRCULATIONAHA.113.005925</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2014 American Heart Association. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 93785 Version 5.0</div></div></div>"},"93788":{"type":"graphic_table","displayName":"Dental luxation injuries","title":"Dental luxation injuries","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Dental luxation injuries</div><div class=\"cntnt\"><img style=\"width:453px; height:481px;\" src=\"images/EM/93788_Dental_luxation_injuries.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 93788 Version 1.0</div></div></div>"},"93790":{"type":"graphic_table","displayName":"Dental management of injuries to primary and permanent teeth","title":"Dental management of injuries to primary and permanent teeth","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dental management of injuries to primary and permanent teeth</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Primary dentition</td> <td class=\"subtitle1\">Permanent dentition</td> </tr> <tr> <td>Concussion/subluxation</td> <td>Observe, soft foods for 1 wk, dental radiograph to rule out root fracture</td> <td>Observe, soft foods for 1 wk, dental radiograph to rule out root fracture</td> </tr> <tr> <td>Luxation</td> <td>Reposition tooth or extract, do not splint</td> <td>Dental radiograph, reposition tooth, splint for 4 wk</td> </tr> <tr> <td>Extrusion</td> <td>Reposition tooth or extract, do not splint</td> <td>Dental radiograph, reposition tooth, splint for 2 wk</td> </tr> <tr> <td>Intrusion</td> <td>Dental radiograph, observe and allow to reerupt, extract if alveolar plate is compromised</td> <td>Dental radiograph, observe and allow to reerupt, surgical or orthodontic repositioning, root canal treatment</td> </tr> <tr> <td>Uncomplicated crown fracture</td> <td>Restore tooth, smooth sharp edges, dental radiograph to rule out root fracture</td> <td>Restore tooth, smooth sharp edges, radiograph to rule out root fracture</td> </tr> <tr> <td>Complicated crown fracture</td> <td>Dental radiograph, pulp treatment, restore or extract tooth, observe for infection</td> <td>Dental radiograph, pulp treatment, restore tooth, observe for infection, may require root canal treatment</td> </tr> <tr> <td>Root fracture</td> <td>Dental radiograph, extract if root fracture is in middle or cervical third of root</td> <td>Dental radiograph, splint, may require root canal treatment; if in cervical third, may need to extract</td> </tr> <tr> <td>Avulsion</td> <td>Do not replant, dental radiograph to rule out intrusion if tooth is not located</td> <td>Do not handle the root, replant within 30 min or place in recommended transport medium (balanced salt solution, cold milk); dental radiograph, replant and splint as soon as possible; systemic antibiotics, soft diet, chlorhexidine, close follow-up</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Pediatrics, Vol. 133, Pages e466-76, Copyright &copy; 2014 by the AAP.</div><div id=\"graphicVersion\">Graphic 93790 Version 4.0</div></div></div>"},"93791":{"type":"graphic_movie","displayName":"Examination of the jugular venous pulse","title":"Examination of the jugular venous pulse","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Examination of the jugular venous pulse</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/93791_Examjugulvenouspulsevid.mp4\" style=\"width:512px;height:304px\"></div><img style=\"width:576px; height:428px;\" src=\"images/CARD/93791_Examjugulvenouspulseimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Estimation of jugular venous pressure is performed with the patient supine with the head of the bed elevated 30 degrees and head turned slightly to the left. A card is placed horizontally at the top of the oscillation point of the right internal jugular venous pulsation just posterior to the sternocleidomastoid muscle. The vertical height of the card above the sternal angle is measured in centimeters (cm). In this patient, the height is about 2 cm. Venous pressure is elevated above normal when it is &gt;3 to 4 cm above the sternal angle with the head of bed elevated to 30 degrees or approximately 8 to 9 cm in total distance above the right atrium.</div><div class=\"graphic_reference\">Reproduced with permission from: Bickley LS. Bates' Guide to Physical Examination and History Taking, 11th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 93791 Version 3.0</div></div></div>"},"93794":{"type":"graphic_picture","displayName":"Posterior tibialis exercise with resistance band","title":"Posterior tibialis exercise with resistance band","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior tibialis exercise with resistance band</div><div class=\"cntnt\"><img style=\"width:362px; height:520px;\" src=\"images/EM/93794_Post_tibia_exrc_resist_band.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows one of the exercises used for eccentric strengthening and rehabilitation of posterior tibialis tendinopathy.</div><div class=\"graphic_reference\">Courtesy of Timothy Ryan Draper, DO, AAFP, CAQ Sports Medicine.</div><div id=\"graphicVersion\">Graphic 93794 Version 1.0</div></div></div>"},"93795":{"type":"graphic_picture","displayName":"Posterior tibialis exercise on step","title":"Posterior tibialis exercise on step","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior tibialis exercise on step</div><div class=\"cntnt\"><img style=\"width:309px; height:527px;\" src=\"images/EM/93795_Post_tibialis_exercis_step.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows an important exercise used for eccentric strengthening and rehabilitation of the posterior tibialis. Note the position of the foot on the step, and the starting position with the heel below the level of the step.</div><div class=\"graphic_reference\">Courtesy of Timothy Ryan Draper, DO, AAFP, CAQ Sports Medicine.</div><div id=\"graphicVersion\">Graphic 93795 Version 1.0</div></div></div>"},"93797":{"type":"graphic_algorithm","displayName":"Approach to mgt device infection","title":"Approach to antibiotic management of adults with cardiac electronic device infection","html":"<div class=\"graphic\"><div style=\"width: 690px\" class=\"figure\"><div class=\"ttl\">Approach to antibiotic management of adults with cardiac electronic&nbsp;device infection</div><div class=\"cntnt\"><img style=\"width:670px; height:516px;\" src=\"images/ID/93797_Apprch_mgt_device_infection.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Duration of antibiotics should be counted from the day of device explantation.</div><div class=\"graphic_footnotes\">CIED: cardiac implantable electronic device; TEE: transesophageal echocardiography.<br />* Extracardiac infection may require tailored therapy depending on individual clinical circumstances.</div><div class=\"graphic_reference\">Original figure modified for this publication. Sohail MR, Uslan DZ, Khan AH, et al. Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections. J Am Coll Cardiol 2007; 49:1851. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 93797 Version 2.0</div></div></div>"},"93798":{"type":"graphic_picture","displayName":"Pneumatic otoscope 2","title":"Pneumatic otoscope","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Pneumatic otoscope</div><div class=\"cntnt\"><img style=\"width:533px; height:182px;\" src=\"images/PC/93798_Pneumatic_otoscope_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Laura Goguen, MD.</div><div id=\"graphicVersion\">Graphic 93798 Version 1.0</div></div></div>"},"93804":{"type":"graphic_table","displayName":"Major categories of cutaneous lupus erythematosus","title":"Major categories of cutaneous lupus erythematosus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major categories of cutaneous lupus erythematosus</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Acute cutaneous LE (ACLE)</td> </tr> <tr> <td class=\"indent1\">Localized ACLE (malar rash, butterfly rash)</td> </tr> <tr> <td class=\"indent1\">Generalized ACLE</td> </tr> <tr> <td class=\"indent1\">Toxic epidermal necrolysis-like eruption</td> </tr> <tr> <td class=\"subtitle1_single\">Subacute cutaneous LE (SCLE)</td> </tr> <tr> <td class=\"indent1\">Annular SCLE</td> </tr> <tr> <td class=\"indent1\">Papulosquamous SCLE</td> </tr> <tr> <td class=\"subtitle1_single\">Chronic cutaneous LE (CCLE)</td> </tr> <tr> <td class=\"indent1\">Localized DLE</td> </tr> <tr> <td class=\"indent1\">Generalized DLE</td> </tr> <tr> <td class=\"indent1\">Hypertrophic DLE/verrucous DLE</td> </tr> <tr> <td class=\"indent1\">Mucosal DLE</td> </tr> <tr> <td class=\"indent1\">Lupus panniculitis/lupus profundus</td> </tr> <tr> <td class=\"indent1\">Lupus tumidus/tumid lupus*</td> </tr> <tr> <td class=\"indent1\">Chilblains LE</td> </tr> <tr> <td class=\"subtitle1_single\">Other clinical variants of cutaneous LE</td> </tr> <tr> <td class=\"indent1\">Lupus-lichen planus overlap syndrome</td> </tr> <tr> <td class=\"indent1\">Rowell syndrome (cutaneous lupus resembling erythema multiforme)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LE: lupus erythematosus; DLE: discoid lupus erythematosus.<br />* Some authors consider reticular erythematous mucinosis a form of tumid lupus.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;<li>Sontheimer RD. The lexicon of cutaneous lupus erythematosus - a review and personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus. Lupus 1997; 6:84.</li>&#xD;&#xA;<li>Lee LA, Werth VP. Lupus erythematosus. In: Dermatology, 3rd ed, Bolognia JL, Jorizzo JL, Rapini RP, et al (Eds), Elsevier Limited, 2012. p.615.</li></ol></div><div id=\"graphicVersion\">Graphic 93804 Version 2.0</div></div></div>"},"93805":{"type":"graphic_diagnosticimage","displayName":"Chest x-ray secundum ASD","title":"Chest radiograph in a six-year-old patient with a large secundum atrial septal defect","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph in a six-year-old patient with a large secundum atrial septal defect</div><div class=\"cntnt\"><img style=\"width:327px; height:354px;\" src=\"images/PEDS/93805_Chst_x_secundum_ASD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The chest radiograph demonstrates moderate cardiomegaly with increased convexity of the right side of the heart (arrowheads). There is a large pulmonary outflow tract (arrow) and increased pulmonary vascularity. These findings are consistent with the presence of a large left-to-right shunt.</div><div class=\"graphic_footnotes\">ASD: atrial septal defect.</div><div id=\"graphicVersion\">Graphic 93805 Version 1.0</div></div></div>"},"93806":{"type":"graphic_waveform","displayName":"ECG primum ASD","title":"Electrocardiogram in a patient with a primum atrial septal defect","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram in a patient with a primum atrial septal defect</div><div class=\"cntnt\"><img style=\"width:598px; height:337px;\" src=\"images/PEDS/93806_ECG_primum_ASD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiography in a patient with a primum ASD with left axis deviation and right ventricular hypertrophy in the right precordial leads of V3 and V2.</div><div class=\"graphic_footnotes\">ASD: atrial septal defect; ECG: electrocardiogram.</div><div id=\"graphicVersion\">Graphic 93806 Version 1.0</div></div></div>"},"93807":{"type":"graphic_table","displayName":"Outline of a gluten-free diet PI","title":"Outline of a gluten-free diet","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Outline of a gluten-free diet</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Foods</td> <td class=\"subtitle1\">Allowed*</td> <td class=\"subtitle1\">Use caution</td> </tr> <tr class=\"divider_bottom\"> <td>Fruits and vegetables</td> <td>Fresh, frozen, and canned </td> <td>Fruits or vegetables with sauces; french fries (these may be coated or cooked in contaminated oil); dates (because dates may be dusted in flour)</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Protein rich foods</td> </tr> <tr> <td class=\"indent1\">Meat, fish, and poultry</td> <td>Plain fresh or frozen meat, fish, and poultry, canned fish (sardines, tuna), eggs</td> <td>Processed meats, hot dogs, sausage, deli meats, imitation fish, meat products, dried meats</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Legumes and nuts</td> <td>Beans, plain nuts, nut butters, nut flours, seeds</td> <td>Baked beans, seasoned or dry roasted nuts and seeds, flavored tofu, miso</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Starches</td> </tr> <tr> <td class=\"indent1\">Grains and others</td> <td>Rice, corn, potato, cornmeal, amaranth, buckwheat, millet, quinoa, certified gluten-free oats, flax, sorghum, tapioca, cassava, yucca</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Grain-based products</td> <td>Bread, pasta, crackers, and cereals made from allowed ingredients</td> <td>Rice pilaf, rice mixes, cold and instant cereals, flavored rice crackers, flavored chips</td> </tr> <tr class=\"divider_bottom\"> <td>Dairy products</td> <td>Milk, cream, sour cream, cheese (cheddar, blue, brie, goat, mozzarella, etc), cottage cheese, cream cheese, most yogurts</td> <td>Cheese spreads, cheese sauces, seasoned shredded cheese, fat free products</td> </tr> <tr class=\"divider_bottom\"> <td>Fats and oils</td> <td>Vegetable oils, margarine, butter, oil sprays (not baking spray)</td> <td>Baking sprays </td> </tr> <tr class=\"divider_bottom\"> <td>Sweets, treats, and desserts</td> <td>Sugar, honey, sugar substitutes, jams, jellies, marmalades, gelatin desserts, pudding made with allowed ingredients, chocolate, chocolate bars, most plain ice cream (but not \"cookie dough\" ice cream), cr&#232;me brul&#233;e, flan</td> <td>Pudding, chocolate, chocolate bars, ice cream with added treats or flavors (such as cookie dough or crunch varities)</td> </tr> <tr> <td>Other foods</td> <td>Olives, pickles, relish, pure spices and herbs, ketchup, plain prepared mustard, salad dressings with allowed ingredients, vinegar (balsamic, cider, distilled white, rice, wine), soda, tea, coffee</td> <td>Prepared soups, sauces (soy sauce, hoisin, barbeque, Worcestershire) specialty mustards, dry mustards, seasoning mixes, salad dressings, flavored teas, flavored coffee, herbal tea (these may have malt flavoring), hot chocolate mixes (these may have malt)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Even foods on the \"allowed\" list may have hidden ingredients that contain gluten. Check the label to be sure that there are no sources of gluten. In particular, avoid all forms of wheat and wheat flours (einkorn, durum, faro, graham, kamut, semolina, spelt), rye, barley, triticale, and malt.</div><div class=\"graphic_reference\">Courtesy of Anne Lee, EdD, RD, LD.</div><div id=\"graphicVersion\">Graphic 93807 Version 7.0</div></div></div>"},"93808":{"type":"graphic_waveform","displayName":"ECG secundum ASD","title":"Electrocardiography of a six-year-old patient with a large secundum atrial septal defect","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Electrocardiography of a six-year-old patient with a large secundum atrial septal defect</div><div class=\"cntnt\"><img style=\"width:600px; height:320px;\" src=\"images/PEDS/93808_ECG_secundum_ASD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram of a large secundum atrial septal defect in a six-year-old. Note the right ventricular hypertrophy and rSR' pattern in lead V1 commonly seen with large secundum atrial septal defects.</div><div class=\"graphic_footnotes\">ASD: atrial septal defect.</div><div id=\"graphicVersion\">Graphic 93808 Version 1.0</div></div></div>"},"93809":{"type":"graphic_diagnosticimage","displayName":"Echo primum ASD","title":"Echocardiography primum atrial septal defect (ASD)","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Echocardiography primum atrial septal defect (ASD)</div><div class=\"cntnt\"><img style=\"width:549px; height:296px;\" src=\"images/PEDS/93809_Echo_primum_ASD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Two-dimensional echocardiographic view demonstrating a primum ASD at the base of the interatrial septum (arrow).<br />(B) Same view with color Doppler flow imaging showing flow across the ASD (arrow).</div><div class=\"graphic_footnotes\">RA: right atrium; LA: left atrium.</div><div id=\"graphicVersion\">Graphic 93809 Version 1.0</div></div></div>"},"93810":{"type":"graphic_diagnosticimage","displayName":"Echo sinus venosus ASD","title":"Echocardiography of a sinus venosus atrial septal defect (ASD)","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Echocardiography of a sinus venosus atrial septal defect (ASD)</div><div class=\"cntnt\"><img style=\"width:546px; height:377px;\" src=\"images/PEDS/93810_Echo_sinus_venosus_ASD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Two-dimensional echocardiographic view demonstrating a&nbsp;sinus venosus ASD (arrow).<br />(B) Same view with color Doppler flow imaging showing flow across the ASD (arrow).</div><div class=\"graphic_footnotes\">RA: right atrium; LA: Left atrium; RUPV: right upper pulmonary vein.</div><div id=\"graphicVersion\">Graphic 93810 Version 1.0</div></div></div>"},"93811":{"type":"graphic_diagnosticimage","displayName":"Transesophageal echo secundum ASD","title":"Transesophageal echocardiography of a moderate size secundum atrial septal defect (ASD) in a child","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Transesophageal echocardiography of a moderate size secundum atrial septal defect (ASD) in a child</div><div class=\"cntnt\"><img style=\"width:548px; height:258px;\" src=\"images/PEDS/93811_Trnssphg_ecghscnd_ASD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Two-dimensional transesophageal echocardiographic view demonstrating a moderate size secundum ASD in a four-year-old child (arrow).<br />(B) Same view with color Doppler flow imaging showing flow across the ASD (arrow). Blue flow is away from transducer.</div><div class=\"graphic_footnotes\">RA: right atrium; LA: left atrium; SVC: superior vena cava; ASD: atrial septal defect.</div><div id=\"graphicVersion\">Graphic 93811 Version 1.0</div></div></div>"},"93812":{"type":"graphic_diagnosticimage","displayName":"Transthoracic echo large secundum ASD","title":"Transthoracic echocardiography of a large secundum atrial septal defect (ASD) in a six-year-old patient","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Transthoracic echocardiography of a large secundum atrial septal defect (ASD) in a six-year-old patient</div><div class=\"cntnt\"><img style=\"width:549px; height:542px;\" src=\"images/PEDS/93812_Trnsthr_ech_lg_sec_ASD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Subcostal two-dimensional echocardiographic view demonstrating a large secundum ASD (arrow).<br />(B) Same view with color Doppler flow imaging showing flow across the ASD (arrow). Red colored flow represents flow towards the transducer.<br />(C) Echocardiographic two-dimensional short axis view demonstrating the dilation of the right ventricle in comparison with the left ventricle.</div><div class=\"graphic_footnotes\">RA: right atrium; LA: left atrium; LV: left ventricle; RV: right ventricle.</div><div id=\"graphicVersion\">Graphic 93812 Version 1.0</div></div></div>"},"93814":{"type":"graphic_table","displayName":"Examples of cutaneous findings that can occur in SLE","title":"Examples of cutaneous findings that can occur in SLE*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of cutaneous findings that can occur in SLE*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Cutaneous lupus erythematosus (ie, acute cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus, chronic cutaneous lupus erythematosus)</td> </tr> <tr> <td>Bullous lupus erythematosus</td> </tr> <tr> <td class=\"sublist1_start\">Nonscarring alopecia</td> </tr> <tr> <td class=\"sublist1\">Lupus hair</td> </tr> <tr> <td class=\"sublist1\">Telogen effluvium</td> </tr> <tr> <td class=\"sublist1_start\">Vascular findings</td> </tr> <tr> <td class=\"sublist1\">Vasculitis <ul> <li>Cutaneous small vessel vasculitis (palpable purpura)</li> <li>Urticarial vasculitis</li> <li>Polyarteritis nodosa-like cutaneous lesions</li> </ul> </td> </tr> <tr> <td class=\"sublist1\">Cutaneous findings associated with antiphospholipid antibodies <ul> <li>Livedo reticularis</li> <li>Leg ulcers</li> <li>Cutaneous necrosis</li> <li>Thrombophlebitis</li> <li>Digital infarcts</li> </ul> </td> </tr> <tr> <td class=\"sublist1\">Acrocyanosis</td> </tr> <tr> <td class=\"sublist1\">Degos disease-like lesions</td> </tr> <tr> <td class=\"sublist1\">Livedoid vasculopathy</td> </tr> <tr> <td class=\"sublist1\">Periungual telangiectasia</td> </tr> <tr> <td class=\"sublist1\">Raynaud&rsquo;s phenomenon</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Not an exhaustive list. Patients with features that overlap systemic lupus erythematous and another connective tissue disease may exhibit cutaneous findings consistent with the latter disease (eg, sclerodactyly, rheumatoid nodules, heliotrope eruption). Other infrequent associations have been reported (eg, erythromelalgia, sweet syndrome, papulonodular mucinosis, porphyria cutanea tarda, anetoderma, etc).</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;<li>Sontheimer RD. The lexicon of cutaneous lupus erythematosus - a review and personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus. Lupus 1997; 6:84.</li>&#xD;&#xA;<li>Lee LA, Werth VP. Lupus erythematosus. In: Dermatology, 3rd ed, Bolognia JL, Jorizzo JL, Rapini RP, et al (Eds), Elsevier Limited, 2012. p.615.</li></ol></div><div id=\"graphicVersion\">Graphic 93814 Version 1.0</div></div></div>"},"93817":{"type":"graphic_diagnosticimage","displayName":"Radiographic findings in P-cPACNS","title":"Radiographic findings in a patient with angiography-positive, progressive cPACNS","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Radiographic findings in a patient with angiography-positive, progressive cPACNS</div><div class=\"cntnt\"><img style=\"width:537px; height:274px;\" src=\"images/ALLRG/93817_Radio_finding_P_cPACNS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 15-year-old boy with left MCA stroke seen on MRI (A) and corresponding MRA (B) showing distal and proximal vessel involvement.</div><div class=\"graphic_footnotes\">cPACNS: childhood primary angiitis of the central nervous system; MCA: middle cerebral artery; MRI: magnetic resonance imaging; MRA: magnetic resonance angiography.</div><div id=\"graphicVersion\">Graphic 93817 Version 1.0</div></div></div>"},"93818":{"type":"graphic_diagnosticimage","displayName":"Radiographic findings in NP-cPACNS","title":"Radiographic findings in a patient with angiography-positive, nonprogressive cPACNS","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Radiographic findings in a patient with angiography-positive, nonprogressive cPACNS</div><div class=\"cntnt\"><img style=\"width:548px; height:319px;\" src=\"images/ALLRG/93818_Radiogrph_fnd_NP_cPACNS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A four-year-old girl with left MCA stroke shown on MRI (A) and corresponding MRA (B) showing beaded appearance of the MCA.</div><div class=\"graphic_footnotes\">cPACNS: childhood primary angiitis of the central nervous system; MCA: middle cerebral artery; MRI: magnetic resonance imaging; MRA: magnetic resonance angiography.</div><div id=\"graphicVersion\">Graphic 93818 Version 2.0</div></div></div>"},"93820":{"type":"graphic_picture","displayName":"Legionella on DGVP agar","title":"<EM>Legionella </EM>on DGVP agar","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\"><EM>Legionella </EM>on DGVP agar</div><div class=\"cntnt\"><img style=\"width:598px; height:358px;\" src=\"images/ID/93820_Legionella_on_DGVP_agar_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Potable water sample on buffered charcoal yeast extract agar showing heavy non-<EM>Legionella</EM> bacterial colonies.<br />(B) The same water sample on dyes, glycine, vancomycin, polymyxin (DGVP) agar now void of competing flora. Typical green colonies of <EM>Legionella pneumophila</EM> are now visible.</div><div class=\"graphic_reference\">Reproduced with permission from: John D Rihs.</div><div id=\"graphicVersion\">Graphic 93820 Version 2.0</div></div></div>"},"93821":{"type":"graphic_picture","displayName":"Smear of toothpaste","title":"Demonstration of a smear of toothpaste","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Demonstration of a smear of toothpaste</div><div class=\"cntnt\"><img style=\"width:516px; height:247px;\" src=\"images/PEDS/93821_Smear_toothpaste.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The picture above demonstrates what is meant by a smear of toothpaste.</div><div id=\"graphicVersion\">Graphic 93821 Version 1.0</div></div></div>"},"93823":{"type":"graphic_picture","displayName":"Endoscopic image of a type I sliding hiatus hernia","title":"Endoscopic image of a type I sliding hiatus hernia","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Endoscopic image of a type I sliding hiatus hernia</div><div class=\"cntnt\"><img style=\"width:511px; height:243px;\" src=\"images/GAST/93823_End_I_slid_hiat_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Retroflexed (A) and forward-looking (B) endoscopic views of a sliding (type I) hiatus hernia. The squamocolumnar junction (SCJ) marks the distal limit of the esophageal epithelium. Distal to the SCJ is the constriction of the diaphragmatic hiatus.</div><div id=\"graphicVersion\">Graphic 93823 Version 1.0</div></div></div>"},"93824":{"type":"graphic_diagnosticimage","displayName":"Barium swallow of a large paraesophageal hernia","title":"Barium swallow of a large paraesophageal hernia","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Barium swallow of a large paraesophageal hernia</div><div class=\"cntnt\"><img style=\"width:536px; height:536px;\" src=\"images/GAST/93824_Bar_swl_lg_prsph_hrna.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Barium swallow of a paraesophageal hernia. Note that as the herniated stomach enlarges, it inverts and twists causing a volvulus. In the extreme, this results in an upside-down stomach. The esophagus is not seen in this image, but if the gastroesophageal junction is at the level of the diaphragm, this would be a type II (paraesophageal) hernia. More commonly, it is above the diaphragm, which makes it a type III (paraesophageal) hernia.</div><div id=\"graphicVersion\">Graphic 93824 Version 1.0</div></div></div>"},"93826":{"type":"graphic_picture","displayName":"Chikungunya hyperpigmentation","title":"Persistent facial hypermelanosis following chikungunya fever","html":"<div class=\"graphic\"><div style=\"width: 681px\" class=\"figure\"><div class=\"ttl\">Persistent facial hypermelanosis following chikungunya fever</div><div class=\"cntnt\"><img style=\"width:661px; height:461px;\" src=\"images/DERM/93826_Chikungunyahyperpigmentat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient developed a reticular hypermelanosis of the facial skin soon after the rash associated with chikungunya fever had resolved.</div><div class=\"graphic_reference\">From: Bandyopadhyay D, Ghosh SK. Mucocutaneous manifestations of Chikungunya fever. Indian J Dermatol 2010; 55:64. DOI: <a href=\"http://www.e-ijd.org/article.asp?issn=0019-5154;year=2010;volume=55;issue=1;spage=64;epage=67;aulast=Bandyopadhyay\" spellcheck=\"true\" target=\"_blank\">10.4103/0019-5154.60356</a>. Reproduced with permission from Wolters Kluwer - MedKnow. Copyright &copy; 2010 Asian Academy of Dermatology and Venereology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 93826 Version 2.0</div></div></div>"},"93828":{"type":"graphic_picture","displayName":"Chikungunya hyperpigmentation nose","title":"Facial hyperpigmentation associated with chikungunya fever","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Facial hyperpigmentation associated with chikungunya fever</div><div class=\"cntnt\"><img style=\"width:597px; height:510px;\" src=\"images/DERM/93828_Chikungunyahyperpgmntnose.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Persistent hyperpigmentation of the nose following chikungunya fever.</div><div class=\"graphic_reference\">From: Riyaz N, Riyaz A, Rahima, et al. Cutaneous manifestations of chikungunya during a recent epidemic in Calicut, north Kerala, south India. Indian J Dermatol Venereol Leprol 2010; 76:671. DOI: <A spellcheck=true href=\"http://www.ijdvl.com/article.asp?issn=0378-6323;year=2010;volume=76;issue=6;spage=671;epage=676;aulast=Riyaz\" target=_blank>10.4103/0378-6323.72466</A>. Reproduced with permission from Wolters Kluwer - MedKnow. Copyright © 2010 Indian Association of Dermatologists, Venereologists&nbsp;and Leprologists. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 93828 Version 2.0</div></div></div>"},"93829":{"type":"graphic_picture","displayName":"Chikungunya pigmentation histopathology","title":"Histopathologic features of post-chikungunya fever hyperpigmentation","html":"<div class=\"graphic\"><div style=\"width: 753px\" class=\"figure\"><div class=\"ttl\">Histopathologic features of post-chikungunya fever hyperpigmentation</div><div class=\"cntnt\"><img style=\"width:733px; height:512px;\" src=\"images/DERM/93829_Chikungunyapigmentathisto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Increased basal pigmentation with melanophages and perivascular lymphocytic infiltrate in pigmented macules (H&amp;E, 40x).</div><div class=\"graphic_footnotes\">H&amp;E: hematoxylin and eosin.</div><div class=\"graphic_reference\">From: Riyaz N, Riyaz A, Rahima, et al. Cutaneous manifestations of chikungunya during a recent epidemic in Calicut, north Kerala, south India. Indian J Dermatol Venereol Leprol 2010; 76:671. DOI: <a href=\"http://www.ijdvl.com/article.asp?issn=0378-6323;year=2010;volume=76;issue=6;spage=671;epage=676;aulast=Riyaz\" spellcheck=\"true\" target=\"_blank\">10.4103/0378-6323.72466</a>. Reproduced with permission from Wolters Kluwer - MedKnow. Copyright &copy; 2010 Indian Association of Dermatologists, Venereologists &amp; Leprologists. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 93829 Version 3.0</div></div></div>"},"93834":{"type":"graphic_figure","displayName":"Pathophysiological effects of obstructive sleep apnea","title":"Pathophysiological effects of obstructive sleep apnea","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">Pathophysiological effects of obstructive sleep apnea</div><div class=\"cntnt\"><img style=\"width:595px; height:365px;\" src=\"images/PULM/93834_Pathophysiolog_effects_OSA.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PNA: parasympathetic nervous system activity; PO<sub>2</sub>: partial pressure of oxygen; PCO<sub>2</sub>: partial pressure of carbon dioxide; SNA: sympathetic nervous system activity; HR: heart rate; BP: blood pressure; LV: left ventricular.</div><div class=\"graphic_reference\">Reproduced from: Bradley TD, Floras JS. Obstructive sleep apnoea and its cardiovascular consequences. Lancet 2009; 373:83. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 93834 Version 1.0</div></div></div>"},"93835":{"type":"graphic_figure","displayName":"Overview of initial evaluation","title":"Overview of the initial evaluation and work up of patients with suspected non-small cell lung cancer","html":"<div class=\"graphic\"><div style=\"width: 677px\" class=\"figure\"><div class=\"ttl\">Overview of the initial evaluation and work up of patients with suspected non-small cell lung cancer</div><div class=\"cntnt\"><img style=\"width:657px; height:399px;\" src=\"images/PULM/93835_Overview_initial_evaluation.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Overview of initial evaluation, diagnosis, staging, and treatment processes. There is significant overlap between cognitive processes. Developing a clinical diagnosis and assessment of the probable stage begins during the initial evaluation. This clinical assessment is subsequently refined on the basis of biopsy specimen findings that are part of formal staging and diagnosis. Similarly, information regarding the patient's functional status, comorbid conditions, and preferences may have an impact on treatment alternatives, and this in turn may have an impact on the type of diagnostic testing strategies chosen.</div><div class=\"graphic_footnotes\">CXR: chest radiograph; CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced from: Ost DE, Yeung SC, Tanoue LT, Gould MK. Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143:e121S. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 93835 Version 2.0</div></div></div>"},"93836":{"type":"graphic_table","displayName":"Clinical findings suggesting metastatic disease","title":"Clinical findings suggesting metastatic disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical findings suggesting metastatic disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Symptoms elicited in history</td> </tr> <tr> <td class=\"indent1\">Constitutional - weight loss &#62;10 pounds</td> </tr> <tr> <td class=\"indent1\">Musculoskeletal - focal skeletal pain</td> </tr> <tr> <td class=\"indent1\">Neurologic - headaches, syncope, seizures, extremity weakness, recent change in mental status</td> </tr> <tr> <td class=\"subtitle1_single\">Signs found on physical exam</td> </tr> <tr> <td class=\"indent1\">Lymphadenopathy (&#62;1 cm)</td> </tr> <tr> <td class=\"indent1\">Hoarseness, superior vena cava syndrome</td> </tr> <tr> <td class=\"indent1\">Bone tenderness</td> </tr> <tr> <td class=\"indent1\">Hepatomegaly (&#62;13 cm span)</td> </tr> <tr> <td class=\"indent1\">Focal neurologic signs, papilledema</td> </tr> <tr> <td class=\"indent1\">Soft tissue mass</td> </tr> <tr> <td class=\"subtitle1_single\">Routine laboratory tests</td> </tr> <tr> <td class=\"indent1\">Hematocrit, &#60;40% in males</td> </tr> <tr> <td class=\"indent1\">Hematocrit, &#60;35% in females</td> </tr> <tr> <td class=\"indent1\">Elevated alkaline phosphatase, GGT, SGOT</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GGT: gamma-glutamyltransferase; SGOT: serum glutamicoxalonacetic transaminase.</div><div class=\"graphic_reference\">Silvestri GA, Littenberg B, Colice GL, 1995. The clinical evaluation for detecting metastatic lung cancer. A meta-analysis. American journal of respiratory and critical care medicine; 152:225-30. Official Journal of the American Thoracic Society. Reprinted with permission of the American Thoracic Society. Copyright &copy; 2014 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 93836 Version 1.0</div></div></div>"},"93837":{"type":"graphic_table","displayName":"Radiographic categories of lung cancer","title":"Computed tomographic-defined categories of lung cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Computed tomographic-defined categories of lung cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Group</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Definition (by chest CT scan)</td> </tr> <tr> <td><strong>A</strong></td> <td>Mediastinal infiltration</td> <td>Tumor mass within the mediastinum such that discrete lymph nodes cannot be distinguished or measured*</td> </tr> <tr> <td><strong>B</strong></td> <td>Enlarged discrete mediastinal nodes</td> <td>Discrete mediastinal nodes &#8805;1 cm in short-axis diameter on a transverse CT image</td> </tr> <tr> <td><strong>C</strong></td> <td>Clinical stage II or central stage I tumor</td> <td>Normal mediastinal nodes (&#60;1 cm) but enlarged N1 nodes (&#8805;1 cm) or a central tumor (within proximal one-third of the hemithorax)</td> </tr> <tr> <td><strong>D</strong></td> <td>Peripheral clinical stage I tumor</td> <td>Normal mediastinal and N1 nodes (&#60;1 cm) and a peripheral tumor (within outer two-thirds of hemithorax)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* This does not include a tumor mass within the lung that is abutting the mediastinum and tangentially involving the mediastinal pleura or fat (this situation pertains to the T stage of the primary tumor and not the N stage of the mediastinum).</div><div class=\"graphic_reference\">Reproduced from: Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143:e211S. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 93837 Version 2.0</div></div></div>"},"93845":{"type":"graphic_figure","displayName":"Nomogram to predict the probability of biochemical recurrence","title":"Nomogram predicting the outcome of early salvage radiotherapy","html":"<div class=\"graphic\"><div style=\"width: 808px\" class=\"figure\"><div class=\"ttl\">Nomogram predicting the outcome of early salvage radiotherapy</div><div class=\"cntnt\"><img style=\"width:788px; height:728px;\" src=\"images/ONC/93845_Nomogram_prob_biochem_recur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Nomogram to predict the probability of biochemical recurrence (BCR) at 5-yr following early salvage radiotherapy (eSRT) for BCR after radical prostatectomy based on pathologic Gleason score, surgical margin status, and prostate-specific antigen at time of eSRT. Instructions: Locate the patient's pathologic Gleason score on the pathologic Gleason score axis. Draw a line straight upwards to the point axis to determine how many points towards the probability of BCR after eSRT the patient receives for his pathologic Gleason score. Repeat the process for each additional variable. Sum the points for each of the predictors. Locate the final sum on the total-point axis. Draw a line straight down to find the patient's probability of BCR at 5-yr after eSRT.<br />(B) Nomogram calibration plot for nomogram predicting 5-yr BCR. Perfect predictions correspond to the 45&deg; line. Points estimated below the 45&deg; line correspond to nomogram overprediction, whereas points situated above the 45&deg; line correspond to nomogram underprediction. Vertical lines indicate the frequency distribution of predicted probabilities.<br />(C) Decision curve analyses demonstrating the net benefit associated with the use of the nomogram. Net benefit can be interpreted as the proportion of all patients who have BCR after eSRT and are recommended for additional cancer therapies if no patients without BCR were treated.</div><div class=\"graphic_footnotes\">PSA: prostate-specific antigen; RT: radiotherapy.</div><div class=\"graphic_reference\">Reproduced from: Briganti A, Karnes RJ, Joniau S, et al. Prediction of Outcome Following Early Salvage Radiotherapy Among Patients with Biochemical Recurrence After Radical Prostatectomy. Eur Urol 2013 Dec 12. DOI: 10.1016/j.eururo.2013.11.045. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 93845 Version 1.0</div></div></div>"},"93846":{"type":"graphic_table","displayName":"Topical analgesics","title":"Topical analgesics for treatment of superficial painful conditions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Topical analgesics for treatment of superficial painful conditions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Topical analgesic</td> <td class=\"subtitle1\">Usual dose (adult)</td> <td class=\"subtitle1\">Characteristics</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Topical nonsteroidal antiinflammatory drugs (NSAIDs)</td> </tr> <tr> <td class=\"indent1\">Diclofenac topical gel<br /> (1%)</td> <td>Apply dose (depends on joint size and location) three to four times daily (maximum total 32 g per day)</td> <td rowspan=\"6\">Applies to all topically administered NSAIDs: <ul class=\"decimal_heading\"> <li>Useful for treatment of musculoskeletal pain and osteoarthritis of superficial joints (eg, wrist, knee,&nbsp;hand) in combination with acetaminophen and/or tramadol, or as an alternative to systemic therapy</li> <li>Minimal systemic absorption</li> <li>Safety data are reassuring despite label warnings on United States products</li> <li>Local skin reactions include rash, itch, or burning (some products contain propylene glycol, a potential irritant and rarely an allergen)</li> <li>Refer to topic review of initial pharmacologic therapy of osteoarthritis</li> </ul> </td> </tr> <tr> <td class=\"indent1\">Diclofenac topical patch<br /> (1.3%)</td> <td>One patch twice daily</td> </tr> <tr> <td class=\"indent1\">Diclofenac topical solution<br /> (1.5, 1.6, or 2%)</td> <td>Apply (depends on joint size and location) two to four times daily</td> </tr> <tr> <td class=\"indent1\">Diclofenac topical spray<br /> (4%); not available in United States</td> <td>Four sprays (total of 32 mg) applied up to three times daily (maximum 120 mg per day); refer to product-specific information</td> </tr> <tr> <td class=\"indent1\">Ibuprofen topical gel (5%); not available in United States</td> <td>1 to 2.5 g of gel up to three times daily (maximum 7.5 g of gel per day); refer to product-specific information</td> </tr> <tr> <td class=\"indent1\">Ketoprofen topical gel (2.5%); not available in United States</td> <td>Apply two to four times daily (usual recommended dose is 15 g of gel per day); refer to product-specific information</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Topical capsaicin</td> </tr> <tr> <td class=\"indent1\">Capsaicin creams, gels, liquids, or lotions<br /> (0.025 to 0.1%)</td> <td>Apply a thin film&nbsp;one to four times daily until benefit achieved or for a one-month trial</td> <td rowspan=\"2\"> <ul> <li>Useful for treatment of osteoarthritis pain and postherpetic neuralgia as an adjunct or alternative to systemic analgesics</li> <li>Local irritation may be intolerable </li> <li>Refer to topic review of initial pharmacologic therapy of osteoarthritis</li> </ul> </td> </tr> <tr> <td class=\"indent1\">Capsaicin topical patches<br /> (standard concentration 0.025, 0.0375%)</td> <td>Apply up to three to four times daily</td> </tr> <tr> <td class=\"indent1\">Capsaicin topical patch<br /> (high concentration 8%)</td> <td> <p>Postherpetic neuralgia (single treatment): Apply up to four patches to the&nbsp;most painful area for&nbsp;60 minutes</p> Treatment may be repeated after three months</td> <td> <ul> <li>Potential option for local pain relief in postherpetic neuralgia</li> <li>High-concentration patch must be administered by a health care professional and monitored for up to two hours after treatment</li> <li>Pretreatment with a local anesthetic (eg, lidocaine) is necessary</li> <li>After application, local cooling measures can&nbsp;decrease discomfort</li> <li>Local pain and irritation may be intolerable</li> <li>Refer to topic review of postherpetic neuralgia</li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Topical lidocaine</td> </tr> <tr> <td class=\"indent1\">Lidocaine topical patch<br /> (5%)</td> <td>One to three patches applied for up to 12 hours in any 24-hour period</td> <td> <ul> <li>Low (3 to 5%) systemic absorption through intact skin</li> <li>Useful for local relief of pain (eg, due to postherpetic neuralgia) in limited areas of intact skin as an adjunct or alternative to systemic analgesics</li> </ul> </td> </tr> <tr> <td class=\"indent1\">Lidocaine topical creams, ointments, and gels<br /> (2 to 4%)</td> <td>Apply a thin film two to four times daily (refer to product-specific instructions)</td> <td> <ul> <li>Useful for local relief of minor superfical skin irritation and pain</li> </ul> </td> </tr> <tr> <td class=\"indent1\">Lidocaine topical cream<br /> (5%)</td> <td>Apply thin film three to four times daily (maximum six times daily)</td> <td> <ul> <li>Useful for local relief of anorectal pain and itching</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Topical analgesic therapies are&nbsp;moderately effective and&nbsp;useful in combination with systemic therapies for reducing medication load and side effects, and potentially, as monotherapy for adults with localized pain and contraindications to systemic therapies.</div><div class=\"graphic_reference\">Prepared with data from:<br /><OL>&#xD;&#xA;<LI>Anon. Drugs for pain. Treatment guidelines from the Medical Letter 2013; 11:31.</LI>&#xD;&#xA;<LI>Barkin R, Beckerman M, Blum S. Should nonsteroidal anti-inflammatory drugs (NSAIDs) be prescribed to the older adult? Drugs Aging 2010; 27:775.</LI>&#xD;&#xA;<LI>Sawynok J. Topical analgesics for neuropathic pain in the elderly: Current and future prospects. Drugs Aging 2014; 31:853.</LI></OL></div><div id=\"graphicVersion\">Graphic 93846 Version 4.0</div></div></div>"},"93848":{"type":"graphic_diagnosticimage","displayName":"Imaging fiducial marker for radiation therapy","title":"Fiducial marker used to guide radiation therapy in lung cancer","html":"<div class=\"graphic\"><div style=\"width: 661px\" class=\"figure\"><div class=\"ttl\">Fiducial marker used to guide radiation therapy in lung cancer</div><div class=\"cntnt\"><img style=\"width:641px; height:480px;\" src=\"images/RADIOL/93848_Img_fiducial_mark_radiation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan of the chest shows a 3 mm nodule in the right upper lobe bronchus. Image B is a magnified view of the lesion (arrowhead). Endoscopic biopsy confirmed a diagnosis of squamous cell carcinoma. Fiducial marker to guide radiation therapy was placed endoscopically. A CT scan (C), and a chest x-ray magnified in D and E show the high density fiducial marker (arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93848 Version 1.0</div></div></div>"},"93849":{"type":"graphic_picture","displayName":"Linear and whorled nevoid hypermelanosis 1","title":"Linear and whorled nevoid hypermelanosis (LWNH)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Linear and whorled nevoid hypermelanosis (LWNH)</div><div class=\"cntnt\"><img style=\"width:443px; height:590px;\" src=\"images/DERM/93849_Linearwhorledhypermelano1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented macules in a streaky configuration along the lines of Blaschko in a child with linear and whorled nevoid hypermelanosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 93849 Version 2.0</div></div></div>"},"93850":{"type":"graphic_picture","displayName":"Linear and whorled nevoid hypermelanosis infant","title":"Linear and whorled nevoid hypermelanosis (LWNH)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Linear and whorled nevoid hypermelanosis (LWNH)</div><div class=\"cntnt\"><img style=\"width:443px; height:590px;\" src=\"images/DERM/93850_Lineawhorlnevoidhypermel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented macules in a streaky configuration along the lines of Blaschko in an infant with linear and whorled nevoid hypermelanosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 93850 Version 1.0</div></div></div>"},"93854":{"type":"graphic_diagnosticimage","displayName":"Imaging pyomyositis","title":"Pyomyositis on CT and US","html":"<div class=\"graphic\"><div style=\"width: 648px\" class=\"figure\"><div class=\"ttl\">Pyomyositis on CT and US</div><div class=\"cntnt\"><img style=\"width:628px; height:435px;\" src=\"images/RADIOL/93854_Imaging_pyomyositis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan through the lower pelvis (A) shows a hypodense right-sided obturator externus muscle (asterisk) and a normal right-sided pectineus muscle (P). The left and right pectineus muscles (P) and left obturator externus muscle (OE) show normal soft tissue density. Image B is a magnified view and modified to highlight the difference in density between the hypodense right OE (asterisk) and normal pectineus muscles (P) and the normal left OE. Image C is an ultrasound of the right groin and shows a hypoechoic right obturator externus (asterisk), a normal right pectineus muscle (P), and a needle (arrow) within an&nbsp;hypoechoic abscess in the muscle. Image D is a magnified view of C. Culture of the aspirate grew<EM> Staphylococcus</EM>.</div><div class=\"graphic_footnotes\">CT: computed tomography; US: ultrasound; P: pectineus muscle; OE: obturator externus muscle.</div><div id=\"graphicVersion\">Graphic 93854 Version 3.0</div></div></div>"},"93880":{"type":"graphic_picture","displayName":"Pea-sized amount of toothpaste","title":"Pea-sized amount of toothpaste","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Pea-sized amount of toothpaste</div><div class=\"cntnt\"><img style=\"width:516px; height:261px;\" src=\"images/PEDS/93880_Pea_sized_toothpaste.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The picture above demonstrates what is meant by a pea-sized amount of toothpaste.</div><div id=\"graphicVersion\">Graphic 93880 Version 1.0</div></div></div>"},"93881":{"type":"graphic_algorithm","displayName":"Mgmt of asthma exacerbations in children - Home rx algorithm","title":"Management of asthma exacerbations in children: Home treatment algorithm for clinicians","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Management of asthma exacerbations in children: Home treatment algorithm for clinicians</div><div class=\"cntnt\"><img style=\"width:597px; height:606px;\" src=\"images/ALLRG/93881_Mgmt_asthma_home_rx_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MDI: metered-dose inhaler; SABA: short-acting beta<sub>2</sub>agonist (quick-relief inhaler); ED: emergency department.</div><div class=\"graphic_reference\">Modified from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</div><div id=\"graphicVersion\">Graphic 93881 Version 1.0</div></div></div>"},"93884":{"type":"graphic_table","displayName":"Characteristics of direct acting antiviral agents for HCV","title":"Characteristics of direct acting antiviral agents for hepatitis C virus infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of direct acting antiviral agents for hepatitis C virus infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Protease inhibitors</td> <td class=\"subtitle1\">Nucleos(t)ide polymerase inhibitors</td> <td class=\"subtitle1\">Non-nucleoside polymerase inhibitors</td> <td class=\"subtitle1\">NS5A inhibitors</td> </tr> <tr> <td><strong>Potency</strong></td> <td>High (varies by HCV genotype)</td> <td>Moderate-to-high (consistent across HCV genotypes and&nbsp;subtypes)</td> <td>Varies by HCV genotype </td> <td>High (against multiple HCV genotypes)</td> </tr> <tr> <td><strong>Barrier to resistance</strong></td> <td>Low (1a &#60;1b)</td> <td>High (1a = 1b)</td> <td>Very low (1a &#60;1b)</td> <td>Low (1a &#60;1b)</td> </tr> <tr> <td><strong>Potential for drug interactions</strong></td> <td>High</td> <td>Low</td> <td>Variable</td> <td>Low-to-moderate</td> </tr> <tr> <td><strong>Toxicity</strong></td> <td>Rash, anemia, &#8593; bilirubin</td> <td>Mitochondrial toxicity, interactions with HIV antiretrovirals (nucleoside reverse transcriptase inhibitors) and ribavirin*</td> <td>Variable</td> <td>Variable</td> </tr> <tr> <td><strong>Dosing</strong></td> <td>daily to three times daily</td> <td>daily to twice daily</td> <td>daily to three times daily</td> <td>daily</td> </tr> <tr> <td><strong>Comments</strong></td> <td>Later&nbsp;generation&nbsp;protease inhibitors are expected to have higher barriers to resistance and be pan-genotype</td> <td> <p>Single target for binding at the active site</p> </td> <td> <p>Many targets for binding at allosteric sites</p> </td> <td>Multiple antiviral mechanisms of action</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The main targets of the direct acting antiviral agents are the HCV-encoded nonstructural (NS) proteins that are vital to the replication of the virus. Protease inhibitors block the function of the NS3/NS4A serine protease. Nucleoside and nonnucloside inhibitors block the function of the NS5B polymerase. The NS5A protein has a presumptive role in the organization of the replication complex and in regulating replication. It is also involved in assembly of the viral particle that is released from the host cell.</div><div class=\"graphic_footnotes\">* Such toxicities have plagued the nucleoside inhibitor class as a whole. However, the first available nucleoside polymerase inhibitor, sofosbuvir,&nbsp;has not been associated with&nbsp;serious&nbsp;toxicity.</div><div class=\"graphic_reference\">Adapted from: Schaefer EA, Chung RT. Anti-hepatitis C virus drugs in development. Gastroenterology 2012; 142:1340.</div><div id=\"graphicVersion\">Graphic 93884 Version 1.0</div></div></div>"},"93885":{"type":"graphic_diagnosticimage","displayName":"CT lymphoma RPF hydronephrosis  ","title":"Lymphoma, RPF, and hydronephrosis on CT","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Lymphoma, RPF, and hydronephrosis on CT</div><div class=\"cntnt\"><img style=\"width:600px; height:252px;\" src=\"images/RADIOL/93885_CT_lymph_RPF_hydroneph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan in axial projection (A) shows stranding (arrow) to the left of the aorta (asterisk) associated with left hydronephrosis (arrowhead). Bulky soft tissue lymphomatous nodes (short arrow) compress the IVC (dashed arrow). Image B shows the strand-like RPF (arrows) surrounding the vessels and the obstructed left ureter (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography; RPF: retroperitoneal fibrosis; IVC: inferior vena cava.</div><div id=\"graphicVersion\">Graphic 93885 Version 1.0</div></div></div>"},"93886":{"type":"graphic_diagnosticimage","displayName":"CT gastric carcinoma RPF","title":"Gastric carcinoma and RPF on CT","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Gastric carcinoma and RPF on CT</div><div class=\"cntnt\"><img style=\"width:599px; height:232px;\" src=\"images/RADIOL/93886_CT_gastr_carcinom_RPF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan in axial projection (A) shows stranding and soft tissue mass (asterisks) in the retroperitoneum associated with right-sided hydronephrosis (arrow). Image B shows the retroperitoneal metastatic gastric carcinoma (asterisks) surrounding the duodenum (d).</div><div class=\"graphic_footnotes\">CT: computed tomography; RPF: retroperitoneal fibrosis.</div><div id=\"graphicVersion\">Graphic 93886 Version 1.0</div></div></div>"},"93887":{"type":"graphic_diagnosticimage","displayName":"CT RPF post-radiation for sarcoma ","title":"RPF post-radiation for childhood sarcoma","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">RPF post-radiation for childhood sarcoma</div><div class=\"cntnt\"><img style=\"width:476px; height:365px;\" src=\"images/RADIOL/93887_CT_RPF_pst_rad_sarcoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan through the upper pelvis shows soft tissue changes (asterisk) representing RPF surrounding a stented right ureter (arrowhead). The patient had childhood sarcoma of the right lower extremity and received radiation therapy.</div><div class=\"graphic_footnotes\">CT: computed tomography; RPF: retroperitoneal fibrosis.</div><div id=\"graphicVersion\">Graphic 93887 Version 1.0</div></div></div>"},"93889":{"type":"graphic_diagnosticimage","displayName":"CT thoracoabdominal aortic RPF","title":"Thoracoabdominal aortic RPF on CT","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thoracoabdominal aortic RPF on CT</div><div class=\"cntnt\"><img style=\"width:413px; height:598px;\" src=\"images/RADIOL/93889_CT_thoracoabd_aort_RPF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT scan through the aortic arch shows soft tissue change (arrowheads) surrounding the arch. Images B and C are sagittal reconstructions and show the full thoracoabdominal extent of biopsy proven RPF (arrowheads).</div><div class=\"graphic_footnotes\">CT: computed tomography; RPF: retroperitoneal fibrosis.</div><div id=\"graphicVersion\">Graphic 93889 Version 1.0</div></div></div>"},"93893":{"type":"graphic_diagnosticimage","displayName":"MRI periaortic RPF  ","title":"Periaortic RPF on MRI","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Periaortic RPF on MRI</div><div class=\"cntnt\"><img style=\"width:599px; height:219px;\" src=\"images/RADIOL/93893_MRI_periaortic_RPF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A T1 weighted MRI through the aortic arch shows a rind of soft tissue around the arch of the aorta (arrow). Image B shows extension of the RPF around the aorta at the aortic hiatus (arrows).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; RPF: retroperitoneal fibrosis.</div><div id=\"graphicVersion\">Graphic 93893 Version 1.0</div></div></div>"},"93901":{"type":"graphic_picture","displayName":"Orbital compartment injury","title":"Orbital compartment injury","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Orbital compartment injury</div><div class=\"cntnt\"><img style=\"width:466px; height:279px;\" src=\"images/EM/93901_Orbital_compart_injury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 65-year-old man was working in his home workshop when he accidentally caught his left eye on a peg hook.<br />(A) Clinical photo of the left eye showing periocular ecchymoses (asterisk), 360 degrees of sub-conjunctival hemorrhages (arrowhead), a conjunctival laceration (dashed arrow), laceration of the medial rectus muscle with the distal portion rotated anteriorly and temporally (short arrow), and partial laceration of the inferior rectus muscle (arrow).<br />(B) A computed tomography scan of the orbits showing a discontinuity in the left medial rectus muscle (axial scan, asterisk) and marked enlargement of the medial and inferior recti muscle diameters (coronal scan, arrowhead and short arrow respectively).</div><div class=\"graphic_reference\">Courtesy of Matthew F Gardiner, MD and Ankoor Shah, MD, PhD.</div><div id=\"graphicVersion\">Graphic 93901 Version 1.0</div></div></div>"},"93902":{"type":"graphic_picture","displayName":"Ocular findings of carotid cavernous fistula","title":"Ocular findings of carotid cavernous fistula","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Ocular findings of carotid cavernous fistula</div><div class=\"cntnt\"><img style=\"width:548px; height:465px;\" src=\"images/EM/93902_Ocu_fnd_carot_cvrn_fst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A six-year-old girl presented with injection of the right eye for four months since being hit with a fishing pole. The examination showed mild proptosis and engorgement of the episcleral vessels.<br />(B)&nbsp;A dilated fundus examination showed dilatation of the retinal vasculature in the right compared to the left eye. A computed tomography angiogram showed a right carotid cavernous fistula.</div><div class=\"graphic_reference\">Courtesy of Matthew F Gardiner, MD and Ankoor Shah, MD, PhD.</div><div id=\"graphicVersion\">Graphic 93902 Version 1.0</div></div></div>"},"93903":{"type":"graphic_picture","displayName":"Palmoplantar pustulosis feet","title":"Palmoplantar pustulosis","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Palmoplantar pustulosis</div><div class=\"cntnt\"><img style=\"width:533px; height:525px;\" src=\"images/DERM/93903_Palmoplntr_pustuloss_feet.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pustules, brown macules (remnants of pustules), erythema, and hyperkeratosis on the soles of the feet.</div><div id=\"graphicVersion\">Graphic 93903 Version 1.0</div></div></div>"},"93904":{"type":"graphic_picture","displayName":"Palmoplantar pustulosis bilateral feet","title":"Palmoplantar pustulosis","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Palmoplantar pustulosis</div><div class=\"cntnt\"><img style=\"width:498px; height:538px;\" src=\"images/DERM/93904_Palmoplntr_pustlss_bi_feet.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous pustules, brown macules (remnants of pustules), erythema, and hyperkeratosis on the soles of the feet.</div><div id=\"graphicVersion\">Graphic 93904 Version 1.0</div></div></div>"},"93905":{"type":"graphic_picture","displayName":"Palmoplantar pustulosis focal","title":"Palmoplantar pustulosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Palmoplantar pustulosis</div><div class=\"cntnt\"><img style=\"width:372px; height:538px;\" src=\"images/DERM/93905_Palmoplantr_pustlss_focal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Focal area of pustules, brown macules (remnants of pustules), erythema, and hyperkeratosis on the sole of the foot.</div><div id=\"graphicVersion\">Graphic 93905 Version 1.0</div></div></div>"},"93907":{"type":"graphic_picture","displayName":"Palmoplantar pustulosis extra-palmoplantar involvement","title":"Palmoplantar pustulosis with extra-palmoplantar involvement","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Palmoplantar pustulosis with extra-palmoplantar involvement</div><div class=\"cntnt\"><img style=\"width:551px; height:435px;\" src=\"images/DERM/93907_Plmp_pst_xtr_plmp_invl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Palmoplantar pustulosis involving the hand (A). Psoriasis-like plaque on the upper extremity (B, C).</div><div id=\"graphicVersion\">Graphic 93907 Version 1.0</div></div></div>"},"93908":{"type":"graphic_picture","displayName":"Nail abnormalities in palmoplantar pustulosis","title":"Nail abnormalities in palmoplantar pustulosis","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Nail abnormalities in palmoplantar pustulosis</div><div class=\"cntnt\"><img style=\"width:502px; height:326px;\" src=\"images/DERM/93908_Nail_abnrm_plmplnt_pustul.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nail involvement in palmoplantar pustulosis. Severe nail pitting associated with distal onycholysis and yellow discoloration resulting in complete nail dystrophy.</div><div id=\"graphicVersion\">Graphic 93908 Version 1.0</div></div></div>"},"93909":{"type":"graphic_picture","displayName":"Palmoplantar plaque psoriasis","title":"Palmoplantar plaque psoriasis","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Palmoplantar plaque psoriasis</div><div class=\"cntnt\"><img style=\"width:537px; height:403px;\" src=\"images/DERM/93909_Palmoplntr_plqu_psoriasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous scaly plaques on the palms in a patient with psoriasis.</div><div id=\"graphicVersion\">Graphic 93909 Version 1.0</div></div></div>"},"93910":{"type":"graphic_picture","displayName":"Dyshidrotic eczema hands","title":"Dyshidrotic eczema","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Dyshidrotic eczema</div><div class=\"cntnt\"><img style=\"width:538px; height:362px;\" src=\"images/DERM/93910_Dyshidrotic_eczema_hands.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vesicles and bullae on the palms and fingers.</div><div id=\"graphicVersion\">Graphic 93910 Version 1.0</div></div></div>"},"93911":{"type":"graphic_picture","displayName":"Acrodermatitis continua of Hallopeau nail bed","title":"Acrodermatitis continua of Hallopeau","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acrodermatitis continua of Hallopeau</div><div class=\"cntnt\"><img style=\"width:423px; height:537px;\" src=\"images/DERM/93911_Acroderm_contin_Hallopeau.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pustules involving the nail bed.</div><div id=\"graphicVersion\">Graphic 93911 Version 1.0</div></div></div>"},"93916":{"type":"graphic_picture","displayName":"Oral burns after caustic ingestion","title":"Superficial burns to the lips and oropharynx after caustic ingestion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superficial burns to the lips and oropharynx after caustic ingestion</div><div class=\"cntnt\"><img style=\"width:384px; height:251px;\" src=\"images/PEDS/93916_Oral_brn_caustic_ingst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photographs showing superficial burns to the lips and oropharynx in a child after ingestion of a caustic substance.</div><div class=\"graphic_reference\">Courtesy of Courtesy of Glenn Isaacson, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 93916 Version 2.0</div></div></div>"},"93918":{"type":"graphic_picture","displayName":"Esophageal burns after caustic ingestion","title":"Esophageal burns after caustic ingestion","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Esophageal burns after caustic ingestion</div><div class=\"cntnt\"><img style=\"width:517px; height:228px;\" src=\"images/PEDS/93918_Esoph_brn_caust_ingst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopy in a child one day after ingestion of a caustic substance reveals moderate esophageal burns (grade 2A and 2B).</div><div class=\"graphic_reference\">Courtesy of Glenn Isaacson, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 93918 Version 1.0</div></div></div>"},"93931":{"type":"graphic_table","displayName":"NCI CTCAE v5 esophageal stenosis","title":"NCI CTCAE v5.0 esophageal stenosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 esophageal stenosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Esophageal stenosis</td> <td>Asymptomatic; clinical or diagnostic observations only; intervention not indicated</td> <td>Symptomatic; altered GI function</td> <td>Severely altered GI function; tube feeding or hospitalization indicated; elective operative intervention indicated</td> <td>Life-threatening consequences; urgent operative intervention indicated</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Esophageal stenosis is characterized by a narrowing of the lumen of the esophagus.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; GI: gastrointestinal.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 93931 Version 4.0</div></div></div>"},"93933":{"type":"graphic_picture","displayName":"Carney complex","title":"Carney complex","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Carney complex</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/93933_Carneycomplex.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spotty hyperpigmentation and intense freckling of the face involving the lips in a boy with Carney complex.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 93933 Version 1.0</div></div></div>"},"93934":{"type":"graphic_table","displayName":"Transfusion thresholds adult","title":"Thresholds for red blood cell transfusion in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Thresholds for red blood cell transfusion in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Hemoglobin threshold for transfusion</td> </tr> <tr> <td>Symptomatic patient (eg, myocardial ischemia)</td> <td>10 g/dL*<sup>[1,2]</sup></td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Hospitalized patient</td> </tr> <tr> <td class=\"sublist1\">Preexisting coronary artery disease</td> <td class=\"sublist_other\">8 g/dL*<sup>[2]</sup></td> </tr> <tr> <td class=\"sublist1\">Acute coronary syndromes</td> <td class=\"sublist_other\">8 to 10 g/dL<sup>&#182;</sup><sup>[2,3]</sup></td> </tr> <tr> <td class=\"sublist1\">Intensive care unit (hemodynamically stable)</td> <td class=\"sublist_other\">7 g/dL*<sup>[4,5]</sup></td> </tr> <tr> <td class=\"sublist1\">Gastrointestinal bleeding (hemodynamically stable)</td> <td class=\"sublist_other\">7 g/dL*<sup>[6]</sup></td> </tr> <tr> <td class=\"sublist1\">Non-cardiac surgery</td> <td class=\"sublist_other\">8 g/dL*<sup>[1]</sup></td> </tr> <tr> <td class=\"sublist1\">Cardiac surgery</td> <td class=\"sublist_other\">7.5 g/dL*<sup>[7,8]</sup></td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Ambulatory outpatient</td> </tr> <tr> <td class=\"sublist1\">Oncology patient in treatment</td> <td class=\"sublist_other\">7 to 8 g/dL<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist1\">Palliative care setting</td> <td class=\"sublist_other\">As needed for symptoms; hospice benefits may vary</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These thresholds are not a substitute for direct assessment of the patient and clinical judgment. Refer to UpToDate topics on red blood cell transfusion and specific clinical settings for further details. Hospitalized patients with heart failure are an especially challenging case because there are no data from large randomized trials, and the improvement in oxygenation from transfusion must be balanced against the risks of worsening heart failure due to the volume of the transfused blood. The authors generally use a threshold of 7 to 8 g/dL in this population, erring on the side of a higher hemoglobin level in those who are expected to be able to better tolerate the volume load.</div><div class=\"graphic_footnotes\">* Based on results from clinical trial(s).<br />¶ There are no large clinical trials yet performed in this setting. These recommendations are based on the authors' opinions.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Carson JL, Terrin ML, Noveck H, et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med 2011; 365:2453.</LI>&#xD;&#xA;<LI>Carson JL, Brooks MM, Abbott JD, et al. Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. Am Heart J 2013; 165:964.</LI>&#xD;&#xA;<LI>Cooper HA, Rao SV, Greenberg MD, et al. Conservative versus liberal red cell transfusion in acute myocardial infarction (the CRIT Randomized Pilot Study). Am J Cardiol 2011; 108:1108.</LI>&#xD;&#xA;<LI>Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group [see comments]. N Engl J Med 1999; 340:409.</LI>&#xD;&#xA;<LI>Lacroix J, Hebert PC, Hutchison JS, et al. Transfusion strategies for patients in pediatric intensive care units. N Engl J Med 2007; 356:1609.</LI>&#xD;&#xA;<LI>Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013; 368:11.</LI>&#xD;&#xA;<LI>Hajjar LA, Vincent JL, Galas FR, et al. Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA 2010; 304:1559.</LI>&#xD;&#xA;<LI>Mazer CD, Whitlock RP, Fergusson DA, et al. Restrictive or liberal red-cell transfusion for cardiac surgery. N Engl J Med 2017; 377:2133.</LI></OL></div><div id=\"graphicVersion\">Graphic 93934 Version 4.0</div></div></div>"},"93944":{"type":"graphic_diagnosticimage","displayName":"Imaging hydronephrosis and retroperitoneal fibrosis","title":"Retroperitoneal fibrosis causing hydronephrosis on imaging","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Retroperitoneal fibrosis causing hydronephrosis on imaging</div><div class=\"cntnt\"><img style=\"width:599px; height:324px;\" src=\"images/RADIOL/93944_Img_hydrss_retro_fibro.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A retrograde pyelogram (A) shows hydronephrosis (arrow) and a long stricture in the mid ureter (arrowhead) overlaid in red in image B. Image C shows signs of aortocaval retroperitoneal fibrosis (arrow) around the calcified atherosclerotic aorta. Image D is a magnified view and and shows retroperitoneal fibrosis (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93944 Version 1.0</div></div></div>"},"93945":{"type":"graphic_picture","displayName":"Medial knee structures to palpate","title":"Medial knee structures to palpate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Medial knee structures to palpate</div><div class=\"cntnt\"><img style=\"width:397px; height:302px;\" src=\"images/EM/93945_Med_knee_struct_palpat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph depicts the general location of the structures that should be palpated&nbsp;during examination of&nbsp;the medial knee.</div><div class=\"graphic_reference\">Courtesy of Anthony I Beutler, MD.</div><div id=\"graphicVersion\">Graphic 93945 Version 3.0</div></div></div>"},"93946":{"type":"graphic_picture","displayName":"Dial test for knee injury","title":"Dial test for knee injury","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Dial test for knee injury</div><div class=\"cntnt\"><img style=\"width:513px; height:308px;\" src=\"images/EM/93946_Dial_test_knee_injury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The dial test is performed to help detect an injury to the posterolateral corner of the knee. External rotation of the tibia&nbsp;is compared while the knees are flexed to 30 degrees and to 90 degrees. A difference of more than 10 to 15 degrees of external rotation compared with the uninjured side constitutes a positive test.</div><div class=\"graphic_reference\">Courtesy of Anthony I Beutler, MD.</div><div id=\"graphicVersion\">Graphic 93946 Version 3.0</div></div></div>"},"93947":{"type":"graphic_movie","displayName":"Echo of stress cardiomyopathy","title":"Echocardiogram of stress cardiomyopathy","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Echocardiogram of stress cardiomyopathy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/RADIOL/93947_LVapicalbalTakotsubovid.mp4\" style=\"width:512px;height:368px\"></div><img style=\"width:440px; height:598px;\" src=\"images/RADIOL/93947_LVapicalbalTakotsuboimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apical four-chamber echocardiographic view of stress cardiomyopathy showing a dilated akinetic left ventricular apex (\"apical ballooning\" appearance). An end-diastolic image is shown at A, and an end-systolic image is shown at B.</div><div class=\"graphic_reference\">Courtesy of Warren Manning, MD.</div><div id=\"graphicVersion\">Graphic 93947 Version 2.0</div></div></div>"},"93949":{"type":"graphic_algorithm","displayName":"Algorithm hyperpigmentation disorders","title":"Algorithm for the diagnosis of hyperpigmentation disorders","html":"<div class=\"graphic\"><div style=\"width: 1078px\" class=\"figure\"><div class=\"ttl\">Algorithm for the diagnosis of hyperpigmentation disorders</div><div class=\"cntnt\"><img style=\"width:1058px; height:646px;\" src=\"images/DERM/93949_Algorithm_hyperpigmentation.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Lapeere H, Boone B, Schepper SD, et al. Hypomelanosis and hypermelanoses. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith L, Katz S, Gilchrest B, et al (Eds), McGraw-Hill, New York 2012. Copyright © 2012 McGraw-Hill Education.</div><div id=\"graphicVersion\">Graphic 93949 Version 3.0</div></div></div>"},"93950":{"type":"graphic_picture","displayName":"Alcoholic hepatitis cirrhosis","title":"Alcoholic hepatitis and cirrhosis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Alcoholic hepatitis and cirrhosis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93950_Alcoholic_hepatitis_cirrhos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ongoing liver injury from alcoholic hepatitis superimposed on a cirrhotic liver (acute on chronic liver injury). Note that there is cholestasis within hepatocytes in addition to steatosis. Broad bands of connective tissue delineate cirrhotic nodules.</div><div id=\"graphicVersion\">Graphic 93950 Version 1.0</div></div></div>"},"93951":{"type":"graphic_picture","displayName":"NASH stage 4","title":"Nonalcoholic steatohepatitis with cirrhosis","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Nonalcoholic steatohepatitis with cirrhosis</div><div class=\"cntnt\"><img style=\"width:524px; height:458px;\" src=\"images/GAST/93951_NASH_stage_4_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Needle biopsy stained with trichrome. Note that bands of fibrous tissue are intersecting the liver parenchyma and enclosing nodules, findings typical of cirrhosis. The hepatocytes contain a moderate amount of fat with ballooning degeneration, indicative of ongoing steatohepatitis.</div><div id=\"graphicVersion\">Graphic 93951 Version 1.0</div></div></div>"},"93952":{"type":"graphic_picture","displayName":"Central hyaline sclerosis","title":"Alcoholic steatohepatitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Alcoholic steatohepatitis</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93952_Central_hyaline_scleros_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Central hyaline sclerosis is fibrous tissue that gets deposited around the central venule. In this trichrome stain, the area on the right represents a centrilobular (perivenular) zone, which appears very dense due to collagen deposition, resulting in partial obliteration of the terminal hepatic venule. Note that although there are only a few steatotic vacuoles, there is prominent ballooning degeneration.</div><div id=\"graphicVersion\">Graphic 93952 Version 1.0</div></div></div>"},"93954":{"type":"graphic_picture","displayName":"Macrovesicular steatosis and inflammatory cells","title":"Nonalcoholic steatohepatitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Nonalcoholic steatohepatitis</div><div class=\"cntnt\"><img style=\"width:590px; height:444px;\" src=\"images/GAST/93954_Macroves_steatosis_inflamm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photo showing mainly macrovesicular steatosis along with inflammatory cells and ballooned hepatocytes. Note the presence of poorly-formed Mallory-Denk hyalines in the lower half of the photomicrograph.</div><div id=\"graphicVersion\">Graphic 93954 Version 1.0</div></div></div>"},"93955":{"type":"graphic_picture","displayName":"Atypical lymphoid infiltrate liver","title":"Atypical lymphoid infiltrate","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Atypical lymphoid infiltrate</div><div class=\"cntnt\"><img style=\"width:590px; height:442px;\" src=\"images/GAST/93955_Atyp_lymph_infiltrate_liver.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Incidental finding of an atypical lymphoid infiltrate within a portal area. Some of the cells appear to spread outward into the parenchyma. Whenever this type of infiltrate is present in a liver biopsy, it is imperative that immunohistochemical studies be performed to determine the phenotype of the cells in order to rule out malignant lymphoma.</div><div id=\"graphicVersion\">Graphic 93955 Version 1.0</div></div></div>"},"93956":{"type":"graphic_picture","displayName":"Large B-cell lymphoma liver","title":"Large B-cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Large B-cell lymphoma</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/93956_Large_B_cell_lymphoma_liver.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view showing cells with large hyperchromatic nuclei with very little cytoplasm. The cells are diffusely arranged and are not forming nodules. Based on the architecture and the results of the immunohistochemical stains, the diagnosis was that of a diffuse large B-cell lymphoma.</div><div id=\"graphicVersion\">Graphic 93956 Version 1.0</div></div></div>"},"93957":{"type":"graphic_picture","displayName":"Hepatosplenic T-cell lymphoma immunostain","title":"Hepatosplenic T-cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Hepatosplenic T-cell lymphoma</div><div class=\"cntnt\"><img style=\"width:612px; height:459px;\" src=\"images/GAST/93957_Hepatosplen_T_cell_lymphoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CD3 immunostain showing that the majority of the cells are positive, as indicated by the cells staining brown (peroxidase-antiperoxidase reaction). The diagnosis of hepatosplenic T-cell lymphoma was confirmed by T-cell gene rearrangement studies (TCR).</div><div id=\"graphicVersion\">Graphic 93957 Version 1.0</div></div></div>"},"93958":{"type":"graphic_picture","displayName":"HCC clear cell type","title":"Hepatocellular carcinoma","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Hepatocellular carcinoma</div><div class=\"cntnt\"><img style=\"width:590px; height:392px;\" src=\"images/GAST/93958_HCC_clear_cell_type_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Moderately-differentiated hepatocellular carcinoma (HCC), clear cell type. The majority of the tumor cells appear to have vacuolated/clear cytoplasm, typical of this type of HCC. Tumor cells are arranged in broad trabeculae with each trabecula consisting of five to six cell-plates lined by endothelial cells. As is typical for HCC, there are no portal tracts, however many unpaired arteries are present.</div><div id=\"graphicVersion\">Graphic 93958 Version 1.0</div></div></div>"},"93959":{"type":"graphic_picture","displayName":"HCC steatohepatitic type","title":"Hepatocellular carcinoma","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Hepatocellular carcinoma</div><div class=\"cntnt\"><img style=\"width:590px; height:427px;\" src=\"images/GAST/93959_HCC_steatohepatitic_type_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In some areas of the tumor, the cells appear to have clear cytoplasm and also appear to be undergoing ballooning degeneration. Additionally, neutrophils are identified surrounding the ballooned tumor cells along with bands of fibrous tissue. These features are typically seen in steatohepatitic-type hepatocellular carcinoma.</div><div id=\"graphicVersion\">Graphic 93959 Version 1.0</div></div></div>"},"93960":{"type":"graphic_picture","displayName":"Ephelides","title":"Ephelides (freckles)","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Ephelides (freckles)</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/93960_Ephelides.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous ephelides on the face of a child with red hair. Note a tendency for confluence in some areas.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 93960 Version 1.0</div></div></div>"},"93966":{"type":"graphic_figure","displayName":"Umbilical cord coiling patterns","title":"Umbilical cord coiling patterns","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Umbilical cord coiling patterns</div><div class=\"cntnt\"><img style=\"width:456px; height:382px;\" src=\"images/OBGYN/93966_Umbilical_cord_coiling_patterns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the four gross umbilical cord coiling patterns.</div><div class=\"graphic_reference\">Modified from: Ernst LM, Minturn L, Huang MH, et al. Gross patterns of umbilical cord coiling: correlations with placental histology and stillbirth. Placenta 2013; 34:583.</div><div id=\"graphicVersion\">Graphic 93966 Version 2.0</div></div></div>"},"93968":{"type":"graphic_table","displayName":"Intraoperative risk mitigation for OSA","title":"Intraoperative risk mitigation strategies for obstructive sleep apnea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intraoperative risk mitigation strategies for obstructive sleep apnea</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Anesthetic risk</td> <td class=\"subtitle1\">Strategies and precautions</td> </tr> <tr class=\"divider_bottom\"> <td>Airway obstruction and respiratory depression with sedatives and opioids</td> <td> <ul> <li>Avoid or minimize sedative premedication </li> <li>Use infusion rather than bolus dosing of sedatives to decrease episodic respiratory depression </li> <li>Consider sedatives without respiratory depressant effects (eg, dexmedetomidine) </li> <li>Use continuous oximetry and ventilation monitoring (eg, capnography) when sedatives are given </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Difficult airway (mask ventilation, supraglottic airway ventilation, laryngoscopy, and intubation)</td> <td> <ul> <li>Use maximally effective preoxygenation (tight-fitting mask, &#62;3 minutes, consider CPAP) </li> <li>Use two-person mask ventilation if mask ventilation is difficult </li> <li>Position with head elevated (reverse Trendelenburg) for laryngoscopy </li> <li>Assure availability of airway adjuncts and personnel for assistance </li> <li>Follow difficult airway guidelines and algorithms </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Prolonged postoperative effects of anesthetic agents (airway obstruction and respiratory depression)</td> <td> <ul> <li>Consider short-acting general anesthetic agents, including intravenous and insoluble volatile agents (eg, desflurane) </li> <li>Minimize opioids by using regional anesthesia or multimodal analgesia techniques as appropriate </li> </ul> </td> </tr> <tr> <td>Post-extubation airway obstruction</td> <td> <ul> <li>Verify full reversal of neuromuscular blockade </li> <li>Extubate with patient awake (fully conscious and cooperative; airway reflexes intact) </li> <li>Extubate and recover in a non-supine position (head-up or lateral) </li> <li>Consider early application of CPAP for patients using it preoperatively, or to treat hypoxemia or obstruction </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CPAP: continuous positive airway pressure.</div><div id=\"graphicVersion\">Graphic 93968 Version 1.0</div></div></div>"},"93970":{"type":"graphic_picture","displayName":"Hepatosplenic T-cell lymphoma","title":"Hepatosplenic T-cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Hepatosplenic T-cell lymphoma</div><div class=\"cntnt\"><img style=\"width:590px; height:381px;\" src=\"images/GAST/93970_Hepatosplen_T_cell_lymphoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of the atypical cells that are present within sinusoids, resulting in the compression of the hepatocyte plates. The atypical cells have convoluted cytoplasm, high nuclear-to-cytoplasmic ratio, and prominent nucleoli.</div><div id=\"graphicVersion\">Graphic 93970 Version 1.0</div></div></div>"},"93971":{"type":"graphic_picture","displayName":"HCC microvascular invasion","title":"Hepatocellular carcinoma","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Hepatocellular carcinoma</div><div class=\"cntnt\"><img style=\"width:590px; height:407px;\" src=\"images/GAST/93971_HCC_microvascular_invas_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this photo, a large vessel with a muscular wall contains a tumor thrombus. Note that this vessel is present within non-neoplastic parenchyma suggesting that this vessel is distant from the tumor. Microvascular invasion affecting a large, thick-walled blood vessel far from the main mass also indicates a worse prognosis.</div><div id=\"graphicVersion\">Graphic 93971 Version 1.0</div></div></div>"},"93972":{"type":"graphic_picture","displayName":"PBC stage 3 trichrome","title":"Primary biliary cholangitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary biliary cholangitis</div><div class=\"cntnt\"><img style=\"width:362px; height:272px;\" src=\"images/GAST/93972_PBC_stage_3_trichrome_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trichrome stain highlighting bridging, fibrous septa that partially surround incomplete fragments of liver tissue. The fragmentation of the liver tissue is indicative of advanced fibrosis. In this case, there is no clear-cut cirrhosis yet. Note that the fibrous tissue has little inflammation, which is typical for any kind of biliary-type fibrosis.</div><div id=\"graphicVersion\">Graphic 93972 Version 2.0</div></div></div>"},"93974":{"type":"graphic_picture","displayName":"Wilson disease high-power","title":"Wilson disease","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Wilson disease</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/93974_Wilson_disease_highpower_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of the hepatocytes within a cirrhotic nodule, showing marked ballooning degeneration in many cells. Mallory-Denk hyalines are present. The rest of the hepatocytes contain steatosis. Note that there is no inflammation.</div><div id=\"graphicVersion\">Graphic 93974 Version 1.0</div></div></div>"},"93976":{"type":"graphic_diagnosticimage","displayName":"Imaging Takayasu aortitis aortography","title":"Takayasu aortitis on aortography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Takayasu aortitis on aortography</div><div class=\"cntnt\"><img style=\"width:302px; height:454px;\" src=\"images/RADIOL/93976_Img_Takayasu_aortitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 13-year-old female with Takayasu aortitis. The aortogram shows tubular narrowing of the isthmus of the aorta (arrow).</div><div id=\"graphicVersion\">Graphic 93976 Version 2.0</div></div></div>"},"93977":{"type":"graphic_diagnosticimage","displayName":"Angiogram catheter-induced thrombosis ","title":"Catheter-induced arterial thrombosis with embolization on angiography ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Catheter-induced arterial thrombosis with embolization on angiography </div><div class=\"cntnt\"><img style=\"width:417px; height:517px;\" src=\"images/RADIOL/93977_Angio_cath_ind_thromb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An angiogram of the external iliac artery shows thrombus in the femoral artery (dashed arrow) surrounding the arterial catheter (arrow). There is distal embolization into the profunda femoral artery (arrowheads).</div><div id=\"graphicVersion\">Graphic 93977 Version 2.0</div></div></div>"},"93979":{"type":"graphic_diagnosticimage","displayName":"CT neutropenic enterocolitis","title":"Neutropenic enterocolitis on CT","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Neutropenic enterocolitis on CT</div><div class=\"cntnt\"><img style=\"width:444px; height:312px;\" src=\"images/RADIOL/93979_CT_neutrop_enterocolit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan through lower abdomen shows severe edema and thickening of the cecal wall (single arrow). There are surrounding ascites (arrowhead) and bubbles of free air (double arrow). The descending colon is uninvolved (dashed arrow). The patient has colon carcinoma and is receiving chemotherapy.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 93979 Version 1.0</div></div></div>"}};